


**CUMULATIVE
SUPPLEMENT 6
JUNE 2021**



**APPROVED
DRUG PRODUCTS**

**WITH
THERAPEUTIC EQUIVALENCE EVALUATIONS**

41st EDITION

Department of Health and Human Services

**Food and Drug Administration
Office of Medical Products and Tobacco
Center for Drug Evaluation and Research
Office of Generic Drugs
Office of Generic Drug Policy**

2021

Prepared By
Food and Drug Administration
Office of Medical Products and Tobacco
Center for Drug Evaluation and Research
Office of Generic Drugs
Office of Generic Drug Policy

**APPROVED DRUG PRODUCTS
with
THERAPEUTIC EQUIVALENCE EVALUATIONS**

41th EDITION

**Cumulative Supplement 6
June 2021**

CONTENTS

PAGE

Contents

1.0	INTRODUCTION.....	v
1.1	HOW TO USE THE CUMULATIVE SUPPLEMENT	vi
1.2	CUMULATIVE SUPPLEMENT CONTENT	vi
1.3	APPLICANT NAME CHANGES	vii
1.4	LEVOTHYROXINE SODIUM	viii
1.5	AVAILABILITY OF THE EDITION.....	ix
1.6	REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST.....	x
1.7	CUMULATIVE SUPPLEMENT LEGEND.....	xi
DRUG PRODUCT LISTS		
	Prescription Drug Product List	1-1
	OTC Drug Product List	2-1
	Drug Products with Approval under Section 505 of the Act Administered by the Center for Biologics Evaluation and Research List	3-1
	Orphan Product Designations and Approvals List	4-1
	Drug Products Which Must Demonstrate in vivo Bioavailability Only if Product Fails to Achieve Adequate Dissolution	5-1
PATENT AND EXCLUSIVITY INFORMATION ADDENDUM		
A.	Patent and Exclusivity Lists	A-1
B.	Patent and Exclusivity Terms	B-1

**APPROVED DRUG PRODUCTS
with
THERAPEUTIC EQUIVALENCE EVALUATIONS**

41st EDITION

**CUMULATIVE SUPPLEMENT 6
JUNE 2021**

1.0 INTRODUCTION

This Cumulative Supplement is one of a series of monthly updates to the *Approved Drug Products with Therapeutic Equivalence Evaluations* (the List, commonly known as the Orange Book). The List is composed of four parts: approved prescription drug products with therapeutic equivalence evaluations; approved over-the-counter (OTC) drug products for those drugs that may not be marketed without NDAs or ANDAs because they are not covered under existing OTC monographs; drug products with approval under Section 505 of the Federal Food, Drug, and Cosmetic Act (FD&C Act) administered by the Center for Biologics Evaluation and Research; and approved products that have never been marketed, are for exportation, are for military use, have been discontinued from marketing and we have not determined that they were withdrawn for safety or effectiveness reasons, or that have had their approvals withdrawn for other than safety or efficacy reasons.

The Cumulative Supplement provides, among other things, information on newly approved drugs and, if necessary, revised therapeutic equivalence evaluations and updated patent and exclusivity data. The Addendum contains appropriate drug patent and exclusivity information required of the Agency by the "Drug Price Competition and Patent Term Restoration Act of 1984" for the Prescription, OTC, Discontinued Drug Product, and Drug Products with Approval under Section 505 of the Act Administered by the Center for Biologics Evaluation and Research Lists.

Because all parts of the publication are subject to changes, additions, or deletions, the List must be used in conjunction with the most current Cumulative Supplement. Users may wish to mark to the left of the ingredient(s) in the List to indicate that changes to that entry appear in the Cumulative Supplement. Drug product information is provided in each Cumulative Supplement for completeness to assist in locating the proper place in the List for the revision.

The presence of any therapeutic equivalence code indicates that the drug product is multisource; the deletion of a therapeutic equivalence code indicates that the drug product has become single source. (An infrequent exception exists when a therapeutic equivalence code is revised. In that case, the deletion of the therapeutic equivalence code is followed immediately by the addition of the revised one.)

Products that have never been marketed, are for exportation, are for military use, have been discontinued from marketing and we have not determined that they were withdrawn for safety or effectiveness reasons or that have had their approvals withdrawn for other than safety or efficacy reasons, will be flagged in this Cumulative Supplement with the "@" symbol to designate their non-marketed status. All products having a "@" symbol in the 12th Cumulative Supplement of this Edition List will then be added to the "Discontinued Drug Product List" appearing in the next Edition. The current Annual Edition Section 2., How To Use The Drug Product Lists, describes the layout and usage of the List.

1.1 HOW TO USE THE CUMULATIVE SUPPLEMENT

New additions to the Prescription Drug Product List and OTC Drug Product List are indicated by the symbol >A>. The Patent and Exclusivity List new additions are indicated by the symbol >A> to the left of Patent Number or Exclusivity Code. The >A> symbol is then dropped in subsequent Cumulative Supplements for that item.

New deletions to the Prescription Drug Product List and OTC Drug Product List are indicated by the symbol >D> (DELETE) to the left of the line. The information line with the >D> symbol is dropped in subsequent Cumulative Supplements for that item.

The Patent and Exclusivity List is arranged in alphabetical order by active ingredient name(s) and trade name. The trade name will follow the active ingredient name separated by a dash symbol. Also shown is the application number and product number (FDA's internal file number) for reference purposes. All patents with their expiration dates are displayed for each application number. Drug substance and drug product patents are indicated as such with DS or DP in the Patent codes column. Use patents are indicated with the symbol "U" followed by a number representing a specific use. Exclusivity information for a specific drug is indicated by an abbreviation followed by the date upon which the exclusivity expires. Refer to the Exclusivity Terms, Section B, in the Patent and Exclusivity Information Addendum for an explanation of all codes and abbreviations. Refer to Section 1.3 for internet access to the most current list of Patent and Exclusivity terms.

1.2 CUMULATIVE SUPPLEMENT CONTENT

Since February 2005, we have been providing daily Electronic Orange Book (EOB) product information for new generic drug approvals. Daily generic updates provide the consumer with the current list of approved generic products which is important for substitution purposes. Previously, a first-time-generic product approved early in the month would not be published in the Cumulative Supplement (CS) for several weeks.

The CS monthly update publish goal is by the end of the following month's second work week (e.g., November's supplement will be updated by the end of the second full work week in December).

Currently, the monthly PDF CS includes:

- Generic product ANDA (Abbreviated New Drug Approval) approvals as of the date of publication.

- All product changes received and processed as of the date of publication.
 - Refer to CS Section 1.7 Cumulative Supplement Legend for types of changes
- New Drug Application (NDA) approvals appear in the CS month they were approved.
- Patent information, also updated daily in the EOB, is current to the date of publication.
- Exclusivity information is updated monthly and is current as of the date of publication.

Every effort is made to ensure the Cumulative Supplement is accurate. Applicant holders are requested to inform the FDA Division of Orange Book Publication and Regulatory Assessment (DOB/PRA) of any changes or corrections. The DOB/PRA can be contacted by email at orangebook@fda.hhs.gov.

1.3 APPLICANT NAME CHANGES

It is not practical to identify in the Cumulative Supplement each product involved when an applicant transfers its entire line of approved drug products to another applicant, or when an applicant changes its name. Therefore, the cumulation of these transfers and name changes will be identified in this section only. Where only partial lines of approved products are transferred between applicants, each approved product involved will appear as an applicant name change entry in the Cumulative Supplement.

It is also not practical to identify each, and every product involved when an applicant name is changed to meet internal publication standards (e.g., MSD or Zenith [Former Abbreviated Names] are changed, respectively to Merck Sharp Dohme or Zenith Labs [New Abbreviated Names]). When this occurs, each product involved (either currently in the Cumulative Supplement or in the following year's edition) will reflect the new abbreviated name. Consequently, it will not appear as an applicant name change entry in the Cumulative Supplement nor will the cumulation of these name changes appear in this section. The Electronic Orange Book Query, updated monthly, will contain the most current applicant holder name.

FORMER APPLICANT NAME
(FORMER ABBREVIATED NAME)

AKORN INC
(AKORN)

AKORN INC
(AKORN INC)

NEW APPLICANT NAME
(NEW ABBREVIATED NAME)

AKORN OPERATING CO LLC
(AKORN)

AKORN OPERATING CO LLC
(AKORN)

1.4 LEVOTHYROXINE SODIUM¹

Because there are multiple reference listed drugs for levothyroxine sodium tablets and some reference listed drugs' sponsors have conducted studies to establish their drugs' therapeutic equivalence to other reference listed drugs, FDA has determined that its usual practice of assigning two or three character therapeutic equivalence codes may be potentially confusing and inadequate for these drug products. Looking at the Orange Book listing alone for a product identified as a reference listed drug or reference standard, it may be difficult to determine to which therapeutic equivalence code the reference listed drugs and/or reference standard designation corresponds. For example, Unithroid 0.3 mg strength has been assigned the therapeutic equivalence codes AB1, AB2, and AB3 and it is identified as the reference listed drug and reference standard, but it is unclear that the reference listed drug and reference standard designations are associated with the AB1 therapeutic equivalence code.

Accordingly, FDA provides the following chart, which identifies (1) a reference listed drug for each therapeutic equivalence code in the Orange Book and (2) and the reference standard products in the Active Section of the Orange Book.²

- Therapeutic equivalence has been established between products that have the same AB+number therapeutic equivalence code (i.e. AB1, AB2, AB3 or AB4).
- More than one therapeutic equivalence code may apply to some products. One common therapeutic equivalence code indicates therapeutic equivalence between products. For example, Unithroid has been assigned therapeutic equivalence codes AB1, AB2, and AB3 therefore Unithroid tablets are considered therapeutically equivalent to other levothyroxine sodium products of the same strength with these therapeutic equivalence codes.

TE Code	Proprietary Name	Applicant	Strength	Appl No	RLD	RS
AB1	UNITHROID	STEVENS J	0.3MG	N021210	RLD	RS
AB2	SYNTHROID	ABBVIE	0.3MG	N021402	RLD	RS
AB3	LEVOXYL	KING PHARMS	0.2MG	N021301	RLD	RS
AB4	THYRO-TABS	ALVOGEN GROUP HOLDINGS 4 LLC	0.3MG	N021116	RLD	-

¹ In previous editions of the Orange Book, FDA provided a chart outlining therapeutic equivalence codes for all .025 mg levothyroxine sodium drug products in the Active Section of the Orange Book. FDA has decided, for ease of review, to revise the chart to identify the NDAs for the reference listed drugs for each therapeutic equivalence code (i.e., AB1, AB2, AB3, and AB4), and their corresponding reference standards, which are identified in 0.2 and 0.3 mg strengths.

² Please consult the Active Section of the Orange Book for information on other strengths.

AB4	LEVOTHYROXINE SODIUM ³	MYLAN	0.3MG	A076187	-	RS
-----	-----------------------------------	-------	-------	---------	---	----

1.5 AVAILABILITY OF THE EDITION

Since 1997, the Electronic Orange Book Query (EOBQ) <http://www.accessdata.fda.gov/scripts/cder/ob/default.cfm>, has been available on the internet and has become the updated-every-month Orange Book. The Query provides searching of the approved drug list by active ingredient, proprietary name, applicant holder, applicant number or patent number. Product search categories are: prescription, over-the-counter, discontinued drugs. There are links to patent and exclusivity information that may be applicable to each product.

Commencing with the 25th edition, the Annual Edition and monthly Cumulative Supplements have been provided in downloadable Portable Document Format (PDF) at the EOB home page by clicking on Publications. The PDF annual and cumulative supplements duplicate previous paper versions. Over time, there will be an archive for the annuals and each year's December Cumulative Supplement.

The downloaded Annual Edition and Cumulative Supplements are also available in a paper version (Approved Drug Products with Therapeutic Equivalence Evaluations, ADP) from the U.S. Government Printing Office: <http://bookstore.gpo.gov>; toll free 866-512-1800.

There are historical lists of Orange Book cumulative supplement product monthly changes at <http://www.fda.gov/Drugs/InformationOnDrugs/ucm086229.htm>. There are ASCII text files of the Orange Book drug product, patent, and exclusivity data at <http://www.fda.gov/Drugs/InformationOnDrugs/ucm129689.htm>. The drug product text files are provided in eobzip.zip format. The files are updated concurrently with the monthly cumulative supplements. The annual Orange Book Edition Appendices A, B, and C in PDF format are updated quarterly.

Effective August 18, 2003, patent submissions for publication in the Orange Book and Docket *95S-0117 need to be submitted on form FDA-3542 which may be downloaded from the FDA Forms List,
 Effective August 18, 2003, patent submissions for publication in the Orange Book and Docket *95S-0117 need to be submitted on form FDA-3542 which may be downloaded from the FDA Forms List,
<https://www.fda.gov/about-fda/reports-manuals-forms/forms>.

³ Lloyd's Thyro-Tabs tablets (NDA 021116) (previously known as Levothroid) previously was listed in the Discontinued Drug Product List section of the Orange Book. It is the RLD for therapeutic equivalents identified with the AB4 code. During this time, Mylan's levothyroxine product (ANDA 076187) was selected as the reference standard for ANDA applicants to use to establish bioequivalence to Thyro-Tabs. It remains the reference standard for ANDA applicants to use to establish bioequivalence to Thyro-Tabs. If an ANDA that uses Mylan's levothyroxine product as its reference standard is approved, the ANDA will receive an AB4 rating. The ANDA applicant also may obtain an AB rating for its product to the other reference listed drugs (i.e., Unithroid, Synthroid, and Levoxyl) by submitting supplements that demonstrate that the generic product is bioequivalent to these other reference listed drugs and satisfies all other therapeutic equivalence criteria with respect to these reference listed drugs. See Letter from Janet Woodcock, M.D., Director, Center for Drug Evaluation and Research, FDA to Teri Nataline, Principal Consultant, Lachman Consultant Services, Inc., Docket No. FDA-2015-P-0403 (May 27, 2016).

The current listing of the Orphan Product Designations and Approvals is available at <https://www.fda.gov/industry/developing-products-rare-diseases-conditions/designating-orphan-product-drugs-and-biological-products>.

1.6 REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST

DESCRIPTION OF REPORT

This report provides summary counts derived from the product information in the Prescription Drug Product List and the current Cumulative Supplement. Products included in the counts are domestically marketed drug products approved for both safety and effectiveness under section 505 of the Federal Food, Drug, and Cosmetic Act. Excluded are approved drug products marketed by distributors; those marketed solely abroad; and those now regarded as medical devices, biologics or foods.

The baseline column (December of the previous Annual Edition) refers to the products in the Prescription Drug Product List. For each three-month period, a column of quarterly data is added which incorporates counts of product activity from the previous quarter(s) with those in the baseline count.

DEFINITIONS

Drug Product

For this report, a drug product is the representation in the Prescription Drug Product List of an active moiety (molecular entity and its salts, esters and derivatives) either as a single ingredient or as a combination product provided in a specific dosage form and strength for a given route of administration with approval for marketing by a firm under a particular generic or trade name.

New Molecular Entity

A new molecular entity is considered an active moiety that has not previously been approved (either as the parent compound or as a salt, ester or derivative of the parent compound) in the United States for use in a drug product either as a single ingredient or as part of a combination.

REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST COUNTS CUMULATIVE BY QUARTER

<u>CATEGORIES</u> <u>COUNTED</u>	<u>DEC</u> <u>2020</u>	<u>MAR</u> <u>2021</u>	<u>JUN</u> <u>2021</u>	<u>SEP</u> <u>2021</u>	<u>DEC</u> <u>2021</u>
DRUG PRODUCTS LISTED SINGLE SOURCE	20478 2659 (13.0%)	20726 2671 (12.9%)	20916 2675 (12.8%)		
MULTISOURCE	17819 (87.0%)	18055 (87.1%)	18241 (87.2%)		
THERAPEUTICALLY EQUIVALENT	17746 (86.7%)	17990 (86.8%)	18175 (86.9%)		

NOT THERAPEUTICALLY EQUIVALENT	73 (0.4%)	65 (0.3%)	66 (0.3%)
EXCEPTIONS ⁴	54 (0.3%)	54 (0.3%)	54 (0.3%)
NEW MOLECULAR ENTITIES APPROVED	22	29	33
NUMBER OF APPLICANTS	1185	1184	1182

1.7 CUMULATIVE SUPPLEMENT LEGEND

The List is sorted by Ingredient(s) and, within each grouping, by the Dosage Form; Route of Administration and then by trade name (or established name of the active ingredient, if no trade name exists).

The individual product record contains the Therapeutic Equivalence Code, Reference Listed Drug symbol, Reference Standard symbol, applicant holder, strength(s), New Drug Application number, product number, and approval date. The application number preceded by "N" is a New Drug Application (NDA or innovator). The application number preceded by an "A" is an Abbreviated New Drug Application (ANDA or generic). The last two columns describe the action. The Action Month is the CS month the action occurred. The OB Action is the type of change that has occurred.

New ingredient(s), new dosage form, new route(s) of administration, new trade names, and new product additions are preceded by >A> during the action month. The change month is the current CS month; the change code for new approvals is NEWA. Following months will display the same information without the >A>.

Changes to currently listed products will list two records. The deleted product record will be preceded by >D>. The product record change addition being made will be preceded by >A>. Following months will display only the >A> record without the >A>. All changes that occur to the product through the Annual year will be listed. The change month and change code will document the change.

The change code and description:

NEWA	New drug product approval
NFTG	New first-time generic approval
CAHN ⁵	Applicant holder firm name has changed
CAIN	Change. There has been a change in the Ingredient(s) name. All products will be deleted under the old name and all products will be added under the changed ingredient(s) name.
CDFR	Change. Dosage Form; Route of Administration
CFTG	Change. A TE Code is added when a first time generic for an innovator is approved.

⁴ Amino acid containing products of varying composition (see Introduction, page xx of the List).

⁵ The Cumulative Supplement (CS) currently displays a condensed 20 character collapsed applicant holder firm name and the Electronic Orange Book (EOB) query may display up to a 250-character full applicant holder firm name. An applicant holder firm name change usually changes both the collapsed name and long name. On occasion, only the long name is changed resulting in the CS displaying only the collapsed name for the >D> and >A> action. The new firm long name will display in the EOB query.

CMFD	Change. The product is moved from the Discontinued Section due to a change in marketing status.
CMKT	Change. RX to OTC marketing status switch.
CMS1	Change. Miscellaneous addition to list.
CMS2	Change. Miscellaneous deletion from list.
CPOT	Change. Potency amount/unit.
CRLD	Change. Reference Listed Drug
CHRS	Change. Reference Standard
CTEC	Change. Therapeutic Equivalence Code.
CTNA	Change. Trade Name.
DISC	Discontinued. The Rx or OTC listed product is not being marketed and will appear in the discontinued section in the next edition.

ABIRATERONE ACETATE

TABLET;ORAL

ABIRATERONE ACETATE

AB	AMNEAL PHARMS	500MG	A208327	002	Dec 23, 2020	Apr	NEWA	
>A>	AB	QILU	500MG	A212462	002	Jun 25, 2021	Jun	NEWA

ACARBOSE

TABLET;ORAL

ACARBOSE

AB	EMCURE PHARMS LTD	25MG	A202271	001	Feb 07, 2012	Apr	CMFD
AB		50MG	A202271	002	Feb 07, 2012	Apr	CMFD
AB		100MG	A202271	003	Feb 07, 2012	Apr	CMFD

ACETAMINOPHEN

POWDER; INTRAVENOUS

ACETAMINOPHEN

+ @ MYLAN LABS LTD 1GM/VIAL

N206610 001 Jan 15, 2021 Jan NEWA

SOLUTION; INTRAVENOUS

ACETAMINOPHEN

+! B BRAUN MEDICAL INC 500MG/50ML (10MG/ML)

N204957 001 Feb 18, 2021 Feb NEWA

+! 1GM/100ML (10MG/ML)

N204957 002 Feb 18, 2021 Feb NEWA

ACETAMINOPHEN; BUTALBITAL

TABLET;ORAL

BUTALBITAL AND ACETAMINOPHEN

>A>	AA	ALVOGEN	300MG;50MG	A207635	001	Jun 05, 2017	Jun	CAHN
>A>	AA		325MG;50MG	A205120	001	Oct 30, 2015	Jun	CAHN
>D>	AA	CNTY LINE PHARMS	300MG;50MG	A207635	001	Jun 05, 2017	Jun	CAHN
>D>	AA		325MG;50MG	A205120	001	Oct 30, 2015	Jun	CAHN

ACETAMINOPHEN; BUTALBITAL; CAFFEINE

CAPSULE;ORAL

BUTALBITAL, ACETAMINOPHEN AND CAFFEINE

AA	XSPIRE PHARMA	300MG;50MG;40MG	A206615	001	Aug 04, 2017	Feb	CAHN
----	---------------	-----------------	---------	-----	--------------	-----	------

TABLET;ORAL

BUTALBITAL, ACETAMINOPHEN AND CAFFEINE

>A>	AA	ALVOGEN	325MG;50MG;40MG	A204984	001	Jan 10, 2017	Jun	CAHN
>D>	AA	CNTY LINE PHARMS	325MG;50MG;40MG	A204984	001	Jan 10, 2017	Jun	CAHN
		@ GRANULES	325MG;50MG;40MG	A040864	001	Dec 01, 2008	Apr	CAHN

ACETAMINOPHEN; BUTALBITAL; CAFFEINE; CODEINE PHOSPHATE

CAPSULE;ORAL

BUTALBITAL, ACETAMINOPHEN, CAFFEINE AND CODEINE PHOSPHATE

AB	NOSTRUM LABS INC	325MG;50MG;40MG;30MG	A075929	001	Apr 22, 2002	Jan	CAHN
----	------------------	----------------------	---------	-----	--------------	-----	------

ACETAMINOPHEN; CODEINE PHOSPHATE

TABLET;ORAL

ACETAMINOPHEN AND CODEINE PHOSPHATE

	@ VINTAGE	300MG;15MG	A089990	001	Sep 30, 1988	Apr	DISC
	@	300MG;30MG	A089805	001	Sep 30, 1988	Apr	DISC
	@	300MG;60MG	A089828	001	Sep 30, 1988	Apr	DISC
AA		300MG;60MG	A089828	001	Sep 30, 1988	Apr	CAHN

ACETAMINOPHEN; HYDROCODONE BITARTRATE

TABLET;ORAL

ANEXSIA 5/325

AA	! SPECGX LLC	325MG;5MG	A040409	001	Oct 20, 2000	Apr	CHRS
	ANEXSIA 7.5/325						
AA	! SPECGX LLC	325MG;7.5MG	A040405	001	Sep 08, 2000	Apr	CHRS
	HYDROCODONE BITARTRATE AND ACETAMINOPHEN						
AA	! SPECGX LLC	325MG;10MG	A040400	001	Jul 26, 2000	Apr	CHRS
	NORCO						
	@ APIL	325MG;2.5MG	A040148	004	Jul 07, 2014	Apr	DISC
	@	325MG;5MG	A040099	001	Jun 25, 1997	Apr	DISC
	@	325MG;5MG	A040148	005	Jul 07, 2014	Apr	DISC
	@	325MG;7.5MG	A040148	003	Sep 12, 2000	Apr	DISC
	@	325MG;10MG	A040148	001	Feb 14, 1997	Apr	DISC

ACETAMINOPHEN; OXYCODONE HYDROCHLORIDE

TABLET; ORAL

OXYCODONE AND ACETAMINOPHEN

AA	CHARTWELL	325MG; 5MG	A207834	001	Aug 15, 2019	Jan CAHN
AA		325MG; 7.5MG	A207834	002	Aug 15, 2019	Jan CAHN
AA		325MG; 10MG	A207834	003	Aug 15, 2019	Jan CAHN
	ROXICET					
	@ HIKMA	325MG; 5MG	A087003	001		Jan DISC

ACETAZOLAMIDE

CAPSULE, EXTENDED RELEASE; ORAL

ACETAZOLAMIDE

AB	ACCORD HLTHCARE	500MG	A207659	001	Oct 18, 2018	Apr CMFD
>D>	! HERITAGE PHARMS INC	500MG	A090779	001	Jul 14, 2011	Jun CAHN
>A>	! INDICUS PHARMA	500MG	A090779	001	Jul 14, 2011	Jun CAHN

TABLET; ORAL

ACETAZOLAMIDE

AB	APPCO	125MG	A211372	001	Feb 22, 2021	Feb NEWA
AB		250MG	A211372	002	Feb 22, 2021	Feb NEWA

ACETYLCYSTEINE

INJECTABLE; INTRAVENOUS

ACETYLCYSTEINE

AP	EXELA PHARMA	6GM/30ML (200MG/ML)	A204797	001	Apr 15, 2021	Apr NEWA
----	--------------	---------------------	---------	-----	--------------	----------

ACLIDINIUM BROMIDE

POWDER, METERED; INHALATION

TUDORZA PRESSAIR

+!	ASTRAZENECA	0.4MG/INH	N202450	001	Jul 23, 2012	Feb CAHN
----	-------------	-----------	---------	-----	--------------	----------

ACLIDINIUM BROMIDE; FORMOTEROL FUMARATE

POWDER, METERED; INHALATION

DUAKLIR PRESSAIR

>D>	ASTRAZENECA	0.4MG/INH; 0.012MG/INH	N210595	001	Mar 29, 2019	Jun CHRS
>A>	+!	0.4MG/INH; 0.012MG/INH	N210595	001	Mar 29, 2019	Jun CHRS
		0.4MG/INH; 0.012MG/INH	N210595	001	Mar 29, 2019	Feb CAHN

ACYCLOVIR

OINTMENT; TOPICAL

ACYCLOVIR

>D>	AB	ANDA REPOSITORY	5%	A206437	001	Jul 31, 2017	Jun DISC
>A>		@	5%	A206437	001	Jul 31, 2017	Jun DISC
	AB	MACLEODS PHARMS LTD	5%	A212444	001	May 19, 2021	May NEWA

SUSPENSION; ORAL

ACYCLOVIR

AB	VISTAPHARM	200MG/5ML	A213951	001	Jan 11, 2021	Jan NEWA
----	------------	-----------	---------	-----	--------------	----------

ACYCLOVIR SODIUM

INJECTABLE; INJECTION

ACYCLOVIR SODIUM

>D>	AP	EXELA PHARMA	EQ 50MG BASE/ML	A207919	001	Jun 17, 2020	Jun CAHN
>A>	AP	NAMIGEN LLC	EQ 50MG BASE/ML	A207919	001	Jun 17, 2020	Jun CAHN
	AP	ZYDUS PHARMS	EQ 50MG BASE/ML	A206535	001	Aug 31, 2018	Jan CHRS
	AP	!	EQ 50MG BASE/ML	A206535	001	Aug 31, 2018	Jan CPOT

ADAPALENE; BENZOYL PEROXIDE

GEL; TOPICAL

EPIDUO FORTE

+!	GALDERMA LABS	0.3%; 2.5%	N207917	001	Jul 15, 2015	Feb CTEC
----	---------------	------------	---------	-----	--------------	----------

ADENOSINE

SOLUTION; INTRAVENOUS

ADENOSINE

AP	EMCURE PHARMS LTD	60MG/20ML (3MG/ML)	A202313	001	Sep 15, 2014	Feb CMFD
AP		90MG/30ML (3MG/ML)	A202313	002	Sep 15, 2014	Feb CMFD

ALBENDAZOLE

TABLET;ORAL

ALBENDAZOLE

AB	DR REDDYS	200MG	A211034	001	Jan 26, 2021	Jan	NEWA
	@ LUPIN LTD	200MG	A211636	001	Jun 10, 2020	Jan	DISC
AB	MSN	200MG	A213435	001	Jan 21, 2021	Jan	NEWA

ALBUTEROL SULFATE

AEROSOL, METERED; INHALATION

ALBUTEROL SULFATE

AB1	SANDOZ INC	EQ 0.09MG BASE/INH	A207085	001	Jun 01, 2021	May	NEWA
-----	------------	--------------------	---------	-----	--------------	-----	------

TABLET;ORAL

ALBUTEROL SULFATE

AB	AIZANT	EQ 2MG BASE	A210948	001	Mar 15, 2019	Feb	CMFD
AB		EQ 4MG BASE	A210948	002	Mar 15, 2019	Feb	CMFD
	@ EYWA	EQ 2MG BASE	A213524	001	Oct 08, 2020	Apr	DISC
	@	EQ 4MG BASE	A213524	002	Oct 08, 2020	Apr	DISC

ALBUTEROL SULFATE; IPRATROPIUM BROMIDE

SOLUTION; INHALATION

ALBUTEROL SULFATE AND IPRATROPIUM BROMIDE

@ AUROBINDO PHARMA LTD EQ 0.083% BASE;0.017%

A206532	001	Jul 08, 2020	Jan	DISC
---------	-----	--------------	-----	------

ALENDRONATE SODIUM

TABLET;ORAL

ALENDRONATE SODIUM

>D>	AB	JUBILANT CADISTA	EQ 5MG BASE	A090557	001	Feb 18, 2010	Jun	DISC
>A>	@		EQ 5MG BASE	A090557	001	Feb 18, 2010	Jun	DISC
>D>	AB		EQ 10MG BASE	A090557	002	Feb 18, 2010	Jun	DISC
>A>	@		EQ 10MG BASE	A090557	002	Feb 18, 2010	Jun	DISC
>D>	AB		EQ 35MG BASE	A090557	003	Feb 18, 2010	Jun	DISC
>A>	@		EQ 35MG BASE	A090557	003	Feb 18, 2010	Jun	DISC
>D>	AB		EQ 70MG BASE	A090557	004	Feb 18, 2010	Jun	DISC
>A>	@		EQ 70MG BASE	A090557	004	Feb 18, 2010	Jun	DISC
	@ US ANTIBIOTICS		EQ 5MG BASE	A079049	003	Aug 04, 2008	May	CAHN
	@		EQ 10MG BASE	A079049	004	Aug 04, 2008	May	CAHN
	@		EQ 35MG BASE	A079049	001	Aug 04, 2008	May	CAHN
	@		EQ 70MG BASE	A079049	002	Aug 04, 2008	May	CAHN

ALENDRONATE SODIUM; CHOLECALCIFEROL

TABLET;ORAL

FOSAMAX PLUS D

>D>	+	MERCK	EQ 70MG BASE;2,800 IU	N021762	001	Apr 07, 2005	Jun	CAHN
>D>	+	!	EQ 70MG BASE;5,600 IU	N021762	002	Apr 26, 2007	Jun	CAHN
>A>	+	ORGANON	EQ 70MG BASE;2,800 IU	N021762	001	Apr 07, 2005	Jun	CAHN
>A>	+	!	EQ 70MG BASE;5,600 IU	N021762	002	Apr 26, 2007	Jun	CAHN

ALISKIREN HEMIFUMARATE; HYDROCHLOROTHIAZIDE

TABLET;ORAL

TEKTURNA HCT

+	@	NODEN PHARMA	EQ 150MG BASE;12.5MG	N022107	001	Jan 18, 2008	May	DISC
+	@		EQ 150MG BASE;25MG	N022107	002	Jan 18, 2008	May	DISC

ALLOPURINOL

TABLET;ORAL

ALLOPURINOL

>D>	AB	APOTEX INC	100MG	A077353	001	Sep 08, 2005	Jun	CAHN
>D>	AB		300MG	A077353	002	Sep 08, 2005	Jun	CAHN
>A>	AB	CHARTWELL	100MG	A077353	001	Sep 08, 2005	Jun	CAHN
>A>	AB		300MG	A077353	002	Sep 08, 2005	Jun	CAHN

ALPRAZOLAM

TABLET;ORAL

ALPRAZOLAM

>D>	AB	MYLAN	0.25MG	A074215	001	Jan 27, 1994	Jun	DISC
>A>	@		0.25MG	A074215	001	Jan 27, 1994	Jun	DISC
>D>	AB		0.5MG	A074215	002	Jan 27, 1994	Jun	DISC
>A>	@		0.5MG	A074215	002	Jan 27, 1994	Jun	DISC
>D>	AB		1MG	A074215	003	Jan 27, 1994	Jun	DISC
>A>	@		1MG	A074215	003	Jan 27, 1994	Jun	DISC
>D>	AB		2MG	A074215	004	Jan 27, 1994	Jun	DISC

	TABLET;ORAL						
	ALPRAZOLAM						
>A>	@	2MG	A074215	004	Jan 27, 1994	Jun	DISC
AB	NOVITIUM PHARMA	0.25MG	A074174	001	Oct 19, 1993	Apr	CMFD
AB		0.5MG	A074174	002	Oct 19, 1993	Apr	CMFD
AB		1MG	A074174	003	Oct 19, 1993	Apr	CMFD
AB		2MG	A074174	004	Oct 19, 1993	Apr	CMFD
	<u>ALPROSTADIL</u>						
	INJECTABLE; INJECTION						
	CAVERJECT						
	+ @	PFIZER	0.005MG/VIAL	N020379	003	Jun 27, 1996	Jan CAHN
AP	+		0.01MG/VIAL	N020379	001	Jul 06, 1995	Jan CAHN
AP	+	!	0.02MG/VIAL	N020379	002	Jul 06, 1995	Jan CAHN
AP	+	!	0.04MG/VIAL	N020379	004	May 19, 1997	Jan CAHN
	CAVERJECT IMPULSE						
		PFIZER	0.01MG/VIAL	N021212	001	Jun 11, 2002	Jan CAHN
			0.02MG/VIAL	N021212	002	Jun 11, 2002	Jan CAHN
	PROSTIN VR PEDIATRIC						
AP	+	!	PFIZER	0.5MG/ML	N018484	001	Jan CAHN
	<u>AMANTADINE HYDROCHLORIDE</u>						
	SYRUP;ORAL						
	AMANTADINE HYDROCHLORIDE						
	@	WOCKHARDT BIO AG	50MG/5ML	A075060	001	Dec 24, 1998	Jan DISC
	TABLET;ORAL						
	AMANTADINE HYDROCHLORIDE						
	@	INVAGEN PHARMS	100MG	A207571	001	Jan 31, 2017	Jan DISC
	TABLET, EXTENDED RELEASE;ORAL						
	OSMOLEX ER						
	+	ADAMAS PHARMA	EQ 129MG BASE	N209410	001	Feb 16, 2018	Jan CAHN
	+	@	EQ 161MG BASE	N209410	004	Apr 22, 2020	Jan CAHN
	+		EQ 193MG BASE	N209410	002	Feb 16, 2018	Jan CAHN
	+	@	EQ 258MG BASE	N209410	003	Feb 16, 2018	May DISC
	+	!	EQ 258MG BASE	N209410	003	Feb 16, 2018	Jan CAHN
	+	ADAMAS PHARMS	EQ 129MG BASE	N209410	001	Feb 16, 2018	Jan CAHN
	+	@	EQ 161MG BASE	N209410	004	Apr 22, 2020	Jan CAHN
	+		EQ 193MG BASE	N209410	002	Feb 16, 2018	Jan CAHN
	+	!	EQ 258MG BASE	N209410	003	Feb 16, 2018	Jan CAHN
	<u>AMINOCAPROIC ACID</u>						
	SOLUTION;ORAL						
	AMICAR						
AA	+	!	AKORN	0.25GM/ML	N015230	002	Feb CPOT
AA	+	!		1.25GM/5ML	N015230	002	Feb CDFR
	AMINOCAPROIC ACID						
AA		AMNEAL	0.25GM/ML	A212780	001	Aug 23, 2019	Feb CPOT
AA			1.25GM/5ML	A212780	001	Aug 23, 2019	Feb CDFR
AA		LEADING PHARMA LLC	0.25GM/ML	A214140	001	Jan 26, 2021	Feb CPOT
AA			1.25GM/5ML	A214140	001	Jan 26, 2021	Feb CDFR
AA		TULEX PHARMS INC	0.25GM/ML	A212494	001	Aug 11, 2020	Feb CPOT
AA			1.25GM/5ML	A212494	001	Aug 11, 2020	Feb CDFR
AA		VISTAPHARM	0.25GM/ML	A212814	001	Feb 26, 2020	Feb CPOT
AA			1.25GM/5ML	A212814	001	Feb 26, 2020	Feb CDFR
	SYRUP;ORAL						
	AMINOCAPROIC ACID						
AA		LEADING PHARMA LLC	1.25GM/5ML	A214140	001	Jan 26, 2021	Jan NEWA
	TABLET;ORAL						
	AMINOCAPROIC ACID						
>A>	AB	EDENBRIDGE PHARMS	500MG	A212110	001	Jun 14, 2021	Jun NEWA
	AB	LEADING PHARMA LLC	500MG	A213928	001	Feb 12, 2021	Feb NEWA
	AB		1GM	A213928	002	Feb 12, 2021	Feb NEWA
	<u>AMIODARONE HYDROCHLORIDE</u>						
	TABLET;ORAL						
	AMIODARONE HYDROCHLORIDE						
AB		RUBICON	100MG	A078578	002	Feb 26, 2021	Feb NEWA
AB			400MG	A078578	003	Feb 26, 2021	Feb NEWA

AMITRIPTYLINE HYDROCHLORIDE

TABLET; ORAL

AMITRIPTYLINE HYDROCHLORIDE

AB	MANKIND PHARMA	10MG	A 213999	001	Feb 19, 2021	Feb	NEWA
AB		25MG	A 213999	002	Feb 19, 2021	Feb	NEWA
AB		50MG	A 213999	003	Feb 19, 2021	Feb	NEWA
AB		75MG	A 213999	004	Feb 19, 2021	Feb	NEWA
AB		100MG	A 213999	005	Feb 19, 2021	Feb	NEWA
AB		150MG	A 213999	006	Feb 19, 2021	Feb	NEWA
>D>	AB	MYLAN	10MG	A 086009	002	Jun	DISC
>A>	@	10MG	A 086009	002		Jun	DISC
>D>	AB		25MG	A 086009	003	Jun	DISC
>A>	@	25MG	A 086009	003		Jun	DISC
>D>	AB		50MG	A 086009	001	Jun	DISC
>A>	@	50MG	A 086009	001		Jun	DISC
>D>	AB		75MG	A 086009	004	Jun	DISC
>A>	@	75MG	A 086009	004		Jun	DISC
>D>	AB		100MG	A 086009	005	Jun	DISC
>A>	@	100MG	A 086009	005		Jun	DISC
>D>	AB		150MG	A 086009	006	Jun	DISC
>A>	@	150MG	A 086009	006		Jun	DISC
AB	UNICHEM	10MG	A 214548	001	May 19, 2021	May	NEWA
AB		25MG	A 214548	002	May 19, 2021	May	NEWA
AB		50MG	A 214548	003	May 19, 2021	May	NEWA
AB		75MG	A 214548	004	May 19, 2021	May	NEWA
AB		100MG	A 214548	005	May 19, 2021	May	NEWA
AB		150MG	A 214548	006	May 19, 2021	May	NEWA

AMLODIPINE BESYLATE

TABLET; ORAL

AMLODIPINE BESYLATE

@	WOCKHARDT	EQ 2.5MG BASE	A 078500	001	Sep 06, 2007	Jan	DISC
@		EQ 5MG BASE	A 078500	002	Sep 06, 2007	Jan	DISC
@		EQ 10MG BASE	A 078500	003	Sep 06, 2007	Jan	DISC

AMLODIPINE BESYLATE; OLMESARTAN MEDOXOMIL

TABLET; ORAL

AMLODIPINE AND OLMESARTAN MEDOXOMIL

>D>	AB	JUBILANT GENERICS	EQ 5MG BASE; 20MG	A 207450	001	May 15, 2017	Jun	DISC
>A>	@		EQ 5MG BASE; 20MG	A 207450	001	May 15, 2017	Jun	DISC
>D>	AB		EQ 5MG BASE; 40MG	A 207450	002	May 15, 2017	Jun	DISC
>A>	@		EQ 5MG BASE; 40MG	A 207450	002	May 15, 2017	Jun	DISC
>D>	AB		EQ 10MG BASE; 20MG	A 207450	003	May 15, 2017	Jun	DISC
>A>	@		EQ 10MG BASE; 20MG	A 207450	003	May 15, 2017	Jun	DISC
>D>	AB		EQ 10MG BASE; 40MG	A 207450	004	May 15, 2017	Jun	DISC
>A>	@		EQ 10MG BASE; 40MG	A 207450	004	May 15, 2017	Jun	DISC

AMMONIA N-13

INJECTABLE; INTRAVENOUS

AMMONIA N 13

AP	NUKEMED	30mCi-300mCi/8ML (3.75-37.5mCi/ML)	A 204455	001	Apr 23, 2015	Jan	CAHN
----	---------	------------------------------------	----------	-----	--------------	-----	------

AMOXICILLIN

CAPSULE; ORAL

AMOXICILLIN

>D>	AB	BELCHER PHARMS	250MG	A 062058	001		Jun	CAHN
>D>	AB		500MG	A 062058	002		Jun	CAHN
>A>	AB	CHARTWELL	250MG	A 062058	001		Jun	CAHN
>A>	AB		500MG	A 062058	002		Jun	CAHN
AB		AMOXIL						
AB	US ANTIBIOTICS	250MG	A 062216	001		May	CAHN	
AB		500MG	A 062216	004		May	CAHN	
AB		FOR SUSPENSION; ORAL						
AB		AMOXIL						
AB	US ANTIBIOTICS	50MG/ML	A 062226	005		May	CAHN	
AB		125MG/5ML	A 062226	001		May	CAHN	
+	@	200MG/5ML	N 050760	001	Apr 15, 1999	May	CAHN	
AB		250MG/5ML	A 062226	002		May	CAHN	
+	@	400MG/5ML	N 050760	002	Apr 15, 1999	May	CAHN	
AB		LAROTID						
AB	US ANTIBIOTICS	125MG/5ML	A 062226	003		May	CAHN	
AB		250MG/5ML	A 062226	004		May	CAHN	

TABLET;ORAL

AMOXIL

+ @ US ANTIBIOTICS	500MG	N050754	002	Jul 10, 1998	May CAHN
+ @	875MG	N050754	001	Jul 10, 1998	May CAHN

TABLET, CHEWABLE;ORAL

AMOXIL

+ @ US ANTIBIOTICS	125MG	N050542	002		May CAHN
@	200MG	N050761	001	Apr 15, 1999	May CAHN
+ @	250MG	N050542	001		May CAHN
@	400MG	N050761	002	Apr 15, 1999	May CAHN

AMOXICILLIN; CLARITHROMYCIN; OMEPRAZOLE

CAPSULE, TABLET, CAPSULE, DELAYED RELEASE;ORAL

OMEPRAZOLE AND CLARITHROMYCIN AND AMOXICILLIN

+ @ CUMBERLAND PHARMS	500MG,N/A,N/A;N/A,500MG,N/A;N/A,N/A,20MG	N050824	001	Feb 08, 2011	May DISC
-----------------------	--	---------	-----	--------------	----------

AMOXICILLIN; CLAVULANATE POTASSIUM

FOR SUSPENSION;ORAL

AMOXICILLIN AND CLAVULANATE POTASSIUM

AB	MICRO LABS LTD INDIA	200MG/5ML;EQ 28.5MG BASE/5ML	A205187	001	May 21, 2021	May NEWA
AB		400MG/5ML;EQ 57MG BASE/5ML	A205187	002	May 21, 2021	May NEWA
	AUGMENTIN '125'					
AB	+ US ANTIBIOTICS	125MG/5ML;EQ 31.25MG BASE/5ML	N050575	001	Aug 06, 1984	May CAHN
	AUGMENTIN '200'					
	+ @ US ANTIBIOTICS	200MG/5ML;EQ 28.5MG BASE/5ML	N050725	001	May 31, 1996	May CAHN
	AUGMENTIN '250'					
AB	+! US ANTIBIOTICS	250MG/5ML;EQ 62.5MG BASE/5ML	N050575	002	Aug 06, 1984	May CAHN
	AUGMENTIN '400'					
	+ @ US ANTIBIOTICS	400MG/5ML;EQ 57MG BASE/5ML	N050725	002	May 31, 1996	May CAHN
	AUGMENTIN ES-600					
AB	+ US ANTIBIOTICS	600MG/5ML;EQ 42.9MG BASE/5ML	N050755	001	Jun 22, 2001	May CAHN
	TABLET;ORAL					
	AUGMENTIN '250'					
	+ @ US ANTIBIOTICS	250MG;EQ 125MG BASE	N050564	001	Aug 06, 1984	May CAHN
	AUGMENTIN '500'					
	+ @ US ANTIBIOTICS	500MG;EQ 125MG BASE	N050564	002	Aug 06, 1984	May CAHN
	AUGMENTIN '875'					
AB	+ US ANTIBIOTICS	875MG;EQ 125MG BASE	N050720	001	Feb 13, 1996	May CAHN
	TABLET, CHEWABLE;ORAL					
	AUGMENTIN '125'					
	+ @ US ANTIBIOTICS	125MG;EQ 31.25MG BASE	N050597	001	Jul 22, 1985	May CAHN
	AUGMENTIN '200'					
	+ @ US ANTIBIOTICS	200MG;EQ 28.5MG BASE	N050726	001	May 31, 1996	May CAHN
	AUGMENTIN '250'					
	+ @ US ANTIBIOTICS	250MG;EQ 62.5MG BASE	N050597	002	Jul 22, 1985	May CAHN
	AUGMENTIN '400'					
	+ @ US ANTIBIOTICS	400MG;EQ 57MG BASE	N050726	002	May 31, 1996	May CAHN
	TABLET, EXTENDED RELEASE;ORAL					
	AUGMENTIN XR					
	+ @ US ANTIBIOTICS	1GM;EQ 62.5MG BASE	N050785	001	Sep 25, 2002	May CAHN

AMPHETAMINE ASPARTATE ; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE

TABLET;ORAL

DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE

AB	RHODES PHARMS	2.5MG;2.5MG;2.5MG;2.5MG	A213111	003	Jan 13, 2021	Jan NEWA
AB		3.75MG;3.75MG;3.75MG;3.75MG	A213111	005	Jan 13, 2021	Jan NEWA
AB		5MG;5MG;5MG;5MG	A213111	006	Jan 13, 2021	Jan NEWA

AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE

TABLET;ORAL

DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE

AB	ASCENT PHARMS INC	1.25MG;1.25MG;1.25MG;1.25MG	A213709	001	Apr 22, 2021	Apr NEWA
AB		1.875MG;1.875MG;1.875MG;1.875MG	A213709	002	Apr 22, 2021	Apr NEWA
AB		2.5MG;2.5MG;2.5MG;2.5MG	A213709	003	Apr 22, 2021	Apr NEWA
AB		3.125MG;3.125MG;3.125MG;3.125MG	A213709	004	Apr 22, 2021	Apr NEWA
AB		3.75MG;3.75MG;3.75MG;3.75MG	A213709	005	Apr 22, 2021	Apr NEWA
AB		5MG;5MG;5MG;5MG	A213709	006	Apr 22, 2021	Apr NEWA
AB		7.5MG;7.5MG;7.5MG;7.5MG	A213709	007	Apr 22, 2021	Apr NEWA
AB	RHODES PHARMS	1.25MG;1.25MG;1.25MG;1.25MG	A213111	001	Jan 13, 2021	Jan NEWA
AB		1.875MG;1.875MG;1.875MG;1.875MG	A213111	002	Jan 13, 2021	Jan NEWA

TABLET;ORAL

DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE

AB		3.125MG;3.125MG;3.125MG;3.125MG	A213111	004	Jan 13, 2021	Jan NEWA
AB		7.5MG;7.5MG;7.5MG;7.5MG	A213111	007	Jan 13, 2021	Jan NEWA

AMPHETAMINE SULFATE

TABLET;ORAL

AMPHETAMINE SULFATE

>D>	AA	GLENMARK PHARMS LTD	5MG	A212186	001	Jan 27, 2021	Jun DISC
>A>		@	5MG	A212186	001	Jan 27, 2021	Jun DISC
	AA		5MG	A212186	001	Jan 27, 2021	Jan NEWA
>D>	AA		10MG	A212186	002	Jan 27, 2021	Jun DISC
>A>		@	10MG	A212186	002	Jan 27, 2021	Jun DISC
	AA		10MG	A212186	002	Jan 27, 2021	Jan NEWA
		@ MAYNE PHARMA	5MG	A213898	001	Jul 14, 2020	Jan DISC
		@	10MG	A213898	002	Jul 14, 2020	Jan DISC
		@ NOVAST LABS	5MG	A213763	001	Aug 24, 2020	Mar DISC
		@	10MG	A213763	002	Aug 24, 2020	Mar DISC
	AA	SPECGX LLC	5MG	A213583	001	Jan 22, 2021	Jan NEWA
	AA		10MG	A213583	002	Jan 22, 2021	Jan NEWA
	AA	SUN PHARM INDS INC	5MG	A214574	001	Jan 27, 2021	Jan NEWA
	AA		10MG	A214574	002	Jan 27, 2021	Jan NEWA

TABLET, ORALLY DISINTEGRATING;ORAL

EVEKEO ODT

+!	ARBOR PHARMS LLC	20MG	N209905	004	Jan 30, 2019	Apr CHRS
----	------------------	------	---------	-----	--------------	----------

AMPICILLIN SODIUM

INJECTABLE;INJECTION

AMPICILLIN SODIUM

		@ HQ SPECLT PHARMA	EQ 125MG BASE/VIAL	A062772	005	Apr 15, 1993	Mar CAHN
AP			EQ 250MG BASE/VIAL	A062772	006	Apr 15, 1993	Mar CAHN
AP			EQ 500MG BASE/VIAL	A062772	007	Apr 15, 1993	Mar CAHN
		@	EQ 500MG BASE/VIAL	A062772	008	Apr 15, 1993	Mar CAHN
AP			EQ 1GM BASE/VIAL	A062772	001	Apr 15, 1993	Mar CAHN
		@	EQ 1GM BASE/VIAL	A062772	002	Apr 15, 1993	Mar CAHN
AP			EQ 2GM BASE/VIAL	A062772	003	Apr 15, 1993	Mar CAHN
		@	EQ 2GM BASE/VIAL	A062772	004	Apr 15, 1993	Mar CAHN
AP			EQ 10GM BASE/VIAL	A063142	001	Apr 15, 1993	Mar CAHN

AMPICILLIN SODIUM; SULBACTAM SODIUM

INJECTABLE;INJECTION

AMPICILLIN AND SULBACTAM

AP		HQ SPECLT PHARMA	EQ 1GM BASE/VIAL;EQ 500MG BASE/VIAL	A065176	001	Nov 30, 2005	Mar CAHN
AP			EQ 2GM BASE/VIAL;EQ 1GM BASE/VIAL	A065176	002	Nov 30, 2005	Mar CAHN
AP			EQ 10GM BASE/VIAL;EQ 5GM BASE/VIAL	A065188	001	Nov 25, 2005	Mar CAHN

ANASTROZOLE

TABLET;ORAL

ANASTROZOLE

		@ US ANTIBIOTICS	1MG	A090732	001	Jun 28, 2010	May CAHN
--	--	------------------	-----	---------	-----	--------------	----------

APREMILAST

TABLET;ORAL

APREMILAST

>A>	AB	AMNEAL	10MG	A211782	001	Jun 30, 2021	Jun NEWA
>A>	AB		20MG	A211782	002	Jun 30, 2021	Jun NEWA
>A>	AB		30MG	A211782	003	Jun 30, 2021	Jun NEWA
	AB	UNICHEM	10MG	A211819	001	Feb 17, 2021	Feb NFTG
	AB		20MG	A211819	002	Feb 17, 2021	Feb NFTG
	AB		30MG	A211819	003	Feb 17, 2021	Feb NFTG

ARFORMOTEROL TARTRATE

SOLUTION;INHALATION

ARFORMOTEROL TARTRATE

>A>		ARFORMOTEROL TARTRATE					
>A>	AN	AXAR PHARMS INC	EQ 0.015MG BASE/2ML	A213762	001	Jun 22, 2021	Jun NFTG
>A>	AN	CIPLA	EQ 0.015MG BASE/2ML	A207306	001	Jun 22, 2021	Jun NFTG
>A>	AN	GLENMARK PHARMS LTD	EQ 0.015MG BASE/2ML	A213132	001	Jun 22, 2021	Jun NFTG

ARGATROBAN

	INJECTABLE; INJECTION							
	ARGATROBAN							
AP	CAPLIN	50MG/50ML (1MG/ML)	A214235	001	Jan 21, 2021	Jan	NFTG	
	INJECTABLE; INTRAVENOUS							
	ARGATROBAN IN SODIUM CHLORIDE							
	+ @ EAGLE PHARMS	50MG/50ML (1MG/ML)	N022434	001	Jun 29, 2011	May	DISC	
	SOLUTION; INTRAVENOUS							
	ARGATROBAN IN SODIUM CHLORIDE							
>A>	+! ACCORD HLTHCARE	50MG/50ML (1MG/ML)	N212035	001	Jun 07, 2021	Jun	NEWA	

ARSENIC TRIOXIDE

	INJECTABLE; INJECTION							
	ARSENIC TRIOXIDE							
	@ AMNEAL	1MG/ML	A210739	001	Jan 25, 2021	May	DISC	
AP		1MG/ML	A210739	001	Jan 25, 2021	Jan	NEWA	
	@ INGENUS PHARMS LLC	2MG/ML	A209315	002	Jan 14, 2021	Feb	DISC	
AP		2MG/ML	A209315	002	Jan 14, 2021	Jan	NEWA	

ASCORBIC ACID; BIOTIN; CHOLECALCIFEROL; CYANOCOBALAMIN; DEXPANTHENOL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE; RIBOFLAVIN; THIAMINE; TOCOPHEROL ACETATE; VITAMIN A; VITAMIN K

	INJECTABLE; INTRAVENOUS							
	INFUVITE PEDIATRIC (PHARMACY BULK PACKAGE)							
	+! SANDOZ CANADA INC	80MG/VIAL; 0.02MG/VIAL; 400 IU/VIAL; 0.001MG/VIAL; 5MG/VIAL; 0.14 MG/VIAL; 17MG/VIAL; 1MG/VIAL; 1.4MG/V IAL; 1.2MG/VIAL; 7 IU/VIAL; 2,300 IU/VIAL; 0.2MG/VIAL	N021265	002	Jan 29, 2004	Feb	CAIN	

ASENAPINE MALEATE

	TABLET; SUBLINGUAL							
	ASENAPINE MALEATE							
AB	BRECKENRIDGE	EQ 5MG BASE	A205960	003	Mar 08, 2021	Feb	NEWA	

ASPIRIN; CAFFEINE; ORPHENADRINE CITRATE

	TABLET; ORAL							
	NORGESIC							
	+ @ BAUSCH	385MG; 30MG; 25MG	N013416	003	Oct 27, 1982	May	CAHN	
	NORGESIC FORTE							
	+ @ BAUSCH	770MG; 60MG; 50MG	N013416	004	Oct 27, 1982	May	CAHN	

ASPIRIN; DIPYRIDAMOLE

	CAPSULE, EXTENDED RELEASE; ORAL							
	ASPIRIN AND DIPYRIDAMOLE							
	@ LANNETT CO INC	25MG; 200MG	A204552	001	Mar 20, 2019	Apr	DISC	

ASPIRIN; HYDROCODONE BITARTRATE

	TABLET; ORAL							
	HYDROCODONE BITARTRATE AND ASPIRIN							
	LGM PHARMA	500MG; 5MG	A205479	001	May 28, 2021	May	NEWA	

ATAZANAVIR SULFATE

	CAPSULE; ORAL							
	ATAZANAVIR SULFATE							
AB	LAURUS LABS LTD	EQ 150MG BASE	A212579	001	Apr 30, 2021	Apr	NEWA	
AB		EQ 200MG BASE	A212579	002	Apr 30, 2021	Apr	NEWA	
AB		EQ 300MG BASE	A212579	003	Apr 30, 2021	Apr	NEWA	

ATOMOXETINE HYDROCHLORIDE

	CAPSULE; ORAL							
	ATOMOXETINE HYDROCHLORIDE							
AB	HETERO LABS LTD V	10MG	A202682	001	Mar 11, 2021	Mar	NEWA	
AB		18MG	A202682	002	Mar 11, 2021	Mar	NEWA	
AB		25MG	A202682	003	Mar 11, 2021	Mar	NEWA	
AB		40MG	A202682	004	Mar 11, 2021	Mar	NEWA	
AB		60MG	A202682	005	Mar 11, 2021	Mar	NEWA	
AB		80MG	A202682	006	Mar 11, 2021	Mar	NEWA	
AB		100MG	A202682	007	Mar 11, 2021	Mar	NEWA	
	@ MYLAN	10MG	A079021	001	Feb 18, 2021	Feb	DISC	
AB		10MG	A079021	001	Feb 18, 2021	Feb	NEWA	
	@	18MG	A079021	002	Feb 18, 2021	Feb	DISC	

CAPSULE;ORAL

ATOMOXETINE HYDROCHLORIDE							
AB		18MG	A079021	002	Feb 18, 2021	Feb	NEWA
	@	25MG	A079021	003	Feb 18, 2021	Feb	DISC
AB		25MG	A079021	003	Feb 18, 2021	Feb	NEWA
	@	40MG	A079021	004	Feb 18, 2021	Feb	DISC
AB		40MG	A079021	004	Feb 18, 2021	Feb	NEWA
	@	60MG	A079021	005	Feb 18, 2021	Feb	DISC
AB		60MG	A079021	005	Feb 18, 2021	Feb	NEWA
	@	80MG	A079021	006	Feb 18, 2021	Feb	DISC
AB		80MG	A079021	006	Feb 18, 2021	Feb	NEWA
	@	100MG	A079021	007	Feb 18, 2021	Feb	DISC
AB		100MG	A079021	007	Feb 18, 2021	Feb	NEWA

ATORVASTATIN CALCIUM

TABLET;ORAL

ATORVASTATIN CALCIUM							
AB	ALKEM LABS LTD	EQ 10MG BASE	A209288	001	Dec 21, 2018	Jan	CAHN
AB		EQ 20MG BASE	A209288	002	Dec 21, 2018	Jan	CAHN
AB		EQ 40MG BASE	A209288	003	Dec 21, 2018	Jan	CAHN
AB		EQ 80MG BASE	A209288	004	Dec 21, 2018	Jan	CAHN

ATORVASTATIN CALCIUM; EZETIMIBE

TABLET;ORAL

LIPTRUZET

+ @	ORGANON	EQ 10MG BASE;10MG	N200153	001	May 03, 2013	Feb	CAHN
+ @		EQ 20MG BASE;10MG	N200153	002	May 03, 2013	Feb	CAHN
+ @		EQ 40MG BASE;10MG	N200153	003	May 03, 2013	Feb	CAHN
+ @		EQ 80MG BASE;10MG	N200153	004	May 03, 2013	Feb	CAHN

ATOVAQUONE

SUSPENSION;ORAL

ATOVAQUONE

AB	BIONPHARMA INC	750MG/5ML	A212918	001	Mar 30, 2021	Mar	NEWA
----	----------------	-----------	---------	-----	--------------	-----	------

ATROPINE SULFATE

SOLUTION;INTRAVENOUS

ATROPINE SULFATE

AP	+! HOSPIRA	1MG/10ML (0.1MG/ML)	N021146	005	Aug 17, 2017	Mar	CTEC
AP	INTL MEDICATION SYS	1MG/10ML (0.1MG/ML)	A212461	001	Oct 05, 2020	Mar	CTEC

SOLUTION;INTRAVENOUS, INTRAMUSCULAR, SUBCUTANEOUS, INTRAOSSEOUS, ENDOTRACHEAL

ATROPINE SULFATE

AP	ACCORD HLTHCARE	8MG/20ML (0.4MG/ML)	A213424	001	Mar 19, 2021	Mar	NFTG
----	-----------------	---------------------	---------	-----	--------------	-----	------

ATROPINE SULFATE; DIPHENOXYLATE HYDROCHLORIDE

TABLET;ORAL

DIPHENOXYLATE HYDROCHLORIDE AND ATROPINE SULFATE

AA	WINDER LABS LLC	0.025MG;2.5MG	A211362	001	Jan 27, 2021	Jan	NEWA
----	-----------------	---------------	---------	-----	--------------	-----	------

ATROPINE SULFATE; EDROPHONIUM CHLORIDE

INJECTABLE;INJECTION

ENLON-PLUS

+ @	MYLAN	0.14MG/ML;10MG/ML	N019678	001	Nov 06, 1991	Jan	CAHN
-----	-------	-------------------	---------	-----	--------------	-----	------

AVAPRITINIB

TABLET;ORAL

AYVAKIT

>A>	+ BLUEPRINT MEDICINES	25MG	N212608	004	Jun 16, 2021	Jun	NEWA
>A>	+	50MG	N212608	005	Jun 16, 2021	Jun	NEWA

AVIBACTAM SODIUM; CEFTAZIDIME

POWDER;INTRAVENOUS

AVYCAZ

+!	ALLERGAN	EQ 0.5GM BASE;2GM/VIAL	N206494	001	Feb 25, 2015	Jan	CDFR
----	----------	------------------------	---------	-----	--------------	-----	------

AZELASTINE HYDROCHLORIDE; FLUTICASONE PROPIONATE

SPRAY, METERED;NASAL

AZELASTINE HYDROCHLORIDE AND FLUTICASONE PROPIONATE

AB	PERRIGO UK FINCO	EQ 0.125MG BASE/SPRAY;0.05MG/SPRAY	A208111	001	Feb 18, 2021	Feb	NEWA
----	------------------	------------------------------------	---------	-----	--------------	-----	------

AZITHROMYCIN

FOR SUSPENSION;ORAL		AZITHROMYCIN							
AB	TARO	EQ 200MG BASE/5ML	A211521	001	Dec 11, 2019	Feb	CMFD		
INJECTABLE;INJECTION		AZITHROMYCIN							
	@ MYLAN ASI	EQ 500MG BASE/VIAL	A065506	001	Mar 24, 2009	Feb	DISC		
TABLET;ORAL		AZITHROMYCIN							
AB	YUNG SHIN PHARM	EQ 500MG BASE	A211318	001	Mar 17, 2021	Mar	NEWA		
AB		EQ 600MG BASE	A211068	001	May 08, 2020	Feb	CMFD		

BACITRACIN

>D>	INJECTABLE;INJECTION									
>D>	BACITRACIN									
>D>	!	XELLIA PHARMS APS	50,000 UNITS/VIAL	A203177	001	Aug 25, 2014	Jun	DISC		
>A>	@		50,000 UNITS/VIAL	A203177	001	Aug 25, 2014	Jun	DISC		

BACLOFEN

INJECTABLE;INTRATHECAL		BACLOFEN							
AP	MAIA PHARMS INC	0.05MG/ML	A210777	001	Jan 15, 2021	Jan	NEWA		
GABLOFEN									
AP	+!	PIRAMAL CRITICAL	0.05MG/ML	N022462	001	Nov 19, 2010	Mar	CHRS	
AP	+		0.05MG/ML	N022462	001	Nov 19, 2010	Mar	CRLD	
AP	+!		0.5MG/ML	N022462	002	Nov 19, 2010	Mar	CHRS	
AP	+		0.5MG/ML	N022462	002	Nov 19, 2010	Mar	CRLD	
AP	+!		2MG/ML	N022462	003	Nov 19, 2010	Mar	CHRS	
AP	+		2MG/ML	N022462	003	Nov 19, 2010	Mar	CRLD	
TABLET;ORAL		BACLOFEN							
>A>	AB	IMPAX	5MG	A077971	003	Jul 07, 2021	Jun	NEWA	
>A>	AB		10MG	A077971	001	Oct 26, 2007	Jun	CAHN	
>A>	AB		20MG	A077971	002	Oct 26, 2007	Jun	CAHN	
>D>	AB	IMPAX LABS	10MG	A077971	001	Oct 26, 2007	Jun	CAHN	
>D>	AB		20MG	A077971	002	Oct 26, 2007	Jun	CAHN	
	AB	INNOGENIX	5MG	A212378	003	Apr 30, 2021	Apr	NEWA	
	AB	KARTHA	5MG	A214374	001	Mar 05, 2021	Feb	NEWA	
	AB		10MG	A214374	002	Mar 05, 2021	Feb	NEWA	
	AB		20MG	A214374	003	Mar 05, 2021	Feb	NEWA	
TABLET, ORALLY DISINTEGRATING;ORAL		KEMSTRO							
	+ @	UCB INC	10MG	N021589	001	Oct 30, 2003	May	CRLD	
	+ @		20MG	N021589	002	Oct 30, 2003	May	CRLD	

BALOXAVIR MARBOXIL

TABLET;ORAL		XOFLUZA							
	+	GENENTECH INC	80MG	N210854	003	Mar 18, 2021	Mar	NEWA	

BENAZEPRIL HYDROCHLORIDE

TABLET;ORAL		LOTENSIN							
AB	+	VALIDUS PHARMS	5MG	N019851	001	Jun 25, 1991	Feb	CAHN	
AB	+		10MG	N019851	002	Jun 25, 1991	Feb	CAHN	
AB	+		20MG	N019851	003	Jun 25, 1991	Feb	CAHN	
AB	+!		40MG	N019851	004	Jun 25, 1991	Feb	CAHN	

BENAZEPRIL HYDROCHLORIDE; HYDROCHLOROTHIAZIDE

TABLET;ORAL		LOTENSIN HCT							
	+ @	VALIDUS PHARMS	5MG;6.25MG	N020033	001	May 19, 1992	Feb	CAHN	
AB	+		10MG;12.5MG	N020033	002	May 19, 1992	Feb	CAHN	
AB	+		20MG;12.5MG	N020033	004	May 19, 1992	Feb	CAHN	
AB	+!		20MG;25MG	N020033	003	May 19, 1992	Feb	CAHN	

BENOXINATE HYDROCHLORIDE; FLUORESCEIN SODIUM

SOLUTION/DROPS;OPHTHALMIC
 FLUORESCEIN SODIUM AND BENOXINATE HYDROCHLORIDE
 +! BAUSCH LOMB IRELAND 0.4%;0.3%

N211039 001 Mar 09, 2020 May CAHN

BENZOYL PEROXIDE; CLINDAMYCIN PHOSPHATE

GEL;TOPICAL
 CLINDAMYCIN PHOSPHATE AND BENZOYL PEROXIDE

AB ENCUBE 5%;1.2%
 AB ! PERRIGO ISRAEL 5%;1.2%
 DUAC
 AB + STIEFEL 5%;1.2%

A212433 001 Apr 28, 2021 Apr NEWA
 A090979 001 Jun 26, 2012 Jan CHRS
 N050741 001 Aug 26, 2002 Jan CHRS

BEPOTASTINE BESILATE

SOLUTION/DROPS;OPHTHALMIC
 BEPOTASTINE BESILATE

AT APOTEX 1.5%
 AT MYLAN 1.5%
 BEPREVE
 AT +! BAUSCH AND LOMB INC 1.5%

A206066 001 Mar 05, 2019 May CMFD
 A206220 001 Mar 18, 2019 May CMFD
 N022288 001 Sep 08, 2009 May CTEC

BETAMETHASONE DIPROPIONATE

LOTION;TOPICAL
 BETAMETHASONE DIPROPIONATE
 @ PHARMGEN EQ 0.05% BASE

A070274 001 Aug 12, 1985 May CAHN

SPRAY;TOPICAL
 SERNIVO

+! PRIMUS PHARMS EQ 0.05% BASE/SPRAY

N208079 001 Feb 05, 2016 Mar CAHN

BETAMETHASONE DIPROPIONATE; CLOTRIMAZOLE

LOTION;TOPICAL
 CLOTRIMAZOLE AND BETAMETHASONE DIPROPIONATE

AB ! TARO EQ 0.05% BASE;1%
 LOTRISONE
 + @ MERCK SHARP DOHME EQ 0.05% BASE;1%

A076493 001 Jul 28, 2004 Feb CHRS
 N020010 001 Dec 08, 2000 Feb DISC

BETHANECHOL CHLORIDE

TABLET;ORAL
 BETHANECHOL CHLORIDE

@ WOCKHARDT 5MG
 @ 50MG

A040532 001 Sep 29, 2003 Jan DISC
 A040518 001 Sep 29, 2003 Jan DISC

BEXAROTENE

CAPSULE;ORAL
 BEXAROTENE

AB TEVA PHARMS USA 75MG

A209931 001 Jan 14, 2021 Jan NEWA

BIMATOPROST

SOLUTION/DROPS;OPHTHALMIC
 BIMATOPROST

@ AKORN 0.03%
 AT ! ALEMBIC PHARMS LTD 0.03%
 AT LUPIN LTD 0.03%

A203299 001 Nov 08, 2018 Feb CAHN
 A210263 001 Apr 12, 2019 Jan CHRS
 A203991 001 Feb 20, 2015 Jan CHRS

BISOPROLOL FUMARATE

TABLET;ORAL
 BISOPROLOL FUMARATE

AB UNICHEM 5MG
 AB ! 10MG

A078635 001 Aug 18, 2009 Apr CAHN
 A078635 002 Aug 18, 2009 Apr CAHN

BIVALIRUDIN

INJECTABLE;INTRAVENOUS
 BIVALIRUDIN

AP HAINAN POLY PHARM 250MG/VIAL

A213078 001 May 28, 2021 May NEWA

BORTEZOMIBINJECTABLE;INTRAVENOUS, SUBCUTANEOUS
VELCADE

+! TAKEDA PHARMS USA 3.5MG/VIAL N021602 001 May 13, 2003 May CAHN

BOSENTANTABLET;ORAL
BOSENTANAB ALEMBIC PHARMS LTD 62.5MG A211461 001 Jan 23, 2020 May CMFD
AB 125MG A211461 002 Jan 23, 2020 May CMFD

TRACLEER

AB + ACTELION 62.5MG N021290 001 Nov 20, 2001 Feb CAHN
AB +! 125MG N021290 002 Nov 20, 2001 Feb CAHN

TABLET, FOR SUSPENSION;ORAL

TRACLEER

+! ACTELION 32MG N209279 001 Sep 05, 2017 Feb CAHN

BRIGATINIBTABLET;ORAL
ALUNBRIG+ TAKEDA PHARMS USA 30MG N208772 001 Apr 28, 2017 May CAHN
+ 90MG N208772 002 Apr 28, 2017 May CAHN
+! 180MG N208772 003 Oct 02, 2017 May CAHN>A> BRINCIDOFIVIR

>A> SUSPENSION;ORAL

>A> TEMBEXA

>A> +! CHIMERIX 10MG/ML N214460 001 Jun 04, 2021 Jun NEWA

>A> TABLET;ORAL

>A> TEMBEXA

>A> +! CHIMERIX 100MG N214461 001 Jun 04, 2021 Jun NEWA

BROMOCRIPTINE MESYLATE

CAPSULE;ORAL

PARLODEL

AB + VALIDUS PHARMS EQ 5MG BASE N017962 002 Mar 01, 1982 Feb CAHN

TABLET;ORAL

PARLODEL

AB + VALIDUS PHARMS EQ 2.5MG BASE N017962 001 Feb CAHN

BUDESONIDE

CAPSULE;ORAL

BUDESONIDE

@ BARR LABS DIV TEVA 3MG A090379 001 Apr 02, 2014 Jan DISC

CAPSULE, DELAYED RELEASE;ORAL

BUDESONIDE

@ ALVOGEN 3MG A206724 001 Nov 23, 2016 Apr CDFR
AB AMNEAL PHARMS 3MG A206200 001 Jul 31, 2017 Apr CDFR
@ BARR LABS DIV TEVA 3MG A090379 001 Apr 02, 2014 Apr CDFR
AB MAYNE PHARMA 3MG A206623 001 Apr 08, 2016 Apr CDFR
AB MYLAN 3MG A090410 001 May 16, 2011 Apr CDFR
AB RISING 3MG A207367 001 Apr 07, 2017 Apr CDFR
AB SCIECURE PHARMA INC 3MG A209041 001 Sep 28, 2017 Apr CDFR
AB ZYDUS PHARMS 3MG A206134 001 May 04, 2017 Apr CDFR

ENTOCORT EC

AB +! PERRIGO PHARMA INTL 3MG N021324 001 Oct 02, 2001 Apr CDFR

SUSPENSION;INHALATION

BUDESONIDE

AN SUN PHARM 0.25MG/2ML A211922 001 Apr 14, 2021 Apr NEWA

AN 0.5MG/2ML A211922 002 Apr 14, 2021 Apr NEWA

AN 1MG/2ML A211922 003 Apr 14, 2021 Apr NEWA

BUPIVACAINE

SOLUTION, EXTENDED RELEASE;INFILTRATION

POSIMIR

+ @ DURECT 660MG/5ML (132MG/ML) N204803 001 Feb 01, 2021 Mar DISC

+! 660MG/5ML (132MG/ML) N204803 001 Feb 01, 2021 Feb NEWA

BUPIVACAINE HYDROCHLORIDE

INJECTABLE; INJECTION

BUPIVACAINE HYDROCHLORIDE

AP	HIKMA PHARMS	0.25%	A205141	001	Feb 11, 2021	Feb	NEWA
AP		0.5%	A205141	002	Feb 11, 2021	Feb	NEWA
BUPIVACAINE HYDROCHLORIDE PRESERVATIVE FREE							
AP	HIKMA PHARMS	0.25%	A204842	001	Feb 11, 2021	Feb	NEWA
AP		0.5%	A204842	002	Feb 11, 2021	Feb	NEWA
AP		0.75%	A204842	003	Feb 11, 2021	Feb	NEWA

>A> BUPIVACAINE; MELOXICAM

>A> SOLUTION, EXTENDED RELEASE; PERIARTICULAR

>A> ZYNRELEF KIT

>A>	+	HERON THERAPS INC	60MG/2.3ML (29.25MG/ML); 1.8MG/2.3ML	N211988	001	May 12, 2021	Jun	NEWA
>A>	+		200MG/7ML (29.25MG/ML); 6MG/7ML (0.88MG/ML)	N211988	002	May 12, 2021	Jun	NEWA
>A>	+		300MG/10.5ML (29.25MG/ML); 9MG/10.5ML	N211988	003	May 12, 2021	Jun	NEWA
>A>	+		400MG/14ML (29.25MG/ML); 12MG/14ML (0.88MG/ML)	N211988	004	May 12, 2021	Jun	NEWA

BUPRENORPHINE

FILM, EXTENDED RELEASE; TRANSDERMAL

BUPRENORPHINE

AB	MYLAN TECHNOLOGIES	5MCG/HR	A210162	001	May 03, 2021	Apr	NEWA	
AB		7.5MCG/HR	A210162	002	May 03, 2021	Apr	NEWA	
AB		10MCG/HR	A210162	003	May 03, 2021	Apr	NEWA	
AB		15MCG/HR	A210162	004	May 03, 2021	Apr	NEWA	
AB		20MCG/HR	A210162	005	May 03, 2021	Apr	NEWA	
>A>	AB	WATSON LABS TEVA	7.5MCG/HR	A204937	005	Jun 29, 2021	Jun	NEWA

BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE

TABLET; SUBLINGUAL

BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE

>A>	AB	ALKEM LABS LTD	EQ 2MG BASE; EQ 0.5MG BASE	A214930	001	Jun 15, 2021	Jun	NEWA
>A>	AB		EQ 8MG BASE; EQ 2MG BASE	A214930	002	Jun 15, 2021	Jun	NEWA
		@ MAYNE PHARMA INC	EQ 2MG BASE; EQ 0.5MG BASE	A206953	001	Jul 17, 2020	Jan	DISC
	AB		EQ 8MG BASE; EQ 2MG BASE	A206953	002	Jul 17, 2020	May	CMFD
		@	EQ 8MG BASE; EQ 2MG BASE	A206953	002	Jul 17, 2020	Jan	DISC

BUPROPION HYDROBROMIDE

TABLET, EXTENDED RELEASE; ORAL

APLENZIN

+	BAUSCH	174MG	N022108	001	Apr 23, 2008	Feb	CAHN
+		348MG	N022108	002	Apr 23, 2008	Feb	CAHN
+	+	522MG	N022108	003	Apr 23, 2008	Feb	CAHN

BUPROPION HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

BUPROPION HYDROCHLORIDE

	@	TORRENT	100MG	A203969	001	Oct 31, 2014	Jan	DISC
	@		150MG	A203969	002	Oct 31, 2014	Jan	DISC
	@		200MG	A203969	003	Oct 31, 2014	Jan	DISC
WELLBUTRIN XL								
AB3	+	BAUSCH	150MG	N021515	001	Aug 28, 2003	Feb	CAHN
AB3	+	+	300MG	N021515	002	Aug 28, 2003	Feb	CAHN

BUSPIRONE HYDROCHLORIDE

TABLET; ORAL

BUSPIRONE HYDROCHLORIDE

AB	RUBICON	5MG	A075521	001	Apr 05, 2002	Feb	CMFD
AB		7.5MG	A075521	004	Mar 16, 2021	Mar	NEWA
AB		10MG	A075521	002	Apr 05, 2002	Feb	CMFD
AB		15MG	A075521	003	Apr 05, 2002	Feb	CMFD
AB		30MG	A075521	005	Mar 16, 2021	Mar	NEWA

BUSULFAN

	INJECTABLE; INJECTION						
	BUSULFAN						
AP	AM REGENT	6MG/ML	A202259	001	Dec 22, 2015	Feb	CAHN

CABERGOLINE

	TABLET; ORAL						
	DOSTINEX						

	+ @ PFIZER	0.5MG	N020664	001	Dec 23, 1996	Jan	CAHN
--	------------	-------	---------	-----	--------------	-----	------

CABOTEGRAVIR SODIUM

	TABLET; ORAL						
	VOCABRIA						

	+! VIIV HLTHCARE	EQ 30MG BASE	N212887	001	Jan 21, 2021	Jan	NEWA
--	------------------	--------------	---------	-----	--------------	-----	------

CABOTEGRAVIR; RILPIVIRINE

	SUSPENSION, EXTENDED RELEASE; INTRAMUSCULAR						
	CABENUVA KIT						

	+! VIIV HLTHCARE	400MG/2ML (200MG/ML); 600MG/2ML (300MG/ML)	N212888	001	Jan 21, 2021	Jan	NEWA
--	------------------	--	---------	-----	--------------	-----	------

	+!	600MG/3ML (200MG/ML); 900MG/3ML (300MG/ML)	N212888	002	Jan 21, 2021	Jan	NEWA
--	----	--	---------	-----	--------------	-----	------

CALCITONIN SALMON

	INJECTABLE; INJECTION						
	CALCITONIN-SALMON						

AP	CUSTOPHARM INC	200 IU/ML	A212416	001	May 14, 2021	May	NFTG
----	----------------	-----------	---------	-----	--------------	-----	------

CALCIUM ACETATE

	TABLET; ORAL						
	CALCIUM ACETATE						

AB	! CHARTWELL MOLECULAR	667MG	A202420	001	Feb 05, 2013	Apr	CHRS
>D>	! PADDOCK LLC	667MG	A091561	001	Apr 13, 2011	Jun	CHRS
>A>	AB	667MG	A091561	001	Apr 13, 2011	Jun	CHRS

CALCIUM GLUCONATE

	SOLUTION; INTRAVENOUS						
	CALCIUM GLUCONATE IN SODIUM CHLORIDE						

>A>	+! HQ SPCLT PHARMA	1GM/100ML (10MG/ML)	N210906	003	Jun 04, 2021	Jun	NEWA
-----	--------------------	---------------------	---------	-----	--------------	-----	------

CAPREOMYCIN SULFATE

>D>	INJECTABLE; INJECTION						
>D>	CAPASTAT SULFATE						

>D>	+! AKORN	EQ 1GM BASE/VIAL	N050095	001		Jun	DISC
-----	----------	------------------	---------	-----	--	-----	------

>A>	+ @	EQ 1GM BASE/VIAL	N050095	001		Jun	DISC
-----	-----	------------------	---------	-----	--	-----	------

CARBAMAZEPINE

	TABLET, EXTENDED RELEASE; ORAL						
	CARBAMAZEPINE						

AB	CSPC OUYI	100MG	A213311	001	Apr 13, 2021	Apr	NEWA
AB		200MG	A213311	002	Apr 13, 2021	Apr	NEWA
AB		400MG	A213311	003	Apr 13, 2021	Apr	NEWA

CARBIDOPA; LEVODOPA

	TABLET; ORAL						
	CARBIDOPA AND LEVODOPA						

AB	SCIEGEN PHARMS INC	10MG; 100MG	A214092	001	May 07, 2021	Apr	NEWA
AB		25MG; 100MG	A214092	002	May 07, 2021	Apr	NEWA
AB		25MG; 250MG	A214092	003	May 07, 2021	Apr	NEWA

CARBOPLATIN

	INJECTABLE; INTRAVENOUS						
	CARBOPLATIN						

AP	! HOSPIRA	50MG/5ML (10MG/ML)	A076517	001	Oct 14, 2004	Mar	CHRS
AP	!	150MG/15ML (10MG/ML)	A076517	002	Oct 14, 2004	Mar	CHRS
AP	!	450MG/45ML (10MG/ML)	A076517	003	Oct 14, 2004	Mar	CHRS
AP	!	600MG/60ML (10MG/ML)	A077059	001	Nov 23, 2004	Mar	CHRS
AP	PHARMACHEMIE BV	50MG/5ML (10MG/ML)	A077269	001	Oct 14, 2004	Mar	CHRS
AP		150MG/15ML (10MG/ML)	A077269	002	Oct 14, 2004	Mar	CHRS
AP		450MG/45ML (10MG/ML)	A077269	003	Oct 14, 2004	Mar	CHRS
AP		600MG/60ML (10MG/ML)	A077269	004	Dec 28, 2007	Mar	CHRS

CARBOPROST TROMETHAMINE

INJECTABLE; INJECTION
 CARBOPROST TROMETHAMINE
 AP SUNNY PHARMTECH INC EQ 0.25MG BASE/ML A213118 001 Mar 25, 2021 Mar NEWA

CARFILZOMIB

POWDER; INTRAVENOUS
 CARFILZOMIB
 >A> AP BRECKENRIDGE 10MG/VIAL A209330 001 Jun 11, 2021 Jun NFTG
 >A> AP 60MG/VIAL A209330 002 Jun 11, 2021 Jun NEWA

CARMUSTINE

INJECTABLE; INJECTION
 CARMUSTINE
 AP JIANGSU HENGRUI MED 100MG/VIAL A211202 001 Mar 12, 2021 Mar NEWA

CASIMERSEN

SOLUTION; INTRAVENOUS
 AMONDYS 45
 +! SAREPTA THERAPS INC 100MG/2ML (50MG/ML) N213026 001 Feb 25, 2021 Feb NEWA

CEFAZOLIN SODIUM

SOLUTION; INTRAVENOUS
 CEFAZOLIN IN PLASTIC CONTAINER
 +! BAXTER HLTHCARE CORP EQ 1GM BASE/50ML (EQ 20MG BASE/ML) N207131 002 Feb 01, 2021 Mar NEWA
 +! EQ 2GM BASE/100ML (EQ 20MG N207131 001 Aug 07, 2015 Mar CRLD
 BASE/ML)
 ! EQ 2GM BASE/100ML (EQ 20MG N207131 001 Aug 07, 2015 Mar CHRS
 BASE/ML)

CEFDINIR

CAPSULE; ORAL
 CEFDINIR
 AB ALKEM LABS LTD 300MG A210220 001 Feb 19, 2021 Feb NEWA
 FOR SUSPENSION; ORAL
 CEFDINIR
 AB ALKEM LABS LTD 125MG/5ML A210534 001 Feb 19, 2021 Feb NEWA
 AB 250MG/5ML A210534 002 Feb 19, 2021 Feb NEWA

CEFEPIME HYDROCHLORIDE

INJECTABLE; INJECTION
 CEFEPIME HYDROCHLORIDE
 @ ASTRAL EQ 1GM BASE/VIAL A212721 001 Jul 21, 2020 Mar DISC
 @ EQ 2GM BASE/VIAL A212721 002 Jul 21, 2020 Mar DISC

CEFIXIME

FOR SUSPENSION; ORAL
 CEFIXIME
 AB ALKEM LABS LTD 100MG/5ML A211775 001 Feb 19, 2021 Feb NEWA
 AB 200MG/5ML A211775 002 Feb 19, 2021 Feb NEWA

CEFOTAXIME SODIUM

INJECTABLE; INJECTION
 CLAFORAN
 + @ VALIDUS PHARMS EQ 500MG BASE/VIAL N050547 001 Feb CAHN
 + @ EQ 1GM BASE/VIAL N050547 002 Feb CAHN
 + @ EQ 2GM BASE/VIAL N050547 003 Feb CAHN
 + @ EQ 10GM BASE/VIAL N050547 004 Dec 29, 1983 Feb CAHN
 CLAFORAN IN DEXTROSE 5% IN PLASTIC CONTAINER
 @ VALIDUS PHARMS EQ 20MG BASE/ML N050596 002 May 20, 1985 Feb CAHN
 @ EQ 40MG BASE/ML N050596 004 May 20, 1985 Feb CAHN
 CLAFORAN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER
 @ VALIDUS PHARMS EQ 20MG BASE/ML N050596 001 May 20, 1985 Feb CAHN
 @ EQ 40MG BASE/ML N050596 003 May 20, 1985 Feb CAHN

CEFTAZIDIME SODIUM

INJECTABLE; INJECTION
 FORTAZ IN PLASTIC CONTAINER
 @ TELIGENT EQ 10MG BASE/ML N050634 001 Apr 28, 1989 Feb CAHN
 + @ EQ 20MG BASE/ML N050634 002 Apr 28, 1989 Feb CAHN
 + @ EQ 40MG BASE/ML N050634 003 Apr 28, 1989 Feb CAHN

CEFUROXIME SODIUMINJECTABLE; INJECTION
ZINACEF

AP	+	TELIGENT	EQ 1.5GM BASE/VIAL	N050558	003	Oct 19, 1983	Feb	CAHN
AP	+		EQ 7.5GM BASE/VIAL	N050558	004	Oct 23, 1986	Feb	CAHN

INJECTABLE; INTRAMUSCULAR, INTRAVENOUS
ZINACEF

AB	+	TELIGENT	EQ 750MG BASE/VIAL	N050558	002	Oct 19, 1983	Feb	CAHN
----	---	----------	--------------------	---------	-----	--------------	-----	------

CELECOXIBCAPSULE; ORAL
CELEBREX

AB	+	UPJOHN	50MG	N020998	004	Dec 15, 2006	Apr	CAHN
AB	+		100MG	N020998	001	Dec 31, 1998	Apr	CAHN
AB	+		200MG	N020998	002	Dec 31, 1998	Apr	CAHN
AB	+		400MG	N020998	003	Aug 29, 2002	Apr	CAHN

CELECOXIB

>D>	AB	ACIC PHARMS	200MG	A212925	001	Dec 09, 2020	Jun	DISC
>A>		@	200MG	A212925	001	Dec 09, 2020	Jun	DISC
>D>	AB		400MG	A212925	002	Dec 09, 2020	Jun	DISC
>A>		@	400MG	A212925	002	Dec 09, 2020	Jun	DISC
>D>	AB	JUBILANT GENERICS	50MG	A207061	001	Apr 04, 2017	Jun	DISC
>A>		@	50MG	A207061	001	Apr 04, 2017	Jun	DISC
>D>	AB		100MG	A207061	002	Apr 04, 2017	Jun	DISC
>A>		@	100MG	A207061	002	Apr 04, 2017	Jun	DISC
>D>	AB		200MG	A207061	003	Apr 04, 2017	Jun	DISC
>A>		@	200MG	A207061	003	Apr 04, 2017	Jun	DISC
>D>	AB		400MG	A207061	004	Apr 04, 2017	Jun	DISC
>A>		@	400MG	A207061	004	Apr 04, 2017	Jun	DISC
	AB	UNICHEM	50MG	A213301	001	Jan 12, 2021	Jan	NEWA
	AB		100MG	A213301	002	Jan 12, 2021	Jan	NEWA
	AB		200MG	A213301	003	Jan 12, 2021	Jan	NEWA
	AB		400MG	A213301	004	Jan 12, 2021	Jan	NEWA
>D>		@ YILING	50MG	A211412	001	Mar 06, 2020	Jun	CMFD
>A>	AB		50MG	A211412	001	Mar 06, 2020	Jun	CMFD
>D>		@	100MG	A211412	002	Mar 06, 2020	Jun	CMFD
>A>	AB		100MG	A211412	002	Mar 06, 2020	Jun	CMFD
>D>		@	200MG	A211412	003	Mar 06, 2020	Jun	CMFD
>A>	AB		200MG	A211412	003	Mar 06, 2020	Jun	CMFD
>D>		@	400MG	A211412	004	Mar 06, 2020	Jun	CMFD
>A>	AB		400MG	A211412	004	Mar 06, 2020	Jun	CMFD

CEPHALEXINCAPSULE; ORAL
KEFLEX

+	@	PRAGMA	EQ 250MG BASE	N050405	002		May	DISC
+	@		EQ 500MG BASE	N050405	003		May	DISC

CHLORDIAZEPOXIDE HYDROCHLORIDE

CAPSULE; ORAL

CHLORDIAZEPOXIDE HYDROCHLORIDE

@	CHARTWELL RX	5MG	A084678	001		Apr	CAHN
@		10MG	A084041	001		Apr	CAHN
@		25MG	A084679	002		Apr	CAHN

CHLORDIAZEPOXIDE HYDROCHLORIDE; CLIDINIUM BROMIDE

CAPSULE; ORAL

CHLORDIAZEPOXIDE HYDROCHLORIDE AND CLIDINIUM BROMIDE

AB		ALKEM LABS LTD	5MG; 2.5MG	A214065	001	Apr 26, 2021	Apr	NEWA
AB		DR REDDYS	5MG; 2.5MG	A214698	001	May 10, 2021	Apr	NEWA

CHLORHEXIDINE GLUCONATE

SOLUTION; DENTAL

CHLORHEXIDINE GLUCONATE

AT		BAJAJ	0.12%	A075561	001	Nov 14, 2000	Feb	CMFD
----	--	-------	-------	---------	-----	--------------	-----	------

CHLORPROMAZINE HYDROCHLORIDE

CONCENTRATE; ORAL

CHLORPROMAZINE HYDROCHLORIDE

GENUS	30MG/ML	A214542	001	Jun 02, 2021	May NEWA
	100MG/ML	A214542	002	Jun 02, 2021	May NEWA

TABLET; ORAL

CHLORPROMAZINE HYDROCHLORIDE

AB	GLENMARK PHARMS LTD	10MG	A212144	001	Mar 23, 2021	Mar NEWA
AB		25MG	A212144	002	Mar 23, 2021	Mar NEWA
AB		50MG	A212144	003	Mar 23, 2021	Mar NEWA
AB		100MG	A212144	004	Mar 23, 2021	Mar NEWA
AB		200MG	A212144	005	Mar 23, 2021	Mar NEWA
AB	LANNETT CO INC	10MG	A212996	001	Jan 22, 2021	Jan NEWA
AB		25MG	A212996	002	Jan 22, 2021	Jan NEWA
AB		50MG	A212996	003	Jan 22, 2021	Jan NEWA
AB		100MG	A212996	004	Jan 22, 2021	Jan NEWA
AB		200MG	A212996	005	Jan 22, 2021	Jan NEWA
	@ MAYNE PHARMA	10MG	A213590	001	Aug 31, 2020	Mar DISC
	@	25MG	A213590	002	Aug 31, 2020	Mar DISC
	@	50MG	A213590	003	Aug 31, 2020	Mar DISC
	@	100MG	A213590	004	Aug 31, 2020	Mar DISC
	@	200MG	A213590	005	Aug 31, 2020	Mar DISC

CHLORPROPAMIDE

TABLET; ORAL

CHLORPROPAMIDE

@ RISING	100MG	A088725	001	Aug 31, 1984	Jan CAHN
@	250MG	A088726	001	Aug 31, 1984	Jan CAHN

CHLORTHALIDONE

TABLET; ORAL

THALITONE

+ CASPER PHARMA LLC	15MG	N019574	001	Dec 20, 1988	May CMFD
BX +!	25MG	N019574	002	Feb 12, 1992	May CMFD

CHLORZOXAZONE

TABLET; ORAL

CHLORZOXAZONE

AB	PAR PHARM INC	375MG	A212743	002	Apr 29, 2021	Apr NEWA
----	---------------	-------	---------	-----	--------------	----------

CHOLESTYRAMINE

POWDER; ORAL

CHOLESTYRAMINE

AB	TAGI	EQ 4GM RESIN/PACKET	A209597	001	Mar 09, 2021	Feb NEWA
AB		EQ 4GM RESIN/SCOOPFUL	A209597	002	Mar 09, 2021	Feb NEWA
	LOCHOLEST LIGHT					
	@ CHARTWELL RX	EQ 4GM RESIN/PACKET	A074562	001	Aug 15, 1996	Apr CAHN
	@	EQ 4GM RESIN/SCOOPFUL	A074562	002	Aug 15, 1996	Apr CAHN

CHOLINE FENOFIBRATE

CAPSULE, DELAYED RELEASE; ORAL

FENOFIBRIC ACID

>D> AB	YICHANG HUMANWELL	EQ 45MG FENOFIBRIC ACID	A212562	001	Dec 23, 2020	Jun DISC
>A>	@	EQ 45MG FENOFIBRIC ACID	A212562	001	Dec 23, 2020	Jun DISC
>D> AB		EQ 135MG FENOFIBRIC ACID	A212562	002	Dec 23, 2020	Jun DISC
>A>	@	EQ 135MG FENOFIBRIC ACID	A212562	002	Dec 23, 2020	Jun DISC

CICLESONIDE

SPRAY, METERED; NASAL

OMNARIS

+! COVIS	0.05MG/SPRAY	N022004	001	Oct 20, 2006	May CPOT
----------	--------------	---------	-----	--------------	----------

CICLOPIROX

GEL; TOPICAL

CICLOPIROX

>A> AB	+! ALVOGEN	0.77%	N020519	001	Jul 21, 1997	Jun CAHN
>D> AB	+! CNTY LINE PHARMS	0.77%	N020519	001	Jul 21, 1997	Jun CAHN

SOLUTION; TOPICAL

CICLOPIROX

	@ AKORN	8%	A078975	001	Feb 17, 2010	Apr DISC
AT	RISING	8%	A078124	001	Sep 18, 2007	May CAHN

CILOSTAZOL

	TABLET;ORAL							
	CILOSTAZOL							
	@ EPIC PHARMA LLC	50MG		A 077022	002	Mar 11, 2005	Jan	CMS1
	@ NOSTRUM LABS INC	50MG		A 077708	001	Sep 28, 2009	Mar	DISC
AB		50MG		A 077708	001	Sep 28, 2009	Jan	CAHN
	@	100MG		A 077708	002	Sep 28, 2009	Mar	DISC
AB		100MG		A 077708	002	Sep 28, 2009	Jan	CAHN

CIMETIDINE

	TABLET;ORAL							
	CIMETIDINE							
	@ NOVITIUM PHARMA	300MG		A 074340	001	Jun 23, 1995	Feb	CAHN
	@	400MG		A 074340	002	Jun 23, 1995	Feb	CAHN
	@	800MG		A 074339	001	Jun 23, 1995	Feb	CAHN

CIPROFLOXACIN

	INJECTABLE, SUSPENSION;OTIC							
	OTIPRIO							
>A>	+! ALK ABELLO	6% (60MG/ML)		N 207986	001	Dec 10, 2015	Jun	CAHN
>D>	+! OTONOMY INC	6% (60MG/ML)		N 207986	001	Dec 10, 2015	Jun	CAHN

CISATRACURIUM BESYLATE

	INJECTABLE;INJECTION							
	CISATRACURIUM BESYLATE							
	@ ZYDUS PHARMS	EQ 2MG BASE/ML		A 213527	001	Aug 31, 2020	Feb	DISC

CLARITHROMYCIN

	TABLET;ORAL							
	CLARITHROMYCIN							
	@ WOCKHARDT	250MG		A 065266	001	May 31, 2006	Jan	DISC
	@	500MG		A 065266	002	May 31, 2006	Jan	DISC

CLASCOTERONE

	CREAM;TOPICAL							
	WINLEVI							
	+ @ CASSIOPEA SPA	1%		N 213433	001	Aug 26, 2020	Mar	DISC

CLINDAMYCIN HYDROCHLORIDE

	CAPSULE;ORAL							
	CLEOCIN HYDROCHLORIDE							
AB	+ PFIZER	EQ 75MG BASE		N 050162	001		Feb	CAHN
AB	+	EQ 150MG BASE		N 050162	002		Feb	CAHN
AB	+!	EQ 300MG BASE		N 050162	003	Apr 14, 1988	Feb	CAHN

CLINDAMYCIN PALMITATE HYDROCHLORIDE

	FOR SOLUTION;ORAL							
	CLEOCIN							
AA	! PFIZER	EQ 75MG BASE/5ML		A 062644	001	Apr 07, 1986	Feb	CAHN

CLINDAMYCIN PHOSPHATE

	CREAM;VAGINAL							
	CLEOCIN							
	@ PFIZER	EQ 2% BASE		N 050680	001	Aug 11, 1992	Feb	CAHN
AB	+!	EQ 2% BASE		N 050680	002	Mar 02, 1998	Feb	CAHN
	GEL;TOPICAL							
	CLEOCIN T							
AB	+! PFIZER	EQ 1% BASE		N 050615	001	Jan 07, 1987	Feb	CAHN
	CLINDAMYCIN PHOSPHATE							
AB	ENCUBE	EQ 1% BASE		A 212438	001	Mar 11, 2021	Mar	NEWA
AB	GLENMARK PHARMS LTD	EQ 1% BASE		A 214251	001	Feb 10, 2021	Jan	NEWA
AB	PERRIGO UK FINCO	EQ 1% BASE		A 212104	001	Dec 31, 2020	Jan	CAHN
	INJECTABLE;INJECTION							
	CLEOCIN PHOSPHATE							
AP	PFIZER	EQ 150MG BASE/ML		A 062803	001	Oct 16, 1987	Feb	CAHN
AP	+!	EQ 150MG BASE/ML		N 050441	001		Feb	CAHN
	CLEOCIN PHOSPHATE IN DEXTROSE 5% IN PLASTIC CONTAINER							
	+ @ PFIZER	EQ 6MG BASE/ML		N 050639	001	Aug 30, 1989	Feb	CAHN
	+ @	EQ 12MG BASE/ML		N 050639	002	Aug 30, 1989	Feb	CAHN
	+ @	EQ 18MG BASE/ML		N 050639	003	Apr 10, 1991	Feb	CAHN

		INJECTABLE; INJECTION							
		CLINDAMYCIN PHOSPHATE							
		@ MYLAN LABS LTD	EQ 150MG BASE/ML	A204748	001	Oct 10, 2017	Jan	DISC	
		LOTION; TOPICAL							
		CLEOCIN T							
AB	+	PFIZER	EQ 1% BASE	N050600	001	May 31, 1989	Feb	CAHN	
		CLINDAMYCIN PHOSPHATE							
AB		GAGE DEVELOPMENT	EQ 1% BASE	A214604	001	Mar 08, 2021	Feb	NEWA	
AB		PERRIGO UK FINCO	EQ 1% BASE	A214604	001	Mar 08, 2021	Mar	CAHN	
>A>	AB	TARO PHARMS	EQ 1% BASE	A214526	001	Jun 28, 2021	Jun	NEWA	
		SOLUTION; TOPICAL							
		CLEOCIN T							
		+ @ PFIZER	EQ 1% BASE	N050537	001		Feb	CAHN	
		+ @ PHARMACIA AND UPJOHN	EQ 1% BASE	N050537	001		Jan	DISC	
		CLINDAMYCIN PHOSPHATE							
AT	!	PERRIGO NEW YORK	EQ 1% BASE	A064050	001	Nov 30, 1995	Jan	CHRS	
		SUPPOSITORY; VAGINAL							
		CLEOCIN							
		+! PFIZER	100MG	N050767	001	Aug 13, 1999	Feb	CAHN	
		SWAB; TOPICAL							
		CLEOCIN							
		+ @ PFIZER	EQ 1% BASE	N050537	002	Feb 22, 1994	Mar	DISC	
AT	+	!	EQ 1% BASE	N050537	002	Feb 22, 1994	Feb	CAHN	
		CLINDAMYCIN PHOSPHATE							
AT	!	PERRIGO NEW YORK	EQ 1% BASE	A065049	001	May 25, 2000	Mar	CHRS	
		<u>CLINDAMYCIN PHOSPHATE; TRETINOIN</u>							
		GEL; TOPICAL							
		ZIANA							
AB	+	BAUSCH	1.2%; 0.025%	N050802	001	Nov 07, 2006	May	CAHN	
		<u>CLOBAZAM</u>							
		SUSPENSION; ORAL							
		CLOBAZAM							
AB		ALKEM LABS LTD	2.5MG/ML	A213039	001	May 06, 2021	Apr	NEWA	
		TABLET; ORAL							
		CLOBAZAM							
>D>	AB	CELLTRION	10MG	A211959	001	Dec 09, 2020	Jun	DISC	
>A>		@	10MG	A211959	001	Dec 09, 2020	Jun	DISC	
>D>	AB		20MG	A211959	002	Dec 09, 2020	Jun	DISC	
>A>		@	20MG	A211959	002	Dec 09, 2020	Jun	DISC	
		@ LANNETT CO INC	10MG	A212092	001	Oct 30, 2019	Mar	DISC	
		@	20MG	A212092	002	Oct 30, 2019	Mar	DISC	
AB		MSN	10MG	A213404	001	May 11, 2021	Apr	NEWA	
AB			20MG	A213404	002	May 11, 2021	Apr	NEWA	
		<u>CLOBETASOL PROPIONATE</u>							
		CREAM; TOPICAL							
		CLOBETASOL PROPIONATE							
AB1		GLASSHOUSE PHARMS	0.05%	A211207	001	Mar 26, 2021	Mar	NEWA	
		IMPOYZ							
		+! PRIMUS PHARMS	0.025%	N209483	001	Nov 28, 2017	Mar	CAHN	
		OINTMENT; TOPICAL							
		CLOBETASOL PROPIONATE							
		@ TORRENT	0.05%	A212926	001	Oct 25, 2019	Jan	DISC	
		SHAMPOO; TOPICAL							
		CLOBETASOL PROPIONATE							
>A>	AB	AMNEAL	0.05%	A214895	001	Jun 14, 2021	Jun	NEWA	
AB		TARO PHARMS	0.05%	A214867	001	Mar 25, 2021	Mar	NEWA	
		SOLUTION; TOPICAL							
		CLOBETASOL PROPIONATE							
AT		PRINSTON INC	0.05%	A213139	001	Feb 08, 2021	Jan	NEWA	
		SPRAY; TOPICAL							
		CLOBETASOL PROPIONATE							
		@ AKORN	0.05%	A207218	001	Apr 28, 2017	Apr	DISC	

CLOFARABINE

SOLUTION; INTRAVENOUS

CLOFARABINE

AP	MEITHEAL	20MG/20ML (1MG/ML)	A213461	001	Oct 23, 2020	Jan	CAHN
	@ NOVAST LABS	20MG/20ML (1MG/ML)	A210270	001	Sep 14, 2018	Mar	DISC

CLOMIPRAMINE HYDROCHLORIDE

CAPSULE; ORAL

CLOMIPRAMINE HYDROCHLORIDE

AB	VGYAAN	25MG	A213221	001	Jun 22, 2020	May	CMFD
AB		50MG	A213221	002	Jun 22, 2020	May	CMFD
AB		75MG	A213221	003	Jun 22, 2020	May	CMFD

CLONAZEPAM

TABLET; ORAL

CLONAZEPAM

@ WATSON LABS

0.5MG

A074964 001 Dec 30, 1997 Apr DISC

@

1MG

A074964 002 Dec 30, 1997 Apr DISC

@

2MG

A074964 003 Dec 30, 1997 Apr DISC

CLONIDINE

SYSTEM; TRANSDERMAL

CATAPRES-TTS-1

AB	+ LAVIPHARM	0.1MG/24HR	N018891	001	Oct 10, 1984	Jan	CAHN
AB	+ TECHNOMED	0.1MG/24HR	N018891	001	Oct 10, 1984	Jan	CAHN

CATAPRES-TTS-2

AB	+ LAVIPHARM	0.2MG/24HR	N018891	002	Oct 10, 1984	Jan	CAHN
AB	+ TECHNOMED	0.2MG/24HR	N018891	002	Oct 10, 1984	Jan	CAHN

CATAPRES-TTS-3

AB	+! LAVIPHARM	0.3MG/24HR	N018891	003	Oct 10, 1984	Jan	CAHN
AB	+! TECHNOMED	0.3MG/24HR	N018891	003	Oct 10, 1984	Jan	CAHN

CLONIDINE HYDROCHLORIDE

INJECTABLE; INJECTION

CLONIDINE HYDROCHLORIDE

AP	! HIKMA FARMACEUTICA	5MG/10ML (0.5MG/ML)	A200300	002	Jan 26, 2011	Mar	CHRS
	DURACLON						
	+ @ MYLAN INSTITUTIONAL	5MG/10ML (0.5MG/ML)	N020615	002	Apr 27, 1999	Mar	DISC

CLOPIDOGREL BISULFATE

TABLET; ORAL

CLOPIDOGREL BISULFATE

AB	POLYGEN PHARMS	EQ 75MG BASE	A213351	001	Jul 17, 2020	Feb	CMFD
AB		EQ 300MG BASE	A213351	002	Jul 17, 2020	Feb	CMFD

CLORAZEPATE DIPOTASSIUM

CAPSULE; ORAL

TRANXENE

	+ @ RECORDATI RARE	3.75MG	N017105	001		May	CRLD
	+ @	7.5MG	N017105	002		May	CRLD
	+ @	15MG	N017105	003		May	CRLD

TABLET; ORAL

CLORAZEPATE DIPOTASSIUM

AB	AUROLIFE PHARMA LLC	3.75MG	A071858	002	Jul 17, 1987	Jan	CAHN
AB		7.5MG	A071858	003	Jul 17, 1987	Jan	CAHN
AB	!	15MG	A071858	001	Jul 17, 1987	Jan	CAHN
	TRANXENE						
	+ @ RECORDATI RARE	3.75MG	N017105	006		May	CRLD
	TRANXENE SD						
	+ @ RECORDATI RARE	11.25MG	N017105	005		May	CRLD
	+ @	22.5MG	N017105	004		May	CRLD

CODEINE PHOSPHATE; PHENYLEPHRINE HYDROCHLORIDE; PROMETHAZINE HYDROCHLORIDE

SYRUP; ORAL

PROMETHAZINE HYDROCHLORIDE, PHENYLEPHRINE HYDROCHLORIDE W/CODEINE PHOSPHATE

AA	AKORN	10MG/5ML; 5MG/5ML; 6.25MG/5ML	A040674	001	Dec 23, 2014	Feb	CAHN
----	-------	-------------------------------	---------	-----	--------------	-----	------

COLESEVELAM HYDROCHLORIDE

FOR SUSPENSION; ORAL

COLESEVELAM HYDROCHLORIDE

GLENMARK PHARMS LTD 1.875GM/PACKET
 @ WATSON LABS INC 1.875GM/PACKET
 @ 3.75GM/PACKET

A202190 001 Jul 16, 2018 Feb CTEC
 A202178 001 Sep 01, 2020 Feb DISC
 A202178 002 Sep 01, 2020 Feb DISC

TABLET; ORAL

COLESEVELAM HYDROCHLORIDE

@ WATSON LABS INC 625MG

A200830 001 Sep 02, 2020 Feb DISC

COLESTIPOL HYDROCHLORIDE

GRANULE; ORAL

COLESTID

AB + PFIZER 5GM/SCOOPFUL
 AB +! 5GM/PACKET

N017563 003 Sep 22, 1995 Feb CAHN
 N017563 004 Sep 22, 1995 Feb CAHN

FLAVORED COLESTID

+ PFIZER 5GM/PACKET
 + 5GM/SCOOPFUL

N017563 001 Feb CAHN
 N017563 002 Feb CAHN

TABLET; ORAL

COLESTID

AB +! PFIZER 1GM

N020222 001 Jul 19, 1994 Feb CAHN

CROTAMITON

CREAM; TOPICAL

EURAX

+ @ JOURNEY 10%

N006927 001 Jan CAHN

LOTION; TOPICAL

EURAX

AT +! JOURNEY 10%

N009112 003 Jan CAHN

CUPRIC SULFATE; MANGANESE SULFATE; SELENIOS ACID; ZINC SULFATE

SOLUTION; INTRAVENOUS

TRALEMENT

+! AM REGENT (1ML) EQ 0.3MG COPPER/ML; EQ 55MCG
 BASE/ML; EQ 60MCG BASE/ML; EQ 3MG
 BASE/ML

N209376 001 Jul 02, 2020 Jan CPOT

+! (5ML) EQ 0.3MG COPPER/ML; EQ 55MCG
 BASE/ML; EQ 60MCG BASE/ML; EQ 3MG
 BASE/ML

N209376 002 Dec 02, 2020 Jan NEWA

CYCLOBENZAPRINE HYDROCHLORIDE

TABLET; ORAL

CYCLOBENZAPRINE HYDROCHLORIDE

@ PLIVA 10MG

A074421 001 Sep 29, 1995 Apr DISC

CYCLOSPORINE

EMULSION; OPHTHALMIC

VERKAZIA

>A> +! SANTEN 0.1%

N214965 001 Jun 23, 2021 Jun NEWA

CYPROHEPTADINE HYDROCHLORIDE

TABLET; ORAL

CYPROHEPTADINE HYDROCHLORIDE

AA QUAGEN 4MG

A212491 001 Feb 24, 2021 Feb NEWA

CYSTEAMINE BITARTRATE

CAPSULE, DELAYED RELEASE; ORAL

PROCYSBI

+ HORIZON EQ 25MG BASE
 +! EQ 75MG BASE

N203389 001 Apr 30, 2013 May CAHN
 N203389 002 Apr 30, 2013 May CAHN

CYTARABINE

INJECTABLE; INJECTION

CYTARABINE

@ MYLAN LABS LTD 20MG/ML

A200914 001 Dec 13, 2011 May DISC

DABIGATRAN ETEXILATE MESYLATE

>A>	PELLET; ORAL							
>A>	PRADAXA							
>A>	+	BOEHRINGER INGELHEIM	EQ 20MG BASE/PACKET	N214358	001	Jun 21, 2021	Jun	NEWA
>A>	+		EQ 30MG BASE/PACKET	N214358	002	Jun 21, 2021	Jun	NEWA
>A>	+		EQ 40MG BASE/PACKET	N214358	003	Jun 21, 2021	Jun	NEWA
>A>	+		EQ 50MG BASE/PACKET	N214358	004	Jun 21, 2021	Jun	NEWA
>A>	+		EQ 110MG BASE/PACKET	N214358	005	Jun 21, 2021	Jun	NEWA
>A>	+		EQ 150MG BASE/PACKET	N214358	006	Jun 21, 2021	Jun	NEWA

DACTINOMYCIN

	INJECTABLE; INJECTION							
	DACTINOMYCIN							
AP	AUROMEDICS PHARMA	0.5MG/VIAL		A203385	001	Nov 09, 2017	Jan	CAHN
AP	MEITHEAL	0.5MG/VIAL		A213463	001	Nov 13, 2020	Feb	CAHN

DAPSONE

	TABLET; ORAL							
	DAPSONE							
>D>	AB	ALVOGEN	25MG	A205429	001	Jan 07, 2016	Jun	CAHN
>A>	AB		25MG	A205429	001	Jan 07, 2016	Jun	CAHN
>D>	AB		100MG	A205429	002	Jan 07, 2016	Jun	CAHN
>A>	AB		100MG	A205429	002	Jan 07, 2016	Jun	CAHN

DAPTOMYCIN

	POWDER; INTRAVENOUS							
	DAPTOMYCIN							
AP	HISUN PHARM HANGZHOU	500MG/VIAL		A212250	001	Apr 21, 2021	Apr	NEWA
>A>	AP	HONG KONG	500MG/VIAL	A213623	001	Jun 29, 2021	Jun	NEWA
>A>	+	HOSPIRA INC	350MG/VIAL	N210282	001	Jun 21, 2021	Jun	NEWA
>A>	+		500MG/VIAL	N210282	002	Jun 21, 2021	Jun	NEWA
	POWDER; IV (INFUSION)							
	DAPTOMYCIN							
>A>	AP	@ DR REDDYS	350MG/VIAL	A211403	001	Aug 31, 2020	May	DISC
		HONG KONG	350MG/VIAL	A213786	001	Jun 29, 2021	Jun	NEWA

DARIFENACIN HYDROBROMIDE

	TABLET, EXTENDED RELEASE; ORAL							
	DARIFENACIN HYDROBROMIDE							
>D>	AB	JUBILANT GENERICS	EQ 7.5MG BASE	A205550	001	Oct 12, 2016	Jun	DISC
>A>	@		EQ 7.5MG BASE	A205550	001	Oct 12, 2016	Jun	DISC
>D>	AB		EQ 15MG BASE	A205550	002	Oct 12, 2016	Jun	DISC
>A>	@		EQ 15MG BASE	A205550	002	Oct 12, 2016	Jun	DISC

DASIGLUCAGON HYDROCHLORIDE

	SOLUTION; SUBCUTANEOUS							
	ZEGALOGUE							
+	!	ZEALAND PHARMA	EQ 0.6MG BASE/0.6ML (EQ 0.6MG BASE/0.6ML)	N214231	001	Mar 22, 2021	May	CAHN
+	!		EQ 0.6MG BASE/0.6ML (EQ 0.6MG BASE/0.6ML)	N214231	001	Mar 22, 2021	Mar	NEWA
	ZEGALOGUE (AUTOINJECTOR)							
+	!	ZEALAND PHARMA	EQ 0.6MG BASE/0.6ML (EQ 0.6MG BASE/0.6ML)	N214231	002	Mar 22, 2021	May	CAHN
+	!		EQ 0.6MG BASE/0.6ML (EQ 0.6MG BASE/0.6ML)	N214231	002	Mar 22, 2021	Mar	NEWA

DECITABINE

	INJECTABLE; INTRAVENOUS							
	DECITABINE							
>A>	AP	@ CIPLA	50MG/VIAL	A208601	001	Nov 16, 2017	May	DISC
	AP	HONG KONG	50MG/VIAL	A212959	001	Jul 02, 2021	Jun	NEWA
	AP	QILU	50MG/VIAL	A212826	001	Apr 12, 2021	Apr	NEWA

DEFERASIROX

	GRANULE; ORAL							
	DEFERASIROX							
AB	AMNEAL	180MG		A214194	001	Feb 09, 2021	Jan	NEWA
AB		360MG		A214194	002	Feb 09, 2021	Jan	NEWA
AB	AUCTA	90MG		A214559	001	Mar 09, 2021	Feb	NEWA
AB		180MG		A214559	002	Mar 09, 2021	Feb	NEWA
AB		360MG		A214559	003	Mar 09, 2021	Feb	NEWA

GRANULE;ORAL								
DEFERASIROX								
AB	MSN	180MG	A214650	001	Mar 17, 2021	Mar	NEWA	
AB		360MG	A214650	002	Mar 17, 2021	Mar	NEWA	
TABLET;ORAL								
DEFERASIROX								
AB	ANNORA PHARMA	90MG	A214341	001	May 14, 2021	May	NEWA	
AB		180MG	A214341	002	May 14, 2021	May	NEWA	
AB		360MG	A214341	003	May 14, 2021	May	NEWA	
AB	CELLTRION	90MG	A212669	001	May 27, 2021	May	NEWA	
AB		180MG	A212669	002	May 27, 2021	May	NEWA	
AB		360MG	A212669	003	May 27, 2021	May	NEWA	
<u>DEFERIPRONE</u>								
TABLET;ORAL								
DEFERIPRONE								
AB	HIKMA	500MG	A213239	001	Mar 29, 2021	Mar	NEWA	
AB	+! CHIESI	500MG	N021825	001	Oct 14, 2011	Mar	CTEC	
<u>DEOXYCHOLIC ACID</u>								
SOLUTION;SUBCUTANEOUS								
DEOXYCHOLIC ACID								
AP	SLAYBACK PHARMA LLC	20MG/2ML (10MG/ML)	A212296	001	Apr 02, 2021	Mar	NFTG	
<u>DESIPRAMINE HYDROCHLORIDE</u>								
TABLET;ORAL								
DESIPRAMINE HYDROCHLORIDE								
>A>	AB	ALEMBIC PHARMS LTD	10MG	A209785	001	Jul 07, 2021	Jun	NEWA
>A>	AB		25MG	A209785	002	Jul 07, 2021	Jun	NEWA
>A>	AB		50MG	A209785	003	Jul 07, 2021	Jun	NEWA
>A>	AB		75MG	A209785	004	Jul 07, 2021	Jun	NEWA
>A>	AB		100MG	A209785	005	Jul 07, 2021	Jun	NEWA
>A>	AB		150MG	A209785	006	Jul 07, 2021	Jun	NEWA
NORPRAMIN								
AB	+ VALIDUS PHARMS	10MG	N014399	007	Feb 11, 1982	Feb	CAHN	
AB	+	25MG	N014399	001		Feb	CAHN	
AB	+	50MG	N014399	003		Feb	CAHN	
AB	+	75MG	N014399	004		Feb	CAHN	
AB	+!	100MG	N014399	005		Feb	CAHN	
AB	+	150MG	N014399	006		Feb	CAHN	
<u>DESLORATADINE; PSEUDOEPHEDRINE SULFATE</u>								
TABLET, EXTENDED RELEASE;ORAL								
CLARINEX-D 12 HOUR								
>D>	+! MERCK SHARP DOHME	2.5MG;120MG	N021313	001	Feb 01, 2006	Jun	CAHN	
>A>	+! ORGANON	2.5MG;120MG	N021313	001	Feb 01, 2006	Jun	CAHN	
<u>DESMOPRESSIN ACETATE</u>								
SPRAY, METERED;NASAL								
NOCTIVA								
+	@ ROIVANT	0.00083MG/SPRAY	N201656	001	Mar 03, 2017	Feb	CAHN	
+	@	0.00166MG/SPRAY	N201656	002	Mar 03, 2017	Feb	CAHN	
<u>DESOGESTREL; ETHINYL ESTRADIOL</u>								
TABLET;ORAL-21								
ORTHO-CEPT								
+	@ JANSSEN PHARMS	0.15MG;0.03MG	N020301	001	Dec 14, 1992	May	CRLD	
TABLET;ORAL-28								
ORTHO-CEPT								
+	@ JANSSEN PHARMS	0.15MG;0.03MG	N020301	002	Dec 14, 1992	May	CRLD	
<u>DESONIDE</u>								
GEL;TOPICAL								
DESONATE								
+	@ LEO PHARMA AS	0.05%	N021844	001	Oct 20, 2006	Mar	DISC	
DESONIDE								
!	CINTEX SVCS	0.05%	A202470	001	May 11, 2020	Mar	CHRS	
		0.05%	A202470	001	May 11, 2020	Mar	CTEC	

DESOXIMETASONE

CREAM; TOPICAL

DESOXIMETASONE

@ AKORN	0.05%
@	0.25%

A203787	001	Jan 06, 2017	Apr	DISC
A203234	001	Jun 12, 2015	Apr	DISC

OINTMENT; TOPICAL

DESOXIMETASONE

AB	!	GLENMARK GENERICS	0.25%
		TOPICORT	
	@	TARO PHARM INDS LTD	0.25%

A202838	001	Sep 20, 2013	Apr	CHRS
A074286	001	Jun 07, 1996	Apr	DISC

DEXAMETHASONE

TABLET; ORAL

DEXAMETHASONE

>A>	BP	ALVOGEN	0.5MG
>A>	BP		0.75MG
>A>	BP		4MG
>A>	BP		6MG
>D>	BP	FERA PHARMS LLC	0.5MG
>D>	BP		0.75MG
>D>	BP		4MG
>D>	BP		6MG
BP	!	HIKMA	1MG
BP	!		2MG

A088481	002	Apr 28, 1983	Jun	CAHN
A088481	003	Apr 28, 1983	Jun	CAHN
A088481	004	Apr 28, 1983	Jun	CAHN
A088481	001	Nov 28, 1983	Jun	CAHN
A088481	002	Apr 28, 1983	Jun	CAHN
A088481	003	Apr 28, 1983	Jun	CAHN
A088481	004	Apr 28, 1983	Jun	CAHN
A088481	001	Nov 28, 1983	Jun	CAHN
A088306	001	Sep 15, 1983	Apr	CHRS
A087916	001	Aug 26, 1982	Apr	CHRS

DEXMEDETOMIDINE HYDROCHLORIDE

INJECTABLE; INJECTION

DEXMEDETOMIDINE HYDROCHLORIDE

AP		GLAND	EQ 200MCG BASE/2ML (EQ 100MCG BASE/ML)
>D>		@ HONG KONG	EQ 200MCG BASE/2ML (EQ 100MCG BASE/ML)
>A>	AP		EQ 200MCG BASE/2ML (EQ 100MCG BASE/ML)

A202126	001	Aug 20, 2015	May	CAHN
A204843	001	Jan 18, 2019	Jun	CMFD
A204843	001	Jan 18, 2019	Jun	CMFD

DEXMETHYLPHENIDATE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

DEXMETHYLPHENIDATE HYDROCHLORIDE

AB		MYLAN	25MG
AB			35MG

A204266	005	May 04, 2021	Apr	NEWA
A204266	006	May 04, 2021	Apr	NEWA

DEXMETHYLPHENIDATE HYDROCHLORIDE; SERDEXMETHYLPHENIDATE CHLORIDE

CAPSULE; ORAL

AZSTARYS

+	COMMAVE THERAP	EQ 5.2MG BASE;EQ 26.1MG BASE
+		EQ 7.8MG BASE;EQ 39.2MG BASE
+	!	EQ 10.4MG BASE;EQ 52.3MG BASE

N212994	001	May 07, 2021	May	NEWA
N212994	002	May 07, 2021	May	NEWA
N212994	003	May 07, 2021	May	NEWA

DEXRAZOXANE HYDROCHLORIDE

INJECTABLE; INJECTION

DEXRAZOXANE HYDROCHLORIDE

AP		AUROMEDICS PHARMA	EQ 250MG BASE/VIAL
AP			EQ 500MG BASE/VIAL
		ZINECARD	
AP	+	PFIZER	EQ 250MG BASE/VIAL
AP	+		EQ 500MG BASE/VIAL

A200752	001	Oct 19, 2011	Jan	CAHN
A200752	002	Oct 19, 2011	Jan	CAHN
N020212	001	May 26, 1995	Mar	CAHN
N020212	002	May 26, 1995	Mar	CAHN

DEXTROAMPHETAMINE SULFATE

TABLET; ORAL

DEXTROAMPHETAMINE SULFATE

AA		ARBOR PHARMS LLC	2.5MG
AA			7.5MG
AA			15MG
AA			20MG
AA			30MG
AA		WINDER LABS LLC	2.5MG
AA			5MG
AA			7.5MG
AA			10MG
AA			15MG
AA			20MG
AA			30MG

A090533	001	Oct 25, 2011	May	CTEC
A090533	003	Oct 25, 2011	May	CTEC
A090533	005	Oct 25, 2011	May	CTEC
A090533	006	Oct 25, 2011	May	CTEC
A090533	007	Oct 25, 2011	May	CTEC
A212160	001	Jun 07, 2021	May	NEWA
A212160	002	Jun 07, 2021	May	NEWA
A212160	003	Jun 07, 2021	May	NEWA
A212160	004	Jun 07, 2021	May	NEWA
A212160	005	Jun 07, 2021	May	NEWA
A212160	006	Jun 07, 2021	May	NEWA
A212160	007	Jun 07, 2021	May	NEWA

DEXTROSE; POTASSIUM CHLORIDE

INJECTABLE; INJECTION

DEXTROSE 5% AND POTASSIUM CHLORIDE 0.075%

@ FRESenius KABI USA 5GM/100ML; 75MG/100ML A212346 001 Sep 10, 2020 Mar DISC

DEXTROSE 5% AND POTASSIUM CHLORIDE 0.15%

@ FRESenius KABI USA 5GM/100ML; 150MG/100ML A212346 002 Sep 10, 2020 Mar DISC

DEXTROSE 5% AND POTASSIUM CHLORIDE 0.224% IN PLASTIC CONTAINER

+ BAXTER HLTHCARE 5GM/100ML; 224MG/100ML N017634 003 Mar CTEC

DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE

INJECTABLE; INJECTION

POTASSIUM CHLORIDE 10MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45%

AP FRESenius KABI USA 5GM/100ML; 74.5MG/100ML; 450MG/100ML A213523 001 Mar 09, 2021 Feb NEWA

POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45%

AP FRESenius KABI USA 5GM/100ML; 149MG/100ML; 450MG/100ML A213523 002 Mar 09, 2021 Feb NEWA

POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9%

AP FRESenius KABI USA 5GM/100ML; 149MG/100ML; 900MG/100ML A213445 001 Mar 09, 2021 Feb NFTG

POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45%

AP FRESenius KABI USA 5GM/100ML; 224MG/100ML; 450MG/100ML A213523 003 Mar 09, 2021 Feb NEWA

POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45%

AP FRESenius KABI USA 5GM/100ML; 298MG/100ML; 450MG/100ML A213523 004 Mar 09, 2021 Feb NEWA

POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9%

AP FRESenius KABI USA 5GM/100ML; 298MG/100ML; 900MG/100ML A213445 002 Mar 09, 2021 Feb NFTG

DEXTROSE; SODIUM CHLORIDE

INJECTABLE; INJECTION

DEXTROSE 2.5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER

AP FRESenius KABI USA 2.5GM/100ML; 450MG/100ML A211190 001 Dec 20, 2019 May CMFD

DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER

AP FRESenius KABI USA 5GM/100ML; 300MG/100ML A211194 001 Aug 26, 2020 May CMFD

@ 5GM/100ML; 300MG/100ML A211194 001 Aug 26, 2020 Feb DISC

AP +! ICU MEDICAL INC 5GM/100ML; 300MG/100ML N017799 001 May CTEC

+! 5GM/100ML; 300MG/100ML N017799 001 Feb CTEC

DEXTROSE 5% AND SODIUM CHLORIDE 0.45%

AP FRESenius KABI USA 5GM/100ML; 450MG/100ML A211276 001 Sep 15, 2020 May CMFD

@ 5GM/100ML; 450MG/100ML A211276 001 Sep 15, 2020 Mar DISC

DEXTROSE 5% AND SODIUM CHLORIDE 0.9%

AP FRESenius KABI USA 5GM/100ML; 900MG/100ML A211211 001 Sep 14, 2020 May CMFD

@ 5GM/100ML; 900MG/100ML A211211 001 Sep 14, 2020 Mar DISC

DIAZEPAM

TABLET; ORAL

DIAZEPAM

@ BARR 2MG A070152 001 Nov 01, 1985 Apr DISC

@ 10MG A070154 001 Nov 01, 1985 Apr DISC

DICLOFENAC POTASSIUM

TABLET; ORAL

CATAFLAM

AB AMICI 50MG A076561 001 Mar 18, 2004 May CTNA

DICLOFENAC SODIUM

GEL; TOPICAL

DICLOFENAC SODIUM

AB ! TARO 3% A206298 001 Apr 28, 2016 Mar CHRS

SOLARAZE

+ @ FOUGERA PHARMS 3% N021005 001 Oct 16, 2000 Mar DISC

SOLUTION; TOPICAL

DICLOFENAC SODIUM

AT AKORN 1.5% A206655 001 Jan 28, 2021 Jan NEWA

@ RISING 1.5% A206715 001 Aug 07, 2017 May CAHN

TABLET, DELAYED RELEASE; ORAL

DICLOFENAC SODIUM

@ MICRO LABS 50MG A074986 001 Feb 26, 1999 Feb CAHN

@ 75MG A074986 002 Feb 26, 1999 Feb CAHN

DICLOXACILLIN SODIUM

CAPSULE;ORAL							
DICLOXACILLIN SODIUM							
@ SANDOZ	EQ 125MG BASE	A 061454	002		Jan	DISC	
@	EQ 250MG BASE	A 061454	001		Jan	DISC	
@	EQ 500MG BASE	A 061454	003		Jan	DISC	
TEVA	EQ 250MG BASE	A 062286	001	Jun 03, 1982	Jan	CTEC	
!	EQ 500MG BASE	A 062286	002	Jun 03, 1982	Jan	CTEC	
AB	!	EQ 500MG BASE	A 062286	002	Jun 03, 1982	Jan	CHRS

DICYCLOMINE HYDROCHLORIDE

INJECTABLE;INJECTION							
DICYCLOMINE HYDROCHLORIDE							
>A> AP	PRAXGEN	10MG/ML	A 212058	001	Apr 26, 2019	Jun	CAHN
>D> AP	SUNGEN PHARMA	10MG/ML	A 212058	001	Apr 26, 2019	Jun	CAHN
SYRUP;ORAL							
DICYCLOMINE HYDROCHLORIDE							
AA	NOVITIUM PHARMA	10MG/5ML	A 214721	001	Apr 23, 2021	Apr	NEWA

DIDANOSINE

CAPSULE, DELAYED REL PELLETS;ORAL						
DIDANOSINE						
@ AUROBINDO PHARMA	125MG	A 090094	001	Sep 24, 2008	Jan	DISC
@	200MG	A 090094	002	Sep 24, 2008	Jan	DISC
@	250MG	A 090094	003	Sep 24, 2008	Jan	DISC
@	400MG	A 090094	004	Sep 24, 2008	Jan	DISC

DIFLORASONE DIACETATE

CREAM;TOPICAL								
DIFLORASONE DIACETATE								
BX	!	ANI PHARMS	0.05%	A 076263	001	Dec 20, 2002	Apr	CAHN
OINTMENT;TOPICAL								
DIFLORASONE DIACETATE								
@ AKORN		0.05%	A 206572	001	Jul 24, 2015	Apr	DISC	

DIHYDROERGOTAMINE MESYLATE

INJECTABLE;INJECTION							
DIHYDROERGOTAMINE MESYLATE							
AP	PROVEPHARM SAS	1MG/ML	A 212046	001	Jan 07, 2020	Jan	CAHN

DILTIAZEM HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL							
DILTIAZEM HYDROCHLORIDE							
AB1	GLENMARK PHARMS LTD	60MG	A 212317	001	Mar 22, 2021	Mar	NEWA
AB1		90MG	A 212317	002	Mar 22, 2021	Mar	NEWA
AB1		120MG	A 212317	003	Mar 22, 2021	Mar	NEWA
AB1	MYLAN	60MG	A 074910	001	May 02, 1997	Mar	CTEC
AB1		90MG	A 074910	002	May 02, 1997	Mar	CTEC
AB1	!	120MG	A 074910	003	May 02, 1997	Mar	CTEC
INJECTABLE;INJECTION							
DILTIAZEM HYDROCHLORIDE							
@ INTL MEDICATION		5MG/ML	A 075749	001	Nov 21, 2001	Jan	DISC

DIMETHYL FUMARATE

CAPSULE, DELAYED RELEASE;ORAL							
DIMETHYL FUMARATE							
AB	PHARMATHEN	120MG	A 210436	001	Mar 26, 2021	Mar	NEWA
AB		240MG	A 210436	002	Mar 26, 2021	Mar	NEWA
@ ZYDUS PHARMS		120MG	A 210538	001	Sep 24, 2020	Feb	DISC
@		240MG	A 210538	002	Sep 24, 2020	Feb	DISC
TECFIDERA							
AB	+ BIOGEN INC	120MG	N 204063	001	Mar 27, 2013	Apr	CAHN
AB	+	240MG	N 204063	002	Mar 27, 2013	Apr	CAHN

DINOPROSTONE

GEL;ENDOCERVICAL							
PREPIDIL							
+!	PFIZER	0.5MG/3GM	N 019617	001	Dec 09, 1992	Jan	CAHN

SUPPOSITORY;VAGINAL
PROSTIN E2

+!	PFIZER	20MG	N017810	001		Jan	CAHN
----	--------	------	---------	-----	--	-----	------

DIPYRIDAMOLE

TABLET;ORAL

DIPYRIDAMOLE

AB	OXFORD PHARMS	25MG	A040542	001	Apr 21, 2006	Jan	CMFD
AB		50MG	A040542	002	Apr 21, 2006	Jan	CMFD
AB		75MG	A040542	003	Apr 21, 2006	Jan	CMFD

DIROXIMEL FUMARATECAPSULE, DELAYED RELEASE;ORAL
VUMERITY

+!	BIOGEN INC	231MG	N211855	001	Oct 29, 2019	Apr	CAHN
----	------------	-------	---------	-----	--------------	-----	------

DISOPYRAMIDE PHOSPHATE

CAPSULE;ORAL

DISOPYRAMIDE PHOSPHATE

@ MAYNE PHARMA

EQ 100MG BASE

A070173 001 May 31, 1985 Feb DISC

@

EQ 150MG BASE

A070173 002 May 31, 1985 Feb DISC

DIVALPROEX SODIUM

CAPSULE, DELAYED REL PELLETS;ORAL

DIVALPROEX SODIUM

@ TEVA PHARMS USA

EQ 125MG VALPROIC ACID

A211505 001 Nov 17, 2020 May DISC

TABLET, DELAYED RELEASE;ORAL

DIVALPROEX SODIUM

@ ANCHEN PHARMS

EQ 500MG VALPROIC ACID

A078411 001 Nov 03, 2008 May DISC

TABLET, EXTENDED RELEASE;ORAL

DIVALPROEX SODIUM

AB AMTA

EQ 250MG VALPROIC ACID

A214462 001 Mar 15, 2021 Mar NEWA

AB

EQ 500MG VALPROIC ACID

A214462 002 Mar 15, 2021 Mar NEWA

DOCETAXEL

INJECTABLE;INJECTION

DOCETAXEL

@ DFB ONCOLOGY LTD

20MG/ML (20MG/ML)

A206177 001 Jan 20, 2017 May DISC

@

80MG/4ML (20MG/ML)

A206177 002 Jan 20, 2017 May DISC

@

200MG/10ML (20MG/ML)

A206177 003 Jan 20, 2017 May DISC

>A> AP

EUGIA PHARMA

20MG/2ML (10MG/ML)

A214575 001 Jun 25, 2021 Jun NEWA

>A> AP

80MG/8ML (10MG/ML)

A214575 002 Jun 25, 2021 Jun NEWA

>A> AP

160MG/16ML (10MG/ML)

A214575 003 Jun 25, 2021 Jun NEWA

>A> AP

GLAND PHARMA LTD

20MG/2ML (10MG/ML)

A213510 001 Jul 01, 2021 Jun NEWA

>A> AP

80MG/8ML (10MG/ML)

A213510 002 Jul 01, 2021 Jun NEWA

>A> AP

160MG/16ML (10MG/ML)

A213510 003 Jul 01, 2021 Jun NEWA

AP

HIKMA

20MG/ML (20MG/ML)

A204490 001 Jan 14, 2021 Jan NEWA

AP

80MG/4ML (20MG/ML)

A204490 002 Jan 14, 2021 Jan NEWA

>D>

@ HONG KONG

20MG/2ML (10MG/ML)

A209634 001 Aug 24, 2018 Jun CMFD

>A> AP

20MG/2ML (10MG/ML)

A209634 001 Aug 24, 2018 Jun CMFD

>D>

@

80MG/8ML (10MG/ML)

A209634 002 Aug 24, 2018 Jun CMFD

>A> AP

80MG/8ML (10MG/ML)

A209634 002 Aug 24, 2018 Jun CMFD

>D>

@

160MG/16ML (10MG/ML)

A209634 003 Aug 24, 2018 Jun CMFD

>A> AP

160MG/16ML (10MG/ML)

A209634 003 Aug 24, 2018 Jun CMFD

@ INGENUS PHARMS LLC

20MG/2ML (10MG/ML)

A207563 001 Aug 31, 2017 Apr DISC

AP

+! SHILPA

20MG/ML (20MG/ML)

N205934 001 Dec 22, 2015 Apr CHRS

AP

+

20MG/ML (20MG/ML)

N205934 001 Dec 22, 2015 Apr CRLD

AP

20MG/ML (20MG/ML)

N205934 001 Dec 22, 2015 Jan CAHN

AP

+!

80MG/4ML (20MG/ML)

N205934 002 Dec 22, 2015 Apr CHRS

AP

+

80MG/4ML (20MG/ML)

N205934 002 Dec 22, 2015 Apr CRLD

AP

80MG/4ML (20MG/ML)

N205934 002 Dec 22, 2015 Jan CAHN

AP

+!

160MG/8ML (20MG/ML)

N205934 003 Dec 22, 2015 Apr CHRS

AP

+

160MG/8ML (20MG/ML)

N205934 003 Dec 22, 2015 Apr CRLD

AP

160MG/8ML (20MG/ML)

N205934 003 Dec 22, 2015 Jan CAHN

DOFETILIDE

CAPSULE;ORAL

DOFETILIDE

@ RICONPHARMA LLC

0.125MG

A212410 001 Dec 27, 2019 Feb DISC

@

0.25MG

A212410 002 Dec 27, 2019 Feb DISC

@

0.5MG

A212410 003 Dec 27, 2019 Feb DISC

DOLASETRON MESYLATE

INJECTABLE; INJECTION

ANZEMET

+ @	VALIDUS PHARMS	12.5MG/0.625ML (20MG/ML)	N020624	002	Sep 11, 1997	Feb CAHN
+ @		100MG/5ML (20MG/ML)	N020624	001	Sep 11, 1997	Feb CAHN
@		500MG/25ML (20MG/ML)	N020624	003	Dec 11, 2001	Feb CAHN

TABLET; ORAL

ANZEMET

+ @	VALIDUS PHARMS	50MG	N020623	001	Sep 11, 1997	Feb CAHN
+ @		100MG	N020623	002	Sep 11, 1997	Feb CAHN

DORZOLAMIDE HYDROCHLORIDE; TIMOLOL MALEATE

SOLUTION/DROPS; OPHTHALMIC

DORZOLAMIDE HYDROCHLORIDE AND TIMOLOL MALEATE

AT	ALEMBIC PHARMS LTD	EQ 2% BASE;EQ 0.5% BASE	A213099	001	May 04, 2021	Apr NEWA
AT	AUROBINDO PHARMA LTD	EQ 2% BASE;EQ 0.5% BASE	A207629	001	May 14, 2021	May NEWA
AT	FDC LTD	EQ 2% BASE;EQ 0.5% BASE	A205295	001	Jun 13, 2019	Feb CMFD

DOXEPIN HYDROCHLORIDE

CAPSULE; ORAL

DOXEPIN HYDROCHLORIDE

AB	ALEMBIC PHARMS LTD	EQ 10MG BASE	A215076	001	Apr 21, 2021	Apr NEWA
AB		EQ 25MG BASE	A215076	002	Apr 21, 2021	Apr NEWA
AB		EQ 50MG BASE	A215076	003	Apr 21, 2021	Apr NEWA
AB		EQ 75MG BASE	A215076	004	Apr 21, 2021	Apr NEWA
AB		EQ 100MG BASE	A215076	005	Apr 21, 2021	Apr NEWA
AB	APPCO	EQ 10MG BASE	A214908	001	Apr 01, 2021	Mar NEWA
AB		EQ 25MG BASE	A214908	002	Apr 01, 2021	Mar NEWA
AB		EQ 50MG BASE	A214908	003	Apr 01, 2021	Mar NEWA
AB		EQ 75MG BASE	A214908	004	Apr 01, 2021	Mar NEWA
AB		EQ 100MG BASE	A214908	005	Apr 01, 2021	Mar NEWA
AB	LEADING PHARMA LLC	EQ 10MG BASE	A211619	001	Mar 09, 2021	Feb NEWA
AB		EQ 25MG BASE	A211619	002	Mar 09, 2021	Feb NEWA
AB		EQ 50MG BASE	A211619	003	Mar 09, 2021	Feb NEWA
AB		EQ 75MG BASE	A211619	004	Mar 09, 2021	Feb NEWA
AB		EQ 100MG BASE	A211619	005	Mar 09, 2021	Feb NEWA
AB		EQ 150MG BASE	A211618	001	Mar 01, 2021	Feb NEWA
	@ UPSHER SMITH LABS	EQ 10MG BASE	A210268	001	Sep 04, 2020	May CAHN
	@	EQ 10MG BASE	A210268	001	Sep 04, 2020	Feb DISC
	@	EQ 25MG BASE	A210268	002	Sep 04, 2020	May CAHN
	@	EQ 25MG BASE	A210268	002	Sep 04, 2020	Feb DISC
	@	EQ 50MG BASE	A210268	003	Sep 04, 2020	May CAHN
	@	EQ 50MG BASE	A210268	003	Sep 04, 2020	Feb DISC
	@	EQ 75MG BASE	A210268	004	Sep 04, 2020	May CAHN
	@	EQ 75MG BASE	A210268	004	Sep 04, 2020	Feb DISC
	@	EQ 100MG BASE	A210268	005	Sep 04, 2020	May CAHN
	@	EQ 100MG BASE	A210268	005	Sep 04, 2020	Feb DISC

TABLET; ORAL

DOXEPIN HYDROCHLORIDE

	@ PAR PHARM INC	EQ 3MG BASE	A202510	001	Jul 24, 2020	Jan DISC
	@	EQ 6MG BASE	A202510	002	Jul 24, 2020	Jan DISC
AB	RK PHARMA	EQ 3MG BASE	A202337	001	Jan 20, 2016	Jan CAHN
AB		EQ 6MG BASE	A202337	002	Jan 20, 2016	Jan CAHN

DOXYCYCLINE

CAPSULE; ORAL

DOXYCYCLINE

	@ MYLAN	EQ 50MG BASE	A208942	001	Jan 21, 2021	Jan DISC
AB		EQ 50MG BASE	A208942	001	Jan 21, 2021	Jan NEWA
	@	EQ 75MG BASE	A208942	002	Jan 21, 2021	Jan DISC
AB		EQ 75MG BASE	A208942	002	Jan 21, 2021	Jan NEWA
	@	EQ 100MG BASE	A208942	003	Jan 21, 2021	Jan DISC
AB		EQ 100MG BASE	A208942	003	Jan 21, 2021	Jan NEWA
	MONODOX					
>D>	+ @ CHARTWELL RX	EQ 50MG BASE	N050641	002	Feb 10, 1992	Jun CMFD
>A>	AB +	EQ 50MG BASE	N050641	002	Feb 10, 1992	Jun CMFD
>D>	+ @	EQ 75MG BASE	N050641	003	Oct 18, 2006	Jun CMFD
>A>	AB +	EQ 75MG BASE	N050641	003	Oct 18, 2006	Jun CMFD
>D>	+ @	EQ 100MG BASE	N050641	001	Dec 29, 1989	Jun CMFD
>A>	AB +	EQ 100MG BASE	N050641	001	Dec 29, 1989	Jun CMFD

FOR SUSPENSION;ORAL

DOXYCYCLINE

>A>	AB	CHARTWELL	EQ 25MG BASE/5ML	A 065454	001	Jul 16, 2008	Jun CAHN
>D>	AB	CHARTWELL LIFE SCI	EQ 25MG BASE/5ML	A 065454	001	Jul 16, 2008	Jun CAHN

DOXYCYCLINE HYCLATE

CAPSULE;ORAL

DOXYCYCLINE HYCLATE

>A>	AB	CHARTWELL	EQ 50MG BASE	A 062500	001	Sep 11, 1984	Jun CAHN
>A>	AB		EQ 100MG BASE	A 062500	002	Sep 11, 1984	Jun CAHN
>D>	AB	CHARTWELL LIFE SCI	EQ 50MG BASE	A 062500	001	Sep 11, 1984	Jun CAHN
>D>	AB		EQ 100MG BASE	A 062500	002	Sep 11, 1984	Jun CAHN

CAPSULE, DELAYED RELEASE;ORAL

DOXYCYCLINE HYCLATE

@ BAUSCH

EQ 75MG BASE

A 065281 001 Dec 21, 2005 May CAHN

@

EQ 100MG BASE

A 065281 002 Dec 21, 2005 May CAHN

INJECTABLE;INJECTION

DOXYCYCLINE HYCLATE

AP WEST-WARD PHARMS INT EQ 100MG BASE/VIAL

A 062992 001 Feb 16, 1989 May CMFD

AP EQ 200MG BASE/VIAL

A 062992 002 Feb 16, 1989 May CMFD

TABLET;ORAL

DOXYCYCLINE HYCLATE

>A>	AB	CHARTWELL	EQ 100MG BASE	A 062505	001	Sep 11, 1984	Jun CAHN
>D>	AB	CHARTWELL LIFE SCI	EQ 100MG BASE	A 062505	001	Sep 11, 1984	Jun CAHN
		@ ORYZA	EQ 100MG BASE	A 213475	001	Mar 10, 2021	Apr DISC
	AB		EQ 100MG BASE	A 213475	001	Mar 10, 2021	Feb NEWA

DROSPIRENONE; ESTETROL

TABLET;ORAL

NEXTSTELLIS

+	!	MAYNE PHARMA	3MG;14.2MG	N 214154	001	Apr 15, 2021	Apr NEWA
---	---	--------------	------------	----------	-----	--------------	----------

DROSPIRENONE; ETHINYL ESTRADIOL

TABLET;ORAL

DROSPIRENONE AND ETHINYL ESTRADIOL

>D>	AB	ALLIED	3MG;0.02MG	A 203291	001	Jul 18, 2017	Jun CAHN
>A>	AB	HLTHCARE	3MG;0.02MG	A 203291	001	Jul 18, 2017	Jun CAHN
>D>	AB	JUBILANT CADISTA	3MG;0.02MG	A 209423	001	Dec 22, 2017	Jun DISC
>A>		@	3MG;0.02MG	A 209423	001	Dec 22, 2017	Jun DISC

TABLET;ORAL-28

DROSPIRENONE AND ETHINYL ESTRADIOL

>D>	AB	JUBILANT CADISTA	3MG;0.03MG	A 210017	001	Sep 10, 2018	Jun DISC
>A>		@	3MG;0.03MG	A 210017	001	Sep 10, 2018	Jun DISC

DROXIDOPA

CAPSULE;ORAL

DROXIDOPA

	AB	AJANTA PHARMA LTD	100MG	A 214391	001	Feb 18, 2021	Feb NFTG
	AB		200MG	A 214391	002	Feb 18, 2021	Feb NFTG
	AB		300MG	A 214391	003	Feb 18, 2021	Feb NFTG
	AB	ALKEM LABS LTD	100MG	A 213911	001	Feb 18, 2021	Feb NFTG
	AB		200MG	A 213911	002	Feb 18, 2021	Feb NFTG
	AB		300MG	A 213911	003	Feb 18, 2021	Feb NFTG
	AB	ANNORA	300MG	A 211726	001	Feb 18, 2021	Feb NFTG
	AB	AUROBINDO PHARMA LTD	100MG	A 214387	001	Feb 18, 2021	Feb NFTG
	AB		200MG	A 214387	002	Feb 18, 2021	Feb NFTG
	AB		300MG	A 214387	003	Feb 18, 2021	Feb NFTG
	AB	BIONPHARMA INC	100MG	A 213033	001	Apr 28, 2021	May CAHN
	AB		200MG	A 213033	002	Apr 28, 2021	May CAHN
	AB		300MG	A 213033	003	Apr 28, 2021	May CAHN
>D>	AB	BLUEPHARMA	100MG	A 214543	001	May 05, 2021	Jun CAHN
	AB		100MG	A 214543	001	May 05, 2021	Apr NEWA
>D>	AB		200MG	A 214543	002	May 05, 2021	Jun CAHN
	AB		200MG	A 214543	002	May 05, 2021	Apr NEWA
>D>	AB		300MG	A 214543	003	May 05, 2021	Jun CAHN
	AB		300MG	A 214543	003	May 05, 2021	Apr NEWA
	AB	HIKMA	100MG	A 212835	001	Feb 18, 2021	Feb NFTG
	AB		200MG	A 212835	002	Feb 18, 2021	Feb NFTG
	AB		300MG	A 212835	003	Feb 18, 2021	Feb NFTG
	AB	LUPIN PHARMS	100MG	A 211652	001	Feb 18, 2021	Feb NFTG
	AB		200MG	A 211652	002	Feb 18, 2021	Feb NFTG
	AB		300MG	A 211652	003	Feb 18, 2021	Feb NFTG

CAPSULE;ORALDROXIDOPA

AB	MSN PHARMS INC	100MG	A211741	001	Feb 18, 2021	Feb	NFTG	
AB		200MG	A211741	002	Feb 18, 2021	Feb	NFTG	
AB		300MG	A211741	003	Feb 18, 2021	Feb	NFTG	
AB	MYLAN API	100MG	A213033	001	Apr 28, 2021	Apr	NEWA	
AB		200MG	A213033	002	Apr 28, 2021	Apr	NEWA	
AB		300MG	A213033	003	Apr 28, 2021	Apr	NEWA	
AB	SCIEGEN PHARMS INC	100MG	A214017	001	Feb 18, 2021	Feb	NFTG	
AB		200MG	A214017	002	Feb 18, 2021	Feb	NFTG	
AB		300MG	A214017	003	Feb 18, 2021	Feb	NFTG	
AB	SUN PHARM	100MG	A214384	001	Feb 18, 2021	Feb	NFTG	
AB		200MG	A214384	002	Feb 18, 2021	Feb	NFTG	
AB		300MG	A214384	003	Feb 18, 2021	Feb	NFTG	
AB	TASMAN PHARMA	100MG	A213661	001	Feb 18, 2021	Feb	NFTG	
AB		200MG	A213661	002	Feb 18, 2021	Feb	NFTG	
AB		300MG	A213661	003	Feb 18, 2021	Feb	NFTG	
AB	TEVA PHARMS USA INC	100MG	A213162	001	Feb 18, 2021	Feb	NFTG	
AB		200MG	A213162	002	Feb 18, 2021	Feb	NFTG	
AB		300MG	A213162	003	Feb 18, 2021	Feb	NFTG	
>A>	AB	TRIS PHARMA INC	100MG	A214543	001	May 05, 2021	Jun	CAHN
>A>	AB		200MG	A214543	002	May 05, 2021	Jun	CAHN
>A>	AB		300MG	A214543	003	May 05, 2021	Jun	CAHN
AB	ZYDUS PHARMS	100MG	A211818	001	Feb 18, 2021	Feb	NFTG	
AB		200MG	A211818	002	Feb 18, 2021	Feb	NFTG	
AB		300MG	A211818	003	Feb 18, 2021	Feb	NFTG	

DULOXETINE HYDROCHLORIDECAPSULE, DELAYED REL PELLETS;ORALDRIZALMA SPRINKLE

+	SUN PHARMA GLOBAL	EQ 20MG BASE	N212516	001	Jul 19, 2019	Apr	CDFR
+		EQ 30MG BASE	N212516	002	Jul 19, 2019	Apr	CDFR
+		EQ 40MG BASE	N212516	003	Jul 19, 2019	Apr	CDFR
+	!	EQ 60MG BASE	N212516	004	Jul 19, 2019	Apr	CDFR

DULOXETINE HYDROCHLORIDE

AB	SUNSHINE	EQ 20MG BASE	A212328	001	Feb 11, 2021	Feb	NEWA
AB		EQ 30MG BASE	A212328	002	Feb 11, 2021	Feb	NEWA
AB		EQ 60MG BASE	A212328	003	Feb 11, 2021	Feb	NEWA

DUTASTERIDECAPSULE;ORALDUTASTERIDE

@	NOSTRUM LABS INC	0.5MG	A204705	001	Nov 20, 2015	Apr	CAHN
---	------------------	-------	---------	-----	--------------	-----	------

ECONAZOLE NITRATEAEROSOL, FOAM;TOPICALECOZA

+	!	RESILIA PHARMS	1%	N205175	001	Oct 24, 2013	Feb	CAHN
---	---	----------------	----	---------	-----	--------------	-----	------

EDETATE CALCIUM DISODIUMINJECTABLE;INJECTIONCALCIUM DISODIUM VERSENATE

+	!	BAUSCH	200MG/ML	N008922	001		May	CAHN
---	---	--------	----------	---------	-----	--	-----	------

TABLET;ORALCALCIUM DISODIUM VERSENATE

@	BAUSCH	500MG	N008922	002			May	CAHN
---	--------	-------	---------	-----	--	--	-----	------

EFAVIRENZTABLET;ORALEFAVIRENZ

>A>	AB	STRIDES PHARMA	600MG	A078509	001	Jun 16, 2021	Jun	NEWA
-----	----	----------------	-------	---------	-----	--------------	-----	------

EFAVIRENZ; LAMIVUDINE; TENOFOVIR DISOPROXIL FUMARATETABLET;ORALEFAVIRENZ, LAMIVUDINE AND TENOFOVIR DISOPROXIL FUMARATE

+	@	AUROBINDO PHARMA LTD	600MG;300MG;300MG	N022343	001	Aug 15, 2018	Feb	DISC
---	---	----------------------	-------------------	---------	-----	--------------	-----	------

EFINACONAZOLESOLUTION; TOPICAL
EFINACONAZOLE

>A>	AB	ACRUX DDS	10%	A211969	001	Jun 21, 2021	Jun	NEWA
	AB	AUROBINDO PHARMA LTD	10%	A212066	001	Mar 29, 2021	Mar	NEWA
		@ PERRIGO PHARMA INTL	10%	A211851	001	Dec 16, 2020	Jan	DISC
	AB	TEVA PHARMS USA	10%	A211827	001	Dec 16, 2020	Feb	CTEC
		JUBLIA						
	AB	+! BAUSCH	10%	N203567	001	Jun 06, 2014	Feb	CTEC

ELEXACAFTOR, IVACAFTOR, TEZACAFTOR; IVACAFTORTABLET; ORAL
TRIKAFTA (COPACKAGED)

>A>	+	VERTEX PHARMS INC	50MG, 37.5MG, 25MG; 75MG	N212273	002	Jun 08, 2021	Jun	NEWA
>A>	+	!	100MG, 75MG, 50MG; 150MG	N212273	001	Oct 21, 2019	Jun	CPOT
		TABLET, TABLET; ORAL						
		TRIKAFTA (COPACKAGED)						
>D>	+	!	VERTEX PHARMS INC 100MG, 75MG, 50MG; N/A, 150MG, N/A	N212273	001	Oct 21, 2019	Jun	CPOT

EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATETABLET; ORAL
EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE

>A>	AB	APOTEX	200MG; 300MG	A208740	001	Jun 16, 2021	Jun	NEWA
	AB	CIPLA	200MG; 300MG	A090958	001	Apr 02, 2021	Mar	NEWA
	AB	LAURUS LABS LTD	200MG; 300MG	A212114	001	Jul 26, 2019	Jan	CMFD
	AB	LUPIN LTD	200MG; 300MG	A204131	001	Jun 04, 2021	May	NEWA
	AB	MACLEODS PHARMS LTD	200MG; 300MG	A203442	001	May 15, 2020	Feb	CMFD
	AB	MYLAN	200MG; 300MG	A206436	001	Apr 09, 2018	Feb	CMFD
	AB	STRIDES PHARMA	200MG; 300MG	A091055	001	Jan 13, 2021	Jan	NEWA
>A>	AB	ZYDUS PHARMS	100MG; 150MG	A212689	002	Jul 01, 2021	Jun	NEWA
>A>	AB		133MG; 200MG	A212689	003	Jul 01, 2021	Jun	NEWA
>A>	AB		167MG; 250MG	A212689	004	Jul 01, 2021	Jun	NEWA

ENZALUTAMIDECAPSULE; ORAL
ENZALUTAMIDE

	AB	ACTAVIS LABS FL INC	40MG	A209614	001	May 14, 2021	May	NFTG
--	----	---------------------	------	---------	-----	--------------	-----	------

EPHEDRINE HYDROCHLORIDESOLUTION; INTRAVENOUS
REZIPRES

>A>	+	ETON	23.5MG/5ML (4.7MG/ML)	N213536	001	Jun 14, 2021	Jun	CAHN
>A>	+	@	47MG/ML (47MG/ML)	N213536	002	Jun 14, 2021	Jun	DISC
>A>	+	@	47MG/5ML (9.4MG/ML)	N213536	003	Jun 14, 2021	Jun	DISC

EPHEDRINE SULFATESOLUTION; INTRAVENOUS
EPHEDRINE SULFATE

>A>	AP	AUROBINDO PHARMA LTD	50MG/ML (50MG/ML)	A214579	001	Jun 14, 2021	Jun	NEWA
-----	----	----------------------	-------------------	---------	-----	--------------	-----	------

EPLERENONETABLET; ORAL
EPLERENONE

	AB	CHARTWELL RX	25MG	A078482	001	Jul 30, 2008	Apr	CAHN	
	AB		50MG	A078482	002	Jul 30, 2008	Apr	CAHN	
		@ PIRAMAL HLTHCARE UK	25MG	A212765	001	Aug 10, 2020	Feb	DISC	
		@	50MG	A212765	002	Aug 10, 2020	Feb	DISC	
		INSPIRA							
	AB	+ UPJOHN	25MG	N021437	001	Sep 27, 2002	Apr	CAHN	
	AB	+	!	50MG	N021437	002	Sep 27, 2002	Apr	CAHN
		@	100MG	N021437	003	Sep 27, 2002	Apr	CAHN	

EPOPROSTENOL SODIUMINJECTABLE; INJECTION
EPOPROSTENOL SODIUM

AP2		SUN PHARM	EQ 0.5MG BASE/VIAL	A210473	001	Jan 15, 2021	Feb	CTEC
AP			EQ 0.5MG BASE/VIAL	A210473	001	Jan 15, 2021	Jan	NFTG
AP2			EQ 1.5MG BASE/VIAL	A210473	002	Jan 15, 2021	Feb	CTEC
AP			EQ 1.5MG BASE/VIAL	A210473	002	Jan 15, 2021	Jan	NFTG
AP1		TEVA PHARMS USA	EQ 0.5MG BASE/VIAL	A078396	001	Apr 23, 2008	Feb	CTEC
AP1			EQ 1.5MG BASE/VIAL	A078396	002	Apr 23, 2008	Feb	CTEC

INJECTABLE; INJECTION

FLOLAN

AP1	+	GLAXOSMITHKLINE LLC	EQ 0.5MG BASE/VIAL	N020444	001	Sep 20, 1995	Feb CTEC
AP1	+		EQ 1.5MG BASE/VIAL	N020444	002	Sep 20, 1995	Feb CTEC

VELETRI

AP2	+	ACTELION	EQ 0.5MG BASE/VIAL	N022260	002	Jun 28, 2012	Feb CAHN
AP2	+		EQ 1.5MG BASE/VIAL	N022260	001	Jun 27, 2008	Feb CAHN
AP2	+	ACTELION PHARMS LTD	EQ 0.5MG BASE/VIAL	N022260	002	Jun 28, 2012	Feb CHRS
AP2	+		EQ 0.5MG BASE/VIAL	N022260	002	Jun 28, 2012	Feb CTEC
AP2	+		EQ 1.5MG BASE/VIAL	N022260	001	Jun 27, 2008	Feb CTEC

EPTIFIBATIDE

INJECTABLE; INJECTION

EPTIFIBATIDE

AP	!	MYLAN LABS LTD	2MG/ML	A203258	001	Jul 20, 2018	Apr CHRS
AP	!		75MG/100ML	A203258	002	Jul 20, 2018	Apr CHRS

INTEGRILIN

	+	@ SCHERING	2MG/ML	N020718	001	May 18, 1998	Apr DISC
	+	@	75MG/100ML	N020718	002	May 18, 1998	Apr DISC

ERGOCALCIFEROL

CAPSULE; ORAL

DRISDOL

AA	+	VALIDUS PHARMS	50,000 IU	N003444	001		Feb CAHN
----	---	----------------	-----------	---------	-----	--	----------

ERLOTINIB HYDROCHLORIDE

TABLET; ORAL

ERLOTINIB HYDROCHLORIDE

AB		MSN	EQ 25MG BASE	A214366	001	May 10, 2021	Apr NEWA
AB			EQ 100MG BASE	A214366	002	May 10, 2021	Apr NEWA
AB			EQ 150MG BASE	A214366	003	May 10, 2021	Apr NEWA

ERTAPENEM SODIUM

INJECTABLE; INTRAMUSCULAR, INTRAVENOUS

ERTAPENEM SODIUM

AP		GLAND PHARMA LTD	EQ 1GM BASE/VIAL	A212040	001	Mar 26, 2021	Mar NEWA
----	--	------------------	------------------	---------	-----	--------------	----------

ERYTHROMYCIN

SOLUTION; TOPICAL

ERYTHRA-DERM

AT		SAPTALIS PHARMS	2%	A062687	001	Feb 05, 1988	Apr CMFD
----	--	-----------------	----	---------	-----	--------------	----------

TABLET; ORAL

ERYTHROMYCIN

>A>	AB	ORANGE	250MG	A213628	001	Jun 28, 2021	Jun NEWA
>A>	AB		500MG	A213628	002	Jun 28, 2021	Jun NEWA
	AB	TEVA PHARMS USA INC	250MG	A214549	001	Feb 11, 2021	Feb NEWA
	AB		500MG	A214549	002	Feb 11, 2021	Feb NEWA

ERYTHROMYCIN ETHYLSUCCINATE

GRANULE; ORAL

ERYTHROMYCIN ETHYLSUCCINATE

	@	PAR PHARM INC	EQ 200MG BASE/5ML	A211991	001	Oct 23, 2019	May DISC
	@		EQ 400MG BASE/5ML	A211991	002	Oct 23, 2019	May DISC

ESLICARBAZEPINE ACETATE

TABLET; ORAL

ESLICARBAZEPINE ACETATE

>A>	AB	DR REDDYS LABS LTD	200MG	A211238	001	Jun 29, 2021	Jun NFTG
>A>	AB		400MG	A211238	002	Jun 29, 2021	Jun NFTG
>A>	AB		600MG	A211238	003	Jun 29, 2021	Jun NFTG
>A>	AB		800MG	A211238	004	Jun 29, 2021	Jun NFTG

ESOMEPRAZOLE MAGNESIUM

CAPSULE, DELAYED REL PELLETS; ORAL

ESOMEPRAZOLE MAGNESIUM

	@	AMTA	EQ 20MG BASE	A213859	001	Nov 18, 2020	May DISC
	@		EQ 40MG BASE	A213859	002	Nov 18, 2020	May DISC
AB		ETHYPHARM	EQ 20MG BASE	A090841	001	Mar 31, 2021	Mar NEWA
AB			EQ 40MG BASE	A090841	002	Mar 31, 2021	Mar NEWA
AB		GRAVITI PHARMS	EQ 20MG BASE	A213486	001	Mar 19, 2021	Mar NEWA
AB			EQ 40MG BASE	A213486	002	Mar 19, 2021	Mar NEWA
AB		INDCHEMIE HEALTH	EQ 40MG BASE	A210559	002	Feb 26, 2021	Feb NEWA

ESTRADIOL

INSERT, EXTENDED RELEASE;VAGINAL
ESTRING

+! PFIZER 0.0075MG/24HR N020472 001 Apr 26, 1996 Jan CAHN

ESTRADIOL CYPIONATE

INJECTABLE; INJECTION
DEPO-ESTRADIOL

@ PFIZER 1MG/ML A085470 001 Mar CAHN
@ 3MG/ML A085470 002 Mar CAHN
! 5MG/ML A085470 003 Mar CAHN

ESTRADIOL; NORETHINDRONE ACETATE; RELUGOLIX

TABLET;ORAL
MYFEMBREE

+! MYOVANT SCIENCES 1MG;0.5MG;40MG N214846 001 May 26, 2021 May NEWA

ESTROPIPATE

TABLET;ORAL
OGEN .625

@ PFIZER 0.75MG A083220 001 Jan CAHN

OGEN 1.25

@ PFIZER 1.5MG A083220 002 Jan CAHN

OGEN 2.5

@ PFIZER 3MG A083220 003 Jan CAHN

OGEN 5

PFIZER 6MG A083220 004 Jan CAHN

ESZOPICLONE

TABLET;ORAL
ESZOPICLONE

@ NOSTRUM LABS INC 1MG A203087 001 May 08, 2019 Jan CAHN

@ 2MG A203087 002 May 08, 2019 Jan CAHN

@ 3MG A203087 003 May 08, 2019 Jan CAHN

ETHACRYNIC ACID

TABLET;ORAL
ETHACRYNIC ACID

>D> AB ALVOGEN 25MG A205709 001 Jul 24, 2018 Jun CAHN

>A> AB 25MG A205709 001 Jul 24, 2018 Jun CAHN

ETHINYL ESTRADIOL; ETONOGESTREL

RING;VAGINAL

ETHINYL ESTRADIOL; ETONOGESTREL

AB TEVA PHARMS USA INC 0.015MG/24HR;0.12MG/24HR A204305 001 Jan 13, 2021 Jan NEWA

ETHINYL ESTRADIOL; NORELGESTROMIN

FILM, EXTENDED RELEASE;TRANSDERMAL

ETHINYL ESTRADIOL AND NORELGESTROMIN

AB AMNEAL 0.035MG/24HR;0.15MG/24HR A213950 001 Feb 25, 2021 Feb NEWA

XULANE

AB ! MYLAN TECHNOLOGIES 0.035MG/24HR;0.15MG/24HR A200910 001 Apr 16, 2014 Feb CTEC

ETHINYL ESTRADIOL; NORETHINDRONE ACETATE

CAPSULE;ORAL

GEMMILY

AB XIROMED 0.02MG;1MG A213317 001 Nov 09, 2020 Mar CAHN

ETOMIDATE

INJECTABLE; INJECTION
ETOMIDATE

>D> AP CAPLIN 2MG/ML A215028 001 Dec 18, 2020 Jun DISC

>A> @ 2MG/ML A215028 001 Dec 18, 2020 Jun DISC

ETRAVIRINE

TABLET;ORAL

ETRAVIRINE

>A> AB AMNEAL 25MG A214196 001 Jun 14, 2021 Jun NFTG

>A> AB 100MG A214196 002 Jun 14, 2021 Jun NFTG

>A> AB 200MG A214196 003 Jun 14, 2021 Jun NFTG

EVEROLIMUS

TABLET; ORAL		AFINITOR	
AB	+ NOVARTIS	10MG	N022334 002 Mar 30, 2009 Feb CTEC
EVEROLIMUS			
	@ BIOCON PHARMA	2.5MG	A214182 001 Feb 11, 2021 Feb DISC
AB		2.5MG	A214182 001 Feb 11, 2021 Feb NEWA
	@	5MG	A214182 002 Feb 11, 2021 Feb DISC
AB		5MG	A214182 002 Feb 11, 2021 Feb NEWA
	@	7.5MG	A214182 003 Feb 11, 2021 Feb DISC
AB		7.5MG	A214182 003 Feb 11, 2021 Feb NEWA
	@	10MG	A214182 004 Feb 11, 2021 Feb DISC
AB		10MG	A214182 004 Feb 11, 2021 Feb NEWA
AB	BRECKENRIDGE	0.25MG	A205432 001 May 20, 2021 May NEWA
AB		0.5MG	A205432 002 May 20, 2021 May NEWA
AB		0.75MG	A205432 003 May 20, 2021 May NEWA
AB		2.5MG	A205426 001 Mar 05, 2021 Feb NEWA
AB		5MG	A205426 002 Mar 05, 2021 Feb NEWA
AB		7.5MG	A205426 003 Mar 05, 2021 Feb NEWA
AB		10MG	A205426 004 Mar 05, 2021 Feb NEWA

EXEMESTANE

TABLET; ORAL		AROMASIN	
AB	+! PFIZER	25MG	N020753 001 Oct 21, 1999 Mar CAHN

EXENATIDE SYNTHETIC

FOR SUSPENSION, EXTENDED RELEASE; SUBCUTANEOUS
BYDUREON

+ @ ASTRAZENECA AB 2MG/VIAL
BYDUREON PEN

N022200 001 Jan 27, 2012 Feb DISC

+ @ ASTRAZENECA AB 2MG

N022200 002 Feb 28, 2014 Feb DISC

EZETIMIBE

TABLET; ORAL		ZETIA	
AB	+! ORGANON	10MG	N021445 001 Oct 25, 2002 Feb CAHN

EZETIMIBE; ROSUVASTATIN CALCIUM

TABLET; ORAL

ROSZET

+ ALTHERA PHARMS 10MG;EQ 5MG BASE

N213072 001 Mar 23, 2021 Mar NEWA

+ 10MG;EQ 5MG BASE

N213072 001 Mar 23, 2021 Mar NEWA

+ 10MG;EQ 10MG BASE

N213072 002 Mar 23, 2021 Mar NEWA

+ 10MG;EQ 10MG BASE

N213072 002 Mar 23, 2021 Mar NEWA

+ 10MG;EQ 20MG BASE

N213072 003 Mar 23, 2021 Mar NEWA

+ 10MG;EQ 20MG BASE

N213072 003 Mar 23, 2021 Mar NEWA

+! 10MG;EQ 40MG BASE

N213072 004 Mar 23, 2021 Mar NEWA

+! 10MG;EQ 40MG BASE

N213072 004 Mar 23, 2021 Mar NEWA

EZETIMIBE; SIMVASTATIN

TABLET; ORAL

EZETIMIBE AND SIMVASTATIN

@ MYLAN 10MG;10MG

A200082 001 Dec 17, 2020 Jan DISC

@ 10MG;20MG

A200082 002 Dec 17, 2020 Jan DISC

@ 10MG;40MG

A200082 003 Dec 17, 2020 Jan DISC

@ 10MG;80MG

A200082 004 Dec 17, 2020 Jan DISC

VYTORIN

AB	+ ORGANON	10MG;10MG	N021687 001 Jul 23, 2004 Feb CAHN
AB	+	10MG;20MG	N021687 002 Jul 23, 2004 Feb CAHN
AB	+	10MG;40MG	N021687 003 Jul 23, 2004 Feb CAHN
AB	+!	10MG;80MG	N021687 004 Jul 23, 2004 Feb CAHN

FAMOTIDINE

FOR SUSPENSION; ORAL

FAMOTIDINE

AB	AKORN	40MG/5ML	A201995 001 May 30, 2014 Feb CAHN
AB	NOVITIUM PHARMA	40MG/5ML	A215043 001 Apr 20, 2021 Apr NEWA

FELODIPINE

TABLET, EXTENDED RELEASE;ORAL
FELODIPINE

>D>	AB	JUBILANT GENERICS	2.5MG	A203983	001	Aug 19, 2016	Jun	DISC
>A>	@		2.5MG	A203983	001	Aug 19, 2016	Jun	DISC
>D>	AB		5MG	A203983	002	Aug 19, 2016	Jun	DISC
>A>	@		5MG	A203983	002	Aug 19, 2016	Jun	DISC
>D>	AB		10MG	A203983	003	Aug 19, 2016	Jun	DISC
>A>	@		10MG	A203983	003	Aug 19, 2016	Jun	DISC

FENOFIBRATE

TABLET;ORAL

FENOFIBRATE

AB	AUSTARPHARMA	48MG	A208476	001	Feb 10, 2021	Jan	NEWA
AB		145MG	A208476	002	Feb 10, 2021	Jan	NEWA

FENOPROFEN CALCIUM

CAPSULE;ORAL

FENOPROFEN CALCIUM

@ RISING

EQ 200MG BASE

A072394 001 Oct 17, 1988

Jan CAHN

@

EQ 300MG BASE

A072395 001 Oct 17, 1988

Jan CAHN

FENTANYL CITRATE

INJECTABLE;INJECTION

FENTANYL CITRATE

>D>	@	FRESENIUS KABI USA	EQ 0.05MG BASE/ML	A212086	001	Sep 01, 2020	Jun	CMFD
>A>	AP		EQ 0.05MG BASE/ML	A212086	001	Sep 01, 2020	Jun	CMFD
	@		EQ 0.05MG BASE/ML	A212086	001	Sep 01, 2020	Mar	DISC

FERRIC CARBOXYMALTOSE

SOLUTION;INTRAVENOUS

INJECTAFER

+! AM REAGENT

1GM IRON/20ML (50MG IRON/ML)

N203565 003 Apr 28, 2021

May NEWA

FERRIC MALTOL

CAPSULE;ORAL

ACCRUFER

+! SHIELD TX

30MG IRON

N212320 001 Jul 25, 2019

Apr CMFD

FERRIC OXYHYDROXIDE

INJECTABLE;INJECTION

DEXFERRUM

@ AM REAGENT

EQ 50MG IRON/ML

N040024 001 Feb 23, 1996

May CAIN

FERRLECIT

AB	+!	SANOFI AVENTIS US	EQ 62.5MG IRON/5ML (EQ 12.5MG IRON/ML)	N020955	001	Feb 18, 1999	May	CPOT
----	----	-------------------	--	---------	-----	--------------	-----	------

AB	+!		62.5MG/5ML	N020955	001	Feb 18, 1999	May	CAIN
----	----	--	------------	---------	-----	--------------	-----	------

INFED

BP	+!	ALLERGAN	EQ 100MG IRON/2ML (EQ 50MG IRON/ML)	N017441	001		May	CAIN
----	----	----------	-------------------------------------	---------	-----	--	-----	------

IRON DEXTRAN

@ SANOFI AVENTIS US

EQ 50MG IRON/ML

N010787 002

May CAIN

PROFERDEX

@ NEW RIVER

EQ 50MG IRON/ML

N017807 001

May CAIN

SODIUM FERRIC GLUCONATE COMPLEX IN SUCROSE

AB		WEST-WARD PHARMS INT	EQ 62.5MG IRON/5ML (EQ 12.5MG IRON/ML)	A078215	001	Mar 31, 2011	May	CPOT
----	--	----------------------	--	---------	-----	--------------	-----	------

AB			62.5MG/5ML	A078215	001	Mar 31, 2011	May	CAIN
----	--	--	------------	---------	-----	--------------	-----	------

INJECTABLE;INTRAVENOUS

VENOFER

+ AM REAGENT

EQ 50MG IRON/2.5ML (EQ 20MG IRON/ML)

N021135 002 Mar 20, 2005

May CPOT

+

EQ 50MG BASE/2.5ML (EQ 20MG BASE/ML)

N021135 002 Mar 20, 2005

May CAIN

@

EQ 65MG IRON/3.25ML (EQ 20MG IRON/ML)

N021135 005 Mar 29, 2013

May CPOT

@

EQ 65MG BASE/3.25ML (EQ 20MG BASE/ML)

N021135 005 Mar 29, 2013

May CAIN

@

EQ 75MG IRON/3.75ML (EQ 20MG IRON/ML)

N021135 003 Mar 29, 2005

May CPOT

@

EQ 75MG BASE/3.75ML (EQ 20MG BASE/ML)

N021135 003 Mar 29, 2005

May CAIN

+!

EQ 100MG IRON/5ML (EQ 20MG

N021135 001 Nov 06, 2000

May CPOT

INJECTABLE; INTRAVENOUS
VENOFER

		IRON/ML)							
+!		EQ 100MG BASE/5ML (EQ 20MG BASE/ML)		N021135	001	Nov 06, 2000	May	CAIN	
+		EQ 200MG IRON/10ML (EQ 20MG IRON/ML)		N021135	004	Feb 09, 2007	May	CPOT	
+		EQ 200MG BASE/10ML (EQ 20MG BASE/ML)		N021135	004	Feb 09, 2007	May	CAIN	

TABLET, CHEWABLE; ORAL
VELPHORO

+!	VIFOR FRESENIUS	EQ 500MG IRON		N205109	001	Nov 27, 2013	May	CPOT	
+!		500MG		N205109	001	Nov 27, 2013	May	CAIN	

FERUMOXYTOLSOLUTION; INTRAVENOUS
FERAHEME

AB	+!	COVIS	EQ 510MG IRON/17ML (EQ 30MG IRON/ML)		N022180	001	Jun 30, 2009	Mar	CAHN
AB		SANDOZ INC	EQ 510MG IRON/17ML (EQ 30MG IRON/ML)		A206604	001	Jan 15, 2021	Jan	NFTG

FINASTERIDETABLET; ORAL
FINASTERIDE

@	ACTAVIS TOTOWA TEVA	5MG		A077914	001	Mar 28, 2007	May	DISC	
---	---------------------	-----	--	---------	-----	--------------	-----	------	--

FINGOLIMOD HYDROCHLORIDECAPSULE; ORAL
FINGOLIMOD HYDROCHLORIDE

>D>	AB	APOTEX	EQ 0.5MG BASE		A207993	001	Dec 18, 2020	Jun	DISC
>A>		@	EQ 0.5MG BASE		A207993	001	Dec 18, 2020	Jun	DISC
	AB	DR REDDYS	EQ 0.5MG BASE		A208000	001	Mar 05, 2021	Feb	NEWA
		@ MYLAN	EQ 0.5MG BASE		A208005	001	Jan 19, 2021	Jan	DISC
	AB		EQ 0.5MG BASE		A208005	001	Jan 19, 2021	Jan	NEWA
		@ ZYDUS PHARMS	EQ 0.5MG BASE		A207994	001	Oct 14, 2020	Mar	DISC

FLECAINIDE ACETATETABLET; ORAL
TAMBOCOR

>A>	+	@ ALVOGEN	50MG		N018830	004	Aug 23, 1988	Jun	CAHN
>A>	+	@	100MG		N018830	001	Oct 31, 1985	Jun	CAHN
>A>	+	@	150MG		N018830	003	Jun 03, 1988	Jun	CAHN
>A>		@	200MG		N018830	002	Oct 31, 1985	Jun	CAHN
>D>	+	@ CNTY LINE PHARMS	50MG		N018830	004	Aug 23, 1988	Jun	CAHN
	+	@	50MG		N018830	004	Aug 23, 1988	Jan	DISC
>D>	+	@	100MG		N018830	001	Oct 31, 1985	Jun	CAHN
	+	@	100MG		N018830	001	Oct 31, 1985	Jan	DISC
>D>	+	@	150MG		N018830	003	Jun 03, 1988	Jun	CAHN
	+	@	150MG		N018830	003	Jun 03, 1988	Jan	DISC
>D>		@	200MG		N018830	002	Oct 31, 1985	Jun	CAHN

FLUDEOXYGLUCOSE F-18INJECTABLE; INTRAVENOUS
FLUDEOXYGLUCOSE F18

AP	CARDINAL HEALTH 414	20-500mCi/ML		A203603	002	Sep 27, 2018	Mar	NEWA	
	NUKEMED	4-500mCi/ML		A203911	001	Apr 22, 2015	Jan	CAHN	
AP	PHARMALOGIC HLDGS	20-200mCi/ML		A203664	001	Feb 04, 2014	Jan	CAHN	
AP	PRECISION NUCLEAR	20-500mCi/ML		A204546	001	Apr 07, 2015	Mar	CTEC	

FLUMAZENILINJECTABLE; INJECTION
FLUMAZENIL

AP	BAXTER HLTHCARE CORP	0.5MG/5ML (0.1MG/ML)		A076755	002	Oct 12, 2004	Mar	CMFD	
AP		1MG/10ML (0.1MG/ML)		A076755	001	Oct 12, 2004	Mar	CMFD	

FLUOCINOLONE ACETONIDEOIL; TOPICAL
FLUOCINOLONE ACETONIDE

AT	SOLARIS PHARMA CORP	0.01%		A212760	001	Apr 02, 2021	Mar	NEWA	
AT		0.01%		A212761	001	Apr 02, 2021	Mar	NEWA	

OIL/DROPS;OTIC

FLUOCINOLONE ACETONIDE

AT	SOLARIS PHARMA CORP	0.01%	A212762	001	Apr 02, 2021	Mar	NEWA
AT	TASMAN PHARMA	0.01%	A213264	001	Feb 05, 2021	Jan	NEWA

FLUOCINONIDE

CREAM;TOPICAL

LIDEX

>A>	+ @ ALVOGEN	0.05%	N016908	002		Jun	CAHN
>D>	+ @ CNTY LINE PHARMS	0.05%	N016908	002		Jun	CAHN

LIDEX-E

>A>	AB2 + ALVOGEN	0.05%	N016908	003		Jun	CAHN
>D>	AB2 + CNTY LINE PHARMS	0.05%	N016908	003		Jun	CAHN

VANOS

AB	+! BAUSCH	0.1%	N021758	001	Feb 11, 2005	May	CAHN
----	-----------	------	---------	-----	--------------	-----	------

GEL;TOPICAL

FLUOCINONIDE

>A>	AB + ALVOGEN	0.05%	N017373	001		Jun	CAHN
>D>	AB + CNTY LINE PHARMS	0.05%	N017373	001		Jun	CAHN

OINTMENT;TOPICAL

LIDEX

>A>	AB + ALVOGEN	0.05%	N016909	002		Jun	CAHN
>D>	AB + CNTY LINE PHARMS	0.05%	N016909	002		Jun	CAHN

SOLUTION;TOPICAL

LIDEX

>A>	AT + ALVOGEN	0.05%	N018849	001	Apr 06, 1984	Jun	CAHN
>D>	AT + CNTY LINE PHARMS	0.05%	N018849	001	Apr 06, 1984	Jun	CAHN

FLUOROURACIL

INJECTABLE;INJECTION

FLUOROURACIL

AP	FRESENIUS KABI USA	500MG/10ML (50MG/ML)	A040279	002	Sep 30, 1998	May	CHRS
AP		1GM/20ML (50MG/ML)	A040279	001	Sep 30, 1998	May	CHRS
AP		2.5GM/50ML (50MG/ML)	A040278	001	Sep 30, 1998	May	CHRS
AP		5GM/100ML (50MG/ML)	A040278	002	Sep 30, 1998	May	CHRS
	@ NOVAST LABS	5GM/100ML (50MG/ML)	A209271	001	Dec 11, 2019	Mar	CPOT
AP	TEVA PHARMS USA	500MG/10ML (50MG/ML)	A040333	001	Jan 27, 2000	May	CHRS

FLUOXETINE HYDROCHLORIDE

CAPSULE;ORAL

FLUOXETINE HYDROCHLORIDE

	@ ACCORD HLTHCARE	EQ 10MG BASE	A202729	001	Aug 27, 2020	Feb	DISC
	@	EQ 20MG BASE	A202729	002	Aug 27, 2020	Feb	DISC
	@	EQ 40MG BASE	A202729	003	Aug 27, 2020	Feb	DISC
>D>	@ CELLTRION	EQ 10MG BASE	A078143	001	Jan 16, 2008	Jun	CAHN
>D>	@	EQ 20MG BASE	A078143	002	Jan 16, 2008	Jun	CAHN
>D>	@	EQ 40MG BASE	A078143	003	Jan 16, 2008	Jun	CAHN
>A>	@ GRANULES	EQ 10MG BASE	A078143	001	Jan 16, 2008	Jun	CAHN
>A>	@	EQ 20MG BASE	A078143	002	Jan 16, 2008	Jun	CAHN
>A>	@	EQ 40MG BASE	A078143	003	Jan 16, 2008	Jun	CAHN

TABLET;ORAL

FLUOXETINE HYDROCHLORIDE

	TORRENT	EQ 10MG BASE	A206937	001	Oct 21, 2016	Mar	CHRS
	!	EQ 20MG BASE	A206937	002	Oct 21, 2016	Mar	CHRS
AB	UPSHER SMITH LABS	EQ 10MG BASE	A211696	001	Jan 30, 2019	May	CAHN
AB		EQ 20MG BASE	A211696	002	Jan 30, 2019	May	CAHN

SARAFEM

	+ @ APIL	EQ 10MG BASE	N021860	001	May 19, 2006	Mar	DISC
	+ @	EQ 20MG BASE	N021860	003	May 19, 2006	Mar	DISC

FLUOXYMESTERONE

TABLET;ORAL

FLUOXYMESTERONE

	@ UPSHER SMITH LABS	10MG	A088342	001	Oct 21, 1983	Jan	DISC
--	---------------------	------	---------	-----	--------------	-----	------

FLUPHENAZINE HYDROCHLORIDE

TABLET;ORAL

FLUPHENAZINE HYDROCHLORIDE

AB	CEROVENE INC	1MG	A214534	001	Jan 07, 2021	Jan	NEWA
AB		2.5MG	A214534	002	Jan 07, 2021	Jan	NEWA
AB		5MG	A214534	003	Jan 07, 2021	Jan	NEWA
AB		10MG	A214534	004	Jan 07, 2021	Jan	NEWA

TABLET;ORAL

FLUPHENAZINE HYDROCHLORIDE

AB	NOVITIUM PHARMA	1MG	A214674	001	Mar 01, 2021	Feb	NEWA
AB		2.5MG	A214674	002	Mar 01, 2021	Feb	NEWA
AB		5MG	A214674	003	Mar 01, 2021	Feb	NEWA
AB		10MG	A214674	004	Mar 01, 2021	Feb	NEWA
AB	ZYDUS	1MG	A214552	001	May 27, 2021	May	NEWA
AB		2.5MG	A214552	002	May 27, 2021	May	NEWA
AB		5MG	A214552	003	May 27, 2021	May	NEWA
AB		10MG	A214552	004	May 27, 2021	May	NEWA

FLURBIPROFEN SODIUM

SOLUTION/DROPS;OPHTHALMIC

FLURBIPROFEN SODIUM

!	BAUSCH AND LOMB	0.03%	A074447	001	Jan 04, 1995	Jan	CHRS
		0.03%	A074447	001	Jan 04, 1995	Jan	CTEC
	OCUFEN						
+	@ ALLERGAN	0.03%	N019404	001	Dec 31, 1986	Jan	DISC

FLUTAMIDE

CAPSULE;ORAL

FLUTAMIDE

	@ CIPLA	125MG	A075780	001	Sep 19, 2001	Mar	DISC
>D>	!	PAR PHARM	A075298	001	Sep 18, 2001	Jun	CAHN
	!		A075298	001	Sep 18, 2001	Mar	CHRS
			A075298	001	Sep 18, 2001	Mar	CTEC
>A>	!	WAYLIS THERAP	A075298	001	Sep 18, 2001	Jun	CAHN

FLUVASTATIN SODIUM

TABLET, EXTENDED RELEASE;ORAL

FLUVASTATIN SODIUM

AB	BEIJING	EQ 80MG BASE	A209397	001	Apr 26, 2021	Apr	NEWA
----	---------	--------------	---------	-----	--------------	-----	------

FLUVOXAMINE MALEATE

CAPSULE, EXTENDED RELEASE;ORAL

FLUVOXAMINE MALEATE

	@ BIONPHARMA INC	100MG	A212182	002	Sep 16, 2020	Feb	DISC
--	------------------	-------	---------	-----	--------------	-----	------

FORMOTEROL FUMARATE

SOLUTION;INHALATION

FORMOTEROL FUMARATE

>A>								
>A>	AN	TEVA PHARMS USA INC	0.02MG/2ML	A091141	001	Jun 22, 2021	Jun	NFTG

FORMOTEROL FUMARATE; MOMETASONE FUROATE

AEROSOL, METERED;INHALATION

DULERA

>D>	+	MERCK SHARP DOHME	0.005MG/INH;0.05MG/INH	N022518	003	Aug 12, 2019	Jun	CAHN
>D>	+	!	0.005MG/INH;0.1MG/INH	N022518	001	Jun 22, 2010	Jun	CAHN
>D>	+	!	0.005MG/INH;0.2MG/INH	N022518	002	Jun 22, 2010	Jun	CAHN
>A>	+	ORGANON	0.005MG/INH;0.05MG/INH	N022518	003	Aug 12, 2019	Jun	CAHN
>A>	+	!	0.005MG/INH;0.1MG/INH	N022518	001	Jun 22, 2010	Jun	CAHN
>A>	+	!	0.005MG/INH;0.2MG/INH	N022518	002	Jun 22, 2010	Jun	CAHN

FOSAPREPITANT DIMEGLUMINE

POWDER;INTRAVENOUS

FOSAPREPITANT DIMEGLUMINE

AP	AUROBINDO PHARMA LTD	EQ 150MG BASE/VIAL	A210625	001	Jan 12, 2021	Jan	NEWA	
	@ MYLAN LABS LTD	EQ 115MG BASE/VIAL	A204015	001	Sep 05, 2019	Mar	DISC	
>A>	AP	PRAXGEN	EQ 150MG BASE/VIAL	A211624	001	Sep 05, 2019	Jun	CAHN
>D>	AP	SUNGEN PHARMA	EQ 150MG BASE/VIAL	A211624	001	Sep 05, 2019	Jun	CAHN

FOSCARNET SODIUM

INJECTABLE;INJECTION

FOSCARNET SODIUM

AP	FRESENIUS KABI USA	2.4GM/100ML	A212483	001	Jan 29, 2021	Jan	NEWA	
AP	GLAND PHARMA LTD	2.4GM/100ML	A213001	001	Apr 21, 2021	Apr	NEWA	
	FOSCAVIR							
AP	+!	CLINIGEN HLTHCARE	2.4GM/100ML	N020068	001	Sep 27, 1991	Jan	CTEC

FOSDENOPTERIN HYDROBROMIDEPOWDER; INTRAVENOUS
NULIBRY

+! ORIGIN EQ 9.5MG BASE/VIAL N214018 001 Feb 26, 2021 Feb NEWA

FULVESTRANTINJECTABLE; INTRAMUSCULAR
FULVESTRANT>A> AO APOTEX 50MG/ML A211730 001 Jun 11, 2021 Jun NEWA
AO AUROMEDICS PHARMA 50MG/ML A208811 001 Jul 23, 2019 Jan CAHNFUROSEMIDEINJECTABLE; INJECTION
FUROSEMIDEAP ACCORD HLTHCARE 10MG/ML A070017 001 Dec 15, 1986 Apr CMFD
AP ATHENEX INC 10MG/ML A214766 001 Jan 27, 2021 Jun NEWA
>A> @ HIKMA 10MG/ML N018267 001 Jun CAHN
>D> @ WEST-WARD PHARMS INT 10MG/ML N018267 001 Jun CAHN

TABLET; ORAL

LASIX

AB + VALIDUS PHARMS 20MG N016273 002 Feb CAHN
AB + 40MG N016273 001 Feb CAHN
AB +! 80MG N016273 003 Feb CAHNGABAPENTINCAPSULE; ORAL
GABAPENTINAB ASCENT PHARMS INC 100MG A214956 001 May 10, 2021 Apr NEWA
AB 300MG A214956 002 May 10, 2021 Apr NEWA
AB 400MG A214956 003 May 10, 2021 Apr NEWA
>D> AB EPIC PHARMA LLC 100MG A207099 001 Mar 24, 2017 Jun CAHN
>D> AB 300MG A207099 002 Mar 24, 2017 Jun CAHN
>D> AB 400MG A207099 003 Mar 24, 2017 Jun CAHN
>A> AB GRAVITI PHARMS 100MG A207099 001 Mar 24, 2017 Jun CAHN
>A> AB 300MG A207099 002 Mar 24, 2017 Jun CAHN
>A> AB 400MG A207099 003 Mar 24, 2017 Jun CAHN
AB ZHEJIANG YONGTAI 100MG A213603 001 Aug 17, 2020 Apr CMFD
@ 100MG A213603 001 Aug 17, 2020 Feb DISC
AB 300MG A213603 002 Aug 17, 2020 Apr CMFD
@ 300MG A213603 002 Aug 17, 2020 Feb DISC
AB 400MG A213603 003 Aug 17, 2020 Apr CMFD
@ 400MG A213603 003 Aug 17, 2020 Feb DISCGALANTAMINE HYDROBROMIDE

TABLET; ORAL

GALANTAMINE HYDROBROMIDE

AB ! YABAO PHARM EQ 4MG BASE A077604 001 Feb 06, 2009 May CHRS
RAZADYNE
+ @ JANSSEN PHARMS EQ 4MG BASE N021169 001 Feb 28, 2001 May DISC
+ @ EQ 8MG BASE N021169 002 Feb 28, 2001 May DISC
+ @ EQ 12MG BASE N021169 003 Feb 28, 2001 May DISCGATIFLOXACINSOLUTION/DROPS; OPHTHALMIC
GATIFLOXACINAT AKORN 0.5% A203189 001 Sep 03, 2014 Feb CAHN
>D> AT MYLAN 0.5% A206446 001 Jun 08, 2018 Jun DISC
>A> @ 0.5% A206446 001 Jun 08, 2018 Jun DISCGEMCITABINE HYDROCHLORIDE

INJECTABLE; INJECTION

GEMCITABINE HYDROCHLORIDE

>A> AP HIKMA INTL PHARMS EQ 200MG BASE/VIAL A206617 001 Jun 25, 2021 Jun NEWA
>A> AP EQ 1GM BASE/VIAL A206617 002 Jun 25, 2021 Jun NEWA
AP ! JIANGSU HANSON PHARM EQ 200MG BASE/VIAL A202485 001 May 07, 2013 Feb CHRS
AP ! EQ 1GM BASE/VIAL A202485 002 May 07, 2013 Feb CHRS
AP MEITHEAL 200MG/5.26ML (38MG/ML) A212129 001 Dec 11, 2020 Jan CAHN
AP 1GM/26.3ML (38MG/ML) A212129 002 Dec 11, 2020 Jan CAHN
AP 2GM/52.6ML (38MG/ML) A212129 003 Dec 11, 2020 Jan CAHN
GEMZAR
+ @ LILLY EQ 200MG BASE/VIAL N020509 001 May 15, 1996 Feb DISC

	INJECTABLE; INJECTION						
	GEMZAR						
	+ @	EQ 1GM BASE/VIAL	N020509	002	May 15, 1996	Feb	DISC
	<u>GEMFIBROZIL</u>						
	TABLET; ORAL						
	GEMFIBROZIL						
AB	ASCENT PHARMS INC	600MG	A214603	001	Jan 13, 2021	Jan	NEWA
	<u>GENTAMICIN SULFATE</u>						
	INJECTABLE; INJECTION						
	GENTAMICIN SULFATE						
>A>	@ HIKMA	EQ 10MG BASE/ML	A062251	002		Jun	CAHN
>A>	@	EQ 40MG BASE/ML	A062251	001		Jun	CAHN
>D>	@ WEST-WARD PHARMS INT	EQ 10MG BASE/ML	A062251	002		Jun	CAHN
>D>	@	EQ 40MG BASE/ML	A062251	001		Jun	CAHN
	<u>GLECAPREVIR; PIBRENTASVIR</u>						
>A>	PELLETS; ORAL						
>A>	MAVYRET						
>A>	+! ABBVIE INC	50MG; 20MG/PACKET	N215110	001	Jun 10, 2021	Jun	NEWA
	<u>GLYBURIDE</u>						
	TABLET; ORAL						
	GLYNASE						
AB	+ PFIZER	1.5MG	N020051	001	Mar 04, 1992	Feb	CAHN
AB	+	3MG	N020051	002	Mar 04, 1992	Feb	CAHN
	+ @	4.5MG	N020051	003	Sep 24, 1993	Feb	CAHN
AB	+!	6MG	N020051	004	Sep 24, 1993	Feb	CAHN
	MICRONASE						
	+ @ PFIZER	1.25MG	N017498	001	May 01, 1984	Feb	CAHN
	@	2.5MG	N017498	002	May 01, 1984	Feb	CAHN
	+ @	5MG	N017498	003	May 01, 1984	Feb	CAHN
	<u>GLYCOPYRROLATE</u>						
	INJECTABLE; INJECTION						
	GLYCOPYRROLATE						
AP	ATHENEX INC	0.2MG/ML	A210083	001	Feb 21, 2020	Jan	CAHN
>A>	AP HONG KONG	0.2MG/ML	A212802	001	Jul 06, 2021	Jun	NEWA
AP	XIROMED	0.2MG/ML	A212227	001	Mar 04, 2021	Feb	NEWA
	TABLET; ORAL						
	ROBINUL						
>D>	+ @ CASPER PHARMA LLC	1MG	N012827	001		Jun	CMFD
>A>	AA +	1MG	N012827	001		Jun	CMFD
	ROBINUL FORTE						
>D>	+ @ CASPER PHARMA LLC	2MG	N012827	002		Jun	CMFD
>A>	AA +	2MG	N012827	002		Jun	CMFD
	<u>GLYCOPYRRONIUM TOSYLATE</u>						
	CLOTH; TOPICAL						
	QBREXZA						
	+! JOURNEY	EQ 2.4% BASE	N210361	001	Jun 28, 2018	May	CAHN
	<u>GRANISETRON HYDROCHLORIDE</u>						
	SOLUTION; ORAL						
	GRANISOL						
	@ INTRA SANA LABS	EQ 2MG BASE/10ML	A078334	001	Feb 28, 2008	Jan	CAHN
	<u>GUANFACINE HYDROCHLORIDE</u>						
	TABLET; ORAL						
	GUANFACINE HYDROCHLORIDE						
AB	! AMNEAL PHARM	EQ 2MG BASE	A075109	002	Nov 25, 1998	Jan	CHRS
	@ MYLAN	EQ 1MG BASE	A074796	001	Jan 27, 1997	Jan	DISC
	@	EQ 2MG BASE	A074796	002	Jan 27, 1997	Jan	DISC
AB	UNICHEM	EQ 1MG BASE	A214689	001	Mar 03, 2021	Feb	NEWA
AB		EQ 2MG BASE	A214689	002	Mar 03, 2021	Feb	NEWA
	TABLET, EXTENDED RELEASE; ORAL						
	GUANFACINE HYDROCHLORIDE						
	@ YICHANG HUMANWELL	EQ 1MG BASE	A213428	001	Nov 25, 2020	May	DISC
	@	EQ 2MG BASE	A213428	002	Nov 25, 2020	May	DISC
	@	EQ 3MG BASE	A213428	003	Nov 25, 2020	May	DISC
	@	EQ 4MG BASE	A213428	004	Nov 25, 2020	May	DISC

HALCINONIDESOLUTION;TOPICAL
HALOG

+! SUN PHARM INDS INC 0.1% N017823 001 Apr CRLD

HALOBETASOL PROPIONATEOINTMENT;TOPICAL
HALOBETASOL PROPIONATE

@ COSETTE 0.05% A077721 001 Sep 07, 2006 Mar DISC
 AB ! PERRIGO ISRAEL 0.05% A076872 001 Dec 16, 2004 Mar CHRS
 ULTRAVATE
 + @ SUN PHARM INDS INC 0.05% N019968 001 Dec 17, 1990 Mar DISC

HALOPERIDOLTABLET;ORAL
HALOPERIDOL

AB CYCLE PHARMS LTD 2MG A071130 001 Feb 17, 1987 Apr CMFD
 AB 5MG A071131 001 Feb 17, 1987 Apr CMFD
 AB 10MG A071132 001 May 12, 1987 Apr CMFD

HALOPERIDOL LACTATECONCENTRATE;ORAL
HALDOL

+ @ ORTHO MCNEIL EQ 2MG BASE/ML N015922 001 Mar CRLD

HEPARIN SODIUMINJECTABLE;INJECTION
HEPARIN SODIUM

>D> AP BE PHARMS 1,000 UNITS/ML A214804 001 Dec 29, 2020 Jun DISC
 >A> @ 1,000 UNITS/ML A214804 001 Dec 29, 2020 Jun DISC
 >D> AP 10,000 UNITS/ML A214839 001 Dec 29, 2020 Jun DISC
 >A> @ 10,000 UNITS/ML A214839 001 Dec 29, 2020 Jun DISC
 HEPARIN SODIUM 1,000 UNITS IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER
 AP FRESENIUS KABI USA 200 UNITS/100ML A212441 001 Jul 24, 2020 Apr CMFD
 @ 200 UNITS/100ML A212441 001 Jul 24, 2020 Jan DISC
 HEPARIN SODIUM 2,000 UNITS IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER
 AP FRESENIUS KABI USA 200 UNITS/100ML A212441 002 Jul 24, 2020 Apr CMFD
 @ 200 UNITS/100ML A212441 002 Jul 24, 2020 Jan DISC
 HEPARIN SODIUM PRESERVATIVE FREE
 @ SHENZHEN TECHDOW 1,000 UNITS/ML A202732 001 Jun 12, 2014 Apr DISC

HYDRALAZINE HYDROCHLORIDETABLET;ORAL
HYDRALAZINE HYDROCHLORIDE

AA UPSHER SMITH LABS 10MG A209251 001 Jul 09, 2018 May CAHN
 AA 25MG A209251 002 Jul 09, 2018 May CAHN
 AA 50MG A209251 003 Jul 09, 2018 May CAHN
 AA 100MG A209251 004 Jul 09, 2018 May CAHN

HYDROCHLOROTHIAZIDECAPSULE;ORAL
MICROZIDE

AB +! TEVA BRANDED PHARM 12.5MG N020504 001 Dec 27, 1996 Mar CAHN

HYDROCHLOROTHIAZIDE; LISINAPRILTABLET;ORAL
ZESTORETIC

AB + ALMATICA 12.5MG;10MG N019888 003 Nov 18, 1993 Jan CAHN
 AB +! 12.5MG;20MG N019888 001 Sep 20, 1990 Jan CAHN
 AB +! 25MG;20MG N019888 002 Jul 20, 1989 Jan CAHN

HYDROCHLOROTHIAZIDE; LOSARTAN POTASSIUMTABLET;ORAL
LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE

>D> AB CADISTA PHARMS 12.5MG;50MG A201845 001 Sep 18, 2012 Jun CAHN
 >D> AB 12.5MG;100MG A201845 002 Sep 18, 2012 Jun CAHN
 >D> AB 25MG;100MG A201845 003 Sep 18, 2012 Jun CAHN
 >A> AB JUBILANT CADISTA 12.5MG;50MG A201845 001 Sep 18, 2012 Jun CAHN
 >A> AB 12.5MG;100MG A201845 002 Sep 18, 2012 Jun CAHN
 >A> AB 25MG;100MG A201845 003 Sep 18, 2012 Jun CAHN

HYDROCHLOROTHIAZIDE; METOPROLOL SUCCINATE

TABLET, EXTENDED RELEASE;ORAL
DUTOPROL

>D>	+	CONCORDIA	12.5MG;EQ 25MG TARTRATE	N021956	001	Aug 28, 2006	Jun	DISC
>A>	+	@	12.5MG;EQ 25MG TARTRATE	N021956	001	Aug 28, 2006	Jun	DISC
>D>	+		12.5MG;EQ 50MG TARTRATE	N021956	002	Aug 28, 2006	Jun	DISC
>A>	+	@	12.5MG;EQ 50MG TARTRATE	N021956	002	Aug 28, 2006	Jun	DISC
>D>	+	!	12.5MG;EQ 100MG TARTRATE	N021956	003	Aug 28, 2006	Jun	DISC
>A>	+	@	12.5MG;EQ 100MG TARTRATE	N021956	003	Aug 28, 2006	Jun	DISC

HYDROCHLOROTHIAZIDE; METOPROLOL TARTRATE

TABLET;ORAL
LOPRESSOR HCT

AB	+	VALIDUS PHARMS	25MG;50MG	N018303	001	Dec 31, 1984	Feb	CAHN
	+	@	25MG;100MG	N018303	002	Dec 31, 1984	Feb	CAHN
	+	@	50MG;100MG	N018303	003	Dec 31, 1984	Feb	CAHN

HYDROCODONE BITARTRATE

CAPSULE, EXTENDED RELEASE;ORAL
ZOHYDRO ER

AB	+	! RECRO GAINESVILLE	10MG	N202880	001	Oct 25, 2013	May	CAHN
AB	+		15MG	N202880	002	Oct 25, 2013	May	CAHN
AB	+		20MG	N202880	003	Oct 25, 2013	May	CAHN
AB	+		30MG	N202880	004	Oct 25, 2013	May	CAHN
AB	+		40MG	N202880	005	Oct 25, 2013	May	CAHN
AB	+		50MG	N202880	006	Oct 25, 2013	May	CAHN

TABLET, EXTENDED RELEASE;ORAL
HYDROCODONE BITARTRATE

AB		ALVOGEN PINE BROOK	20MG	A208269	001	Mar 01, 2021	Feb	NFTG
AB			30MG	A208269	002	Mar 01, 2021	Feb	NFTG
AB			40MG	A208269	003	Mar 01, 2021	Feb	NFTG
AB			60MG	A208269	004	Mar 01, 2021	Feb	NFTG
AB			80MG	A208269	005	Mar 01, 2021	Feb	NFTG
AB			100MG	A208269	006	Mar 01, 2021	Feb	NFTG
AB			120MG	A208269	007	Mar 01, 2021	Feb	NFTG

HYDROCODONE BITARTRATE; IBUPROFEN

TABLET;ORAL

HYDROCODONE BITARTRATE AND IBUPROFEN

AB		NOSTRUM LABS INC	5MG;200MG	A077727	001	Nov 06, 2006	Jan	CAHN
AB			7.5MG;200MG	A077723	001	Nov 06, 2006	Jan	CAHN
			10MG;200MG	A077723	002	Nov 06, 2006	Mar	CTEC
AB			10MG;200MG	A077723	002	Nov 06, 2006	Jan	CAHN
		REPREXAIN						
	@	AMNEAL PHARMS NY	2.5MG;200MG	A076642	003	Oct 19, 2007	Mar	DISC
	@		10MG;200MG	A076642	004	Oct 19, 2007	Mar	DISC

HYDROCORTISONE

CREAM;TOPICAL
SYNACORT

	@	BAUSCH	0.5%	A087459	001		May	CAHN
	@		1%	A087458	001		May	CAHN
	@		2.5%	A087457	001		May	CAHN

ENEMA;RECTAL
COLOCORT

AB		CHARTWELL	100MG/60ML	A075172	001	Dec 03, 1999	Apr	CAHN
----	--	-----------	------------	---------	-----	--------------	-----	------

HYDROCORTISONE PROBUTATE

CREAM;TOPICAL
PANDEL

+	!	ANI PHARMS	0.1%	N020453	001	Feb 28, 1997	Apr	CAHN
---	---	------------	------	---------	-----	--------------	-----	------

HYDROCORTISONE SODIUM PHOSPHATE

INJECTABLE;INJECTION
HYDROCORTONE

+	@	MERCK	EQ 50MG BASE/ML	N012052	001		Feb	CRLD
---	---	-------	-----------------	---------	-----	--	-----	------

HYDROCORTISONE VALERATE

CREAM; TOPICAL
HYDROCORTISONE VALERATE

AB COSETTE 0.2% A213724 001 Feb 11, 2021 Feb NEWA

HYDROMORPHONE HYDROCHLORIDE

TABLET; ORAL
HYDROMORPHONE HYDROCHLORIDE

@ LANNETT CO INC 2MG A077471 002 Dec 09, 2009 Mar DISC
@ 4MG A077471 003 Dec 09, 2009 Mar DISC
@ 8MG A077471 001 Dec 09, 2009 Mar DISC

HYDROXYPROGESTERONE CAPROATE

SOLUTION; INTRAMUSCULAR
MAKENA

AP1 +! COVIS 1250MG/5ML (250MG/ML) N021945 001 Feb 03, 2011 Mar CAHN
MAKENA PRESERVATIVE FREE
AP +! COVIS 250MG/ML (250MG/ML) N021945 002 Feb 19, 2016 Mar CAHN
SOLUTION; SUBCUTANEOUS
MAKENA (AUTOINJECTOR)
+! COVIS 275MG/1.1ML (250MG/ML) N021945 004 Feb 14, 2018 Mar CAHN

HYDROXYUREA

TABLET; ORAL
SIKLOS

+! ADDMEDICA SAS 1GM N208843 002 Dec 21, 2017 Mar CHRS

HYDROXYZINE HYDROCHLORIDE

TABLET; ORAL
HYDROXYZINE HYDROCHLORIDE

AB PRINSTON INC 10MG A040580 003 May 27, 2005 Feb CMS1
AB 25MG A040580 002 May 27, 2005 Feb CMS1

IBANDRONATE SODIUM

INJECTABLE; INTRAVENOUS
IBANDRONATE SODIUM

>A> AP NANG KUANG PHARM CO EQ 3MG BASE/3ML A204329 001 Jun 16, 2021 Jun NEWA

IBREXAFUNGERP CITRATE

>A> TABLET; ORAL
>A> BREXAFEMME
>A> +! SCYNEXIS EQ 150MG BASE N214900 001 Jun 01, 2021 Jun NEWA

IBRUTINIB

CAPSULE; ORAL
IBRUTINIB

AB ZYDUS 70MG A211344 001 Mar 31, 2021 Mar NFTG
AB 140MG A211344 002 Mar 31, 2021 Mar NFTG

IBUPROFEN

TABLET; ORAL
IBUPROFEN

@ VINTAGE PHARMS 400MG A071644 001 Feb 01, 1988 Feb DISC

IBUTILIDE FUMARATE

INJECTABLE; INJECTION
CORVERT

AP +! PFIZER 0.1MG/ML N020491 001 Dec 28, 1995 Feb CAHN

ICATIBANT ACETATE

INJECTABLE; SUBCUTANEOUS
ICATIBANT ACETATE

@ DR REDDYS EQ 30MG BASE/3ML (EQ 10MG BASE/ML) A213054 001 Oct 05, 2020 May DISC
GLENMARK PHARMS LTD EQ 30MG BASE/3ML (EQ 10MG BASE/ML) A213222 001 May 21, 2021 May NEWA

ICOSAPENT ETHYL

		CAPSULE; ORAL							
		ICOSAPENT ETHYL							
>A>	AB	APOTEX	1GM	A209437	001	Jun 30, 2021	Jun	NEWA	
		@ TEVA PHARMS USA	500MG	A209525	001	Sep 11, 2020	Mar	DISC	
		@	1GM	A209525	002	Sep 11, 2020	Mar	DISC	
		VASCEPA							
		+ AMARIN PHARMS	500MG	N202057	002	Feb 16, 2017	Mar	CTEC	

ILOPROST

SOLUTION; INHALATION
VENTAVIS

+!	ACTELION	10MCG/ML (10MCG/ML)	N021779	002	Dec 08, 2005	Feb	CAHN
@		20MCG/2ML (10MCG/ML)	N021779	001	Dec 29, 2004	Feb	CAHN
+!		20MCG/ML (20MCG/ML)	N021779	003	Aug 07, 2009	Feb	CAHN

IMIQUIMOD

CREAM; TOPICAL
IMIQUIMOD

AB	TARO	3.75%	A205971	001	Jan 26, 2021	Jan	NFTG
----	------	-------	---------	-----	--------------	-----	------

INDOCYANINE GREEN

INJECTABLE; INJECTION
INDOCYANINE GREEN

>D>	AP	DIAGNOSTIC GREEN	25MG/VIAL	A040811	001	Nov 21, 2007	Jun	CAHN
>A>	AP	RENEW PHARMS	25MG/VIAL	A040811	001	Nov 21, 2007	Jun	CAHN

INDOMETHACIN

CAPSULE; ORAL
INDOMETHACIN

	@	JUBILANT GENERICS	25MG	A205215	001	Aug 25, 2017	Jan	DISC	
	@		50MG	A205215	002	Aug 25, 2017	Jan	DISC	
		TIVORBEX							
	+ @	GENUS	20MG	N204768	001	Feb 24, 2014	Apr	DISC	
	+ @		40MG	N204768	002	Feb 24, 2014	Apr	DISC	
		CAPSULE, EXTENDED RELEASE; ORAL INDOMETHACIN							
>D>	AB	@ AUROBINDO PHARMA LTD	75MG	A204243	001	Dec 27, 2016	Jan	DISC	
>A>		JUBILANT GENERICS	75MG	A202706	001	Oct 05, 2015	Jun	DISC	
		@	75MG	A202706	001	Oct 05, 2015	Jun	DISC	

INFIGRATINIB PHOSPHATE

CAPSULE; ORAL
TRUSELTIQ

+	QED THERAP	25MG	N214622	001	May 28, 2021	May	NEWA
+!		100MG	N214622	002	May 28, 2021	May	NEWA

IOPAMIDOL

INJECTABLE; INJECTION
ISOVUE-300

+!	BRACCO	61%	N018735	002	Dec 31, 1985	Jan	CTEC	
		ISOVUE-370						
+!	BRACCO	76%	N018735	003	Dec 31, 1985	Jan	CTEC	
		SCANLUX-300						
	@	SANOCHEMIA CORP USA	61%	A090394	001	Jun 18, 2010	Jan	DISC
		SCANLUX-370						
	@	SANOCHEMIA CORP USA	76%	A090394	002	Jun 18, 2010	Jan	DISC

IRBESARTAN

TABLET; ORAL
IRBESARTAN

@	US ANTIBIOTICS	75MG	A203161	001	Sep 27, 2012	May	CAHN
@		150MG	A203161	002	Sep 27, 2012	May	CAHN
@		300MG	A203161	003	Sep 27, 2012	May	CAHN

IRINOTECAN HYDROCHLORIDE

INJECTABLE; INJECTION
 IRINOTECAN HYDROCHLORIDE
 @ US ANTIBIOTICS 40MG/2ML (20MG/ML)
 @ 100MG/5ML (20MG/ML)

A 078953 001 Apr 15, 2010 May CAHN
 A 078953 002 Apr 15, 2010 May CAHN

ISOPROTERENOL HYDROCHLORIDE

INJECTABLE; INJECTION
 ISOPROTERENOL HYDROCHLORIDE

AP AMRING PHARMS 0.2MG/ML
 AP AUROBINDO PHARMA LTD 0.2MG/ML
 AP MICRO LABS 0.2MG/ML

A 211237 001 May 19, 2021 May NEWA
 A 211864 001 Feb 09, 2021 Jan NEWA
 A 210845 001 Feb 16, 2021 Feb NEWA

ISOTRETINOIN

CAPSULE; ORAL
 AMNESTEEM

AB1 MYLAN PHARMS INC 10MG
 AB1 20MG
 AB1 40MG

A 075945 001 Nov 08, 2002 Mar CTEC
 A 075945 002 Nov 08, 2002 Mar CTEC
 A 075945 003 Nov 08, 2002 Mar CTEC

CLARAVIS

AB1 TEVA PHARMS USA 10MG
 AB1 20MG
 AB1 30MG
 AB1 ! 40MG

A 076356 001 Apr 11, 2003 Mar CTEC
 A 076135 002 Apr 11, 2003 Mar CTEC
 A 076135 003 May 11, 2006 Mar CTEC
 A 076135 001 Apr 11, 2003 Mar CTEC

ISOTRETINOIN

AB2 ACTAVIS LABS FL 10MG
 AB2 20MG
 AB2 25MG
 AB2 30MG
 AB2 35MG
 AB2 40MG
 AB1 AMNEAL PHARMS NY 10MG
 AB1 20MG
 AB1 30MG
 AB1 40MG
 AB2 UPSHER SMITH LABS 40MG
 MYORISAN
 AB1 DOUGLAS PHARMS 10MG
 AB1 20MG
 AB1 30MG
 AB1 40MG

A 205063 001 Mar 31, 2021 Mar NFTG
 A 205063 002 Mar 31, 2021 Mar NFTG
 A 205063 003 Mar 31, 2021 Mar NFTG
 A 205063 004 Mar 31, 2021 Mar NFTG
 A 205063 005 Mar 31, 2021 Mar NFTG
 A 205063 006 Mar 31, 2021 Mar NFTG
 A 207792 001 Sep 29, 2017 Mar CTEC
 A 207792 002 Sep 29, 2017 Mar CTEC
 A 207792 003 Sep 29, 2017 Mar CTEC
 A 207792 004 Sep 29, 2017 Mar CTEC
 A 213571 001 Apr 12, 2021 Apr NEWA
 A 076485 001 Jan 19, 2012 Mar CTEC
 A 076485 002 Jan 19, 2012 Mar CTEC
 A 076485 004 Aug 25, 2015 Mar CTEC
 A 076485 003 Jan 19, 2012 Mar CTEC

ZENATANE

AB1 DR REDDYS LABS LTD 10MG
 AB1 20MG
 AB1 30MG
 AB1 40MG

A 202099 001 Mar 25, 2013 Mar CTEC
 A 202099 002 Mar 25, 2013 Mar CTEC
 A 202099 004 Feb 23, 2015 Mar CTEC
 A 202099 003 Mar 25, 2013 Mar CTEC

ITRACONAZOLE

TABLET; ORAL
 ONMEL

+ @ SEBELA IRELAND LTD 200MG

N 022484 001 Apr 29, 2010 Apr DISC

IVERMECTIN

TABLET; ORAL
 STROMEKTOL

+ @ MERCK SHARP DOHME 6MG

N 050742 001 Nov 22, 1996 Feb CRLD

IVOSIDENIB

TABLET; ORAL
 TIBSOVO

+! SERVIER 250MG

N 211192 001 Jul 20, 2018 Apr CAHN

IXAZOMIB CITRATE

CAPSULE; ORAL
 NINLARO

+ TAKEDA PHARMS USA EQ 2.3MG BASE
 + EQ 3MG BASE
 +! EQ 4MG BASE

N 208462 001 Nov 20, 2015 May CAHN
 N 208462 002 Nov 20, 2015 May CAHN
 N 208462 003 Nov 20, 2015 May CAHN

KETAMINE HYDROCHLORIDEINJECTABLE; INJECTION
KETAMINE HYDROCHLORIDE

AP	AUROMEDICS PHARMA	EQ 10MG BASE/ML	A 076092	001	Sep 30, 2008	Jan	CAHN
AP		EQ 50MG BASE/ML	A 076092	002	Dec 28, 2001	Jan	CAHN
AP		EQ 100MG BASE/ML	A 076092	003	Oct 25, 2002	Jan	CAHN

KETOCONAZOLEAEROSOL, FOAM; TOPICAL
KETOCONAZOLE

AT	XIROMED	2%	A 213601	001	May 21, 2021	May	NEWA
----	---------	----	----------	-----	--------------	-----	------

CREAM; TOPICAL
KETOCONAZOLE

AB	ENCUBE	2%	A 212443	001	May 20, 2021	May	NEWA
----	--------	----	----------	-----	--------------	-----	------

TABLET; ORAL
KETOCONAZOLE

	@ MYLAN	200MG	A 075597	001	Dec 23, 1999	Mar	DISC
--	---------	-------	----------	-----	--------------	-----	------

KETOPROFENCAPSULE; ORAL
KETOPROFEN

	@ RISING	50MG	A 074024	001	Dec 29, 1995	Jan	CAHN
	@	75MG	A 074024	002	Dec 29, 1995	Jan	CAHN

KETOROLAC TROMETHAMINEINJECTABLE; INJECTION
KETOROLAC TROMETHAMINE

	@ AUROBINDO PHARMA LTD	15MG/ML	A 212939	001	Oct 20, 2020	Apr	DISC
	@	30MG/ML	A 212939	002	Oct 20, 2020	Apr	DISC
	@ HOSPIRA	15MG/ML	A 074993	001	Jan 27, 1999	Mar	DISC

SOLUTION/DROPS; OPHTHALMIC
KETOROLAC TROMETHAMINE

>D>	AT	AUROBINDO PHARMA LTD	0.5%	A 205190	001	Dec 03, 2020	Jun	DISC
>A>		@	0.5%	A 205190	001	Dec 03, 2020	Jun	DISC

LABETALOL HYDROCHLORIDEINJECTABLE; INJECTION
LABETALOL HYDROCHLORIDE

AP	BAXTER HLTHCARE CORP	5MG/ML	A 076051	001	Jul 05, 2002	Mar	CMFD
----	----------------------	--------	----------	-----	--------------	-----	------

LACTULOSESOLUTION; ORAL
LACTULOSE

>D>		@ TORRENT	10GM/15ML	A 207786	001	Jun 11, 2018	Jun	CMFD
>A>	AA		10GM/15ML	A 207786	001	Jun 11, 2018	Jun	CMFD

SOLUTION; ORAL, RECTAL
LACTULOSE

>D>		@ TORRENT	10GM/15ML	A 203762	001	Mar 27, 2015	Jun	CMFD
>A>	AA		10GM/15ML	A 203762	001	Mar 27, 2015	Jun	CMFD

LAMIVUDINETABLET; ORAL
LAMIVUDINE

>A>	AB	CENTAUR PHARMS PVT	150MG	A 203586	001	Nov 21, 2016	Jun	CAHN
>D>	AB	PHARMA LIFE	150MG	A 203586	001	Nov 21, 2016	Jun	CAHN

LAMIVUDINE; TENOFOVIR DISOPROXIL FUMARATETABLET; ORAL
LAMIVUDINE AND TENOFOVIR DISOPROXIL FUMARATE
+ @ AUROBINDO PHARMA LTD 300MG; 300MG

				N 022344	001	May 15, 2018	Feb	DISC
--	--	--	--	----------	-----	--------------	-----	------

LAMOTRIGINETABLET; ORAL
LAMOTRIGINE

>D>		@ CELLTRION	25MG	A 078982	001	Jan 27, 2009	Jun	CAHN
>D>		@	100MG	A 078982	002	Jan 27, 2009	Jun	CAHN
>D>		@	150MG	A 078982	003	Jan 27, 2009	Jun	CAHN
>D>		@	200MG	A 078982	004	Jan 27, 2009	Jun	CAHN
>A>		@ GRANULES	25MG	A 078982	001	Jan 27, 2009	Jun	CAHN
>A>		@	100MG	A 078982	002	Jan 27, 2009	Jun	CAHN

TABLET;ORAL							
LAMOTRIGINE							
>A>		@	150MG	A078982	003	Jan 27, 2009	Jun CAHN
>A>		@	200MG	A078982	004	Jan 27, 2009	Jun CAHN
TABLET, CHEWABLE;ORAL							
LAMOTRIGINE							
>D>	AB	JUBILANT GENERICS	5MG	A200220	001	Feb 28, 2011	Jun DISC
>A>		@	5MG	A200220	001	Feb 28, 2011	Jun DISC
>D>	AB		25MG	A200220	002	Feb 28, 2011	Jun DISC
>A>		@	25MG	A200220	002	Feb 28, 2011	Jun DISC
TABLET, ORALLY DISINTEGRATING;ORAL							
LAMOTRIGINE							
	AB	AJANTA PHARMA LTD	25MG	A213271	001	Jan 19, 2021	Jan NEWA
	AB		50MG	A213271	002	Jan 19, 2021	Jan NEWA
	AB		100MG	A213271	003	Jan 19, 2021	Jan NEWA
	AB		200MG	A213271	004	Jan 19, 2021	Jan NEWA
<u>LANSOPRAZOLE</u>							
CAPSULE, DELAYED REL PELLETS;ORAL							
PREVACID							
>D>	AB	+ TAKEDA PHARMS USA	15MG	N020406	001	May 10, 1995	Jun DISC
>A>		+ @	15MG	N020406	001	May 10, 1995	Jun DISC
TABLET, ORALLY DISINTEGRATING, DELAYED RELEASE;ORAL							
LANSOPRAZOLE							
	AB	DR REDDYS LABS LTD	15MG	A210465	001	Feb 01, 2021	Jan NEWA
	AB		30MG	A210465	002	Feb 01, 2021	Jan NEWA
<u>LASMIDITAN SUCCINATE</u>							
TABLET;ORAL							
REYVOW							
		+ ELI LILLY AND CO	EQ 50MG BASE	N211280	001	Jan 31, 2020	May CPOT
		+	EQ 100MG BASE	N211280	002	Jan 31, 2020	May CHRS
		+!	EQ 100MG BASE	N211280	002	Jan 31, 2020	May CPOT
		+!	EQ 200MG BASE	N211280	003	Dec 18, 2020	May CHRS
		+	EQ 200MG BASE	N211280	003	Dec 18, 2020	May CPOT
<u>LEFLUNOMIDE</u>							
TABLET;ORAL							
LEFLUNOMIDE							
>A>	AB	AET PHARMA	10MG	A213497	001	May 10, 2021	Jun CAHN
>A>	AB		20MG	A213497	002	May 10, 2021	Jun CAHN
	AB	AUROBINDO PHARMA LTD	10MG	A213652	001	Mar 29, 2021	Mar NEWA
	AB		20MG	A213652	002	Mar 29, 2021	Mar NEWA
>D>	AB	AXUNIO	10MG	A213497	001	May 10, 2021	Jun CAHN
	AB		10MG	A213497	001	May 10, 2021	Apr NEWA
>D>	AB		20MG	A213497	002	May 10, 2021	Jun CAHN
	AB		20MG	A213497	002	May 10, 2021	Apr NEWA
<u>LENALIDOMIDE</u>							
CAPSULE;ORAL							
LENALIDOMIDE							
	AB	NATCO PHARMA LTD	5MG	A201452	001	May 21, 2021	May NFTG
	AB		10MG	A201452	002	May 21, 2021	May NFTG
	AB		15MG	A201452	003	May 21, 2021	May NFTG
	AB		25MG	A201452	004	May 21, 2021	May NFTG
<u>LETROZOLE</u>							
TABLET;ORAL							
LETROZOLE							
		@ APOTEX INC	2.5MG	A091303	001	Apr 19, 2012	Jan DISC
<u>LEUCOVORIN CALCIUM</u>							
TABLET;ORAL							
LEUCOVORIN CALCIUM							
	AB	EPIC PHARMA LLC	EQ 10MG BASE	A074544	003	May 19, 2021	May NEWA
	AB		EQ 15MG BASE	A074544	004	May 19, 2021	May NEWA

LEUPROLIDE MESYLATEEMULSION;SUBCUTANEOUS
CAMCEVI KIT

+! FORESEE PHARMS EQ 42MG BASE N211488 001 May 25, 2021 May NEWA

LEVETIRACETAMINJECTABLE;INTRAVENOUS
LEVETIRACETAM

>D>	AP	JUBILANT GENERICS	500MG/5ML (100MG/ML)	A206838	001	Jun 02, 2016	Jun DISC
>A>		@	500MG/5ML (100MG/ML)	A206838	001	Jun 02, 2016	Jun DISC
		LEVETIRACETAM IN SODIUM CHLORIDE					
	AP	AUROBINDO PHARMA LTD	1GM/100ML (10MG/ML)	A207160	002	Jan 04, 2017	Feb CPOT
	AP		1.5GM/100ML (15MG/ML)	A207160	003	Jan 04, 2017	Feb CPOT
	AP	GLAND PHARMA LTD	1GM/100ML (10MG/ML)	A206880	002	Oct 25, 2017	Feb CPOT
	AP		1.5GM/100ML (15MG/ML)	A206880	003	Oct 25, 2017	Feb CDFR
	AP	+! HQ SPECIALITY PHARMA	1GM/100ML (10MG/ML)	N202543	002	Nov 09, 2011	Feb CPOT
	AP	+!	1.5GM/100ML (15MG/ML)	N202543	003	Nov 09, 2011	Feb CPOT
	AP	NEXUS PHARMS	1GM/100ML (10MG/ML)	A213532	002	Jul 06, 2020	Feb CPOT
	AP		1.5GM/100ML (15MG/ML)	A213532	003	Jul 06, 2020	Feb CPOT

SOLUTION;ORAL

LEVETIRACETAM

AA AKORN 100MG/ML A090601 001 Feb 28, 2012 Feb CAHN

TABLET;ORAL

LEVETIRACETAM

		@ NOSTRUM LABS INC	250MG	A090511	001	Aug 18, 2011	Mar DISC
	AB		250MG	A090511	001	Aug 18, 2011	Jan CAHN
		@	500MG	A090511	002	Aug 18, 2011	Mar DISC
	AB		500MG	A090511	002	Aug 18, 2011	Jan CAHN
		@	750MG	A090511	003	Aug 18, 2011	Mar DISC
	AB		750MG	A090511	003	Aug 18, 2011	Jan CAHN
		@	1GM	A090511	004	Aug 18, 2011	Mar DISC
	AB		1GM	A090511	004	Aug 18, 2011	Jan CAHN
>A>	AB	SCIEGEN PHARMS INC	750MG	A215069	001	Jun 11, 2021	Jun NEWA
>A>	AB		1GM	A215069	002	Jun 11, 2021	Jun NEWA

TABLET, EXTENDED RELEASE;ORAL

ELEPSIA XR

	+	TRIPOINT	1GM	N204417	001	Dec 20, 2018	Jan CAHN
	+	!	1.5GM	N204417	002	Dec 20, 2018	Jan CAHN

LEVETIRACETAM

AB OVERSEAS 750MG A212688 001 Jun 11, 2020 May CMFD

LEVOBUNOLOL HYDROCHLORIDE

SOLUTION/DROPS;OPHTHALMIC

BETAGAN

>D>							
>D>	AT	+! ALLERGAN	0.25%	N019814	001	Jun 28, 1989	Jun DISC
>A>		+ @	0.25%	N019814	001	Jun 28, 1989	Jun DISC

LEVOCETIRIZINE DIHYDROCHLORIDE

SOLUTION;ORAL

XYZAL

+ @ SANOFI AVENTIS US 2.5MG/5ML N022157 001 Jan 28, 2008 Apr DISC

TABLET;ORAL

LEVOCETIRIZINE DIHYDROCHLORIDE

	AB	!	GLENMARK GENERICS	5MG	A090385	001	Feb 24, 2011	Apr CHRS
		@	GRANULES	5MG	A090486	001	Mar 26, 2013	Apr CAHN
		@	NEOPHARMA	5MG	A204323	001	Dec 20, 2016	Mar DISC
		@	US ANTIBIOTICS	5MG	A204323	001	Dec 20, 2016	May CAHN
			XYZAL					
		+ @	SANOFI AVENTIS US	5MG	N022064	001	May 25, 2007	Apr DISC

LEVOFLOXACIN

TABLET;ORAL

LEVOFLOXACIN

>A>	AB		CADILA	250MG	A077652	001	Sep 07, 2012	Jun CAHN
>A>	AB			500MG	A077652	002	Sep 07, 2012	Jun CAHN
>A>	AB			750MG	A077652	003	Sep 07, 2012	Jun CAHN
>D>	AB		JUBILANT GENERICS	250MG	A203613	001	Jun 19, 2015	Jun DISC
>A>		@		250MG	A203613	001	Jun 19, 2015	Jun DISC
>D>	AB			500MG	A203613	002	Jun 19, 2015	Jun DISC
>A>		@		500MG	A203613	002	Jun 19, 2015	Jun DISC
>D>	AB		ZYDUS PHARMS USA INC	250MG	A077652	001	Sep 07, 2012	Jun CAHN

TABLET;ORAL
LEVOFLOXACIN

>D>	AB		500MG		A 077652	002	Sep 07, 2012	Jun	CAHN
>D>	AB		750MG		A 077652	003	Sep 07, 2012	Jun	CAHN

LEVORPHANOL TARTRATE

TABLET;ORAL
LEVORPHANOL TARTRATE

	AB		NOVITIUM PHARMA	3MG	A 213479	002	Jan 12, 2021	Jan	NEWA
	AB	!	SENTYNL THERAPS INC	3MG	A 074278	003	Jun 18, 2018	Jan	CTEC
>A>	AB		SUN PHARM INDS INC	2MG	A 213906	001	Jun 17, 2021	Jun	NEWA

LEVOTHYROXINE SODIUM

CAPSULE;ORAL
LEVOTHYROXINE SODIUM

			@ TEVA PHARMS USA INC	0.075MG	A 211369	001	Oct 28, 2020	Apr	DISC
AB				0.112MG	A 211369	003	Apr 16, 2021	Apr	NFTG
			@	0.15MG	A 211369	002	Oct 28, 2020	Apr	DISC
			TIROSINT						
	+		INSTITUT BIOCHIMIQUE	0.075MG	N 021924	004	Oct 13, 2006	Apr	CTEC
	+			0.15MG	N 021924	007	Oct 13, 2006	Apr	CTEC

POWDER;INTRAVENOUS

LEVOTHYROXINE SODIUM

			@ DR REDDYS	100MCG/VIAL	A 208837	001	Mar 27, 2020	Feb	DISC
--	--	--	-------------	-------------	----------	-----	--------------	-----	------

SOLUTION;INTRAVENOUS

LEVOTHYROXINE SODIUM

	+	!	CUSTOPHARM INC	100MCG/ML	N 214253	001	May 17, 2021	May	NEWA
--	---	---	----------------	-----------	----------	-----	--------------	-----	------

SOLUTION;ORAL

THYQUIDITY

	+	!	VISTAPHARM	100MCG/5ML	N 214047	001	Nov 30, 2020	Apr	CAHN
--	---	---	------------	------------	----------	-----	--------------	-----	------

TIROSINT-SOL

	+		INSTITUT BIOCHIMIQUE	37.5MCG/ML	N 206977	013	Jan 13, 2021	Jan	NEWA
	+			44MCG/ML	N 206977	014	Jan 13, 2021	Jan	NEWA
	+			62.5MCG/ML	N 206977	015	Jan 13, 2021	Jan	NEWA

LIDOCAINE

OINTMENT;TOPICAL

LIDOCAINE

AT			QUAGEN	5%	A 212695	001	Apr 20, 2021	Apr	NEWA
			@ RISING	5%	A 208604	001	Sep 20, 2017	May	CAHN

PATCH;TOPICAL

LIDOCAINE

	AB		NAL PHARM	5%	A 205882	001	Apr 29, 2021	Apr	NEWA
>D>	AB		NOVEN PHARMS INC	5%	A 203265	001	Dec 01, 2020	Jun	DISC
>A>			@	5%	A 203265	001	Dec 01, 2020	Jun	DISC

LIDOCAINE HYDROCHLORIDE

JELLY;TOPICAL

XYLOCAINE

	+	@	AKORN	2%	N 008816	001		Jan	DISC
--	---	---	-------	----	----------	-----	--	-----	------

SOLUTION;ORAL

LIDOCAINE HYDROCHLORIDE VISCOUS

AT			LANNETT CO INC	2%	A 040708	001	Feb 27, 2007	Jan	CMFD
----	--	--	----------------	----	----------	-----	--------------	-----	------

LINACLOTIDE

CAPSULE;ORAL

LINACLOTIDE

			@ MYLAN	145MCG	A 209564	001	Feb 09, 2021	Feb	DISC
AB				145MCG	A 209564	001	Feb 09, 2021	Jan	NFTG
			@	290MCG	A 209564	002	Feb 09, 2021	Feb	DISC
AB				290MCG	A 209564	002	Feb 09, 2021	Jan	NFTG

LINZESS

	+	!	ALLERGAN	145MCG	N 202811	001	Aug 30, 2012	Feb	CTEC
	+			290MCG	N 202811	002	Aug 30, 2012	Feb	CTEC

LINCOMYCIN HYDROCHLORIDE

INJECTABLE;INJECTION

LINCOCIN

AP	+	!	PFIZER	EQ 300MG BASE/ML	N 050317	001		Feb	CAHN
----	---	---	--------	------------------	----------	-----	--	-----	------

LINCOMYCIN HYDROCHLORIDE

AP			PRAXGEN	EQ 300MG BASE/ML	A 212770	001	Mar 12, 2021	Mar	NEWA
----	--	--	---------	------------------	----------	-----	--------------	-----	------

LIOETHYRONINE SODIUM

TABLET; ORAL

LIOETHYRONINE SODIUM

AB	ZYDUS	EQ 0.005MG BASE	A214803	001	Jan 22, 2021	Jan	NEWA
AB		EQ 0.025MG BASE	A214803	002	Jan 22, 2021	Jan	NEWA
AB		EQ 0.05MG BASE	A214803	003	Jan 22, 2021	Jan	NEWA

LISINOPRIL

TABLET; ORAL

LISINOPRIL

AB	YILING	20MG	A208920	001	Mar 04, 2021	Feb	NEWA
AB		30MG	A208920	002	Mar 04, 2021	Feb	NEWA
AB		40MG	A208920	003	Mar 04, 2021	Feb	NEWA

LOPINAVIR; RITONAVIR

TABLET; ORAL

LOPINAVIR AND RITONAVIR

AB	HETERO LABS LTD III	100MG;25MG	A091677	001	Jun 04, 2021	May	NFTG
AB		200MG;50MG	A091677	002	Jun 04, 2021	May	NFTG

LORAZEPAM

CONCENTRATE; ORAL

LORAZEPAM

AA	AKORN	2MG/ML	A200169	001	Jan 30, 2012	Feb	CAHN
----	-------	--------	---------	-----	--------------	-----	------

LOSARTAN POTASSIUM

TABLET; ORAL

LOSARTAN POTASSIUM

>D>	AB	CADISTA PHARMS	25MG	A201170	001	Sep 18, 2012	Jun	CAHN
>D>	AB		50MG	A201170	002	Sep 18, 2012	Jun	CAHN
>D>	AB		100MG	A201170	003	Sep 18, 2012	Jun	CAHN
>A>	AB	JUBILANT CADISTA	25MG	A201170	001	Sep 18, 2012	Jun	CAHN
>A>	AB		50MG	A201170	002	Sep 18, 2012	Jun	CAHN
>A>	AB		100MG	A201170	003	Sep 18, 2012	Jun	CAHN

LOTEPREDNOL ETABONATE

GEL; OPHTHALMIC

LOTEPREDNOL ETABONATE

AB	AKORN	0.5%	A212080	001	Feb 10, 2021	Jan	NFTG
----	-------	------	---------	-----	--------------	-----	------

SUSPENSION/DROPS; OPHTHALMIC

LOTEPREDNOL ETABONATE

AB	SUN PHARM	0.5%	A212450	001	Feb 26, 2021	Feb	NEWA
----	-----------	------	---------	-----	--------------	-----	------

LULICONAZOLE

CREAM; TOPICAL

LUZU

+	!	BAUSCH	1%	N204153	001	Nov 14, 2013	May	CAHN
---	---	--------	----	---------	-----	--------------	-----	------

LURASIDONE HYDROCHLORIDE

TABLET; ORAL

LURASIDONE HYDROCHLORIDE

AB	ALEMBIC PHARMS LTD	20MG	A213248	001	May 13, 2021	May	NEWA
AB		40MG	A213248	002	May 13, 2021	May	NEWA
AB		60MG	A213248	003	May 13, 2021	May	NEWA
AB		80MG	A213248	004	May 13, 2021	May	NEWA
AB		120MG	A213248	005	May 13, 2021	May	NEWA
AB	WATSON LABS TEVA	20MG	A208016	001	Feb 02, 2021	Jan	NEWA
AB		40MG	A208016	002	Feb 02, 2021	Jan	NEWA
AB		60MG	A208016	003	Feb 02, 2021	Jan	NEWA
AB		80MG	A208016	004	Feb 02, 2021	Jan	NEWA
AB		120MG	A208016	005	Feb 02, 2021	Jan	NEWA

MACITENTAN

TABLET; ORAL

MACITENTAN

AB	ZYDUS	10MG	A211224	001	Apr 06, 2021	Mar	NFTG
----	-------	------	---------	-----	--------------	-----	------

MAGNESIUM SULFATEINJECTABLE; INJECTION
MAGNESIUM SULFATE

AP	B BRAUN MEDICAL INC	2GM/50ML (40MG/ML)	A207967	001	Apr 26, 2021	Apr	NEWA
AP		4GM/100ML (40MG/ML)	A207967	002	Apr 26, 2021	Apr	NEWA
AP		4GM/50ML (80MG/ML)	A207967	003	Apr 26, 2021	Apr	NEWA
MAGNESIUM SULFATE IN DEXTROSE 5% IN PLASTIC CONTAINER							
AP	BAXTER HLTHCARE CORP	1GM/100ML	A211965	001	Aug 11, 2020	Feb	CMFD
MAGNESIUM SULFATE IN PLASTIC CONTAINER							
AP	BAXTER HLTHCARE CORP	2GM/50ML (40MG/ML)	A211966	001	Jun 01, 2020	Feb	CMFD
AP		4GM/50ML (80MG/ML)	A211966	002	Jun 01, 2020	Feb	CMFD
AP		4GM/100ML (40MG/ML)	A211966	003	Jun 01, 2020	Feb	CMFD

MAPROTILINE HYDROCHLORIDETABLET; ORAL
MAPROTILINE HYDROCHLORIDE

>A>	@ HERITAGE PHARMA	50MG	A072163	001	Jun 01, 1988	Jun	CAHN
>D>	@ WATSON LABS TEVA	50MG	A072163	001	Jun 01, 1988	Jun	CAHN

MEDROXYPROGESTERONE ACETATEINJECTABLE; INJECTION
DEPO-PROVERA

	+ @ PFIZER	100MG/ML	N012541	002		Mar	CAHN
AB	+	150MG/ML	N020246	001	Oct 29, 1992	Mar	CAHN
	+ @	400MG/ML	N012541	003		May	DISC
	+	400MG/ML	N012541	003		Mar	CAHN
INJECTABLE; SUBCUTANEOUS DEPO-SUBQ PROVERA 104							
	+	104MG/0.65ML	N021583	001	Dec 17, 2004	Mar	CAHN
TABLET; ORAL PROVERA							
AB	+ PFIZER	2.5MG	N011839	001		Mar	CAHN
AB	+	5MG	N011839	003		Mar	CAHN
AB	+	10MG	N011839	004		Mar	CAHN

MEFENAMIC ACIDCAPSULE; ORAL
MEFENAMIC ACID

	@ STRIDES PHARMA	250MG	A209209	001	Sep 18, 2020	Mar	DISC
--	------------------	-------	---------	-----	--------------	-----	------

MELOXICAMCAPSULE; ORAL
MELOXICAM

AB	LUPIN LTD	5MG	A209487	001	Jun 01, 2020	Feb	CTEC
AB	!	10MG	A209487	002	Jun 01, 2020	Feb	CTEC
AB	NOVITIUM PHARMA	5MG	A211398	001	Mar 09, 2021	Feb	NEWA
AB		10MG	A211398	002	Mar 09, 2021	Feb	NEWA

MELPHALANTABLET; ORAL
MELPHALAN

!	ALVOGEN	2MG	A207809	001	Mar 22, 2017	Jan	CAHN
---	---------	-----	---------	-----	--------------	-----	------

MELPHALAN FLUFENAMIDEPOWDER; INTRAVENOUS
PEPAXTO

+	ONCOPEPTIDES AB	20MG/VIAL	N214383	001	Feb 26, 2021	Feb	NEWA
---	-----------------	-----------	---------	-----	--------------	-----	------

MELPHALAN FLUFENAMIDE HYDROCHLORIDEPOWDER; INTRAVENOUS
PEPAXTO

+	ONCOPEPTIDES AB	EQ 20MG BASE/VIAL	N214383	001	Feb 26, 2021	Mar	CPOT
+		20MG/VIAL	N214383	001	Feb 26, 2021	Mar	CAIN

MELPHALAN HYDROCHLORIDEINJECTABLE; INJECTION
ALKERAN

	+ @ APOTEX	EQ 50MG BASE/VIAL	N020207	001	Nov 18, 1992	Jan	DISC
MELPHALAN HYDROCHLORIDE							
AP	HONG KONG	EQ 50MG BASE/VIAL	A212960	001	May 28, 2021	May	NEWA

MEMANTINE HYDROCHLORIDECAPSULE, EXTENDED RELEASE;ORAL
MEMANTINE HYDROCHLORIDE

AB	YICHANG HUMANWELL	7MG	A211100	001	Apr 02, 2021	Mar	NEWA
AB		14MG	A211100	002	Apr 02, 2021	Mar	NEWA
AB		21MG	A211100	003	Apr 02, 2021	Mar	NEWA
AB		28MG	A211100	004	Apr 02, 2021	Mar	NEWA

SOLUTION;ORAL

MEMANTINE HYDROCHLORIDE

AA	SETON PHARMS	2MG/ML	A210319	001	Aug 31, 2020	May	CAHN
----	--------------	--------	---------	-----	--------------	-----	------

TABLET;ORAL

MEMANTINE HYDROCHLORIDE

>D>	AB	JUBILANT GENERICS	5MG	A091585	001	Oct 13, 2015	Jun	DISC
>A>		@	5MG	A091585	001	Oct 13, 2015	Jun	DISC
>D>	AB		10MG	A091585	002	Oct 13, 2015	Jun	DISC
>A>		@	10MG	A091585	002	Oct 13, 2015	Jun	DISC

MEPERIDINE HYDROCHLORIDE

INJECTABLE; INJECTION

DEMEROL

@	VALIDUS PHARMS	25MG/ML	N005010	007		Feb	CAHN
@		50MG/ML	N005010	002		Feb	CAHN
@		75MG/ML	N005010	009		Feb	CAHN
@		100MG/ML	N005010	003		Feb	CAHN

SYRUP;ORAL

DEMEROL

@	VALIDUS PHARMS	50MG/5ML	N005010	005		Feb	CAHN
---	----------------	----------	---------	-----	--	-----	------

TABLET;ORAL

DEMEROL

+	@	VALIDUS PHARMS	50MG	N005010	001		Feb	CAHN
+	@		100MG	N005010	004		Feb	CAHN

MEPROBAMATE

TABLET;ORAL

MEPROBAMATE

AA	!	ALEMBIC PHARMS LTD	200MG	A090122	001	Feb 18, 2009	Mar	CHRS
AA	!		400MG	A090122	002	Feb 18, 2009	Mar	CHRS
	@	WATSON LABS	200MG	A083304	001		Mar	DISC
	@		400MG	A083308	001		Mar	DISC

MEROPENEM; VABORBACTAM

POWDER; INTRAVENOUS

VABOMERE

+	!	REMPEX	1GM/VIAL;1GM/VIAL	N209776	001	Aug 29, 2017	Feb	CAHN
---	---	--------	-------------------	---------	-----	--------------	-----	------

METFORMIN HYDROCHLORIDE

TABLET;ORAL

METFORMIN HYDROCHLORIDE

>A>	AB	CHARTWELL	500MG	A075972	001	Jan 24, 2002	Jun	CAHN
>A>			625MG	A075972	005	Jan 24, 2002	Jun	CAHN
>A>			750MG	A075972	004	Jan 24, 2002	Jun	CAHN
>A>	AB		850MG	A075972	002	Jan 24, 2002	Jun	CAHN
>A>	AB		1GM	A075972	003	Jan 24, 2002	Jun	CAHN
>D>	AB	CHARTWELL LIFE SCI	500MG	A075972	001	Jan 24, 2002	Jun	CAHN
>D>			625MG	A075972	005	Jan 24, 2002	Jun	CAHN
>D>			750MG	A075972	004	Jan 24, 2002	Jun	CAHN
>D>	AB		850MG	A075972	002	Jan 24, 2002	Jun	CAHN
>D>	AB		1GM	A075972	003	Jan 24, 2002	Jun	CAHN
	@	INDICUS PHARMA	500MG	A079148	001	Nov 25, 2008	May	DISC
	@		850MG	A079148	002	Nov 25, 2008	May	DISC
	@		1GM	A079148	003	Nov 25, 2008	May	DISC

TABLET, EXTENDED RELEASE;ORAL

METFORMIN HYDROCHLORIDE

AB3		AJANTA PHARMA LTD	500MG	A213962	001	Mar 09, 2021	Feb	NEWA
AB3			1GM	A213962	002	Mar 09, 2021	Feb	NEWA
	@	APOTEX	500MG	A076706	001	Dec 14, 2004	Apr	DISC
AB3		GRANULES	500MG	A213344	001	Jan 12, 2021	Jan	NEWA
AB3			1GM	A213344	002	Jan 12, 2021	Jan	NEWA
AB3		SCIEGEN PHARMS INC	500MG	A213334	001	Apr 16, 2021	Apr	NEWA
AB3			1GM	A213334	002	Apr 16, 2021	Apr	NEWA

METFORMIN HYDROCHLORIDE; PIOGLITAZONE HYDROCHLORIDE

TABLET; ORAL

PIOGLITAZONE HYDROCHLORIDE AND METFORMIN HYDROCHLORIDE

@	TORRENT PHARMS LTD	500MG;EQ 15MG BASE	A202001	001	Feb 13, 2013	Jan	DISC
@		850MG;EQ 15MG BASE	A202001	002	Feb 13, 2013	Jan	DISC

METHADONE HYDROCHLORIDE

CONCENTRATE; ORAL

METHADONE HYDROCHLORIDE

AA	LANNETT CO INC	10MG/ML	A212094	001	Mar 03, 2021	Feb	NEWA
----	----------------	---------	---------	-----	--------------	-----	------

METHENAMINE HIPPURATE

TABLET; ORAL

HIPREX

+ @	VALIDUS PHARMS	1GM	N017681	001		Mar	DISC
AB	+	1GM	N017681	001		Feb	CAHN

METHENAMINE HIPPURATE

AB	!	AUROBINDO PHARMA LTD	1GM	A205661	001	Jul 05, 2016	Mar	CHRS
----	---	----------------------	-----	---------	-----	--------------	-----	------

METHOCARBAMOL

TABLET; ORAL

METHOCARBAMOL

>D>	AA	@ AUROBINDO PHARMA LTD	750MG	A213967	001	Aug 12, 2020	Feb	DISC
	AA	GRANULATION TECH	500MG	A212623	001	Apr 30, 2021	Jun	CAHN
	AA		500MG	A212623	001	Apr 30, 2021	Apr	NEWA
>D>	AA		750MG	A212623	002	Apr 30, 2021	Jun	CAHN
	AA		750MG	A212623	002	Apr 30, 2021	Apr	NEWA
>A>	AA	MLV	500MG	A212623	001	Apr 30, 2021	Jun	CAHN
>A>	AA		750MG	A212623	002	Apr 30, 2021	Jun	CAHN

METHOTREXATE SODIUM

INJECTABLE; INJECTION

METHOTREXATE PRESERVATIVE FREE

>D>	AP	FRESENIUS KABI USA	EQ 25MG BASE/ML	A040265	001	Feb 26, 1999	Jun	DISC
>A>		@	EQ 25MG BASE/ML	A040265	001	Feb 26, 1999	Jun	DISC
			METHOTREXATE SODIUM PRESERVATIVE FREE					
		@ MYLAN LABS LTD	EQ 250MG BASE/10ML (EQ 25MG BASE/ML)	A201529	004	Mar 29, 2012	May	DISC

TABLET; ORAL

METHOTREXATE SODIUM

AB		LOTUS PHARM CO LTD	EQ 2.5MG BASE	A209787	001	Apr 23, 2021	Apr	NEWA
----	--	--------------------	---------------	---------	-----	--------------	-----	------

METHYLERGONOVINE MALEATE

TABLET; ORAL

METHYLERGONOVINE MALEATE

AB		RISING	0.2MG	A211919	001	Jan 15, 2021	Jan	NEWA
----	--	--------	-------	---------	-----	--------------	-----	------

METHYLPHENIDATE HYDROCHLORIDE

SOLUTION; ORAL

METHYLPHENIDATE HYDROCHLORIDE

AA		ASCENT PHARMS INC	5MG/5ML	A207417	001	Jan 29, 2021	Jan	NEWA
AA			10MG/5ML	A207417	002	Jan 29, 2021	Jan	NEWA
		@ LANNETT CO INC	5MG/5ML	A207414	001	Dec 16, 2020	Jan	DISC
		@	10MG/5ML	A207414	002	Dec 16, 2020	Jan	DISC

TABLET; ORAL

METHYLPHENIDATE HYDROCHLORIDE

>A>		@ ALVOGEN	5MG	A206840	001	Sep 15, 2016	Jun	CAHN
>A>		@	10MG	A206840	002	Sep 15, 2016	Jun	CAHN
>A>		@	20MG	A206840	003	Sep 15, 2016	Jun	CAHN
>D>		@ CNTY LINE PHARMS	5MG	A206840	001	Sep 15, 2016	Jun	CAHN
>D>		@	10MG	A206840	002	Sep 15, 2016	Jun	CAHN
>D>		@	20MG	A206840	003	Sep 15, 2016	Jun	CAHN

TABLET, EXTENDED RELEASE; ORAL

METHYLPHENIDATE HYDROCHLORIDE

>A>	AB	ALVOGEN	10MG	A204772	001	Feb 29, 2016	Jun	CAHN
>A>	AB		20MG	A204772	002	Feb 29, 2016	Jun	CAHN
>D>	AB	CNTY LINE PHARMS	10MG	A204772	001	Feb 29, 2016	Jun	CAHN
>D>	AB		20MG	A204772	002	Feb 29, 2016	Jun	CAHN

METHYLPREDNISOLONE

TABLET; ORAL

METHYLPREDNISOLONE

AB	PRAXGEN	4MG	A212262	001	Jun 27, 2019	Feb CAHN
----	---------	-----	---------	-----	--------------	----------

METHYLPREDNISOLONE SODIUM SUCCINATE

INJECTABLE; INJECTION

METHYLPREDNISOLONE SODIUM SUCCINATE

AP	GENEYORK PHARMS	EQ 40MG BASE/VIAL	A212396	001	Apr 20, 2021	Apr NEWA
AP		EQ 125MG BASE/VIAL	A212396	002	Apr 20, 2021	Apr NEWA
AP		EQ 500MG BASE/VIAL	A212396	003	Apr 20, 2021	Apr NEWA
AP		EQ 1GM BASE/VIAL	A212396	004	Apr 20, 2021	Apr NEWA
AP		EQ 2GM BASE/VIAL	A212396	005	Apr 20, 2021	Apr NEWA
AP	TIANJIN KINGYORK	EQ 40MG BASE/VIAL	A212396	001	Apr 20, 2021	May CAHN
AP		EQ 125MG BASE/VIAL	A212396	002	Apr 20, 2021	May CAHN
AP		EQ 500MG BASE/VIAL	A212396	003	Apr 20, 2021	May CAHN
AP		EQ 1GM BASE/VIAL	A212396	004	Apr 20, 2021	May CAHN
AP		EQ 2GM BASE/VIAL	A212396	005	Apr 20, 2021	May CAHN

METOLAZONE

TABLET; ORAL

METOLAZONE

AB	BAYSHORE PHARMS LLC	2.5MG	A214799	001	Mar 30, 2021	Mar NEWA
AB		5MG	A214799	002	Mar 30, 2021	Mar NEWA
AB		10MG	A214799	003	Mar 30, 2021	Mar NEWA
AB	INNOGENIX	2.5MG	A213827	001	Mar 30, 2021	Mar NEWA
AB		5MG	A213827	002	Mar 30, 2021	Mar NEWA
AB		10MG	A213827	003	Mar 30, 2021	Mar NEWA
AB	! SANDOZ	5MG	A076466	001	Dec 19, 2003	May CHRS
AB	!	10MG	A076466	002	Dec 19, 2003	May CHRS
	ZAROXOLYN					
	+ @ LANNETT CO INC	2.5MG	N017386	001		May DISC
	+ @	5MG	N017386	002		May DISC
	+ @	10MG	N017386	003		May DISC

METOPROLOL SUCCINATE

TABLET, EXTENDED RELEASE; ORAL

METOPROLOL SUCCINATE

AB	ACTAVIS ELIZABETH	EQ 25MG TARTRATE	A204161	001	Nov 25, 2016	May CMFD
AB		EQ 50MG TARTRATE	A204161	002	Nov 25, 2016	May CMFD
AB		EQ 100MG TARTRATE	A204161	003	Nov 25, 2016	May CMFD
AB		EQ 200MG TARTRATE	A204161	004	Nov 25, 2016	May CMFD
AB	YICHANG HUMANWELL	EQ 100MG TARTRATE	A213854	001	Feb 12, 2021	Feb NEWA
AB		EQ 200MG TARTRATE	A213854	002	Feb 12, 2021	Feb NEWA

METOPROLOL TARTRATE

TABLET; ORAL

LOPRESSOR

AB	+ VALIDUS PHARMS	50MG	N017963	001		Feb CAHN
AB	+	100MG	N017963	002		Feb CAHN

MEXILETINE HYDROCHLORIDE

CAPSULE; ORAL

MEXILETINE HYDROCHLORIDE

AB	RICONPHARMA LLC	150MG	A214352	001	Jan 25, 2021	Jan NEWA
AB		200MG	A214352	002	Jan 25, 2021	Jan NEWA
AB		250MG	A214352	003	Jan 25, 2021	Jan NEWA

MICAFUNGIN SODIUM

INJECTABLE; INTRAVENOUS

MICAFUNGIN SODIUM

AP	XELLIA PHARMS APS	EQ 50MG BASE/VIAL	A211713	001	Jun 02, 2021	May NEWA
AP		EQ 100MG BASE/VIAL	A211713	002	Jun 02, 2021	May NEWA

POWDER; INTRAVENOUS

MICAFUNGIN

>A>							
>A>	+!	PAR STERILE PRODUCTS	EQ 50MG BASE/VIAL	N212156	001	Jun 16, 2021	Jun NEWA
>A>	+!		EQ 100MG BASE/VIAL	N212156	002	Jun 16, 2021	Jun NEWA

MIDAZOLAM

SOLUTION;INTRAVENOUS

MIDAZOLAM IN 0.9% SODIUM CHLORIDE

+!	INFORLIFE	50MG/50ML (1MG/ML)	N211844	001	Mar 22, 2021	Mar	NEWA
+		100MG/100ML (1MG/ML)	N211844	002	Mar 22, 2021	Mar	NEWA

MIDODRINE HYDROCHLORIDE

TABLET;ORAL

MIDODRINE HYDROCHLORIDE

AB	ALEMBIC PHARMS LTD	2.5MG	A214734	001	Jan 21, 2021	Jan	NEWA
AB		5MG	A214734	002	Jan 21, 2021	Jan	NEWA
AB		10MG	A214734	003	Jan 21, 2021	Jan	NEWA

MIGLITOL

TABLET;ORAL

GLYSET

AB	+!	PFIZER	25MG	N020682	001	Dec 18, 1996	Feb	CAHN
AB	+		50MG	N020682	002	Dec 18, 1996	Feb	CAHN
AB	+		100MG	N020682	003	Dec 18, 1996	Feb	CAHN

MILRINONE LACTATE

INJECTABLE;INJECTION

MILRINONE LACTATE

AP	CAPLIN	EQ 1MG BASE/ML	A214380	001	Apr 16, 2021	Apr	NEWA
----	--------	----------------	---------	-----	--------------	-----	------

MINOCYCLINE HYDROCHLORIDE

AEROSOL, FOAM;TOPICAL

AMZEEQ

+!	VYNE	EQ 4% BASE	N212379	001	Oct 18, 2019	Mar	CAHN
----	------	------------	---------	-----	--------------	-----	------

ZILXI

+!	VYNE	EQ 1.5% BASE	N213690	001	May 28, 2020	Mar	CAHN
----	------	--------------	---------	-----	--------------	-----	------

CAPSULE;ORAL

DYNACIN

>A>	AB	ALVOGEN	EQ 50MG BASE	A063067	003	Aug 14, 1990	Jun	CAHN
>A>	AB		EQ 75MG BASE	A063067	002	Sep 15, 1999	Jun	CAHN
>A>	AB		EQ 100MG BASE	A063067	001	Jul 31, 1990	Jun	CAHN
>D>	AB	CNTY LINE PHARMS	EQ 50MG BASE	A063067	003	Aug 14, 1990	Jun	CAHN
>D>	AB		EQ 75MG BASE	A063067	002	Sep 15, 1999	Jun	CAHN
>D>	AB		EQ 100MG BASE	A063067	001	Jul 31, 1990	Jun	CAHN

INJECTABLE;INJECTION

MINOCIN

+!	REMPEX	EQ 100MG BASE/VIAL	N050444	001		May	CAHN
----	--------	--------------------	---------	-----	--	-----	------

TABLET, EXTENDED RELEASE;ORAL

MINOCYCLINE HYDROCHLORIDE

@ BARR LABS INC

@

@

@

SOLODYN

+	@	BAUSCH	EQ 45MG BASE	N050808	001	May 08, 2006	May	CAHN
AB	+		EQ 55MG BASE	N050808	008	Aug 27, 2010	May	CAHN
AB	+		EQ 65MG BASE	N050808	004	Jul 23, 2009	May	CAHN
AB	+		EQ 80MG BASE	N050808	007	Aug 27, 2010	May	CAHN
+	@		EQ 90MG BASE	N050808	002	May 08, 2006	May	CAHN
AB	+		EQ 105MG BASE	N050808	006	Aug 27, 2010	May	CAHN
AB	+!		EQ 115MG BASE	N050808	005	Jul 23, 2009	May	CAHN
+	@		EQ 135MG BASE	N050808	003	May 08, 2006	May	CAHN

MINOXIDIL

TABLET;ORAL

LONITEN

+	@	PFIZER	2.5MG	N018154	001		Feb	CAHN
---	---	--------	-------	---------	-----	--	-----	------

+	@		10MG	N018154	003		Feb	CAHN
---	---	--	------	---------	-----	--	-----	------

MIRABEGRON

FOR SUSPENSION, EXTENDED RELEASE;ORAL

MYRBETRIQ GRANULES

+!	APGDI	8MG/ML	N213801	001	Mar 25, 2021	Mar	NEWA
----	-------	--------	---------	-----	--------------	-----	------

MOMETASONE FUROATEAEROSOL, METERED; INHALATION
ASMANEX HFA

>D>	+	MERCK SHARP DOHME	0.05MG/INH	N205641	003	Aug 12, 2019	Jun	CAHN
>D>	+		0.10MG/INH	N205641	001	Apr 25, 2014	Jun	CAHN
>D>	+	!	0.20MG/INH	N205641	002	Apr 25, 2014	Jun	CAHN
>A>	+	ORGANON	0.05MG/INH	N205641	003	Aug 12, 2019	Jun	CAHN
>A>	+		0.10MG/INH	N205641	001	Apr 25, 2014	Jun	CAHN
>A>	+	!	0.20MG/INH	N205641	002	Apr 25, 2014	Jun	CAHN

OINTMENT; TOPICAL

MOMETASONE FUROATE

@ TORRENT

0.1%

A207899 001 Jul 13, 2018 Jan DISC

POWDER; INHALATION

ASMANEX TWISTHALER

>D>	+	MERCK SHARP DOHME	0.11MG/INH	N021067	002	Feb 01, 2008	Jun	CAHN
>D>	+	!	0.22MG/INH	N021067	001	Mar 30, 2005	Jun	CAHN
>A>	+	ORGANON	0.11MG/INH	N021067	002	Feb 01, 2008	Jun	CAHN
>A>	+	!	0.22MG/INH	N021067	001	Mar 30, 2005	Jun	CAHN

SPRAY, METERED; NASAL

MOMETASONE FUROATE

AB ! APOTEX INC

0.05MG/SPRAY

A091161 001 Mar 22, 2016 May CHRS

NASONEX

+ @ ORGANON

0.05MG/SPRAY

N020762 001 Oct 01, 1997 May DISC

AB +!

0.05MG/SPRAY

N020762 001 Oct 01, 1997 Feb CAHN

MORPHINE SULFATE

CAPSULE, EXTENDED RELEASE; ORAL

KADIAN

+ @ ALLERGAN

40MG

N020616 009 Jul 09, 2012 May DISC

+ @

70MG

N020616 010 Jul 09, 2012 May DISC

+ @

130MG

N020616 011 Jul 09, 2012 May DISC

+ @

150MG

N020616 012 Jul 09, 2012 May DISC

+ @

200MG

N020616 007 Feb 27, 2007 May DISC

MORPHINE SULFATE

IMPAX LABS INC

40MG

A200411 007 Jul 25, 2018 May CTEC

INJECTABLE; INJECTION

MORPHINE SULFATE

+! HOSPIRA INC

50MG/ML

N202515 006 Apr 29, 2021 Apr NEWA

INTL MEDICATION SYS

1MG/ML

A202861 001 Apr 29, 2021 Apr NFTA

SOLUTION; ORAL

MORPHINE SULFATE

@ ANI PHARMS

10MG/5ML

A205509 001 Apr 17, 2018 Jan DISC

@

20MG/5ML

A205509 002 Apr 17, 2018 Jan DISC

@

100MG/5ML

A205509 003 Apr 17, 2018 Jan DISC

AA WINDER LABS LLC

10MG/5ML

A211454 001 Feb 12, 2021 Feb NEWA

AA

20MG/5ML

A211454 002 Feb 12, 2021 Feb NEWA

AA

100MG/5ML

A211454 003 Feb 12, 2021 Feb NEWA

TABLET; ORAL

MORPHINE SULFATE

AB UPSHER SMITH LABS

15MG

A210610 001 Jul 22, 2019 May CAHN

AB

30MG

A210610 002 Jul 22, 2019 May CAHN

MOXIFLOXACIN HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

MOXIFLOXACIN HYDROCHLORIDE

AT1 UPSHER SMITH LABS EQ 0.5% BASE

A212616 001 Feb 10, 2021 Jan NEWA

MYCOPHENOLATE MOFETIL HYDROCHLORIDE

INJECTABLE; INJECTION

MYCOPHENOLATE MOFETIL HYDROCHLORIDE

AP AMNEAL 500MG/VIAL

A211374 001 Mar 05, 2021 Feb NEWA

AP MEITHEAL 500MG/VIAL

A212130 001 Jan 15, 2021 Jan CAHN

AP NANJING KING-FRIEND 500MG/VIAL

A212130 001 Jan 15, 2021 Jan NEWA

MYCOPHENOLIC ACID

TABLET, DELAYED RELEASE; ORAL

MYCOPHENOLIC ACID

AB AMTA 180MG

A214376 001 Feb 10, 2021 Jan NEWA

AB 360MG

A214376 002 Feb 10, 2021 Jan NEWA

NABUMETONE

TABLET; ORAL

NABUMETONE

AB	ANNORA PHARMA	500MG	A 090445	001	Jan 12, 2011	Mar	CAHN
AB		750MG	A 090445	002	Jan 12, 2011	Mar	CAHN

NADOLOL

TABLET; ORAL

NADOLOL

	@ NOVAST LABS	20MG	A 210786	001	Jun 01, 2018	May	DISC
	@	40MG	A 210786	002	Jun 01, 2018	May	DISC
	@	80MG	A 210786	003	Jun 01, 2018	May	DISC
AB	VGYAAN	20MG	A 212856	001	Sep 13, 2019	May	CMFD
AB		40MG	A 212856	002	Sep 13, 2019	May	CMFD
AB		80MG	A 212856	003	Sep 13, 2019	May	CMFD

NALOXONE HYDROCHLORIDE

INJECTABLE; INJECTION

NALOXONE HYDROCHLORIDE

AP	AUROBINDO PHARMA LTD	1MG/ML	A 213279	001	Jan 14, 2021	Jan	NEWA
AP	BAXTER HLTHCARE CORP	0.4MG/ML	A 214785	001	Jan 29, 2021	Jan	NEWA
	SPRAY; NASAL						
	KLOXXADO						
+!	HIKMA	8MG/SPRAY	N 212045	001	Apr 29, 2021	Apr	NEWA

NAPROXEN

SUSPENSION; ORAL

NAPROXEN

AB	NOVITIUM PHARMA	25MG/ML	A 211910	001	Mar 10, 2021	Feb	NEWA
----	-----------------	---------	----------	-----	--------------	-----	------

TABLET; ORAL

NAPROXEN

AB	GRANULES	250MG	A 074140	001	Dec 21, 1993	Feb	CMFD
AB		375MG	A 074140	002	Dec 21, 1993	Feb	CMFD
AB		500MG	A 074140	003	Dec 21, 1993	Feb	CMFD

NEOSTIGMINE METHYLSULFATE

SOLUTION; INTRAVENOUS

NEOSTIGMINE METHYLSULFATE

AP	CAPLIN	5MG/10ML (0.5MG/ML)	A 213074	001	Apr 20, 2021	Apr	NEWA
AP		10MG/10ML (1MG/ML)	A 213074	002	Apr 20, 2021	Apr	NEWA
AP	HONG KONG	5MG/10ML (0.5MG/ML)	A 212804	001	Apr 05, 2021	Mar	NEWA
AP		10MG/10ML (1MG/ML)	A 212804	002	Apr 05, 2021	Mar	NEWA
AP	MEITHEAL	5MG/10ML (0.5MG/ML)	A 212804	001	Apr 05, 2021	Apr	CAHN
AP		10MG/10ML (1MG/ML)	A 212804	002	Apr 05, 2021	Apr	CAHN

NIACIN

TABLET, EXTENDED RELEASE; ORAL

NIACIN

>D>	AB	JUBILANT GENERICS	500MG	A 209156	001	May 14, 2018	Jun	DISC
>A>		@	500MG	A 209156	001	May 14, 2018	Jun	DISC
>D>	AB		750MG	A 209156	002	May 14, 2018	Jun	DISC
>A>		@	750MG	A 209156	002	May 14, 2018	Jun	DISC
>D>	AB		1GM	A 209156	003	May 14, 2018	Jun	DISC
>A>		@	1GM	A 209156	003	May 14, 2018	Jun	DISC

NICARDIPINE HYDROCHLORIDE

CAPSULE; ORAL

NICARDIPINE HYDROCHLORIDE

AB	ANI PHARMS	20MG	A 074670	001	Oct 28, 1996	May	CMFD
AB		30MG	A 074670	002	Oct 28, 1996	May	CMFD
AB	EPIC PHARMA	20MG	A 074928	001	Mar 19, 1998	May	C TEC
AB	!	30MG	A 074928	002	Mar 19, 1998	May	C TEC

INJECTABLE; INJECTION

NICARDIPINE HYDROCHLORIDE

AP	!	AM REGENT	25MG/10ML (2.5MG/ML)	A 090534	001	Nov 17, 2009	Apr	C TEC
	!		25MG/10ML (2.5MG/ML)	A 090534	001	Nov 17, 2009	Feb	CHRS
AP		AUROBINDO PHARMA LTD	25MG/10ML (2.5MG/ML)	A 211121	001	Apr 08, 2021	Apr	NEWA
>A>	AP	SUN PHARM	25MG/10ML (2.5MG/ML)	N 078405	001	Nov 17, 2009	Jun	CMFD
>D>		@ SUN PHARMA GLOBAL	25MG/10ML (2.5MG/ML)	N 078405	001	Nov 17, 2009	Jun	CMFD

NIFEDIPINE

TABLET, EXTENDED RELEASE;ORAL
NIFEDIPINE

>D>	AB2	ELITE	90MG	A212016	001	Nov 18, 2020	Jun DISC
>A>	@		90MG	A212016	001	Nov 18, 2020	Jun DISC
	@	PAR PHARM	30MG	A077899	001	Dec 13, 2006	Apr DISC
	@		60MG	A077899	002	Dec 13, 2006	Apr DISC
	@		90MG	A077899	003	May 25, 2012	Apr DISC

NISOLDIPINE

TABLET, EXTENDED RELEASE;ORAL
NISOLDIPINE

!	MYLAN	20MG	A079051	001	Jul 25, 2008	Jan CHRS
		30MG	A079051	002	Jul 25, 2008	Jan CHRS

NITROFURANTOIN, MACROCRYSTALLINE

CAPSULE;ORAL
NITROFURANTOIN

>A>	AB	ALEMBIC PHARMS LTD	25MG	A211935	001	Jun 25, 2021	Jun NEWA
>A>	AB		50MG	A211935	002	Jun 25, 2021	Jun NEWA
>A>	AB		100MG	A211935	003	Jun 25, 2021	Jun NEWA

NITROGLYCERIN

FILM, EXTENDED RELEASE;TRANSDERMAL
MINITRAN

@	BAUSCH	0.4MG/HR	A089773	001	Aug 30, 1996	May CAHN	
>D>		POWDER;SUBLINGUAL					
>D>		GONITRO					
>D>	+	POHL BOSKAMP	0.4MG/PACKET	N208424	001	Jun 08, 2016	Jun DISC
>A>	+	@	0.4MG/PACKET	N208424	001	Jun 08, 2016	Jun DISC
		TABLET;SUBLINGUAL					
		NITROGLYCERIN					
AB		RUBICON	0.3MG	A209779	001	May 03, 2021	Apr NEWA
AB			0.4MG	A209779	002	May 03, 2021	Apr NEWA
AB			0.6MG	A209779	003	May 03, 2021	Apr NEWA

NOREPINEPHRINE BITARTRATE

INJECTABLE;INJECTION
NOREPINEPHRINE BITARTRATE

AP		ANDERSEN GLOBAL	EQ 1MG BASE/ML	A214455	001	Jan 22, 2021	Jan NEWA
AP		BRECKENRIDGE	EQ 1MG BASE/ML	A214455	001	Jan 22, 2021	Mar CAHN
AP		GLAND PHARMA LTD	EQ 1MG BASE/ML	A214323	001	May 06, 2021	Apr NEWA
AP		SUN PHARM	EQ 1MG BASE/ML	A211980	001	Jan 29, 2021	Jan NEWA
		SOLUTION;INTRAVENOUS					
		NOREPINEPHRINE BITARTRATE IN 5% DEXTROSE					
+	!	BAXTER HLTHCARE CORP	EQ 4MG BASE/250ML (EQ 16MCG BASE/ML)	N214313	001	Jan 15, 2021	Jan NEWA
+	!		EQ 8MG BASE/250ML (EQ 32MCG BASE/ML)	N214313	002	Jan 15, 2021	Jan NEWA

NORTRIPTYLINE HYDROCHLORIDE

CAPSULE;ORAL
NORTRIPTYLINE HYDROCHLORIDE

AB		ZYDUS	EQ 10MG BASE	A213441	001	Feb 24, 2021	Feb NEWA
AB			EQ 50MG BASE	A213441	003	Feb 24, 2021	Feb NEWA
AB			EQ 75MG BASE	A213441	004	Feb 24, 2021	Feb NEWA

NYSTATIN

OINTMENT;TOPICAL
NYSTATIN

AT		MACLEODS PHARMS LTD	100,000 UNITS/GM	A213826	001	Jan 14, 2021	Jan NEWA
		SUSPENSION;ORAL					
		NYSTATIN					
>A>	AA	NIVAGEN PHARMS INC	100,000 UNITS/ML	A062832	001	Dec 27, 1991	Jun CAHN
>D>	AA	SOCORRO	100,000 UNITS/ML	A062832	001	Dec 27, 1991	Jun CAHN

NYSTATIN; TRIAMCINOLONE ACETONIDE

CREAM; TOPICAL

NYSTATIN AND TRIAMCINOLONE ACETONIDE

AT	ALEOR DERMACEUTICALS	100,000 UNITS/GM;0.1%	A214090	001	Mar 31, 2021	Mar	NEWA
----	----------------------	-----------------------	---------	-----	--------------	-----	------

OFLOXACIN

SOLUTION/DROPS; OPHTHALMIC

OFLOXACIN

>D>	@ ALVOGEN	0.3%	A076830	001	Aug 31, 2004	Jun	CAHN
>A>	@	0.3%	A076830	001	Aug 31, 2004	Jun	CAHN
	@	0.3%	A076830	001	Aug 31, 2004	Jan	DISC

SOLUTION/DROPS; OTIC

OFLOXACIN

>D>	@ ALVOGEN	0.3%	A090395	001	Aug 11, 2009	Jun	CAHN
>A>	@	0.3%	A090395	001	Aug 11, 2009	Jun	CAHN

TABLET; ORAL

FLOXIN

+ @	JANSSEN PHARMS	200MG	N019735	001	Dec 28, 1990	Jan	CRLD
+ @		300MG	N019735	002	Dec 28, 1990	Jan	CRLD
+ @		400MG	N019735	003	Dec 28, 1990	Jan	CRLD

OFLOXACIN

AB	LARKEN LABS	400MG	A076093	003	Sep 02, 2003	May	CMFD
----	-------------	-------	---------	-----	--------------	-----	------

OLANZAPINE; SAMIDORPHAN L-MALATE

TABLET; ORAL

LYBALVI

+!	ALKERMES INC	5MG;EQ 10MG BASE	N213378	001	May 28, 2021	May	NEWA
+		10MG;EQ 10MG BASE	N213378	002	May 28, 2021	May	NEWA
+		15MG;EQ 10MG BASE	N213378	003	May 28, 2021	May	NEWA
+		20MG;EQ 10MG BASE	N213378	004	May 28, 2021	May	NEWA

OLOPATADINE HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

OLOPATADINE HYDROCHLORIDE

>D>	AT	AKORN	EQ 0.1% BASE	A204532	001	Jan 10, 2017	Jun	CMKT
>D>			EQ 0.2% BASE	A204723	001	Dec 05, 2017	Jun	CMKT
			EQ 0.2% BASE	A204723	001	Dec 05, 2017	Mar	CTEC

SPRAY, METERED; NASAL

OLOPATADINE HYDROCHLORIDE

AB	AMNEAL	0.665MG/SPRAY	A210901	001	Jan 28, 2020	Mar	CMFD
	@	0.665MG/SPRAY	A210901	001	Jan 28, 2020	Jan	DISC

OMEGA-3-ACID ETHYL ESTERS

CAPSULE; ORAL

LOVAZA

AB	+!	WOODWARD	1GM CONTAINS AT LEAST 900MG OF THE ETHYL ESTERS OF OMEGA-3 FATTY ACIDS	N021654	001	Nov 10, 2004	Feb	CAHN
----	----	----------	--	---------	-----	--------------	-----	------

ONDANSETRON

FILM; ORAL

ZUPLENZ

+ @	AQUESTIVE	4MG	N022524	001	Jul 02, 2010	Feb	CAHN
+ @		8MG	N022524	002	Jul 02, 2010	Feb	CAHN

ONDANSETRON HYDROCHLORIDE

INJECTABLE; INJECTION

ONDANSETRON HYDROCHLORIDE

>D>	AP	HOSPIRA	EQ 2MG BASE/ML	A077840	001	Jan 19, 2007	Jun	DISC
>A>		@	EQ 2MG BASE/ML	A077840	001	Jan 19, 2007	Jun	DISC
			ONDANSETRON HYDROCHLORIDE PRESERVATIVE FREE					
		@ EMCURE PHARMS LTD	EQ 2MG BASE/ML	A078945	001	Jan 03, 2013	May	DISC

ORITAVANCIN DIPHOSPHATE

POWDER; INTRAVENOUS

KIMYRSA

+!	MELINTA THERAP	EQ 1.2GM BASE/VIAL	N214155	001	Mar 12, 2021	Mar	NEWA
+!	MELINTA THERAP	EQ 400MG BASE/VIAL	N206334	001	Aug 06, 2014	May	CAHN

ORPHENADRINE CITRATE

TABLET, EXTENDED RELEASE;ORAL
NORFLEX

+ @ BAUSCH	100MG	N012157	001		May CAHN
ORPHENADRINE CITRATE					
@ IMPAX PHARMS	100MG	A040368	001	Jun 23, 2000	Jan DISC

OSELTAMIVIR PHOSPHATE

CAPSULE;ORAL
OSELTAMIVIR PHOSPHATE

@ MYLAN	EQ 30MG BASE	A210157	001	Jan 21, 2021	Jan DISC
AB	EQ 30MG BASE	A210157	001	Jan 21, 2021	Jan NEWA
@	EQ 45MG BASE	A210157	002	Jan 21, 2021	Jan DISC
AB	EQ 45MG BASE	A210157	002	Jan 21, 2021	Jan NEWA
@	EQ 75MG BASE	A210157	003	Jan 21, 2021	Jan DISC
AB	EQ 75MG BASE	A210157	003	Jan 21, 2021	Jan NEWA

OXALIPLATIN

INJECTABLE;INTRAVENOUS
OXALIPLATIN

@ CIPLA	50MG/10ML (5MG/ML)	A208523	001	Feb 10, 2017	May DISC
@	100MG/20ML (5MG/ML)	A208523	002	Feb 10, 2017	May DISC

OXCARBAZEPINE

SUSPENSION;ORAL
OXCARBAZEPINE

>A> AB	GLASSHOUSE PHARMS	300MG/5ML	A212428	001	Jun 21, 2021	Jun NEWA
--------	-------------------	-----------	---------	-----	--------------	----------

OXICONAZOLE NITRATE

LOTION;TOPICAL
OXISTAT

+! ANI PHARMS	EQ 1% BASE	N020209	001	Sep 30, 1992	Apr CAHN
---------------	------------	---------	-----	--------------	----------

OXYBUTYNIN CHLORIDE

TABLET;ORAL
OXYBUTYNIN CHLORIDE

AB	APPCO	5MG	A209025	001	Dec 21, 2017	Jan CAHN
>D> AB	STRIDES PHARMA	5MG	A208165	001	Dec 17, 2020	Jun DISC
>A>	@	5MG	A208165	001	Dec 17, 2020	Jun DISC

OXYCODONE HYDROCHLORIDE

CAPSULE;ORAL
OXYCODONE HYDROCHLORIDE

@ LANNETT CO INC	5MG	A203823	001	Aug 01, 2014	Apr DISC
------------------	-----	---------	-----	--------------	----------

SOLUTION;ORAL
OXYCODONE HYDROCHLORIDE

AA	QUAGEN	5MG/5ML	A213761	001	Jun 02, 2021	May NEWA
AA		100MG/5ML	A213761	002	Jun 02, 2021	May NEWA

TABLET;ORAL
OXAYDO

+ ZYLA	5MG	N202080	001	Jun 17, 2011	Mar CRLD
+ OXYCODONE HYDROCHLORIDE	7.5MG	N202080	002	Jun 17, 2011	Mar CRLD

AB	ALVOGEN	5MG	A202116	001	Dec 30, 2011	Apr CAHN
AB		15MG	A202116	002	Dec 30, 2011	Apr CAHN
AB		30MG	A202116	003	Dec 30, 2011	Apr CAHN

OXYMETHOLONE

TABLET;ORAL
ANADROL-50

+ @ MYLAN SPECIALITY LP	50MG	N016848	001		Apr DISC
-------------------------	------	---------	-----	--	----------

OZANIMOD HYDROCHLORIDE

CAPSULE;ORAL
ZEPOSIA

+ CELGENE INTL	EQ 0.23MG BASE	N209899	001	Mar 25, 2020	May CPOT
+ OZANIMOD HYDROCHLORIDE	EQ 0.46MG BASE	N209899	002	Mar 25, 2020	May CPOT
+!	EQ 0.92MG BASE	N209899	003	Mar 25, 2020	May CPOT

PACLITAXELINJECTABLE; INJECTION
PACLITAXEL

AP	ACCORD HLTHCARE	6MG/ML	A205720	001	Aug 17, 2018	May CMFD
	@ MYLAN LABS LTD	6MG/ML	A091540	001	Sep 29, 2011	Mar DISC

PALIPERIDONE PALMITATE

SUSPENSION, EXTENDED RELEASE; INTRAMUSCULAR

>A>	PALIPERIDONE PALMITATE					
>A>	TEVA PHARMS USA	39MG/0.25ML (39MG/0.25ML)	A211149	001	Jul 06, 2021	Jun NFTG
>A>	AP	78MG/0.5ML (78MG/0.5ML)	A211149	002	Jul 06, 2021	Jun NFTG
>A>	AP	117MG/0.75ML (117MG/0.75ML)	A211149	003	Jul 06, 2021	Jun NFTG
>A>	AP	156MG/ML (156MG/ML)	A211149	004	Jul 06, 2021	Jun NFTG
>A>	AP	234MG/1.5ML (156MG/ML)	A211149	005	Jul 06, 2021	Jun NFTG

PALONOSETRON HYDROCHLORIDEINJECTABLE; INTRAVENOUS
ALOXI

+	@ HELSINN HLTHCARE	EQ 0.075MG BASE/1.5ML (EQ 0.05MG BASE/ML)	N021372	002	Feb 29, 2008	Apr DISC
+	@	EQ 0.25MG BASE/5ML (EQ 0.05MG BASE/ML)	N021372	001	Jul 25, 2003	Apr DISC
	PALONOSETRON HYDROCHLORIDE					
AP	ACCORD HLTHCARE	EQ 0.25MG BASE/5ML (EQ 0.05MG BASE/ML)	A204615	001	Mar 15, 2021	Mar NEWA
AP	! DR REDDYS LABS LTD	EQ 0.25MG BASE/5ML (EQ 0.05MG BASE/ML)	A201533	002	Apr 21, 2016	Apr CHRS
>A>	EMCURE PHARMS LTD	EQ 0.075MG BASE/1.5ML (EQ 0.05MG BASE/ML)	A202951	001	Jun 29, 2021	Jun NEWA
>A>	AP	EQ 0.25MG BASE/5ML (EQ 0.05MG BASE/ML)	A202951	002	Jun 29, 2021	Jun NEWA
	@ HOSPIRA INC	EQ 0.075MG BASE/1.5ML (EQ 0.05MG BASE/ML)	A207005	002	Sep 19, 2018	Apr DISC
	@ QILU	EQ 0.075MG BASE/1.5ML (EQ 0.05MG BASE/ML)	A205648	002	Sep 19, 2018	Apr DISC
	@ TEVA PHARMS USA	EQ 0.075MG BASE/1.5ML (EQ 0.05MG BASE/ML)	A090713	002	Mar 23, 2018	Apr DISC
	SOLUTION; INTRAVENOUS					
	PALONOSETRON HYDROCHLORIDE					
+	@ FRESENIUS KABI USA	EQ 0.25MG BASE/5ML (EQ 0.05MG BASE/ML)	N208109	001	Nov 21, 2017	May DISC

PANTOPRAZOLE SODIUMTABLET, DELAYED RELEASE; ORAL
PANTOPRAZOLE SODIUM

>D>	AB	JUBILANT GENERICS	EQ 20MG BASE	A090901	001	Aug 30, 2011	Jun DISC
>A>		@	EQ 20MG BASE	A090901	001	Aug 30, 2011	Jun DISC
>D>	AB		EQ 40MG BASE	A090901	002	Aug 30, 2011	Jun DISC
>A>		@	EQ 40MG BASE	A090901	002	Aug 30, 2011	Jun DISC

PAROXETINE HYDROCHLORIDETABLET, EXTENDED RELEASE; ORAL
PAROXETINE HYDROCHLORIDE

AB	CSPC OUYI	EQ 12.5MG BASE	A213485	001	Feb 16, 2021	Feb NEWA
AB		EQ 25MG BASE	A213485	002	Feb 16, 2021	Feb NEWA
AB		EQ 37.5MG BASE	A213485	003	Feb 16, 2021	Feb NEWA

PATIROMER SORBITE CALCIUMPOWDER; ORAL
VELTASSA

>D>	+	RELYPSA INC	EQ 8.4GM BASE/PACKET	N205739	001	Oct 21, 2015	Jun CAHN
>D>		+	EQ 16.8GM BASE/PACKET	N205739	002	Oct 21, 2015	Jun CAHN
>D>		+	EQ 25.2GM BASE/PACKET	N205739	003	Oct 21, 2015	Jun CAHN
>A>		+	EQ 8.4GM BASE/PACKET	N205739	001	Oct 21, 2015	Jun CAHN
>A>		+	EQ 16.8GM BASE/PACKET	N205739	002	Oct 21, 2015	Jun CAHN
>A>		+	EQ 25.2GM BASE/PACKET	N205739	003	Oct 21, 2015	Jun CAHN

PEGCETACOPLANSOLUTION; SUBCUTANEOUS
EMPAVELI

+	!	APELLIS PHARMS	1080MG/20ML (54MG/ML)	N215014	001	May 14, 2021	May NEWA
---	---	----------------	-----------------------	---------	-----	--------------	----------

PEMETREXEDSOLUTION; INTRAVENOUS
PEMETREXED

+ @	ACTAVIS LLC	100MG/4ML (25MG/ML)	N208419	001	Aug 21, 2020	Jan	DISC
+ @		500MG/20ML (25MG/ML)	N208419	002	Aug 21, 2020	Jan	DISC
+ @		1GM/40ML (25MG/ML)	N208419	003	Aug 21, 2020	Jan	DISC

PENICILLIN G POTASSIUMINJECTABLE; INJECTION
PENICILLIN G POTASSIUM
HQ SPECLT PHARMA

		1,000,000 UNITS/VIAL	A065149	001	Jul 23, 2009	Mar	CAHN
AP		5,000,000 UNITS/VIAL	A065149	002	Jul 23, 2009	Mar	CAHN
AP		20,000,000 UNITS/VIAL	A065149	003	Jul 23, 2009	Mar	CAHN

PENICILLIN V POTASSIUMFOR SOLUTION; ORAL
PENICILLIN V POTASSIUM
@ DAVA PHARMS INC
@
PENICILLIN-VK

		EQ 125MG BASE/5ML	A062981	001	Feb 10, 1989	Mar	DISC
		EQ 250MG BASE/5ML	A062981	002	Feb 10, 1989	Mar	DISC
	TEVA	EQ 125MG BASE/5ML	A060456	001		Mar	CTEC
!		EQ 250MG BASE/5ML	A060456	002		Mar	CTEC

PENTAMIDINE ISETHIONATEINJECTABLE; INJECTION
PENTAMIDINE ISETHIONATE

AP	EMCURE PHARMS LTD	300MG/VIAL	A213806	001	Jan 07, 2021	Jan	NEWA
----	-------------------	------------	---------	-----	--------------	-----	------

PENTOXIFYLLINETABLET, EXTENDED RELEASE; ORAL
PENTOXIL

	@ UPSHER SMITH LABS	400MG	A074962	001	Mar 31, 1999	May	DISC
	TRENTAL						
+ @	VALIDUS PHARMS	400MG	N018631	001	Aug 30, 1984	Feb	CAHN

PERAMPANELTABLET; ORAL
FYCOMPA

>D>	AB	+ EISAI INC	2MG	N202834	001	Oct 22, 2012	Jun	CTEC
>A>			2MG	N202834	001	Oct 22, 2012	Jun	CTEC
>D>	AB	+	4MG	N202834	002	Oct 22, 2012	Jun	CTEC
>A>			4MG	N202834	002	Oct 22, 2012	Jun	CTEC
>D>	AB	+	6MG	N202834	003	Oct 22, 2012	Jun	CTEC
>A>			6MG	N202834	003	Oct 22, 2012	Jun	CTEC
>D>	AB	+	8MG	N202834	004	Oct 22, 2012	Jun	CTEC
>A>			8MG	N202834	004	Oct 22, 2012	Jun	CTEC
>D>	AB	+	10MG	N202834	005	Oct 22, 2012	Jun	CTEC
>A>			10MG	N202834	005	Oct 22, 2012	Jun	CTEC
>D>	AB	+!	12MG	N202834	006	Oct 22, 2012	Jun	CTEC
>A>		+!	12MG	N202834	006	Oct 22, 2012	Jun	CTEC

PHENYLEPHRINE HYDROCHLORIDESOLUTION; INTRAVENOUS
BIORPHEN

+!	ETON PHARMS	0.5MG/5ML (0.1MG/ML)	N212909	001	Oct 21, 2019	Feb	CPOT
+ @		10MG/ML (10MG/ML)	N212909	002	Mar 11, 2021	Apr	DISC
+!		10MG/ML (10MG/ML)	N212909	002	Mar 11, 2021	Mar	NEWA

PHENYLEPHRINE HYDROCHLORIDE

AP2	AUROBINDO PHARMA LTD	10MG/ML (10MG/ML)	A210696	001	Jan 07, 2021	Jan	NEWA
AP1	GLAND PHARMA LTD	10MG/ML (10MG/ML)	A211920	003	Apr 08, 2021	Apr	NEWA
AP2	+! HIKMA	10MG/ML (10MG/ML)	N203826	001	Dec 20, 2012	Jan	CAHN
AP2	+!	50MG/5ML (10MG/ML)	N203826	002	Jun 19, 2019	Jan	CAHN
AP2	+!	100MG/10ML (10MG/ML)	N203826	003	Jun 19, 2019	Jan	CAHN
AP1	PROVEPHARM SAS	10MG/ML (10MG/ML)	A211081	001	Jul 17, 2020	Jan	CAHN
AP1		50MG/5ML (10MG/ML)	A211081	002	Jul 17, 2020	Jan	CAHN
AP1		100MG/10ML (10MG/ML)	A211081	003	Jul 17, 2020	Jan	CAHN

PHENYLEPHRINE HYDROCHLORIDE; PROMETHAZINE HYDROCHLORIDE

SYRUP; ORAL

	PHENYLEPHRINE HYDROCHLORIDE AND PROMETHAZINE HYDROCHLORIDE						
AA	AKORN	5MG/5ML; 6.25MG/5ML	A040675	001	Dec 23, 2014	Feb	CAHN

PHYTONADIONE

INJECTABLE; INJECTION

	PHYTONADIONE						
BP	+! INTL MEDICATION	1MG/0.5ML	A083722	001		May	CRLD

PIFLUFOLASTAT F-18

SOLUTION; INTRAVENOUS

	PYLARIFY						
	+! PROGENICS PHARMS INC	50ML (1-80mCi/ML)	N214793	001	May 26, 2021	May	NEWA

PIOGLITAZONE HYDROCHLORIDE

TABLET; ORAL

	PIOGLITAZONE HYDROCHLORIDE						
AB	ANNORA PHARMA	EQ 15MG BASE	A204133	001	Apr 07, 2014	Jan	CAHN
AB		EQ 30MG BASE	A204133	002	Apr 07, 2014	Jan	CAHN
AB		EQ 45MG BASE	A204133	003	Apr 07, 2014	Jan	CAHN
AB	SHUANGCHENG	EQ 15MG BASE	A210165	001	Jan 22, 2021	Jan	NEWA
AB		EQ 30MG BASE	A210165	002	Jan 22, 2021	Jan	NEWA
AB		EQ 45MG BASE	A210165	003	Jan 22, 2021	Jan	NEWA

PIPERACILLIN SODIUM; TAZOBACTAM SODIUM

INJECTABLE; INJECTION

	PIPERACILLIN AND TAZOBACTAM						
	@ MYLAN LABS LTD	EQ 2GM BASE/VIAL; EQ 250MG BASE/VIAL	A065458	001	Aug 15, 2014	Apr	DISC
	@	EQ 3GM BASE/VIAL; EQ 375MG BASE/VIAL	A065458	002	Aug 15, 2014	Mar	DISC
AP	PROVEPHARM SAS	EQ 2GM BASE/VIAL; EQ 250MG BASE/VIAL	A207847	001	Jan 13, 2017	Jan	CAHN
AP		EQ 3GM BASE/VIAL; EQ 375MG BASE/VIAL	A207847	002	Jan 13, 2017	Jan	CAHN
AP		EQ 36GM BASE/VIAL; EQ 4.5GM BASE/VIAL	A207848	002	Jan 13, 2017	Jan	CAHN
AP		EQ 4GM BASE/VIAL; EQ 500MG BASE/VIAL	A207847	003	Jan 13, 2017	Jan	CAHN
AP		EQ 12GM BASE/VIAL; EQ 1.5GM BASE/VIAL	A207848	001	May 11, 2018	Jan	CAHN
AP	SAGENT PHARMS INC	EQ 2GM BASE/VIAL; EQ 250MG BASE/VIAL	A208674	001	Feb 16, 2021	Feb	NEWA
AP		EQ 3GM BASE/VIAL; EQ 375MG BASE/VIAL	A208674	002	Feb 16, 2021	Feb	NEWA
AP		EQ 4GM BASE/VIAL; EQ 500MG BASE/VIAL	A208674	003	Feb 16, 2021	Feb	NEWA
AP		EQ 36GM BASE/VIAL; EQ 4.5GM BASE/VIAL	A208675	001	Feb 16, 2021	Feb	NEWA
AP	! WOCKHARDT BIO AG	EQ 2GM BASE/VIAL; EQ 250MG BASE/VIAL	A206996	001	Mar 22, 2017	Jan	CHRS
AP	!	EQ 3GM BASE/VIAL; EQ 375MG BASE/VIAL	A206996	002	Mar 22, 2017	Jan	CHRS
AP	!	EQ 4GM BASE/VIAL; EQ 500MG BASE/VIAL	A206996	003	Mar 22, 2017	Jan	CHRS
AP	!	EQ 36GM BASE/VIAL; EQ 4.5GM BASE/VIAL	A207146	001	Mar 17, 2017	Jan	CHRS
	ZOSYN						
	+ @ WYETH PHARMS	EQ 2GM BASE/VIAL; EQ 250MG BASE/VIAL	N050684	001	Oct 22, 1993	Jan	DISC
	+ @	EQ 3GM BASE/VIAL; EQ 375MG BASE/VIAL	N050684	002	Oct 22, 1993	Jan	DISC
	+ @	EQ 4GM BASE/VIAL; EQ 500MG BASE/VIAL	N050684	003	Oct 22, 1993	Jan	DISC
	+ @	EQ 36GM BASE/VIAL; EQ 4.5GM BASE/VIAL	N050684	004	Oct 22, 1993	Jan	DISC

PIRBUTEROL ACETATE

AEROSOL, METERED; INHALATION

	MAXAIR						
	@ BAUSCH	EQ 0.2MG BASE/INH	N020014	001	Nov 30, 1992	May	CAHN

PIROXICAM

	CAPSULE;ORAL						
	PIROXICAM						
AB	NOSTRUM LABS INC	10MG	A074118	002	Jun 15, 1993	Jan	CMS1

POLYMYXIN B SULFATE

	INJECTABLE;INJECTION						
	POLYMYXIN B SULFATE						
	@ GLAND	EQ 500,000 UNITS BASE/VIAL	A207322	001	Apr 14, 2016	May	DISC
AP	! XELLIA PHARMS APS	EQ 500,000 UNITS BASE/VIAL	A202766	001	Jan 15, 2014	May	CHRS

POMALIDOMIDE

	CAPSULE;ORAL						
	POMALIDOMIDE						
	@ BRECKENRIDGE	1MG	A210111	001	Oct 30, 2020	Feb	DISC
	@	2MG	A210111	002	Oct 30, 2020	Feb	DISC
	@	3MG	A210111	003	Oct 30, 2020	Feb	DISC
	@	4MG	A210111	004	Oct 30, 2020	Feb	DISC
	@ EUGIA PHARMA	1MG	A210249	001	Oct 30, 2020	Apr	DISC
	@	2MG	A210249	002	Oct 30, 2020	Apr	DISC
	@	3MG	A210249	003	Oct 30, 2020	Apr	DISC
	@	4MG	A210249	004	Oct 30, 2020	Apr	DISC
	POMALYST						
+	CELGENE	1MG	N204026	001	Feb 08, 2013	Apr	CTEC
+		2MG	N204026	002	Feb 08, 2013	Apr	CTEC
+		3MG	N204026	003	Feb 08, 2013	Apr	CTEC
+	!	4MG	N204026	004	Feb 08, 2013	Apr	CTEC

PONATINIB HYDROCHLORIDE

	TABLET;ORAL						
	ICLUSIG						
+	TAKEDA PHARMS USA	EQ 10MG BASE	N203469	004	Dec 18, 2020	May	CAHN
+		EQ 15MG BASE	N203469	001	Dec 14, 2012	May	CAHN
+		EQ 30MG BASE	N203469	003	Apr 23, 2015	May	CAHN
+	!	EQ 45MG BASE	N203469	002	Dec 14, 2012	May	CAHN

PONESIMOD

	TABLET;ORAL						
	PONVORY						
+	JANSSEN PHARMS	2MG	N213498	001	Mar 18, 2021	Mar	NEWA
+		3MG	N213498	002	Mar 18, 2021	Mar	NEWA
+		4MG	N213498	003	Mar 18, 2021	Mar	NEWA
+		5MG	N213498	004	Mar 18, 2021	Mar	NEWA
+		6MG	N213498	005	Mar 18, 2021	Mar	NEWA
+		7MG	N213498	006	Mar 18, 2021	Mar	NEWA
+		8MG	N213498	007	Mar 18, 2021	Mar	NEWA
+		9MG	N213498	008	Mar 18, 2021	Mar	NEWA
+		10MG	N213498	009	Mar 18, 2021	Mar	NEWA
+	!	20MG	N213498	010	Mar 18, 2021	Mar	NEWA

POSACONAZOLE

	FOR SUSPENSION, DELAYED RELEASE;ORAL						
	NOXAFIL POWDERMIX KIT						
+	! MSD MERCK CO	300MG	N214770	001	May 31, 2021	May	NEWA
	TABLET, DELAYED RELEASE;ORAL						
	POSACONAZOLE						
AB	AET PHARMA	100MG	A213454	001	Feb 01, 2021	Jan	NEWA

POTASSIUM CHLORIDE

	CAPSULE, EXTENDED RELEASE;ORAL						
	POTASSIUM CHLORIDE						
AB	GRANULES	8MEQ	A214686	001	Feb 16, 2021	Feb	NEWA
AB		10MEQ	A214686	002	Feb 16, 2021	Feb	NEWA
	FOR SOLUTION;ORAL						
	POTASSIUM CHLORIDE						
AA	STRIDES PHARMA	20MEQ	A211667	001	Mar 11, 2021	Mar	NEWA
	INJECTABLE;INJECTION						
	POTASSIUM CHLORIDE 10MEQ						
	@ FRESENIUS KABI USA	14.9MG/ML	A211087	001	Sep 09, 2020	Mar	DISC
	@	746MG/100ML	A211087	002	Sep 09, 2020	Mar	DISC
AP	NEXUS PHARMS	14.9MG/ML	A214727	001	Mar 18, 2021	Mar	NFTG

INJECTABLE; INJECTION						
POTASSIUM CHLORIDE 10MEQ						
AP		745MG/100ML	A214727	002	Mar 18, 2021	Mar NFTG
POTASSIUM CHLORIDE 20MEQ						
	@ FRESENIUS KABI USA	29.8MG/ML	A211087	003	Sep 09, 2020	Mar DISC
AP		1.49GM/100ML	A211087	005	May 07, 2021	Apr NEWA
AP	NEXUS PHARMS	29.8MG/ML	A214727	003	Mar 18, 2021	Mar NFTG
AP		1.49GM/100ML	A214727	004	Mar 18, 2021	Mar NFTG
POTASSIUM CHLORIDE 40MEQ						
	@ FRESENIUS KABI USA	2.98GM/100ML	A211087	004	Sep 09, 2020	Mar DISC
AP	NEXUS PHARMS	2.98GM/100ML	A214727	005	Mar 18, 2021	Mar NFTG
SOLUTION; ORAL						
POTASSIUM CHLORIDE						
AA	GRANULES	20MEQ/15ML	A213392	001	Jan 29, 2021	Jan NEWA
AA		40MEQ/15ML	A213392	002	Jan 29, 2021	Jan NEWA
AA	SAPTALIS PHARMS	20MEQ/15ML	A211648	001	May 21, 2021	May NEWA
AA		40MEQ/15ML	A211648	002	May 21, 2021	May NEWA
TABLET, EXTENDED RELEASE; ORAL						
POTASSIUM CHLORIDE						
AB1	AMTA	10MEQ	A214395	001	Jan 28, 2021	Jan NEWA
AB1		20MEQ	A214395	002	Jan 28, 2021	Jan NEWA
AB1	AUROBINDO PHARMA LTD	10MEQ	A214728	001	Mar 31, 2021	Mar NEWA
AB1		15MEQ	A214728	002	Mar 31, 2021	Mar NEWA
AB1		20MEQ	A214728	003	Mar 31, 2021	Mar NEWA
	@ CENTAUR PHARMS PVT	10MEQ	A213588	001	Aug 21, 2020	Mar DISC
	@	20MEQ	A213588	002	Aug 21, 2020	Mar DISC
<u>POTASSIUM CHLORIDE; SODIUM CHLORIDE</u>						
INJECTABLE; INJECTION						
POTASSIUM CHLORIDE 0.15% IN SODIUM CHLORIDE 0.45%						
	+! BAXTER HLTHCARE	150MG/100ML; 450MG/100ML	N017648	005	Nov 26, 2002	Mar CTNA
	+!	150MG/100ML; 450MG/100ML	N017648	005	Nov 26, 2002	Mar CTEC
	@ FRESENIUS KABI USA	150MG/100ML; 450MG/100ML	A212347	001	Sep 17, 2020	Mar DISC
POTASSIUM CHLORIDE 0.15% IN SODIUM CHLORIDE 0.9%						
AP	+! BAXTER HLTHCARE	150MG/100ML; 900MG/100ML	N017648	001		Mar CTNA
AP	+!	150MG/100ML; 900MG/100ML	N017648	001		Mar CHRS
AP	FRESENIUS KABI USA	150MG/100ML; 900MG/100ML	A212347	003	Jun 02, 2021	May NEWA
POTASSIUM CHLORIDE 0.3% AND SODIUM CHLORIDE 0.9%						
	+! BAXTER HLTHCARE	300MG/100ML; 900MG/100ML	N017648	002		Mar CTNA
	+!	300MG/100ML; 900MG/100ML	N017648	002		Mar CHRS
	+	300MG/100ML; 900MG/100ML	N017648	002		Mar CTEC
	@ FRESENIUS KABI USA	300MG/100ML; 900MG/100ML	A212347	002	Sep 17, 2020	Mar DISC
SODIUM CHLORIDE 0.9% AND POTASSIUM CHLORIDE 0.075%						
	@ BAXTER HLTHCARE	75MG/100ML; 900MG/100ML	N017648	004		Mar CTNA
<u>POTASSIUM CITRATE</u>						
TABLET, EXTENDED RELEASE; ORAL						
POTASSIUM CITRATE						
AB	ASCENT PHARMS INC	5MEQ	A214420	001	Feb 05, 2021	Jan NEWA
AB		10MEQ	A214420	002	Feb 05, 2021	Jan NEWA
AB		15MEQ	A214420	003	Feb 05, 2021	Jan NEWA
AB	BIONPHARMA INC	10MEQ	A212799	001	Jun 29, 2020	Apr CMFD
	@	10MEQ	A212799	001	Jun 29, 2020	Feb DISC
AB		15MEQ	A212799	002	Jun 29, 2020	Apr CMFD
	@	15MEQ	A212799	002	Jun 29, 2020	Feb DISC
AB	EYWA	5MEQ	A214426	001	Feb 19, 2021	Feb NEWA
AB		10MEQ	A214426	002	Feb 19, 2021	Feb NEWA
AB		15MEQ	A214426	003	Feb 19, 2021	Feb NEWA
<u>PRALSETINIB</u>						
CAPSULE; ORAL						
GAVRETO						
	+! GENENTECH INC	100MG	N213721	001	Sep 04, 2020	Mar CAHN
<u>PRAMIPEXOLE DIHYDROCHLORIDE</u>						
TABLET; ORAL						
PRAMIPEXOLE DIHYDROCHLORIDE						
AB	NOSTRUM LABS INC	0.125MG	A091450	001	Oct 08, 2010	Apr CAHN
AB		0.25MG	A091450	002	Oct 08, 2010	Apr CAHN
AB		0.5MG	A091450	003	Oct 08, 2010	Apr CAHN
AB		1MG	A091450	004	Oct 08, 2010	Apr CAHN
AB		1.5MG	A091450	005	Oct 08, 2010	Apr CAHN

TABLET, EXTENDED RELEASE;ORAL
PRAMIPEXOLE DIHYDROCHLORIDE

>A>	AB	XIAMEN LP PHARM CO	0.375MG	A212797	001	Jun 11, 2021	Jun NEWA
>A>	AB		0.75MG	A212797	002	Jun 11, 2021	Jun NEWA

PRASUGREL HYDROCHLORIDE

TABLET;ORAL
PRASUGREL

		@ DR REDDYS LABS LTD	EQ 5MG BASE	A205926	001	Jul 07, 2020	Jan DISC
		@	EQ 10MG BASE	A205926	002	Jul 07, 2020	Jan DISC

PRAVASTATIN SODIUM

TABLET;ORAL
PRAVACHOL

>D>	AB	+ BRISTOL MYERS SQUIBB	20MG	N019898	003	Oct 31, 1991	Jun DISC
>A>		+ @	20MG	N019898	003	Oct 31, 1991	Jun DISC
>D>	AB	+	40MG	N019898	004	Mar 22, 1993	Jun DISC
>A>		+ @	40MG	N019898	004	Mar 22, 1993	Jun DISC
>D>	AB	+!	80MG	N019898	008	Dec 18, 2001	Jun DISC
>A>		+ @	80MG	N019898	008	Dec 18, 2001	Jun DISC

PRAVASTATIN SODIUM

	AB	BIOCON PHARMA	10MG	A209869	001	Apr 13, 2018	Jan CAHN
	AB		20MG	A209869	002	Apr 13, 2018	Jan CAHN
	AB		40MG	A209869	003	Apr 13, 2018	Jan CAHN
	AB		80MG	A209869	004	Apr 13, 2018	Jan CAHN
		@ HISUN PHARM HANGZHOU	20MG	A206061	001	Nov 23, 2018	Jan DISC
		@	40MG	A206061	002	Nov 23, 2018	Jan DISC
		@	80MG	A206061	003	Nov 23, 2018	Jan DISC
>D>	AB	TEVA PHARMS	80MG	A077793	001	Jan 15, 2008	Jun CHRS
>A>	AB	!	80MG	A077793	001	Jan 15, 2008	Jun CHRS

PRAZOSIN HYDROCHLORIDE

CAPSULE;ORAL

PRAZOSIN HYDROCHLORIDE

	AB	ANI PHARMS	EQ 1MG BASE	A072577	002	May 16, 1989	Feb CMFD
	AB		EQ 2MG BASE	A072577	001	May 16, 1989	Feb CMFD
	AB		EQ 5MG BASE	A072577	003	May 16, 1989	Feb CMFD

PREDNISOLONE

SYRUP;ORAL

PREDNISOLONE

AA		CHARTWELL RX	15MG/5ML	A040323	001	May 13, 1999	Mar CMFD
----	--	--------------	----------	---------	-----	--------------	----------

TABLET;ORAL

PREDNISOLONE

		@ RISING	5MG	A084773	001		Jan CAHN
--	--	----------	-----	---------	-----	--	----------

PREDNISOLONE SODIUM PHOSPHATE

SOLUTION;ORAL

PREDNISOLONE SODIUM PHOSPHATE

		@ BAUSCH	EQ 15MG BASE/5ML	A075250	001	Jul 12, 2002	May CAHN
--	--	----------	------------------	---------	-----	--------------	----------

PREDNISON

TABLET;ORAL

PREDNISON

>A>	AB	NOVITIUM PHARMA	1MG	A215246	001	Jul 06, 2021	Jun NEWA
		@ RISING	10MG	A089983	001	Jan 12, 1989	Jan CAHN
		@	20MG	A085813	001		Jan CAHN
		@	50MG	A089984	001	Jan 12, 1989	Jan CAHN
	AB	STRIDES PHARMA	10MG	A208412	001	Feb 11, 2021	Feb NEWA
	AB		20MG	A208412	002	Feb 11, 2021	Feb NEWA

TABLET, DELAYED RELEASE;ORAL

RAYOS

		+ HORIZON	1MG	N202020	001	Jul 26, 2012	Apr CAHN
		+	2MG	N202020	002	Jul 26, 2012	Apr CAHN
		+!	5MG	N202020	003	Jul 26, 2012	Apr CAHN

PREGABALIN

CAPSULE;ORAL

LYRICA

	AB	+ UPJOHN	25MG	N021446	001	Dec 30, 2004	Apr CAHN
	AB	+	50MG	N021446	002	Dec 30, 2004	Apr CAHN
	AB	+	75MG	N021446	003	Dec 30, 2004	Apr CAHN

CAPSULE;ORAL									
LYRICA									
AB	+		100MG		N021446	004	Dec 30, 2004	Apr	CAHN
AB	+		150MG		N021446	005	Dec 30, 2004	Apr	CAHN
AB	+		200MG		N021446	006	Dec 30, 2004	Apr	CAHN
AB	+		225MG		N021446	007	Dec 30, 2004	Apr	CAHN
AB	+	!	300MG		N021446	008	Dec 30, 2004	Apr	CAHN
PREGABALIN									
AB		ALKEM LABS LTD	25MG		A207799	007	Sep 30, 2019	Feb	CMS1
AB			50MG		A207799	008	Sep 30, 2019	Feb	CMS1
>A>	AB	APOTEX	25MG		A211685	001	Jul 07, 2021	Jun	NEWA
>A>	AB		50MG		A211685	002	Jul 07, 2021	Jun	NEWA
>A>	AB		75MG		A211685	003	Jul 07, 2021	Jun	NEWA
>A>	AB		100MG		A211685	004	Jul 07, 2021	Jun	NEWA
>A>	AB		150MG		A211685	005	Jul 07, 2021	Jun	NEWA
>A>	AB		200MG		A211685	006	Jul 07, 2021	Jun	NEWA
>A>	AB		225MG		A211685	007	Jul 07, 2021	Jun	NEWA
>A>	AB		300MG		A211685	008	Jul 07, 2021	Jun	NEWA
SOLUTION;ORAL									
LYRICA									
AA	+	UPJOHN	20MG/ML		N022488	001	Jan 04, 2010	Apr	CAHN
TABLET, EXTENDED RELEASE;ORAL									
LYRICA CR									
AB	+	UPJOHN	82.5MG		N209501	001	Oct 11, 2017	Apr	CAHN
AB	+		165MG		N209501	002	Oct 11, 2017	Apr	CAHN
AB	+	!	330MG		N209501	003	Oct 11, 2017	Apr	CAHN
PREGABALIN									
>A>	AB	ALVOGEN	82.5MG		A211687	001	Jul 06, 2021	Jun	NEWA
>A>	AB		165MG		A211687	002	Jul 06, 2021	Jun	NEWA
>A>	AB		330MG		A211687	003	Jul 06, 2021	Jun	NEWA
	AB	ALVOGEN PINE BROOK	82.5MG		A211593	001	Apr 13, 2021	Apr	NFTG
	AB		165MG		A211593	002	Apr 13, 2021	Apr	NFTG
	AB		330MG		A211593	003	Apr 13, 2021	Apr	NFTG
	AB	APOTEX	165MG		A213313	001	Apr 13, 2021	Apr	NFTG
	AB		330MG		A213313	002	Apr 13, 2021	Apr	NFTG
	AB	MSN	82.5MG		A213226	001	Apr 13, 2021	Apr	NFTG
	AB		165MG		A213226	002	Apr 13, 2021	Apr	NFTG
	AB		330MG		A213226	003	Apr 13, 2021	Apr	NFTG
	AB	MYLAN	82.5MG		A211948	001	Apr 13, 2021	Apr	NFTG
>A>	AB		330MG		A211431	001	Jul 02, 2021	Jun	NEWA
	AB	SUN PHARM	82.5MG		A211889	001	Apr 13, 2021	Apr	NFTG
	AB		165MG		A211889	002	Apr 13, 2021	Apr	NFTG
	AB		330MG		A211889	003	Apr 13, 2021	Apr	NFTG
<u>PROCHLORPERAZINE EDISYLATE</u>									
INJECTABLE;INJECTION									
PROCHLORPERAZINE EDISYLATE									
AP		CAPLIN	EQ 5MG BASE/ML		A214379	001	Apr 22, 2021	Apr	NEWA
<u>PROMETHAZINE HYDROCHLORIDE</u>									
SYRUP;ORAL									
PROMETHAZINE HYDROCHLORIDE									
		@ AMNEAL PHARMS	6.25MG/5ML		A040882	001	Dec 30, 2009	Feb	DISC
<u>PROPAFENONE HYDROCHLORIDE</u>									
CAPSULE, EXTENDED RELEASE;ORAL									
PROPAFENONE HYDROCHLORIDE									
AB		ZYDUS	225MG		A214184	001	Apr 21, 2021	Apr	NEWA
AB			325MG		A214184	002	Apr 21, 2021	Apr	NEWA
AB			425MG		A214184	003	Apr 21, 2021	Apr	NEWA
<u>PROPANTHELINE BROMIDE</u>									
TABLET;ORAL									
PROPANTHELINE BROMIDE									
		@ HIKMA	15MG		A080927	002		Apr	DISC
<u>PROPRANOLOL HYDROCHLORIDE</u>									
TABLET;ORAL									
PROPRANOLOL HYDROCHLORIDE									
		@ WATSON LABS	60MG		A070178	002	Apr 23, 2018	Apr	DISC

PROPYLTHIOURACIL

TABLET;ORAL

PROPYLTHIOURACIL

BD	QUAGEN	50MG		A 080154	001			Mar	CMFD
----	--------	------	--	----------	-----	--	--	-----	------

PYRAZINAMIDE

TABLET;ORAL

PYRAZINAMIDE

AB	NOVITIUM PHARMA	500MG		A 080157	001			Apr	CMFD
----	-----------------	-------	--	----------	-----	--	--	-----	------

QUETIAPINE FUMARATE

TABLET;ORAL

QUETIAPINE FUMARATE

>D>	AB	JUBILANT GENERICS	EQ 25MG BASE	A 203150	001	Nov 26, 2013		Jun	DISC
>A>		@	EQ 25MG BASE	A 203150	001	Nov 26, 2013		Jun	DISC

TABLET, EXTENDED RELEASE;ORAL

QUETIAPINE FUMARATE

>D>	AB	ANCHEN PHARMS	EQ 150MG BASE	A 090757	001	Dec 01, 2017		Jun	DISC
>A>		@	EQ 150MG BASE	A 090757	001	Dec 01, 2017		Jun	DISC
>D>	AB		EQ 200MG BASE	A 090757	002	Dec 01, 2017		Jun	DISC
>A>		@	EQ 200MG BASE	A 090757	002	Dec 01, 2017		Jun	DISC
>D>	AB		EQ 300MG BASE	A 090757	003	Dec 01, 2017		Jun	DISC
>A>		@	EQ 300MG BASE	A 090757	003	Dec 01, 2017		Jun	DISC
>D>	AB		EQ 400MG BASE	A 090757	004	Dec 01, 2017		Jun	DISC
>A>		@	EQ 400MG BASE	A 090757	004	Dec 01, 2017		Jun	DISC
		@ MYLAN	EQ 50MG BASE	A 202228	001	Feb 02, 2021		Feb	DISC
AB		@	EQ 50MG BASE	A 202228	001	Feb 02, 2021		Jan	NEWA
		@	EQ 150MG BASE	A 202228	002	Feb 02, 2021		Feb	DISC
AB		@	EQ 150MG BASE	A 202228	002	Feb 02, 2021		Jan	NEWA
		@	EQ 200MG BASE	A 202228	003	Feb 02, 2021		Feb	DISC
AB		@	EQ 200MG BASE	A 202228	003	Feb 02, 2021		Jan	NEWA
		@	EQ 300MG BASE	A 202228	004	Feb 02, 2021		Feb	DISC
AB		@	EQ 300MG BASE	A 202228	004	Feb 02, 2021		Jan	NEWA
		@	EQ 400MG BASE	A 202228	005	Feb 02, 2021		Feb	DISC
AB		@	EQ 400MG BASE	A 202228	005	Feb 02, 2021		Jan	NEWA

QUINIDINE GLUCONATE

TABLET, EXTENDED RELEASE;ORAL

QUINIDINE GLUCONATE

	@ RISING	324MG		A 089894	001	Dec 15, 1988		Jan	CAHN
--	----------	-------	--	----------	-----	--------------	--	-----	------

RANITIDINE HYDROCHLORIDE

CAPSULE;ORAL

RANITIDINE HYDROCHLORIDE

>D>	AB	AUROBINDO PHARMA LTD	EQ 150MG BASE	A 211058	001	Jul 16, 2018		Jun	DISC
>A>		@	EQ 150MG BASE	A 211058	001	Jul 16, 2018		Jun	DISC
>D>	AB		EQ 300MG BASE	A 211058	002	Jul 16, 2018		Jun	DISC
>A>		@	EQ 300MG BASE	A 211058	002	Jul 16, 2018		Jun	DISC

SYRUP;ORAL

RANITIDINE HYDROCHLORIDE

>D>	AA	AUROBINDO PHARMA LTD	EQ 15MG BASE/ML	A 090623	001	Jul 28, 2010		Jun	DISC
>A>		@	EQ 15MG BASE/ML	A 090623	001	Jul 28, 2010		Jun	DISC

TABLET;ORAL

RANITIDINE HYDROCHLORIDE

	@ WOCKHARDT LTD	EQ 150MG BASE		A 075208	001	Dec 17, 1998		Jan	DISC
	@	EQ 300MG BASE		A 075208	002	Dec 17, 1998		Jan	DISC

RANOLAZINE

TABLET, EXTENDED RELEASE;ORAL

RANOLAZINE

AB	ACCORD HLTHCARE	500MG		A 212930	001	May 18, 2021		May	NEWA
AB		1GM		A 212930	002	May 18, 2021		May	NEWA
	@ AMNEAL	500MG		A 207690	001	Mar 11, 2021		Apr	DISC
AB		500MG		A 207690	001	Mar 11, 2021		Mar	NEWA
	@	1GM		A 207690	002	Mar 11, 2021		Apr	DISC
AB		1GM		A 207690	002	Mar 11, 2021		Mar	NEWA
AB	GRAVITI PHARMS	500MG		A 212889	001	Jan 28, 2021		Jan	NEWA
AB		1GM		A 212889	002	Jan 28, 2021		Jan	NEWA
AB	PRAXGEN	500MG		A 212781	001	Mar 23, 2020		Feb	CAHN
AB		1GM		A 212781	002	Mar 23, 2020		Feb	CAHN

RILUZOLEFILM;ORAL
EXSERVAN

+! MITSUBISHI HOLDINGS 50MG N212640 001 Nov 22, 2019 Feb CAHN

RISPERIDONETABLET, ORALLY DISINTEGRATING;ORAL
RISPERDAL

+ @ JANSSEN PHARMS 0.5MG N021444 001 Apr 02, 2003 Feb DISC

+ @ 1MG N021444 002 Apr 02, 2003 Feb DISC

+ @ 2MG N021444 003 Apr 02, 2003 Feb DISC

+ @ 3MG N021444 004 Dec 23, 2004 Feb DISC

+ @ 4MG N021444 005 Dec 23, 2004 Feb DISC

RISPERIDONE

AB ! JUBILANT GENERICS 1MG A090839 002 Nov 04, 2011 Feb CHRS

RITONAVIRCAPSULE;ORAL
RITONAVIR

@ HIKMA 100MG A205801 001 Dec 03, 2020 Mar DISC

RIZATRIPTAN BENZOATETABLET, ORALLY DISINTEGRATING;ORAL
RIZATRIPTAN BENZOATE

>D> AB JUBILANT GENERICS EQ 5MG BASE A203334 001 Oct 16, 2015 Jun DISC

>A> @ EQ 5MG BASE A203334 001 Oct 16, 2015 Jun DISC

>D> AB EQ 10MG BASE A203334 002 Oct 16, 2015 Jun DISC

>A> @ EQ 10MG BASE A203334 002 Oct 16, 2015 Jun DISC

ROPINIROLE HYDROCHLORIDETABLET, EXTENDED RELEASE;ORAL
REQUIP XL

>D> AB +! GLAXOSMITHKLINE LLC EQ 2MG BASE N022008 001 Jun 13, 2008 Jun DISC

>A> + @ EQ 2MG BASE N022008 001 Jun 13, 2008 Jun DISC

>D> AB + EQ 6MG BASE N022008 006 Apr 10, 2009 Jun DISC

>A> + @ EQ 6MG BASE N022008 006 Apr 10, 2009 Jun DISC

>D> AB + EQ 12MG BASE N022008 005 Oct 31, 2008 Jun DISC

>A> + @ EQ 12MG BASE N022008 005 Oct 31, 2008 Jun DISC

ROPINIROLE HYDROCHLORIDE

>D> AB DR REDDYS LABS LTD EQ 2MG BASE A201576 001 Jun 06, 2012 Jun CHRS

>A> AB ! EQ 2MG BASE A201576 001 Jun 06, 2012 Jun CHRS

ROPIVACAINE HYDROCHLORIDESOLUTION;INJECTION
NAROPIN

+ @ FRESENIUS KABI USA 50MG/10ML (5MG/ML) N020533 013 May 01, 1998 Mar CRLD

+ @ 75MG/10ML (7.5MG/ML) N020533 012 Sep 24, 1996 Mar CRLD

ROPIVACAINE HYDROCHLORIDE

@ MYLAN ASI 150MG/30ML (5MG/ML) A090318 002 Sep 23, 2014 Jan DISC

@ 200MG/20ML (10MG/ML) A090318 004 Sep 23, 2014 Jan DISC

ROSUVASTATIN CALCIUMTABLET;ORAL
CRESTOR

AB + IPR EQ 5MG BASE N021366 002 Aug 12, 2003 Apr CPOT

AB + EQ 10MG BASE N021366 003 Aug 12, 2003 Apr CPOT

AB +! EQ 40MG BASE N021366 005 Aug 12, 2003 Apr CPOT

ROSUVASTATIN CALCIUM

AB ACCORD HLTHCARE EQ 5MG BASE A206434 001 Oct 31, 2016 Apr CPOT

AB EQ 10MG BASE A206434 002 Oct 31, 2016 Apr CPOT

AB EQ 20MG BASE A206434 003 Oct 31, 2016 Apr CPOT

AB EQ 40MG BASE A206434 004 Oct 31, 2016 Apr CPOT

AB ALKEM LABS LTD EQ 5MG BASE A206465 001 Mar 21, 2017 Apr CPOT

AB EQ 10MG BASE A206465 002 Mar 21, 2017 Apr CPOT

AB EQ 20MG BASE A206465 003 Mar 21, 2017 Apr CPOT

AB EQ 40MG BASE A206465 004 Mar 21, 2017 Apr CPOT

AB ALLIED EQ 5MG BASE A079168 001 Jul 19, 2016 Apr CPOT

AB EQ 10MG BASE A079168 002 Jul 19, 2016 Apr CPOT

AB EQ 20MG BASE A079168 003 Jul 19, 2016 Apr CPOT

AB EQ 40MG BASE A079168 004 Jul 19, 2016 Apr CPOT

@ AMNEAL PHARMS CO EQ 5MG BASE A208850 001 Oct 16, 2018 Apr CPOT

TABLET;ORAL		ROSUVASTATIN CALCIUM							
	@		EQ 10MG BASE	A208850	002	Oct 16,	2018	Apr	CPOT
	@		EQ 20MG BASE	A208850	003	Oct 16,	2018	Apr	CPOT
	@		EQ 40MG BASE	A208850	004	Oct 16,	2018	Apr	CPOT
	@	APOTEX INC	EQ 5MG BASE	A079145	001	Jul 19,	2016	Apr	CPOT
	@		EQ 10MG BASE	A079145	002	Jul 19,	2016	Apr	CPOT
	@		EQ 20MG BASE	A079145	003	Jul 19,	2016	Apr	CPOT
	@		EQ 40MG BASE	A079145	004	Jul 19,	2016	Apr	CPOT
AB		AUROBINDO PHARMA LTD	EQ 5MG BASE	A079170	001	Jul 19,	2016	Apr	CPOT
AB			EQ 10MG BASE	A079170	002	Jul 19,	2016	Apr	CPOT
AB			EQ 20MG BASE	A079170	003	Jul 19,	2016	Apr	CPOT
AB			EQ 40MG BASE	A079170	004	Jul 19,	2016	Apr	CPOT
AB		CADILA PHARMS LTD	EQ 5MG BASE	A207453	001	Nov 23,	2016	Apr	CPOT
AB			EQ 10MG BASE	A207453	002	Nov 23,	2016	Apr	CPOT
AB			EQ 20MG BASE	A207453	003	Nov 23,	2016	Apr	CPOT
AB			EQ 40MG BASE	A207453	004	Nov 23,	2016	Apr	CPOT
AB		CHANGZHOU PHARM	EQ 5MG BASE	A207408	001	Oct 31,	2016	Apr	CPOT
AB			EQ 10MG BASE	A207408	002	Oct 31,	2016	Apr	CPOT
AB			EQ 20MG BASE	A207408	003	Oct 31,	2016	Apr	CPOT
AB			EQ 40MG BASE	A207408	004	Oct 31,	2016	Apr	CPOT
AB		GLENMARK PHARMS	EQ 5MG BASE	A079172	001	Jul 19,	2016	Apr	CPOT
AB			EQ 10MG BASE	A079172	002	Jul 19,	2016	Apr	CPOT
AB			EQ 20MG BASE	A079172	003	Jul 19,	2016	Apr	CPOT
AB			EQ 40MG BASE	A079172	004	Jul 19,	2016	Apr	CPOT
AB		HETERO LABS LTD V	EQ 5MG BASE	A207616	001	Oct 31,	2016	Apr	CPOT
AB			EQ 10MG BASE	A207616	002	Oct 31,	2016	Apr	CPOT
AB			EQ 20MG BASE	A207616	003	Oct 31,	2016	Apr	CPOT
AB			EQ 40MG BASE	A207616	004	Oct 31,	2016	Apr	CPOT
	@	INVENTIA	EQ 5MG BASE	A207653	001	Feb 05,	2021	May	DISC
AB			EQ 5MG BASE	A207653	001	Feb 05,	2021	Apr	CPOT
AB			5MG	A207653	001	Feb 05,	2021	Jan	NEWA
	@		EQ 10MG BASE	A207653	002	Feb 05,	2021	May	DISC
AB			EQ 10MG BASE	A207653	002	Feb 05,	2021	Apr	CPOT
AB			10MG	A207653	002	Feb 05,	2021	Jan	NEWA
	@		EQ 20MG BASE	A207653	003	Feb 05,	2021	May	DISC
AB			EQ 20MG BASE	A207653	003	Feb 05,	2021	Apr	CPOT
AB			20MG	A207653	003	Feb 05,	2021	Jan	NEWA
	@		EQ 40MG BASE	A207653	004	Feb 05,	2021	May	DISC
AB			EQ 40MG BASE	A207653	004	Feb 05,	2021	Apr	CPOT
AB			40MG	A207653	004	Feb 05,	2021	Jan	NEWA
AB		LUPIN	EQ 5MG BASE	A205587	001	Jul 31,	2017	Apr	CPOT
AB			EQ 10MG BASE	A205587	002	Jul 31,	2017	Apr	CPOT
AB			EQ 20MG BASE	A205587	003	Jul 31,	2017	Apr	CPOT
AB			EQ 40MG BASE	A205587	004	Jul 31,	2017	Apr	CPOT
AB		MSN	EQ 5MG BASE	A208898	001	Nov 22,	2017	Apr	CPOT
AB			EQ 10MG BASE	A208898	002	Nov 22,	2017	Apr	CPOT
AB			EQ 20MG BASE	A208898	003	Nov 22,	2017	Apr	CPOT
AB			EQ 40MG BASE	A208898	004	Nov 22,	2017	Apr	CPOT
	@	MYLAN	EQ 5MG BASE	A079161	001	Jul 19,	2016	Apr	CPOT
	@		EQ 10MG BASE	A079161	002	Jul 19,	2016	Apr	CPOT
	@		EQ 20MG BASE	A079161	003	Jul 19,	2016	Apr	CPOT
	@		EQ 40MG BASE	A079161	004	Jul 19,	2016	Apr	CPOT
AB		RENATA	EQ 5MG BASE	A207062	001	Oct 31,	2016	Apr	CPOT
AB			EQ 10MG BASE	A207062	002	Oct 31,	2016	Apr	CPOT
AB			EQ 20MG BASE	A207062	003	Oct 31,	2016	Apr	CPOT
AB			EQ 40MG BASE	A207062	004	Oct 31,	2016	Apr	CPOT
AB		SANDOZ INC	EQ 5MG BASE	A079171	001	Jul 19,	2016	Apr	CPOT
AB			EQ 10MG BASE	A079171	002	Jul 19,	2016	Apr	CPOT
AB			EQ 20MG BASE	A079171	003	Jul 19,	2016	Apr	CPOT
AB			EQ 40MG BASE	A079171	004	Jul 19,	2016	Apr	CPOT
	@	SCIEGEN PHARMS INC	EQ 5MG BASE	A206381	001	Apr 24,	2019	Apr	CPOT
	@		EQ 10MG BASE	A206381	002	Apr 24,	2019	Apr	CPOT
	@		EQ 20MG BASE	A206381	003	Apr 24,	2019	Apr	CPOT
	@		EQ 40MG BASE	A206381	004	Apr 24,	2019	Apr	CPOT
AB		SHANDONG	EQ 5MG BASE	A207375	001	May 07,	2019	Apr	CPOT
AB			EQ 10MG BASE	A207375	002	May 07,	2019	Apr	CPOT
AB			EQ 20MG BASE	A207375	003	May 07,	2019	Apr	CPOT
AB			EQ 40MG BASE	A207375	004	May 07,	2019	Apr	CPOT
AB		SUN PHARM	EQ 5MG BASE	A079169	001	Jul 19,	2016	Apr	CPOT
AB			EQ 10MG BASE	A079169	002	Jul 19,	2016	Apr	CPOT
AB			EQ 20MG BASE	A079169	003	Jul 19,	2016	Apr	CPOT
AB			EQ 40MG BASE	A079169	004	Jul 19,	2016	Apr	CPOT
	@	SUNSHINE	EQ 5MG BASE	A210667	001	Apr 01,	2020	Apr	CPOT

TABLET;ORAL

ROSUVASTATIN CALCIUM							
	@	EQ 10MG BASE	A210667	002	Apr 01, 2020	Apr	CPOT
	@	EQ 20MG BASE	A210667	003	Apr 01, 2020	Apr	CPOT
	@	EQ 40MG BASE	A210667	004	Apr 01, 2020	Apr	CPOT
	@ TEVA PHARMS USA	EQ 5MG BASE	A079166	001	Jul 19, 2016	Apr	CPOT
	@	EQ 10MG BASE	A079166	002	Jul 19, 2016	Apr	CPOT
	@	EQ 20MG BASE	A079166	003	Jul 19, 2016	Apr	CPOT
	@	EQ 40MG BASE	A079166	004	Jul 19, 2016	Apr	CPOT
AB	TORRENT	EQ 5MG BASE	A201619	001	Oct 31, 2016	Apr	CPOT
AB		EQ 10MG BASE	A201619	002	Oct 31, 2016	Apr	CPOT
AB		EQ 20MG BASE	A201619	003	Oct 31, 2016	Apr	CPOT
AB		EQ 40MG BASE	A201619	004	Oct 31, 2016	Apr	CPOT
	@ UMEDICA LABS PVT LTD	EQ 5MG BASE	A207626	001	Apr 09, 2019	Apr	CPOT
	@	EQ 10MG BASE	A207626	002	Apr 09, 2019	Apr	CPOT
	@	EQ 20MG BASE	A207626	003	Apr 09, 2019	Apr	CPOT
	@	EQ 40MG BASE	A207626	004	Apr 09, 2019	Apr	CPOT
AB	WATSON LABS INC	EQ 5MG BASE	A079167	001	Apr 29, 2016	Apr	CPOT
AB		EQ 10MG BASE	A079167	002	Apr 29, 2016	Apr	CPOT
AB		EQ 20MG BASE	A079167	003	Apr 29, 2016	Apr	CPOT
AB		EQ 40MG BASE	A079167	004	Apr 29, 2016	Apr	CPOT
AB	ZHEJIANG YONGTAI	EQ 5MG BASE	A212059	001	Nov 04, 2019	Apr	CPOT
AB		5MG	A212059	001	Nov 04, 2019	Feb	CMFD
AB		EQ 10MG BASE	A212059	002	Nov 04, 2019	Apr	CPOT
AB		10MG	A212059	002	Nov 04, 2019	Feb	CMFD
AB		EQ 20MG BASE	A212059	003	Nov 04, 2019	Apr	CPOT
AB		20MG	A212059	003	Nov 04, 2019	Feb	CMFD
AB		EQ 40MG BASE	A212059	004	Nov 04, 2019	Apr	CPOT
AB		40MG	A212059	004	Nov 04, 2019	Feb	CMFD
	@ ZYDUS PHARMS	EQ 5MG BASE	A206513	001	Mar 01, 2019	Apr	CPOT
	@	EQ 10MG BASE	A206513	002	Mar 01, 2019	Apr	CPOT
	@	EQ 20MG BASE	A206513	003	Mar 01, 2019	Apr	CPOT
	@	EQ 40MG BASE	A206513	004	Mar 01, 2019	Apr	CPOT

RUFINAMIDE

SUSPENSION;ORAL

RUFINAMIDE							
AB	ALKEM LABS LTD	40MG/ML	A213410	001	Feb 23, 2021	Feb	NEWA

TABLET;ORAL

RUFINAMIDE							
AB	HETERO LABS LTD III	200MG	A204993	001	May 11, 2021	Apr	NEWA
AB		400MG	A204993	002	May 11, 2021	Apr	NEWA
AB	MYLAN	200MG	A205095	001	May 16, 2016	May	CMFD
AB		400MG	A205095	002	May 16, 2016	May	CMFD

SAPROPTERIN DIHYDROCHLORIDE

POWDER;ORAL

SAPROPTERIN DIHYDROCHLORIDE							
AB	DR REDDYS	100MG/PACKET	A209452	001	Mar 30, 2021	Mar	NEWA

TABLET;ORAL

SAPROPTERIN DIHYDROCHLORIDE							
>A> AB	DR REDDYS	100MG	A207685	001	Jun 15, 2021	Jun	NEWA

SCOPOLAMINE

SYSTEM;TRANSDERMAL

TRANSDERM SCOP							
AB	+! BAXTER HLTHCARE CORP	1MG/72HR	N017874	001		Mar	CAHN

SELEGILINE HYDROCHLORIDE

CAPSULE;ORAL

SELEGILINE HYDROCHLORIDE							
AB	NOVITIUM PHARMA	5MG	A075352	001	Nov 30, 1998	Apr	CMFD

SELENIOS ACID

SOLUTION;INTRAVENOUS

SELENIOS ACID							
+!	AM REGENT	EQ 60MCG BASE/ML (EQ 60MCG BASE/ML)	N209379	002	Jan 25, 2021	Jan	NEWA

SELEXIPAGTABLET;ORAL
UPTRAVI

+	ACTELION	0.2MG	N207947	001	Dec 21, 2015	Feb CAHN
+	!	0.4MG	N207947	002	Dec 21, 2015	Feb CAHN
+		0.6MG	N207947	003	Dec 21, 2015	Feb CAHN
+		0.8MG	N207947	004	Dec 21, 2015	Feb CAHN
+		1MG	N207947	005	Dec 21, 2015	Feb CAHN
+		1.2MG	N207947	006	Dec 21, 2015	Feb CAHN
+		1.4MG	N207947	007	Dec 21, 2015	Feb CAHN
+		1.6MG	N207947	008	Dec 21, 2015	Feb CAHN

SELINEXORTABLET;ORAL
XPOVIO

+	KARYOPHARM THERAPS	40MG	N212306	002	Apr 15, 2021	Apr NEWA
+		50MG	N212306	003	Apr 15, 2021	Apr NEWA
+		60MG	N212306	004	Apr 15, 2021	Apr NEWA

SEMAGLUTIDE>A> SOLUTION;SUBCUTANEOUS
>A> WEGOVY

>A>	+	!	NOVO	0.25MG/0.5ML (0.25MG/0.5ML)	N215256	001	Jun 04, 2021	Jun NEWA
>A>	+	!		0.5MG/0.5ML (0.5MG/0.5ML)	N215256	002	Jun 04, 2021	Jun NEWA
>A>	+	!		1MG/0.5ML (1MG/0.5ML)	N215256	003	Jun 04, 2021	Jun NEWA
>A>	+	!		1.7MG/0.75ML (1.7MG/0.75ML)	N215256	004	Jun 04, 2021	Jun NEWA
>A>	+	!		2.4MG/0.75ML (2.4MG/0.75ML)	N215256	005	Jun 04, 2021	Jun NEWA

SERTRALINE HYDROCHLORIDETABLET;ORAL
SERTRALINE HYDROCHLORIDE

AB	ACI HEALTHCARE LTD	EQ 25MG BASE	A076881	001	Feb 06, 2007	Jan CMFD
AB		EQ 50MG BASE	A076881	002	Feb 06, 2007	Jan CMFD
AB		EQ 100MG BASE	A076881	003	Feb 06, 2007	Jan CMFD
AB	ASCENT PHARMS INC	EQ 25MG BASE	A214790	001	May 03, 2021	Apr NEWA
AB		EQ 50MG BASE	A214790	002	May 03, 2021	Apr NEWA
AB		EQ 100MG BASE	A214790	003	May 03, 2021	Apr NEWA
AB	GRANULES	EQ 25MG BASE	A078403	001	Jan 08, 2008	May CAHN
AB		EQ 50MG BASE	A078403	002	Jan 08, 2008	May CAHN
AB		EQ 100MG BASE	A078403	003	Jan 08, 2008	May CAHN
AB	SCIEGEN PHARMS INC	EQ 25MG BASE	A076442	001	Apr 30, 2007	Apr CMFD
AB		EQ 50MG BASE	A076442	002	Apr 30, 2007	Apr CMFD
AB		EQ 100MG BASE	A076442	003	Apr 30, 2007	Apr CMFD

SEVELAMER CARBONATEFOR SUSPENSION;ORAL
SEVELAMER CARBONATE

AB	BIONPHARMA INC	800MG/PACKET	A209374	001	May 17, 2021	May NEWA
	@ IMPAX	800MG/PACKET	A211316	001	Nov 20, 2020	Mar DISC
	@	2.4GM/PACKET	A211316	002	Nov 20, 2020	Mar DISC

TABLET;ORAL
SEVELAMER CARBONATE

AB	ANXIN	800MG	A212970	001	Apr 09, 2020	Mar CMFD
AB	LUPIN LTD	800MG	A204600	001	Jan 14, 2021	Jan NEWA

SEVELAMER HYDROCHLORIDETABLET;ORAL
SEVELAMER HYDROCHLORIDE

>A>	AB	LUPIN LTD	400MG	A213145	001	Jun 16, 2021	Jun NEWA
>A>	AB		800MG	A213145	002	Jun 16, 2021	Jun NEWA

SILDENAFIL CITRATEFOR SUSPENSION;ORAL
SILDENAFIL CITRATE

AB	APPCO	EQ 10MG BASE/ML	A213814	001	Apr 29, 2021	Apr NEWA
AB	HETERO LABS LTD V	EQ 10MG BASE/ML	A213014	001	May 11, 2021	Apr NEWA

TABLET;ORAL
SILDENAFIL CITRATE

AB	REYOUNG	EQ 25MG BASE	A208494	001	Jun 12, 2020	Mar CAHN
AB		EQ 50MG BASE	A208494	002	Jun 12, 2020	Mar CAHN
AB		EQ 100MG BASE	A208494	003	Jun 12, 2020	Mar CAHN

TABLET;ORAL

SILDENAFIL CITRATE

>A>	AB	UMEDICA LABS PVT LTD	EQ 25MG BASE	A209302	003	Jun 15, 2021	Jun NEWA
		@ WATSON LABS INC	EQ 25MG BASE	A202506	001	Nov 25, 2020	May DISC
		@	EQ 50MG BASE	A202506	002	Nov 25, 2020	May DISC
		@	EQ 100MG BASE	A202506	003	Nov 25, 2020	May DISC

SIMVASTATIN

TABLET;ORAL

SIMVASTATIN

	AB	BIOCON PHARMA	5MG	A078034	001	Dec 20, 2006	Mar CAHN
	AB		10MG	A078034	002	Dec 20, 2006	Mar CAHN
	AB		20MG	A078034	003	Dec 20, 2006	Mar CAHN
	AB		40MG	A078034	004	Dec 20, 2006	Mar CAHN
	AB		80MG	A078034	005	Dec 20, 2006	Mar CAHN
	AB	HISUN PHARM HANGZHOU	10MG	A206557	001	Nov 13, 2017	Apr CMFD
	AB		20MG	A206557	002	Nov 13, 2017	Apr CMFD
	AB		40MG	A206557	003	Nov 13, 2017	Apr CMFD
	AB		80MG	A206557	004	Nov 13, 2017	Apr CMFD
>D>	AB	LUPIN	80MG	A078103	004	May 11, 2007	Jun CHRS
>A>	AB	!	80MG	A078103	004	May 11, 2007	Jun CHRS
		ZOCOR					
	AB	+ ORGANON	5MG	N019766	001	Dec 23, 1991	Feb CAHN
	AB	+	10MG	N019766	002	Dec 23, 1991	Feb CAHN
	AB	+	20MG	N019766	003	Dec 23, 1991	Feb CAHN
	AB	+	40MG	N019766	004	Dec 23, 1991	Feb CAHN
>D>	AB	+	80MG	N019766	005	Jul 10, 1998	Jun DISC
>A>	AB	+ @	80MG	N019766	005	Jul 10, 1998	Jun DISC
	AB	+	80MG	N019766	005	Jul 10, 1998	Feb CAHN

SINECATECHINS

OINTMENT;TOPICAL

VEREGEN

	+	ANI PHARMS	15%	N021902	001	Oct 31, 2006	Apr CAHN
--	---	------------	-----	---------	-----	--------------	----------

SIROLIMUS

TABLET;ORAL

SIROLIMUS

	AB	ALKEM LABS LTD	0.5MG	A214753	001	Mar 12, 2021	Mar NEWA
	AB		1MG	A214753	002	Mar 12, 2021	Mar NEWA
	AB		2MG	A214753	003	Mar 12, 2021	Mar NEWA

SODIUM ACETATE

INJECTABLE;INJECTION

SODIUM ACETATE

	AP	MILLA PHARMS	2MEQ/ML	A214805	001	May 04, 2021	Apr NFTG
--	----	--------------	---------	---------	-----	--------------	----------

SODIUM BENZOATE; SODIUM PHENYLACETATE

SOLUTION;INTRAVENOUS

SODIUM PHENYLACETATE AND SODIUM BENZOATE

>A>	+	MAIA PHARMS INC	10%;10% (2GM/20ML;2GM/20ML)	N215025	001	Jun 10, 2021	Jun NEWA
-----	---	-----------------	-----------------------------	---------	-----	--------------	----------

SODIUM CHLORIDE

INJECTABLE;INJECTION

SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

>D>	AP	JUBILANT CADISTA	9MG/ML	A203352	001	May 18, 2016	Jun DISC
>A>	@		9MG/ML	A203352	001	May 18, 2016	Jun DISC

SODIUM CHLORIDE 23.4%

FRESENIUS KABI USA

SOLUTION;INTRAVENOUS

SODIUM CHLORIDE 14.6%

FRESENIUS KABI USA

	AP		50MEQ/20ML (2.5MEQ/ML)	A212070	001	Apr 28, 2021	Apr NFTG
			100MEQ/40ML (2.5MEQ/ML)	A212070	002	Apr 28, 2021	Apr NFTG

SODIUM FLUORIDE F-18

INJECTABLE;INTRAVENOUS

SODIUM FLUORIDE F-18

	AP	NUKEMED	10-200mCi/ML	A203912	001	Apr 22, 2015	Jan CAHN
--	----	---------	--------------	---------	-----	--------------	----------

SODIUM NITROPRUSSIDEINJECTABLE; INJECTION
SODIUM NITROPRUSSIDE

>D>	AP	AUROBINDO PHARMA LTD	25MG/ML	A211934	001	Dec 10, 2020	Jun	DISC
>A>		@	25MG/ML	A211934	001	Dec 10, 2020	Jun	DISC

SODIUM PHOSPHATE, DIBASIC, ANHYDROUS; SODIUM PHOSPHATE, MONOBASIC, MONOHYDRATETABLET; ORAL
MONOBASIC SODIUM PHOSPHATE AND DIBASIC SODIUM PHOSPHATE

AB		NOVEL LABS INC	0.398GM;1.102GM	A079247	001	Dec 30, 2011	Jan	CMFD
AB	+!	SALIX PHARMS	0.398GM;1.102GM	N021892	001	Mar 16, 2006	Jan	CTEC

SODIUM POLYSTYRENE SULFONATEPOWDER; ORAL, RECTAL
KIONEX

AA		ANI PHARMS	454GM/BOT	A040029	001	Feb 06, 1998	Mar	CAHN
AA		L PERRIGO CO	454GM/BOT	A040029	001	Feb 06, 1998	Mar	CAHN

SUSPENSION; ORAL, RECTAL
KIONEX

	@	ANI PHARMS	15GM/60ML	A040028	001	Sep 17, 2007	Mar	CAHN
	@	L PERRIGO CO	15GM/60ML	A040028	001	Sep 17, 2007	Mar	CAHN
	@	ANI PHARMS	15GM/60ML	A090590	001	May 13, 2011	Mar	CAHN
	@	L PERRIGO CO	15GM/60ML	A090590	001	May 13, 2011	Mar	CAHN

SOFOSBUVIR; VELPATASVIR

>A>		PELLETS; ORAL						
>A>		EPCLUSA						
>A>	+	GILEAD SCIENCES INC	150MG;37.5MG/PACKET	N214187	001	Jun 10, 2021	Jun	NEWA
>A>	+!		200MG;50MG/PACKET	N214187	002	Jun 10, 2021	Jun	NEWA

SOLIFENACIN SUCCINATETABLET; ORAL
SOLIFENACIN SUCCINATE

>D>	AB	AJANTA PHARMA LTD	5MG	A205483	001	May 20, 2019	Jun	DISC
>A>		@	5MG	A205483	001	May 20, 2019	Jun	DISC
>D>	AB		10MG	A205483	002	May 20, 2019	Jun	DISC
>A>		@	10MG	A205483	002	May 20, 2019	Jun	DISC
		@ ZYDUS PHARMS	5MG	A207721	001	Oct 19, 2020	Mar	DISC
		@	10MG	A207721	002	Oct 19, 2020	Mar	DISC

SORAFENIB TOSYLATETABLET; ORAL
NEXAVAR

+!	BAYER HLTHCARE	EQ 200MG BASE	N021923	001	Dec 20, 2005	May	CTEC
	@ TEVA PHARMS USA INC	EQ 200MG BASE	A209567	001	Nov 12, 2020	May	DISC

SOTALOL HYDROCHLORIDETABLET; ORAL
SOTALOL HYDROCHLORIDE

	@	MYLAN	80MG	A077616	001	Feb 07, 2007	Feb	DISC
	@		120MG	A077616	002	Feb 07, 2007	Feb	DISC
	@		160MG	A077616	003	Feb 07, 2007	Feb	DISC

SOTORASIBTABLET; ORAL
LUMAKRAS

+!	AMGEN INC	120MG	N214665	001	May 28, 2021	May	NEWA
----	-----------	-------	---------	-----	--------------	-----	------

STERILE WATER FOR INJECTIONLIQUID; N/A
STERILE WATER FOR INJECTION

!	NEPHRON	100% (5ML)	A211222	001	Feb 10, 2021	Jan	NEWA
---	---------	------------	---------	-----	--------------	-----	------

SUCCINYLCHOLINE CHLORIDE

INJECTABLE; INJECTION
SUCCINYLCHOLINE CHLORIDE

AP	ACCORD HLTHCARE	20MG/ML	A213705	001	May 20, 2020	Mar	CMFD
AP	HIKMA	20MG/ML	A213229	001	Jun 12, 2020	Apr	CMFD
	@	20MG/ML	A213229	001	Jun 12, 2020	Feb	DISC
AP	SAGENT PHARMS INC	20MG/ML	A215022	001	Mar 29, 2021	Mar	NEWA

SULFAMETHOXAZOLE

TABLET; ORAL
SULFAMETHOXAZOLE
@ RISING

500MG

A085844 001

Jan CAHN

SULFASALAZINE

TABLET; ORAL
AZULFIDINE
SULFASALAZINE

AB	+! PFIZER	500MG	N007073	001		Mar	CAHN
>D>	@ CHARTWELL	500MG	A080197	001		Jun	CMFD
>A>	AB	500MG	A080197	001		Jun	CMFD

TABLET, DELAYED RELEASE; ORAL
AZULFIDINE EN-TABS

AB	+! PFIZER	500MG	N007073	002	Apr 06, 1983	Mar	CAHN
----	-----------	-------	---------	-----	--------------	-----	------

SULFISOXAZOLE

TABLET; ORAL
SULFISOXAZOLE
@ RISING

500MG

A085628 001

Jan CAHN

SUMATRIPTAN

SPRAY; NASAL
SUMATRIPTAN

AB	CIPLA	20MG/SPRAY	A214209	001	Feb 22, 2021	Feb	NEWA
AB	FLORIDA	20MG/SPRAY	A208967	001	Feb 17, 2021	Mar	CAHN
AB	PHARMASERVE NW	20MG/SPRAY	A208967	001	Feb 17, 2021	Feb	NEWA

SUMATRIPTAN SUCCINATE

INJECTABLE; SUBCUTANEOUS
SUMATRIPTAN SUCCINATE

@ MYLAN ASI EQ 6MG BASE/0.5ML (EQ 12MG
BASE/ML)

A090314 001 Jun 10, 2010 May DISC

@ EQ 6MG BASE/0.5ML (EQ 12MG
BASE/ML)

A090641 001 Jul 28, 2010 Jan DISC

SPRAY; NASAL
SUMATRIPTAN

AB	PERRIGO UK FINCO	5MG/SPRAY	A213465	002	Sep 21, 2020	Feb	CMS1
----	------------------	-----------	---------	-----	--------------	-----	------

TACROLIMUS

CAPSULE; ORAL
TACROLIMUS
@ CONCORD BIOTECH LTD

EQ 0.5MG BASE

A213112 001 Nov 10, 2020 Apr DISC

TADALAFIL

TABLET; ORAL
CIALIS

AB1	+ LILLY	2.5MG	N021368	004	Jan 07, 2008	Feb	CTEC
AB1	+	5MG	N021368	001	Nov 21, 2003	Feb	CTEC
AB1	+	10MG	N021368	002	Nov 21, 2003	Feb	CTEC

TADALAFIL

AB1	ACCORD HLTHCARE	2.5MG	A209167	001	Mar 26, 2019	Feb	CTEC
AB1		5MG	A209167	002	Mar 26, 2019	Feb	CTEC
AB1		10MG	A209167	003	Oct 23, 2019	Feb	CTEC
AB1	AJANTA PHARMA LTD	2.5MG	A209654	001	Mar 26, 2019	Feb	CTEC
AB1		5MG	A209654	002	Mar 26, 2019	Feb	CTEC
AB1		10MG	A209654	003	Mar 26, 2019	Feb	CTEC
AB1	ALEMBIC PHARMS LTD	2.5MG	A204809	001	Mar 26, 2019	Feb	CTEC
AB1		5MG	A204809	002	Mar 26, 2019	Feb	CTEC
AB1		10MG	A204809	003	Mar 26, 2019	Feb	CTEC
AB1	AMNEAL PHARMS CO	2.5MG	A209744	001	Mar 26, 2019	Feb	CTEC
AB1		5MG	A209744	002	Mar 26, 2019	Feb	CTEC
AB1		10MG	A209744	003	Mar 26, 2019	Feb	CTEC

TABLET;ORAL

TADALAFIL

AB1	AUROBINDO PHARMA LTD	2.5MG	A206285	001	Mar 26, 2019	Feb CTEC
AB1		5MG	A206285	002	Mar 26, 2019	Feb CTEC
AB1		10MG	A206285	003	Mar 26, 2019	Feb CTEC
AB1	CIPLA	2.5MG	A209539	001	Mar 26, 2019	Feb CTEC
AB1		5MG	A209539	002	Mar 26, 2019	Feb CTEC
AB1		10MG	A209539	003	Mar 26, 2019	Feb CTEC
AB1	DR REDDYS LABS LTD	2.5MG	A210069	001	Mar 26, 2019	Feb CTEC
AB1		5MG	A210069	002	Mar 26, 2019	Feb CTEC
AB1		10MG	A210069	003	Mar 26, 2019	Feb CTEC
	@ GLENMARK PHARMS LTD	2.5MG	A210716	001	Dec 29, 2020	Feb DISC
	@	5MG	A210716	002	Dec 29, 2020	Feb DISC
	@	10MG	A210716	003	Dec 29, 2020	Feb DISC
	@	20MG	A210716	004	Dec 29, 2020	Feb DISC
AB1	HETERO LABS LTD III	2.5MG	A209908	001	Mar 26, 2019	Feb CTEC
AB1		5MG	A209908	002	Mar 26, 2019	Feb CTEC
AB1		10MG	A209908	003	Mar 26, 2019	Feb CTEC
AB1	LUPIN LTD	2.5MG	A210567	001	Mar 26, 2019	Feb CTEC
AB1		5MG	A210567	002	Mar 26, 2019	Feb CTEC
AB1		10MG	A210567	003	Mar 26, 2019	Feb CTEC
AB1	MACLEODS PHARMS LTD	2.5MG	A207244	001	Oct 07, 2019	Feb CTEC
AB1		5MG	A207244	002	Oct 07, 2019	Feb CTEC
AB1		10MG	A207244	003	Oct 07, 2019	Feb CTEC
AB1	MYLAN	2.5MG	A206956	001	Apr 29, 2019	Feb CTEC
AB1		5MG	A206956	001	Apr 29, 2019	Feb CTEC
AB1		10MG	A206956	002	Apr 29, 2019	Feb CTEC
AB1	QILU	2.5MG	A210420	001	Mar 26, 2019	Feb CTEC
AB1		5MG	A210420	002	Mar 26, 2019	Feb CTEC
AB1		10MG	A210420	003	Mar 26, 2019	Feb CTEC
AB1	SUN PHARM	2.5MG	A208934	001	Mar 26, 2019	Feb CTEC
AB1		5MG	A208934	002	Mar 26, 2019	Feb CTEC
AB1		10MG	A208934	003	Mar 26, 2019	Feb CTEC
AB1	SUNSHINE	2.5MG	A211335	001	Mar 26, 2019	Feb CTEC
AB1		5MG	A211335	002	Mar 26, 2019	Feb CTEC
AB1		10MG	A211335	003	Mar 26, 2019	Feb CTEC
AB1	TEVA PHARMS USA	2.5MG	A090141	001	May 22, 2018	Feb CTEC
AB1		5MG	A090141	002	May 22, 2018	Feb CTEC
AB1		10MG	A090141	003	May 22, 2018	Feb CTEC
AB1	TORRENT	2.5MG	A211839	001	Mar 26, 2019	Feb CTEC
AB1		5MG	A211839	002	Mar 26, 2019	Feb CTEC
AB1		10MG	A211839	003	Mar 26, 2019	Feb CTEC
AB1	UMEDICA LABS PVT LTD	2.5MG	A211298	001	Oct 23, 2020	Feb CTEC
AB1		5MG	A211298	002	Oct 23, 2020	Feb CTEC
AB1		10MG	A211298	003	Oct 23, 2020	Feb CTEC
AB1	UNICHEM	2.5MG	A209250	001	Mar 26, 2019	Feb CTEC
AB1		5MG	A209250	002	Mar 26, 2019	Feb CTEC
AB1		10MG	A209250	003	Mar 26, 2019	Feb CTEC
AB1	YANGLING BUCHANG	2.5MG	A208824	001	Oct 27, 2020	Feb CTEC
AB1		5MG	A208824	002	Oct 27, 2020	Feb CTEC
AB1		10MG	A208824	003	Oct 27, 2020	Feb CTEC
AB1	ZYDUS PHARMS	2.5MG	A206693	001	Mar 26, 2019	Feb CTEC
AB1		5MG	A206693	002	Mar 26, 2019	Feb CTEC
AB1		10MG	A206693	003	Mar 26, 2019	Feb CTEC

TAMSULOSIN HYDROCHLORIDE

CAPSULE;ORAL

TAMSULOSIN HYDROCHLORIDE

>D>	AB	ANCHEN PHARMS	0.4MG	A202010	001	Jan 04, 2013	Jun DISC
>A>	@		0.4MG	A202010	001	Jan 04, 2013	Jun DISC

TAVABOROLE

SOLUTION;TOPICAL

TAVABOROLE

AB	CIPLA	5%	A212224	001	Feb 09, 2021	Jan NEWA
AB	FLATWING	5%	A211963	001	Feb 03, 2021	Feb CPOT
AB		5.0%	A211963	001	Feb 03, 2021	Jan NEWA
AB	IDENTIRX	5%	A211963	001	Feb 03, 2021	Feb CAHN
AB	LUPIN LTD	5%	A212168	001	Feb 08, 2021	Jan NEWA
AB	TARO PHARMS	5%	A212215	001	May 07, 2021	Apr NEWA

TELMISARTAN

TABLET; ORAL

TELMISARTAN

AB	CELLTRION	20MG	A 078710	001	Jan 08, 2014	Feb	CMFD
AB		40MG	A 078710	002	Jan 08, 2014	Feb	CMFD
AB		80MG	A 078710	003	Jan 08, 2014	Feb	CMFD

TEMOZOLOMIDE

CAPSULE; ORAL

TEMOZOLOMIDE

@	HERITAGE	5MG	A 078879	001	Mar 01, 2010	Feb	CAHN
@		20MG	A 078879	002	Mar 01, 2010	Feb	CAHN
@		100MG	A 078879	003	Mar 01, 2010	Feb	CAHN
@		140MG	A 078879	005	Mar 01, 2010	Feb	CAHN
@		180MG	A 078879	006	Mar 01, 2010	Feb	CAHN
@		250MG	A 078879	004	Mar 01, 2010	Feb	CAHN
@	WATSON LABS TEVA	5MG	A 203959	001	Apr 18, 2017	Jan	DISC
@		20MG	A 203959	002	Apr 18, 2017	Jan	DISC
@		100MG	A 203959	003	Apr 18, 2017	Jan	DISC
@		140MG	A 203959	004	Apr 18, 2017	Jan	DISC
@		250MG	A 203959	005	Apr 18, 2017	Jan	DISC

TEPOTINIB HYDROCHLORIDE

TABLET; ORAL

TEPMETKO

+!	EMD SERONO INC	EQ 225MG BASE	N 214096	001	Feb 03, 2021	Feb	NEWA
----	----------------	---------------	----------	-----	--------------	-----	------

TERAZOSIN HYDROCHLORIDE

CAPSULE; ORAL

TERAZOSIN HYDROCHLORIDE

AB	HERITAGE PHARMA	EQ 1MG BASE	A 075614	002	Jan 30, 2001	May	CMFD
AB		EQ 2MG BASE	A 075614	001	Jan 30, 2001	May	CMFD
AB		EQ 5MG BASE	A 075614	003	Jan 30, 2001	May	CMFD
AB		EQ 10MG BASE	A 075614	004	Jan 30, 2001	May	CMFD

TERIFLUNOMIDE

TABLET; ORAL

TERIFLUNOMIDE

@	IMPAX	14MG	A 209677	001	Jun 17, 2020	Feb	DISC
---	-------	------	----------	-----	--------------	-----	------

TESTOSTERONE

GEL; TRANSDERMAL

TESTOSTERONE

AB2	ACTAVIS LABS UT INC	1.62% (20.25MG/1.25GM PACKET)	A 204570	002	Jul 17, 2020	Feb	NEWA
AB2		1.62% (40.5MG/2.5GM PACKET)	A 204570	003	Jul 17, 2020	Feb	NEWA

GEL, METERED; TRANSDERMAL

TESTOSTERONE

AB	ALEOR DERMACEUTICALS	1.62% (20.25MG/1.25GM ACTUATION)	A 213922	001	Mar 03, 2021	Feb	NEWA
----	----------------------	----------------------------------	----------	-----	--------------	-----	------

SOLUTION, METERED; TRANSDERMAL

TESTOSTERONE

>A>	AT	ALEOR DERMACEUTICALS	30MG/1.5ML ACTUATION	A 212882	001	Jun 14, 2021	Jun	NEWA
		@ APOTEX	30MG/1.5ML ACTUATION	A 209181	001	Nov 25, 2020	May	DISC
	AT	DASH PHARMS	30MG/1.5ML ACTUATION	A 212301	001	Jan 11, 2021	May	CAHN
	AT	FEMPHARM	30MG/1.5ML ACTUATION	A 212301	001	Jan 11, 2021	Jan	NEWA

TESTOSTERONE CYPIONATE

INJECTABLE; INJECTION

DEPO-TESTOSTERONE

@	PFIZER	50MG/ML	A 085635	001		Mar	CAHN
AO	!	100MG/ML	A 085635	002		Mar	CAHN
AO	!	200MG/ML	A 085635	003		Mar	CAHN

TETRABENAZINE

TABLET; ORAL

TETRABENAZINE

@	AJANTA PHARMA LTD	12.5MG	A 213621	001	Dec 04, 2020	May	DISC
@		25MG	A 213621	002	Dec 04, 2020	May	DISC

TETRACAINE HYDROCHLORIDESOLUTION;OPHTHALMIC
TETRACAINE HYDROCHLORIDE

+! BAUSCH LOMB IRELAND 0.5%

N210821 001 Mar 12, 2019 May CAHN

THALLOUS CHLORIDE TL-201INJECTABLE;INJECTION
THALLOUS CHLORIDE TL 201

>D> AP +! GE HEALTHCARE 1mCi/ML

N018110 002 Feb 27, 1996 Jun DISC

>A> + @ 1mCi/ML

N018110 002 Feb 27, 1996 Jun DISC

THEOPHYLLINE

TABLET, EXTENDED RELEASE;ORAL

THEOPHYLLINE

AB ALEMBIC PHARMS LTD 300MG

A090430 001 Oct 27, 2010 May CTEC

AB ! 450MG

A090430 002 Oct 27, 2010 May CTEC

AB GLENMARK PHARMS LTD 300MG

A212184 001 Jun 03, 2021 May NEWA

AB 450MG

A212184 002 Jun 03, 2021 May NEWA

THIAMINE HYDROCHLORIDEINJECTABLE;INJECTION
THIAMINE HYDROCHLORIDE

AP WEST-WARD PHARMS INT 100MG/ML

A080575 001 Apr CMFD

THIORIDAZINE HYDROCHLORIDE

TABLET;ORAL

THIORIDAZINE HYDROCHLORIDE

MYLAN 10MG

A088004 002 Mar 15, 1983 Jan CTEC

25MG

A088004 003 Mar 15, 1983 Jan CTEC

50MG

A088004 004 Mar 15, 1983 Jan CTEC

! 100MG

A088004 001 Nov 18, 1983 Jan CTEC

@ SUN PHARM INDUSTRIES 10MG

A089953 004 Aug 01, 1986 Jan DISC

@ 25MG

A089953 003 Aug 01, 1986 Jan DISC

@ 50MG

A089953 002 Aug 01, 1986 Jan DISC

@ 100MG

A089953 001 Oct 07, 1988 Jan DISC

THIOTEPAPOWDER;INTRACAVITARY, INTRAVENOUS, INTRAVESICAL
THIOTEPA

AP GLAND PHARMA LTD 15MG/VIAL

A214222 001 Mar 08, 2021 Feb NEWA

TIAGABINE HYDROCHLORIDE

TABLET;ORAL

TIAGABINE HYDROCHLORIDE

@ WILSHIRE PHARMS INC 2MG

A206857 001 Oct 13, 2017 Jan DISC

@ 4MG

A206857 002 Oct 13, 2017 Jan DISC

@ 12MG

A206857 003 Oct 13, 2017 Jan DISC

@ 16MG

A206857 004 Oct 13, 2017 Jan DISC

TIGECYCLINE

POWDER;INTRAVENOUS

TIGECYCLINE

AP HONG KONG 50MG/VIAL

A214020 001 May 13, 2021 May NEWA

TIMOLOL MALEATE

SOLUTION, GEL FORMING/DROPS;OPHTHALMIC

TIMOLOL MALEATE

AB ! ALEMBIC PHARMS LTD EQ 0.25% BASE

A212942 001 Oct 22, 2020 Apr CHRS

AB ! EQ 0.5% BASE

A212942 002 Oct 22, 2020 Apr CHRS

TIMOPTIC-XE

AB + VALEANT PHARMS LLC EQ 0.25% BASE

N020330 001 Nov 04, 1993 Apr CHRS

AB + EQ 0.5% BASE

N020330 002 Nov 04, 1993 Apr CHRS

SOLUTION/DROPS;OPHTHALMIC

TIMOLOL MALEATE

AT MANKIND PHARMA EQ 0.25% BASE

A078771 001 Sep 28, 2009 Apr CAHN

AT1 EQ 0.5% BASE

A078771 002 Sep 28, 2009 Apr CAHN

TIOPRONINTABLET;ORAL
TIOPRONIN

AB	TEVA PHARMS USA INC	100MG	A214326	001	Apr 26, 2021	Apr	NFTG
----	---------------------	-------	---------	-----	--------------	-----	------

TIOTROPIUM BROMIDESPRAY, METERED; INHALATION
SPIRIVA RESPIMAT

+!	BOEHRINGER INGELHEIM	EQ 0.00125MG BASE/INH	N021936	002	Sep 15, 2015	Mar	CHRS
----	----------------------	-----------------------	---------	-----	--------------	-----	------

TIROFIBAN HYDROCHLORIDESOLUTION; INTRAVENOUS
AGGRASTAT

+	MEDICURE	EQ 5MG BASE/100ML (EQ 0.05MG BASE/ML)	N020913	002	May 17, 2002	Apr	CDFR
@		EQ 25MG BASE/500ML (EQ 0.05MG BASE/ML)	N020913	001	May 14, 1998	Apr	CDFR

AP	GLAND PHARMA LTD	EQ 12.5MG BASE/250ML (EQ 0.05MG BASE/ML)	A206888	001	Apr 08, 2021	Apr	NFTG
----	------------------	--	---------	-----	--------------	-----	------

TIVOZANIB HYDROCHLORIDECAPSULE;ORAL
FOTIVDA

+	AVEO PHARMS	EQ 0.89MG BASE	N212904	001	Mar 10, 2021	Mar	NEWA
+!		EQ 1.34MG BASE	N212904	002	Mar 10, 2021	Mar	NEWA

TIZANIDINE HYDROCHLORIDE

CAPSULE;ORAL

TIZANIDINE HYDROCHLORIDE

>D>	AB	PAR PHARM INC	EQ 2MG BASE	A207199	001	Mar 14, 2017	Jun	DISC
>A>	@		EQ 2MG BASE	A207199	001	Mar 14, 2017	Jun	DISC
>D>	AB		EQ 4MG BASE	A207199	002	Mar 14, 2017	Jun	DISC
>A>	@		EQ 4MG BASE	A207199	002	Mar 14, 2017	Jun	DISC
>D>	AB		EQ 6MG BASE	A207199	003	Mar 14, 2017	Jun	DISC
>A>	@		EQ 6MG BASE	A207199	003	Mar 14, 2017	Jun	DISC

TABLET;ORAL

TIZANIDINE HYDROCHLORIDE

AB	CADILA	EQ 2MG BASE	A208187	001	Mar 09, 2018	Feb	CAHN
AB		EQ 4MG BASE	A208187	002	Mar 09, 2018	Feb	CAHN
	@ MYLAN	EQ 2MG BASE	A076354	001	Mar 28, 2003	Jan	DISC
	@	EQ 4MG BASE	A076354	002	Mar 28, 2003	Feb	DISC

TOBRAMYCINSOLUTION; INHALATION
TOBRAMYCIN

AN	ALKEM LABS LTD	300MG/5ML	A212848	001	Apr 01, 2021	Mar	NEWA
AN	AUROBINDO PHARMA LTD	300MG/5ML	A210871	001	Jan 22, 2021	Jan	NEWA

SOLUTION/DROPS;OPHTHALMIC
TOBRAMYCIN

AT	GLAND PHARMA LTD	0.3%	A212628	001	Mar 09, 2021	Feb	NEWA
----	------------------	------	---------	-----	--------------	-----	------

TOBRAMYCIN SULFATE

INJECTABLE; INJECTION

TOBRAMYCIN SULFATE

AP	GLAND PHARMA LTD	EQ 10MG BASE/ML	A209621	001	Feb 11, 2021	Feb	NEWA
AP		EQ 40MG BASE/ML	A209621	002	Feb 11, 2021	Feb	NEWA
AP		EQ 1.2GM BASE/VIAL	A211189	001	May 18, 2021	May	NEWA
		TOBRAMYCIN SULFATE (PHARMACY BULK)					
AP	! FRESENIUS KABI USA	EQ 40MG BASE/ML	A065120	001	Nov 29, 2002	Jan	CTEC
AP	GLAND PHARMA LTD	EQ 40MG BASE/ML	A209346	001	Feb 09, 2021	Jan	NEWA

TOFACITINIB CITRATE

SOLUTION;ORAL

XELJANZ

+!	PFIZER	EQ 1MG/ML BASE	N213082	001	Sep 25, 2020	Feb	CMS1
----	--------	----------------	---------	-----	--------------	-----	------

TABLET;ORAL

TOFACITINIB CITRATE

AB	AJANTA PHARMA LTD	EQ 10MG BASE	A212943	001	Jun 01, 2021	May	NFTG
----	-------------------	--------------	---------	-----	--------------	-----	------

TOLCAPONE

TABLET; ORAL

TOLCAPONE

	@ ALVOGEN	100MG	A207729	001	Jul 29, 2020	Jan DISC
--	-----------	-------	---------	-----	--------------	----------

TOLTERODINE TARTRATE

CAPSULE, EXTENDED RELEASE; ORAL

TOLTERODINE TARTRATE

AB	AJANTA PHARMA LTD	2MG	A213397	001	May 19, 2020	Jan CMFD
AB		4MG	A213397	002	May 19, 2020	Jan CMFD
AB	AMTA	2MG	A213858	001	Feb 02, 2021	Jan NEWA
AB		4MG	A213858	002	Feb 02, 2021	Jan NEWA

TOLVAPTAN

TABLET; ORAL

SAMSCA

	+ OTSUKA	15MG	N022275	001	May 19, 2009	Feb CAHN
AB	+!	30MG	N022275	002	May 19, 2009	Feb CAHN
	+ @	60MG	N022275	003	May 19, 2009	Feb CAHN

TOPIRAMATE

CAPSULE, EXTENDED RELEASE; ORAL

TOPIRAMATE

AB2	GLENMARK PHARMS LTD	25MG	A210278	001	Feb 01, 2021	Jan NFTG
AB2		50MG	A210278	002	Feb 01, 2021	Jan NFTG
AB2		100MG	A210278	003	Feb 01, 2021	Jan NFTG
AB2		150MG	A210278	004	Feb 01, 2021	Jan NFTG
AB2		200MG	A210278	005	Feb 01, 2021	Jan NFTG
AB1	ZYDUS PHARMS	25MG	A207382	001	Nov 24, 2017	Jan CTEC
AB1		50MG	A207382	002	Nov 24, 2017	Jan CTEC
AB1		100MG	A207382	003	Nov 24, 2017	Jan CTEC
	TROKENDI XR					
AB1	+ SUPERNUS PHARMS	25MG	N201635	001	Aug 16, 2013	Jan CTEC
AB1	+!	50MG	N201635	002	Aug 16, 2013	Jan CTEC
AB1	+!	100MG	N201635	003	Aug 16, 2013	Jan CTEC

TORSEMIDE

TABLET; ORAL

SOAANZ

>A>						
>A>	+ SARFE PHARMS	20MG	N213218	001	Jun 14, 2021	Jun NEWA
>A>	+!	60MG	N213218	002	Jun 14, 2021	Jun NEWA

TRAMADOL HYDROCHLORIDE

TABLET; ORAL

TRAMADOL HYDROCHLORIDE

	@ GRAVITI PHARMS	50MG	A075968	001	Jun 25, 2002	Apr CAHN
AB	POLYGEN PHARMS	50MG	A206706	001	Jul 02, 2019	Feb CMFD

TABLET, EXTENDED RELEASE; ORAL

TRAMADOL HYDROCHLORIDE

	@ ANCHEN PHARMS	100MG	A200491	001	Jun 27, 2012	Apr DISC
	@	200MG	A200491	002	Jun 27, 2012	Apr DISC
	@	300MG	A200491	003	Jun 27, 2012	Apr DISC

TRANEXAMIC ACID

INJECTABLE; INJECTION

CYKLOKAPRON

AP	+! PFIZER	100MG/ML	N019281	001	Dec 30, 1986	Mar CAHN
	TRANEXAMIC ACID					
>D>	@ CAPLIN	100MG/ML	A212360	001	Jul 17, 2019	Jun CMFD
>A>	AP	100MG/ML	A212360	001	Jul 17, 2019	Jun CMFD
AP	PROVEPHARM SAS	100MG/ML	A212676	001	Jul 17, 2019	Jan CAHN
	@ ZYDUS PHARMS	100MG/ML	A205228	001	Jul 17, 2017	Apr DISC
	TRANEXAMIC ACID					
>D>	@ ANI PHARMS	650MG	A203256	001	Jul 25, 2016	Jun CMFD
>A>	AB	650MG	A203256	001	Jul 25, 2016	Jun CMFD
	@ APOTEX INC	650MG	A202286	001	Jan 27, 2014	Mar DISC

TRANYLCYPROMINE SULFATE

TABLET;ORAL

TRANYLCYPROMINE SULFATE

AB	NOVITIUM PHARMA	EQ 10MG BASE	A206856	001	Apr 17, 2018	Apr	CAHN
----	-----------------	--------------	---------	-----	--------------	-----	------

TRAVOPROST

SOLUTION/DROPS;OPHTHALMIC

TRAVOPROST

AT	MICRO LABS	0.004%	A203767	001	Mar 19, 2021	Mar	NEWA
----	------------	--------	---------	-----	--------------	-----	------

TRAZODONE HYDROCHLORIDE

TABLET;ORAL

TRAZODONE HYDROCHLORIDE

>D>	AB	ALVOGEN	50MG	A071636	001	Apr 18, 1988	Jun	DISC
>A>	@		50MG	A071636	001	Apr 18, 1988	Jun	DISC
>D>	AB		100MG	A071514	001	Apr 18, 1988	Jun	DISC
>A>	@		100MG	A071514	001	Apr 18, 1988	Jun	DISC
	AB	AUROLIFE PHARMA LLC	50MG	A204852	001	Feb 05, 2020	Feb	CMFD
	AB		100MG	A204852	002	Feb 05, 2020	Feb	CMFD
	AB		150MG	A204852	003	Feb 05, 2020	Feb	CMFD
	AB		300MG	A204852	004	Feb 05, 2020	Feb	CMFD
	@	RISING	50MG	A072484	001	Apr 30, 1990	Jan	CAHN

TREPROSTINIL

INJECTABLE;IV (INFUSION), SUBCUTANEOUS

TREPROSTINIL

AP	ALEMBIC GLOBAL	1MG/ML	A211574	001	Feb 11, 2021	Feb	NEWA	
AP		2.5MG/ML	A211574	002	Feb 11, 2021	Feb	NEWA	
AP		5MG/ML	A211574	003	Feb 11, 2021	Feb	NEWA	
AP		10MG/ML	A211574	004	Feb 11, 2021	Feb	NEWA	
>D>		SOLUTION;INTRAVENOUS, SUBCUTANEOUS						
>D>		REMODULIN						
>D>		UNITED THERAP	20MG/20ML (1MG/ML)	N208276	001	Jul 30, 2018	Jun	DISC
>A>	@		20MG/20ML (1MG/ML)	N208276	001	Jul 30, 2018	Jun	DISC
>D>			50MG/20ML (2.5MG/ML)	N208276	002	Jul 30, 2018	Jun	DISC
>A>	@		50MG/20ML (2.5MG/ML)	N208276	002	Jul 30, 2018	Jun	DISC
>D>			100MG/20ML (5MG/ML)	N208276	003	Jul 30, 2018	Jun	DISC
>A>	@		100MG/20ML (5MG/ML)	N208276	003	Jul 30, 2018	Jun	DISC
>D>			200MG/20ML (10MG/ML)	N208276	004	Jul 30, 2018	Jun	DISC
>A>	@		200MG/20ML (10MG/ML)	N208276	004	Jul 30, 2018	Jun	DISC

TRIAMCINOLONE ACETONIDE

CREAM;TOPICAL

TRIAMCINOLONE ACETONIDE

AT	SAPTALIS PHARMS	0.025%	A040671	001	Jun 09, 2006	Jan	CAHN
AT		0.1%	A040671	002	Jun 09, 2006	Jan	CAHN

OINTMENT;TOPICAL

TRIAMCINOLONE ACETONIDE

AT	PERRIGO ISRAEL	0.05%	A212460	001	Feb 05, 2021	Jan	NEWA
----	----------------	-------	---------	-----	--------------	-----	------

TRIAZOLAM

TABLET;ORAL

HALCION

AB	+ PFIZER	0.125MG	N017892	003	Apr 26, 1985	Feb	CAHN
AB	+!	0.25MG	N017892	001	Nov 15, 1982	Feb	CAHN
	@	0.5MG	N017892	002	Nov 15, 1982	Feb	CAHN

TRIENTINE HYDROCHLORIDE

CAPSULE;ORAL

CLOVIQUE

>D>	AB	CHARTWELL RX	250MG	A209731	001	Oct 21, 2019	Jun	DISC
>A>	@		250MG	A209731	001	Oct 21, 2019	Jun	DISC
	AB		250MG	A209731	001	Oct 21, 2019	Mar	CAHN
		TRIENTINE HYDROCHLORIDE						
>D>	AB	CHARTWELL RX	250MG	A209415	001	Sep 16, 2019	Jun	DISC
>A>	@		250MG	A209415	001	Sep 16, 2019	Jun	DISC
	AB		250MG	A209415	001	Sep 16, 2019	Mar	CAHN

<u>TRILACICLIB DIHYDROCHLORIDE</u>							
POWDER; INTRAVENOUS							
COSELA							
	+ !	G1 THERAP	EQ 300MG BASE/VIAL	N214200	001	Feb 12, 2021	Feb NEWA
<u>TRIMETHOBENZAMIDE HYDROCHLORIDE</u>							
CAPSULE; ORAL							
TIGAN							
	+ @	KING PHARMS LLC	300MG	N017531	006	Dec 13, 2001	Apr DISC
TRIMETHOBENZAMIDE HYDROCHLORIDE							
AB	!	SUN PHARM INDUSTRIES	300MG	A076570	001	Aug 28, 2003	Apr CHRS
<u>TROSPIUM CHLORIDE</u>							
CAPSULE, EXTENDED RELEASE; ORAL							
TROSPIUM CHLORIDE							
AB		AMTA	60MG	A214760	001	Apr 30, 2021	Apr NEWA
<u>UMBRALISIB TOSYLATE</u>							
TABLET; ORAL							
UKONIQ							
	+ !	TG THERAPS	EQ 200MG BASE	N213176	001	Feb 05, 2021	Feb NEWA
<u>URSODIOL</u>							
CAPSULE; ORAL							
URSODIOL							
AB		STRIDES PHARMA	300MG	A210344	001	Jan 22, 2021	Jan NEWA
<u>VALBENZAZINE TOSYLATE</u>							
CAPSULE; ORAL							
INGREZZA							
	+	NEUROCRINE	EQ 60MG BASE	N209241	003	Apr 23, 2021	May NEWA
<u>VALGANCICLOVIR HYDROCHLORIDE</u>							
TABLET; ORAL							
VALGANCICLOVIR HYDROCHLORIDE							
AB		MYLAN	EQ 450MG BASE	A205151	001	Mar 03, 2021	Feb NEWA
<u>VALPROIC ACID</u>							
SYRUP; ORAL							
VALPROIC ACID							
AA		CHARTWELL RX	250MG/5ML	A075782	001	Dec 22, 2000	Mar CMFD
<u>VANCOMYCIN HYDROCHLORIDE</u>							
INJECTABLE; INJECTION							
VANCOMYCIN HYDROCHLORIDE							
	@	HIKMA	EQ 500MG BASE/VIAL	A203300	001	Aug 11, 2020	Feb DISC
	@		EQ 1GM BASE/VIAL	A203300	002	Aug 11, 2020	Feb DISC
	!	HOSPIRA	EQ 1.5GM BASE/VIAL	A062912	003	Jul 10, 2020	May CMFD
<u>VARDENAFIL HYDROCHLORIDE</u>							
TABLET; ORAL							
LEVITRA							
	+ @	BAYER HLTHCARE	EQ 5MG BASE	N021400	001	Aug 19, 2003	Apr DISC
	+ @		EQ 10MG BASE	N021400	002	Aug 19, 2003	Apr DISC
<u>VASOPRESSIN</u>							
SOLUTION; INTRAVENOUS							
VASOSTRICT							
	+ !	PAR STERILE PRODUCTS	20UNITS/100ML (0.2UNITS/ML)	N204485	005	Apr 21, 2021	Apr NEWA
<u>VENLAFAXINE HYDROCHLORIDE</u>							
TABLET; ORAL							
VENLAFAXINE HYDROCHLORIDE							
	@	MYLAN	EQ 25MG BASE	A077166	001	Jun 13, 2008	Jan DISC
	@		EQ 37.5MG BASE	A077166	002	Jun 13, 2008	Jan DISC
	@		EQ 50MG BASE	A077166	003	Jun 13, 2008	Jan DISC
	@		EQ 75MG BASE	A077166	004	Jun 13, 2008	Jan DISC
	@		EQ 100MG BASE	A077166	005	Jun 13, 2008	Jan DISC

TABLET, EXTENDED RELEASE;ORAL
VENLAFAXINE HYDROCHLORIDE

>A>	AB	ALKEM LABS LTD	EQ 37.5MG BASE	A214127	001	Jun 10, 2021	Jun NEWA
>A>	AB		EQ 75MG BASE	A214127	002	Jun 10, 2021	Jun NEWA
>A>	AB		EQ 150MG BASE	A214127	003	Jun 10, 2021	Jun NEWA
>A>	AB		EQ 225MG BASE	A214127	004	Jun 10, 2021	Jun NEWA
>A>	AB	APPCO	EQ 150MG BASE	A214609	001	Jun 30, 2021	Jun NEWA
>A>	AB		EQ 225MG BASE	A214609	002	Jun 30, 2021	Jun NEWA
	AB	DEXCEL PHARMA	EQ 75MG BASE	A213927	001	Jan 21, 2021	Jan NEWA

VERICIGUAT

TABLET;ORAL
VERQUVO

+		MERCK SHARP DOHME	2.5MG	N214377	001	Jan 19, 2021	Jan NEWA
+			5MG	N214377	002	Jan 19, 2021	Jan NEWA
+	!		10MG	N214377	003	Jan 19, 2021	Jan NEWA

VIGABATRIN

FOR SOLUTION;ORAL
VIGABATRIN

AA		ANNORA PHARMA	500MG/PACKET	A213519	001	Jan 26, 2021	Jan NEWA
AA		DEXCEL PHARMA	500MG/PACKET	A214992	001	May 13, 2021	May NEWA

TABLET;ORAL
VIGABATRIN

AB		DR REDDYS	500MG	A211539	001	Jan 29, 2021	Jan NEWA
----	--	-----------	-------	---------	-----	--------------	----------

VILAZODONE HYDROCHLORIDE

TABLET;ORAL

VILAZODONE HYDROCHLORIDE

AB		ACCORD HLTHCARE	10MG	A208209	001	Apr 27, 2021	Apr NEWA
AB			20MG	A208209	002	Apr 27, 2021	Apr NEWA
AB			40MG	A208209	003	Apr 27, 2021	Apr NEWA
AB		INVAGEN PHARMS	10MG	A208200	001	Apr 07, 2021	Mar NEWA
AB			40MG	A208200	002	Apr 07, 2021	Mar NEWA

VILOXAZINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL

QELBREE

+		SUPERNUS PHARMS	EQ 100MG BASE	N211964	001	Apr 02, 2021	Apr NEWA
+			EQ 150MG BASE	N211964	002	Apr 02, 2021	Apr NEWA
+	!		EQ 200MG BASE	N211964	003	Apr 02, 2021	Apr NEWA

VINORELBINE TARTRATE

INJECTABLE;INJECTION
VINORELBINE TARTRATE

@ FRESENIUS KABI USA EQ 10MG BASE/ML

A076849 001 Apr 18, 2005 Jan DISC

VOCLOSPORIN

CAPSULE;ORAL

LUPKYNIS

+	!	AURINIA	7.9MG	N213716	001	Jan 22, 2021	Jan NEWA
---	---	---------	-------	---------	-----	--------------	----------

VORICONAZOLE

INJECTABLE;INTRAVENOUS
VORICONAZOLE

AP		ALMAJECT	200MG/VIAL	A206398	001	Mar 23, 2016	Feb CAHN
----	--	----------	------------	---------	-----	--------------	----------

ZINC CHLORIDE

INJECTABLE;INJECTION
ZINC CHLORIDE

AP		EXELA PHARMA	EQ 1MG ZINC/ML	A212007	001	May 21, 2021	May NFTG
----	--	--------------	----------------	---------	-----	--------------	----------

ZOLPIDEM TARTRATE

TABLET, ORALLY DISINTEGRATING;ORAL

TOVALT ODT

+	@	BIOVAIL LABS INTL	5MG	N021412	001	Apr 25, 2007	Apr CRLD
+	@		10MG	N021412	002	Apr 25, 2007	Apr CRLD

ZONISAMIDE

CAPSULE; ORAL

ZONEGRAN

AB	+	CONCORDIA	25MG	N020789	003	Aug 22, 2003	Mar	CAHN
	+	@	50MG	N020789	002	Aug 22, 2003	Mar	CAHN
AB	+	!	100MG	N020789	001	Mar 27, 2000	Mar	CAHN

ZONISAMIDE

>D>	AB	CELLTRION	25MG	A077636	003	Jul 27, 2006	Jun	CAHN
>D>	AB		50MG	A077636	002	Jul 27, 2006	Jun	CAHN
>D>	AB		100MG	A077636	001	Dec 22, 2005	Jun	CAHN
>A>	AB	GRANULES	25MG	A077636	003	Jul 27, 2006	Jun	CAHN
>A>	AB		50MG	A077636	002	Jul 27, 2006	Jun	CAHN
>A>	AB		100MG	A077636	001	Dec 22, 2005	Jun	CAHN
	AB	UNICHEM	25MG	A214492	001	Jan 26, 2021	Jan	NEWA
	AB		50MG	A214492	002	Jan 26, 2021	Jan	NEWA
	AB		100MG	A214492	003	Jan 26, 2021	Jan	NEWA

ACETAMINOPHEN; ASPIRIN; CAFFEINE

TABLET;ORAL

ACETAMINOPHEN, ASPIRIN AND CAFFEINE

GRANULES

250MG;250MG;65MG

A214039 001 Feb 23, 2021 Feb NEWA

ASPIRIN

CAPSULE;ORAL

VAZALORE

>A> + PLX PHARMA 81MG N203697 002 Feb 26, 2021 Jun NEWA

AZELASTINE HYDROCHLORIDE

SPRAY, METERED;NASAL

ASTEPRO ALLERGY

>A> +! BAYER HLTHCARE 0.2055MG/SPRAY N213872 001 Jun 17, 2021 Jun NEWA

>A> CHILDREN'S ASTEPRO ALLERGY

>A> +! BAYER HLTHCARE 0.2055MG/SPRAY N213872 002 Jun 17, 2021 Jun NEWA

BUDESONIDE

SPRAY, METERED;NASAL

RHINOCORT ALLERGY

+! J AND J CONSUMER INC 0.032MG/SPRAY

N020746 003 Mar 23, 2015 Mar CAHN

CETIRIZINE HYDROCHLORIDE

CAPSULE;ORAL

CETIRIZINE HYDROCHLORIDE ALLERGY

APOTEX 10MG

A207235 001 Aug 12, 2016 Mar CMFD

@ 10MG

A207235 001 Aug 12, 2016 Jan DISC

TABLET;ORAL

CETIRIZINE HYDROCHLORIDE ALLERGY

@ CIPLA LTD 5MG

A077318 001 Jul 25, 2013 May DISC

@ 10MG

A077318 002 Jul 25, 2013 May DISC

TABLET, CHEWABLE;ORAL

CHILDREN'S ZYRTEC ALLERGY

+ @ J AND J CONSUMER INC 2.5MG

N021621 007 Nov 30, 2020 Apr DISC

DEXTROMETHORPHAN HYDROBROMIDE; GUAIFENESIN

TABLET, EXTENDED RELEASE;ORAL

GUAIFENESIN AND DEXTROMETHORPHAN HYDROBROMIDE

>A> SUN PHARM 30MG;600MG A214781 001 Jul 01, 2021 Jun NEWA

>A> 60MG;1.2GM A214781 002 Jul 01, 2021 Jun NEWA

DICLOFENAC SODIUM

GEL;TOPICAL

DICLOFENAC SODIUM

AUROLIFE PHARMA LLC 1%

A204306 001 May 06, 2019 May CAHN

>A> PERRIGO 1% A211253 001 May 16, 2019 Jun CAHN

>D> PERRIGO UK FINCO 1% A211253 001 May 16, 2019 Jun CAHN

FEXOFENADINE HYDROCHLORIDE

SUSPENSION;ORAL

CHILDREN'S FEXOFENADINE HYDROCHLORIDE ALLERGY

>D> @ TARO 30MG/5ML A208123 001 Nov 09, 2017 Jun CMFD

>A> 30MG/5ML A208123 001 Nov 09, 2017 Jun CMFD

CHILDREN'S FEXOFENADINE HYDROCHLORIDE HIVES

>D> @ TARO 30MG/5ML A208123 002 Nov 09, 2017 Jun CMFD

>A> 30MG/5ML A208123 002 Nov 09, 2017 Jun CMFD

TABLET;ORAL

FEXOFENADINE HYDROCHLORIDE

>D> @ L PERRIGO CO 60MG A212971 001 Feb 24, 2020 Jun CMFD

>A> 60MG A212971 001 Feb 24, 2020 Jun CMFD

>D> @ 180MG A212971 002 Feb 24, 2020 Jun CMFD

>A> 180MG A212971 002 Feb 24, 2020 Jun CMFD

FLUTICASONE PROPIONATE

SPRAY, METERED;NASAL

FLONASE ALLERGY RELIEF

+ GLAXOSMITHKLINE CONS 0.05MG/SPRAY

N205434 001 Jul 23, 2014 Apr CHRS

FLUTICASONE PROPIONATE

! HIKMA 0.05MG/SPRAY

A207957 001 May 26, 2016 Apr CHRS

IBUPROFEN

SUSPENSION; ORAL

IBUPROFEN

GUARDIAN DRUG 100MG/5ML
 STRIDES PHARMA 100MG/5ML

A210149 001 Aug 17, 2018 Jan CMFD
 A211666 001 Feb 22, 2021 Feb NEWA

TABLET; ORAL

IBUPROFEN

@ MERRO PHARM 200MG
 @ YICHANG HUMANWELL 200MG

A070985 001 Oct 02, 1987 Apr DISC
 A214003 001 Oct 19, 2020 Apr DISC

IVERMECTIN

LOTION; TOPICAL

IVERMECTIN

TARO 0.5%

A210720 001 May 06, 2020 May CMKT

KETOCONAZOLE

SHAMPOO; TOPICAL

NIZORAL ANTI-DANDRUFF

+! KRAMER 1%

N020310 001 Oct 10, 1997 Feb CTNA

LEVOCETIRIZINE DIHYDROCHLORIDE

TABLET; ORAL

LEVOCETIRIZINE DIHYDROCHLORIDE

APOTEX 5MG

A211443 001 Apr 21, 2021 Apr NEWA

LOPERAMIDE HYDROCHLORIDE; SIMETHICONE

TABLET; ORAL

LOPERAMIDE HYDROCHLORIDE AND SIMETHICONE

GUARDIAN DRUG 2MG;125MG
 HETERO LABS LTD V 2MG;125MG

A214541 001 May 27, 2021 May NEWA
 A211438 001 Jun 17, 2021 Jun NEWA

>A>

LORATADINE

SYRUP; ORAL

LORATADINE

HETERO LABS LTD III 1MG/ML

A210409 001 May 07, 2021 Apr NEWA

TABLET; ORAL

LORATADINE

UNIQUE PHARM 10MG

A214684 001 Jan 07, 2021 Jan NEWA

TABLET, ORALLY DISINTEGRATING; ORAL

LORATADINE

@ GLAXOSMITHKLINE 10MG
 @ TENSHI 5MG

A075822 001 Feb 10, 2003 Jan DISC
 A212795 001 Sep 18, 2020 Jun CMFD

>D>

>A>

5MG

A212795 001 Sep 18, 2020 Jun CMFD

@ 5MG

A212795 001 Sep 18, 2020 Mar DISC

>D>

>A>

@ 10MG
 @ 10MG

A213294 001 Oct 30, 2020 Jun CMFD
 A213294 001 Oct 30, 2020 Jun CMFD

@ 10MG

A213294 001 Oct 30, 2020 Mar DISC

NICOTINE POLACRILEX

TROCHE/LOZENGE; ORAL

NICORETTE

+ GLAXOSMITHKLINE EQ 2MG BASE
 +! EQ 4MG BASE

N022360 001 May 18, 2009 Mar CAHN
 N022360 002 May 18, 2009 Mar CAHN

LOPATADINE HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

OLOPATADINE HYDROCHLORIDE

>A> AKORN EQ 0.1% BASE A204532 001 Jan 10, 2017 Jun CMKT
 >A> EQ 0.2% BASE A204723 001 Dec 05, 2017 Jun CMKT
 ALEMBIC PHARMS LTD EQ 0.1% BASE A209919 001 Dec 07, 2018 Feb CMKT
 EQ 0.2% BASE A209420 001 Apr 29, 2019 Jan CMKT
 APOTEX INC EQ 0.2% BASE A090918 001 Dec 05, 2017 Jan CMKT
 BARR LABS INC EQ 0.2% BASE A090848 001 Jul 13, 2015 Feb CMKT
 >A> @ BAUSCH EQ 0.1% BASE A206046 001 Jul 26, 2017 Jun CAHN
 >D> @ CIPLA EQ 0.1% BASE A206046 001 Jul 26, 2017 Jun CAHN
 @ EQ 0.2% BASE A206087 001 Dec 05, 2017 Mar CMKT
 FDC LTD EQ 0.1% BASE A209282 001 Sep 26, 2019 Feb CMKT
 >D> MICRO LABS LTD INDIA EQ 0.2% BASE A204620 001 Jun 16, 2020 Jun CAHN
 MYLAN EQ 0.1% BASE A204392 001 Mar 21, 2018 Feb CMKT
 >A> EQ 0.2% BASE A204620 001 Jun 16, 2020 Jun CAHN
 USV EQ 0.1% BASE A203152 001 Dec 07, 2015 Apr CMKT

OMEPRAZOLE

TABLET, DELAYED RELEASE;ORAL
OMEPRAZOLE

APOTEX 20MG A210070 001 Feb 11, 2019 May CMFD

POLYETHYLENE GLYCOL 3350

FOR SOLUTION;ORAL
POLYETHYLENE GLYCOL 3350

ANNORA PHARMA 17GM/SCOOPFUL A214990 001 Apr 14, 2021 Apr NEWA

RANITIDINE HYDROCHLORIDE

TABLET;ORAL

RANITIDINE HYDROCHLORIDE

>D>	AUROBINDO PHARMA LTD	EQ 75MG BASE	A207579	001	Nov 13, 2017	Jun	DISC
>A>	@	EQ 75MG BASE	A207579	001	Nov 13, 2017	Jun	DISC
>D>		EQ 150MG BASE	A207578	001	Nov 13, 2017	Jun	DISC
>A>	@	EQ 150MG BASE	A207578	001	Nov 13, 2017	Jun	DISC
	@ WOCKHARDT	EQ 75MG BASE	A076760	001	Feb 24, 2006	Jan	DISC
	ZANTAC 150						
+	@ SANOFI US	EQ 150MG BASE	N021698	001	Aug 31, 2004	Apr	DISC
+	@	EQ 150MG BASE	N021698	002	Mar 13, 2007	Apr	DISC
	ZANTAC 75						
+	@ SANOFI US	EQ 75MG BASE	N020520	001	Dec 19, 1995	Apr	DISC

**DRUG PRODUCTS WITH APPROVAL UNDER SECTION 505 OF THE ACT
ADMINISTERED BY THE CENTER FOR BIOLOGICS EVALUATION AND
RESEARCH LIST**

CUMULATIVE SUPPLEMENT NUMBER 06 JUNE 2021

NO JUNE 2021 APPROVALS

ORPHAN PRODUCT DESIGNATIONS AND APPROVALS LIST

The list of Orphan Designations and Approvals is available at:

[https://www.fda.gov/industry/developing-products-rare-diseases-conditions/designating-orphan-product-drugs-and-biological-products.](https://www.fda.gov/industry/developing-products-rare-diseases-conditions/designating-orphan-product-drugs-and-biological-products)

**DRUG PRODUCTS WHICH MUST DEMONSTRATE *IN VIVO* BIOAVAILABILITY
ONLY IF PRODUCT FAILS TO ACHIEVE ADEQUATE DISSOLUTION**

NO JUNE 2021 ADDITIONS

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2021

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ABALOPARATIDE - TYMLOS</u>						
N 208743 001	10996208	Apr 30, 2038	DP			
<u>ACLIDINIUM BROMIDE - TUDORZA PRESSAIR</u>						
N 202450 001 >A>	11000517	Mar 13, 2029	DP U-2513			
<u>ACLIDINIUM BROMIDE; FORMOTEROL FUMARATE - DUAKLIR PRESSAIR</u>						
N 210595 001 >A>	11000517	Mar 13, 2029	DP U-2513			
<u>ALBUTEROL SULFATE - PROAIR DIGIHALER</u>						
N 205636 002	10918816	Dec 14, 2035	DP			
	>A> 11000653	Dec 18, 2038	DP			
<u>ALENDRONATE SODIUM - BINOSTO</u>						
N 202344 001	9592195	Dec 05, 2031	DP			
<u>AMANTADINE HYDROCHLORIDE - OSMOLEX ER</u>						
N 209410 001	8389578	Jan 22, 2028	U-219			
	8389578	Jan 22, 2028	U-3054			
	8796337	Nov 23, 2025	U-219			
	8796337	Nov 23, 2025	U-2497			
	8796337	Nov 23, 2025	U-3054			
	8889740	Nov 23, 2025	DP			
	8895614	Nov 23, 2025	DP			
	8895615	Nov 23, 2025	U-219			
	8895615	Nov 23, 2025	U-3054			
	8895616	Nov 23, 2025	U-219			
	8895616	Nov 23, 2025	U-3054			
	8895617	Nov 23, 2025	U-219			
	8895617	Nov 23, 2025	U-3054			
	8895618	Nov 23, 2025	DP			
	8987333	Nov 23, 2025	DP			
	9072697	Nov 23, 2025	U-219			
	9072697	Nov 23, 2025	U-3054			
<u>AMANTADINE HYDROCHLORIDE - OSMOLEX ER</u>						
N 209410 002	8389578	Jan 22, 2028	U-219			
	8389578	Jan 22, 2028	U-3054			
	8796337	Nov 23, 2025	U-219			
	8796337	Nov 23, 2025	U-2497			
	8796337	Nov 23, 2025	U-3054			
	8889740	Nov 23, 2025	DP			
	8895614	Nov 23, 2025	DP			
	8895615	Nov 23, 2025	U-219			
	8895615	Nov 23, 2025	U-3054			
	8895616	Nov 23, 2025	U-219			
	8895616	Nov 23, 2025	U-3054			
	8895617	Nov 23, 2025	U-219			
	8895617	Nov 23, 2025	U-3054			
	8895618	Nov 23, 2025	DP			
	8987333	Nov 23, 2025	DP			
	9072697	Nov 23, 2025	U-219			
	9072697	Nov 23, 2025	U-3054			
<u>AMANTADINE HYDROCHLORIDE - OSMOLEX ER</u>						
N 209410 003	8389578	Jan 22, 2028	U-219			
	8389578	Jan 22, 2028	U-3054			
	8796337	Nov 23, 2025	U-219			
	8796337	Nov 23, 2025	U-2497			
	8796337	Nov 23, 2025	U-3054			
	8889740	Nov 23, 2025	DP			
	8895614	Nov 23, 2025	DP			
	8895615	Nov 23, 2025	U-219			
	8895615	Nov 23, 2025	U-3054			
	8895616	Nov 23, 2025	U-219			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2021

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>AMANTADINE HYDROCHLORIDE - OSMOLEX ER</u>						
N 209410 003	8895616	Nov 23, 2025	U-3054			
	8895617	Nov 23, 2025	U-219			
	8895617	Nov 23, 2025	U-3054			
	8895618	Nov 23, 2025	DP			
	8987333	Nov 23, 2025	DP			
	9072697	Nov 23, 2025	U-219			
	9072697	Nov 23, 2025	U-3054			
<u>AMANTADINE HYDROCHLORIDE - OSMOLEX ER</u>						
N 209410 004	8389578	Jan 22, 2028	U-219			
	8389578	Jan 22, 2028	U-3054			
	8796337	Nov 23, 2025	U-219			
	8796337	Nov 23, 2025	U-2497			
	8796337	Nov 23, 2025	U-3054			
	8889740	Nov 23, 2025	DP			
	8895614	Nov 23, 2025	DP			
	8895615	Nov 23, 2025	U-219			
	8895615	Nov 23, 2025	U-3054			
	8895616	Nov 23, 2025	U-219			
	8895616	Nov 23, 2025	U-3054			
	8895617	Nov 23, 2025	U-219			
	8895617	Nov 23, 2025	U-3054			
	8895618	Nov 23, 2025	DP			
	8987333	Nov 23, 2025	DP			
	9072697	Nov 23, 2025	U-219			
	9072697	Nov 23, 2025	U-3054			
<u>AMINOLEVULINIC ACID HYDROCHLORIDE - LEVULAN</u>						
N 020965 001 >A>	10357567	Jan 12, 2038	U-3163			
<u>AMLODIPINE BENZOATE - KATERZIA</u>						
N 211340 001	10894039	Oct 06, 2037	U-185			
	10894039	Oct 06, 2037	U-3			
	10952998	Oct 06, 2037	DP			
	10959991	Oct 06, 2037	U-158			
	10959991	Oct 06, 2037	U-39			
<u>AMLODIPINE BESYLATE; CELECOXIB - CONSENSI</u>						
N 210045 001	10925835	Jun 14, 2038	U-2410			
	10945960	Jun 14, 2038	DP			
<u>AMLODIPINE BESYLATE; CELECOXIB - CONSENSI</u>						
N 210045 002	10925835	Jun 14, 2038	U-2410			
	10945960	Jun 14, 2038	DP			
<u>AMLODIPINE BESYLATE; CELECOXIB - CONSENSI</u>						
N 210045 003	10925835	Jun 14, 2038	U-2410			
	10945960	Jun 14, 2038	DP			
<u>AMPHETAMINE SULFATE - EVEKEO ODT</u>						
N 209905 005 >A>	10130580	Apr 19, 2024	DP			
>A>	10441554	Mar 10, 2037	DP			
<u>APOMORPHINE HYDROCHLORIDE - KYNMOBI</u>						
N 210875 001	10888499	Feb 14, 2022	DP			
	10959943	Apr 19, 2036	U-2825			
<u>APOMORPHINE HYDROCHLORIDE - KYNMOBI</u>						
N 210875 002	10888499	Feb 14, 2022	DP			
	10959943	Apr 19, 2036	U-2825			
<u>APOMORPHINE HYDROCHLORIDE - KYNMOBI</u>						
N 210875 003	10888499	Feb 14, 2022	DP			
	10959943	Apr 19, 2036	U-2825			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2021

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>APOMORPHINE HYDROCHLORIDE - KYNMOBI</u>						
N 210875 003	10888499	Feb 14, 2022	DP			
	10959943	Apr 19, 2036	U-2825			
<u>APOMORPHINE HYDROCHLORIDE - KYNMOBI</u>						
N 210875 004	10888499	Feb 14, 2022	DP			
	10959943	Apr 19, 2036	U-2825			
<u>APOMORPHINE HYDROCHLORIDE - KYNMOBI</u>						
N 210875 005	10888499	Feb 14, 2022	DP			
	10959943	Apr 19, 2036	U-2825			
<u>APREPITANT - CINVANTI</u>						
N 209296 001	10953018	Sep 18, 2035	U-2161			
<u>ARIPIPIRAZOLE - ABILIFY MAINTENA KIT</u>						
N 202971 001	10980803	Sep 24, 2033	U-1632			
	10980803	Sep 24, 2033	U-543			
<u>ARIPIPIRAZOLE - ABILIFY MAINTENA KIT</u>						
N 202971 002	10980803	Sep 24, 2033	U-1632			
	10980803	Sep 24, 2033	U-543			
<u>ARIPIPIRAZOLE - ABILIFY MAINTENA KIT</u>						
N 202971 003	10980803	Sep 24, 2033	U-1632			
	10980803	Sep 24, 2033	U-543			
<u>ARIPIPIRAZOLE - ABILIFY MAINTENA KIT</u>						
N 202971 004	10980803	Sep 24, 2033	U-1632			
	10980803	Sep 24, 2033	U-543			
<u>ASCORBIC ACID; POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM ASCORBATE; SODIUM CHLORIDE; SODIUM SULFATE - PLENVU</u>						
N 209381 001	10918723	Sep 10, 2033	U-2310			
<u>ASENAPINE MALEATE - ASENAPINE MALEATE</u>						
A 206098 002					PC	Jun 08, 2021
<u>ATROPINE SULFATE - ATROPINE SULFATE</u>						
A 213424 001					CGT	Sep 21, 2021
<u>AXITINIB - INLYTA</u>						
N 202324 001	10869924	Nov 05, 2036	U-3044			
<u>AXITINIB - INLYTA</u>						
N 202324 002	10869924	Nov 05, 2036	U-3044			
<u>AZACITIDINE - ONUREG</u>						
N 214120 001					ODE-320	Sep 01, 2027
<u>AZACITIDINE - ONUREG</u>						
N 214120 002					ODE-320	Sep 01, 2027
<u>BALOXAVIR MARBOXIL - XOFLUZA</u>						
N 210854 003					I-811 NCE	Oct 16, 2022 Oct 24, 2023
<u>BALOXAVIR MARBOXIL - XOFLUZA</u>						
N 214410 001					NCE	Oct 24, 2023

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2021

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>BEMPEDOIC ACID - NEXLETOL</u>						
N 211616 001	10941095	Dec 23, 2023	U-2747			
<u>BEMPEDOIC ACID; EZETIMIBE - NEXLIZET</u>						
N 211617 001	10941095	Dec 23, 2023	U-2746			
<u>BEROTRALSTAT HYDROCHLORIDE - ORLADEYO</u>						
N 214094 001					NCE ODE-333	Dec 03, 2025 Dec 03, 2027
<u>BEROTRALSTAT HYDROCHLORIDE - ORLADEYO</u>						
N 214094 002					NCE ODE-333	Dec 03, 2025 Dec 03, 2027
<u>BICTEGRAVIR SODIUM; EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE - BIKTARVY</u>						
N 210251 001					M-82	Feb 24, 2024
<u>BREMELANOTIDE ACETATE - VYLEESI (AUTOINJECTOR)</u>						
N 210557 001	6794489	Jun 28, 2025	DS DP			
<u>BREXANOLONE - ZULRESSO</u>						
N 211371 001	10940156	Mar 08, 2037	U-2552			
<u>BREXPIPIRAZOLE - REXULTI</u>						
N 205422 001	RE48059	Dec 23, 2028	DS			
<u>BREXPIPIRAZOLE - REXULTI</u>						
N 205422 002	RE48059	Dec 23, 2028	DS			
<u>BREXPIPIRAZOLE - REXULTI</u>						
N 205422 003	RE48059	Dec 23, 2028	DS			
<u>BREXPIPIRAZOLE - REXULTI</u>						
N 205422 004	RE48059	Dec 23, 2028	DS			
<u>BREXPIPIRAZOLE - REXULTI</u>						
N 205422 005	RE48059	Dec 23, 2028	DS			
<u>BREXPIPIRAZOLE - REXULTI</u>						
N 205422 006	RE48059	Dec 23, 2028	DS			
<u>BRINCIDOFOVIR - TEMBEXA</u>						
N 214460 001	>A> 9303051	Aug 31, 2031	DS DP U-3165		>A> NP	Jun 04, 2024
<u>BRINCIDOFOVIR - TEMBEXA</u>						
N 214461 001	>A> 10112909	Oct 10, 2034	U-3165		>A> NP	Jun 04, 2024
	>A> 10487061	Oct 10, 2034	DP U-3165			
	>A> 8962829	Oct 10, 2034	DS DP			
	>A> 9303051	Aug 31, 2031	DS DP U-3165			
	>A> 9371344	Oct 10, 2034	DP			
<u>BRIVARACETAM - BRIVIACT</u>						
N 205836 001					NPP	May 10, 2021
<u>BRIVARACETAM - BRIVIACT</u>						
N 205836 002					NPP	May 10, 2021
<u>BRIVARACETAM - BRIVIACT</u>						
N 205836 003					NPP	May 10, 2021

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2021

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>BRIVARACETAM - BRIVIACT</u>						
N 205836	004				NPP	May 10, 2021
<u>BRIVARACETAM - BRIVIACT</u>						
N 205836	005				NPP	May 10, 2021
<u>BRIVARACETAM - BRIVIACT</u>						
N 205838	001				NPP	May 10, 2021
<u>BROMOCRIPTINE MESYLATE - CYCLOSET</u>						
N 020866	001	11000522	Apr 30, 2032	U-3119		
		11000522	Apr 30, 2032	U-3120		
		11000522	Apr 30, 2032	U-3121		
		11000522	Apr 30, 2032	U-3122		
<u>BUPIVACAINE - EXPAREL</u>						
N 022496	001				NPP	Mar 22, 2024
<u>BUPIVACAINE - EXPAREL</u>						
N 022496	002				NPP	Mar 22, 2024
<u>BUPIVACAINE - POSIMIR</u>						
N 204803	001	8153149	Sep 15, 2025	DP	NP	Feb 01, 2024
		8153661	Sep 15, 2025	U-3074		
		8753665	Sep 15, 2025	DP U-3074		
		8846072	Sep 15, 2025	DP U-3074		
<u>BUPIVACAINE; MELOXICAM - ZYNRELEF KIT</u>						
N 211988	001	10098957	Apr 20, 2035	U-3118	>A> NP	May 12, 2024
		10213510	Apr 20, 2035	DP U-3118		
		10398686	Mar 13, 2034	DP		
		10632199	Apr 20, 2035	DP U-3118		
		10898575	Apr 20, 2035	DP U-3118		
		10980886	Apr 20, 2035	DP		
		9592227	Mar 13, 2034	DP U-3118		
		9694079	Apr 20, 2035	DP U-3118		
		9744163	Mar 13, 2034	DP		
		9801945	Apr 20, 2035	DP U-3118		
		9913909	Mar 13, 2034	U-3118		
<u>BUPIVACAINE; MELOXICAM - ZYNRELEF KIT</u>						
N 211988	002	10098957	Apr 20, 2035	U-3118	>A> NP	May 12, 2024
		10213510	Apr 20, 2035	DP U-3118		
		10398686	Mar 13, 2034	DP		
		10632199	Apr 20, 2035	DP U-3118		
		10898575	Apr 20, 2035	DP U-3118		
		10980886	Apr 20, 2035	DP		
		9592227	Mar 13, 2034	DP U-3118		
		9694079	Apr 20, 2035	DP U-3118		
		9744163	Mar 13, 2034	DP		
		9801945	Apr 20, 2035	DP U-3118		
		9913909	Mar 13, 2034	U-3118		
<u>BUPIVACAINE; MELOXICAM - ZYNRELEF KIT</u>						
N 211988	003	10098957	Apr 20, 2035	U-3118	>A> NP	May 12, 2024
		10213510	Apr 20, 2035	DP U-3118		
		10398686	Mar 13, 2034	DP		
		10632199	Apr 20, 2035	DP U-3118		
		10898575	Apr 20, 2035	DP U-3118		
		10980886	Apr 20, 2035	DP		
		9592227	Mar 13, 2034	DP U-3118		
		9694079	Apr 20, 2035	DP U-3118		
		9744163	Mar 13, 2034	DP		
		9801945	Apr 20, 2035	DP U-3118		
		9913909	Mar 13, 2034	U-3118		

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2021

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>BUPIVACAINE; MELOXICAM - ZYNRELEF KIT</u>						
N 211988 004	10098957	Apr 20, 2035	U-3118		>A> NP	May 12, 2024
	10213510	Apr 20, 2035	DP U-3118			
	10398686	Mar 13, 2034	DP			
	10632199	Apr 20, 2035	DP U-3118			
	10898575	Apr 20, 2035	DP U-3118			
	10980886	Apr 20, 2035	DP			
	9592227	Mar 13, 2034	DP U-3118			
	9694079	Apr 20, 2035	DP U-3118			
	9744163	Mar 13, 2034	DP			
	9801945	Apr 20, 2035	DP U-3118			
	9913909	Mar 13, 2034	U-3118			
<u>BUPRENORPHINE - SUBLOCADE</u>						
N 209819 001	11000520	Nov 06, 2035	U-3111			
<u>BUPRENORPHINE - SUBLOCADE</u>						
N 209819 002	11000520	Nov 06, 2035	U-3111			
<u>BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - ZUBSOLV</u>						
N 204242 001	10946010	Sep 18, 2032	DP			
	>A> 11020388	Sep 18, 2032	DP U-3131			
<u>BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - ZUBSOLV</u>						
N 204242 002	10874661	Sep 18, 2032	DP			
	10946010	Sep 18, 2032	DP			
	>A> 11020387	Sep 18, 2032	DP U-3131			
	>A> 11020388	Sep 18, 2032	DP U-3131			
<u>BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - ZUBSOLV</u>						
N 204242 003	10946010	Sep 18, 2032	DP			
	>A> 11020387	Sep 18, 2032	DP U-3131			
	>A> 11020388	Sep 18, 2032	DP U-3131			
<u>BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - ZUBSOLV</u>						
N 204242 004	10946010	Sep 18, 2032	DP			
	>A> 11020387	Sep 18, 2032	DP U-3131			
	>A> 11020388	Sep 18, 2032	DP U-3131			
<u>BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - ZUBSOLV</u>						
N 204242 005	10946010	Sep 18, 2032	DP			
	>A> 11020387	Sep 18, 2032	DP U-3131			
	>A> 11020388	Sep 18, 2032	DP U-3131			
<u>BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - ZUBSOLV</u>						
N 204242 006	10946010	Sep 18, 2032	DP			
	>A> 11020388	Sep 18, 2032	DP U-3131			
<u>CABAZITAXEL - JEVTANA KIT</u>						
N 201023 001					M-128	Dec 18, 2023
<u>CABOTEGRAVIR SODIUM - VOCABRIA</u>						
N 212887 001	10927129	Apr 28, 2026	DS DP		NCE	Jan 21, 2026
	8410103	Apr 28, 2026	DS DP U-3061			
<u>CABOTEGRAVIR; RILPIVIRINE - CABENUVA KIT</u>						
N 212888 001	10927129	Apr 28, 2026	DS DP		NCE	Jan 21, 2026
	6838464	Feb 26, 2021	DS DP			
	7125879	Apr 21, 2025	DS DP U-3059			
	8080551	Apr 11, 2023	DS DP			
	8410103	Apr 28, 2026	DS DP U-3060			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2021

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>CABOTEGRAVIR; RILPIVIRINE - CABENUVA KIT</u>						
N 212888 002	10927129	Apr 28, 2026	DS DP		NCE	Jan 21, 2026
	6838464	Feb 26, 2021	DS DP			
	7125879	Apr 21, 2025	DS DP U-3059			
	8080551	Apr 11, 2023	DS DP			
	8410103	Apr 28, 2026	DS DP U-3060			
<u>CABOZANTINIB S-MALATE - CABOMETYX</u>						
N 208692 001					I-854	Jan 22, 2024
<u>CABOZANTINIB S-MALATE - CABOMETYX</u>						
N 208692 002					I-854	Jan 22, 2024
<u>CABOZANTINIB S-MALATE - CABOMETYX</u>						
N 208692 003					I-854	Jan 22, 2024
<u>CALCITONIN SALMON - CALCITONIN-SALMON</u>						
A 212416 001					CGT	Nov 10, 2021
<u>CALCIUM OXYBATE; MAGNESIUM OXYBATE; POTASSIUM OXYBATE; SODIUM OXYBATE - XYWAV</u>						
N 212690 001	10864181	Mar 15, 2033	U-3017		>A> ODE-231	Jul 21, 2027
<u>CANGRELOR - KENGREAL</u>						
N 204958 001	8680052	Mar 09, 2033	U-2979			
<u>CANNABIDIOL - EPIDIOLEX</u>						
N 210365 001	10918608	Oct 14, 2035	U-3071		ODE-326	Jul 31, 2027
	10918608	Oct 14, 2035	U-3072		ODE-332	Jul 31, 2027
	10918608	Oct 14, 2035	U-3073			
	10966939	Jun 17, 2035	DP U-2780			
	10966939	Jun 17, 2035	DP U-2781			
<u>CARGLUMIC ACID - CARBAGLU</u>						
N 022562 001					ODE-345	Jan 22, 2028
<u>CASIMERSEN - AMONDYS 45</u>						
N 213026 001	10287586	Nov 12, 2030	DS DP		NCE	Feb 25, 2026
	10533174	May 04, 2021	DP		ODE-347	Feb 25, 2028
	10781450	Nov 12, 2030	U-3089			
	8524880	Apr 02, 2026	DS DP U-3087			
	8524880	Apr 02, 2026	DS DP U-3088			
	9228187	Nov 12, 2030	DS DP			
	9416361	May 04, 2021	DS			
	9447415	Jun 28, 2025	DS DP			
	9758783	Nov 12, 2030	U-3088			
	9758783	Nov 12, 2030	U-3089			
<u>CEFTOLOZANE SULFATE; TAZOBACTAM SODIUM - ZERBAXA</u>						
N 206829 001	10933053	Sep 09, 2034	U-3090			
	10933053	Sep 09, 2034	U-3091			
<u>CERITINIB - ZYKADIA</u>						
N 211225 001					ODE*	Apr 29, 2021
					ODE*	May 26, 2024
<u>CHLORPROMAZINE HYDROCHLORIDE - CHLORPROMAZINE HYDROCHLORIDE</u>						
A 212144 001					CGT	Sep 20, 2021
<u>CHLORPROMAZINE HYDROCHLORIDE - CHLORPROMAZINE HYDROCHLORIDE</u>						
A 212144 002					CGT	Sep 20, 2021

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2021

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>CHLORPROMAZINE HYDROCHLORIDE - CHLORPROMAZINE HYDROCHLORIDE</u>						
A 212144	003				CGT	Sep 20, 2021
<u>CHLORPROMAZINE HYDROCHLORIDE - CHLORPROMAZINE HYDROCHLORIDE</u>						
A 212144	004				CGT	Sep 20, 2021
<u>CHLORPROMAZINE HYDROCHLORIDE - CHLORPROMAZINE HYDROCHLORIDE</u>						
A 212144	005				CGT	Sep 20, 2021
<u>CITRIC ACID; LACTIC ACID; POTASSIUM BITARTRATE - PHEXXI</u>						
N 208352	001	6706276	Mar 06, 2022	DP		
<u>CITRIC ACID; MAGNESIUM OXIDE; SODIUM PICOSULFATE - CLENPIO</u>						
N 209589	001				NPP	Aug 15, 2021
<u>COBICISTAT; DARUNAVIR; EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE - SYMTUZA</u>						
N 210455	001	10786518	Jul 19, 2038	U-2978		
<u>COCAINE HYDROCHLORIDE - NUMBRINO</u>						
N 209575	001				NCE NP	Dec 14, 2022 Jan 10, 2023
<u>COCAINE HYDROCHLORIDE - GOPRELTO</u>						
N 209963	001	10894012	Feb 07, 2037	U-3014		
		10933060	Feb 07, 2037	U-3014		
		10973811	Feb 07, 2037	U-2226		
		10987347	Feb 07, 2037	U-2225		
<u>CRIZOTINIB - XALKORI</u>						
N 202570	001				I-852 ODE-328	Jan 14, 2024 Jan 14, 2028
<u>CRIZOTINIB - XALKORI</u>						
N 202570	002				I-852 ODE-328	Jan 14, 2024 Jan 14, 2028
<u>CUPRIC SULFATE; MANGANESE SULFATE; SELENIOUS ACID; ZINC SULFATE - TRALEMENT</u>						
N 209376	002				NCE	Apr 30, 2024
<u>CYCLOPHOSPHAMIDE - CYCLOPHOSPHAMIDE</u>						
N 212501	001	10993952	Feb 15, 2036	DP		
<u>CYCLOPHOSPHAMIDE - CYCLOPHOSPHAMIDE</u>						
N 212501	002	10993952	Feb 15, 2036	DP		
<u>CYCLOSPORINE - CEQUA</u>						
N 210913	001	10918694	Feb 28, 2037	DP		
<u>CYSTEAMINE BITARTRATE - PROCYSBI</u>						
N 203389	001	10905662	Aug 16, 2036	U-1399		
<u>CYSTEAMINE BITARTRATE - PROCYSBI</u>						
N 203389	002	10905662	Aug 16, 2036	U-1399		
<u>CYSTEAMINE BITARTRATE - PROCYSBI</u>						
N 213491	001	10905662	Aug 16, 2036	U-1399	ODE*	Aug 14, 2022
		8026284	Sep 22, 2027	U-1399	ODE*	Dec 22, 2024
		8026284*PED	Mar 22, 2028		PED	Feb 14, 2023
		9173851	Jun 17, 2034	DP		
		9173851*PED	Dec 17, 2034			
		9192590	Jan 26, 2027	U-1399		
		9192590*PED	Jul 26, 2027			
		9198882	Jan 26, 2027	U-1399		

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2021

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>CYSTEAMINE BITARTRATE - PROCYSBI</u>						
N 213491 001	9198882*PED	Jul 26, 2027				
	9233077	Jun 17, 2034	DP			
	9233077*PED	Dec 17, 2034				
<u>CYSTEAMINE BITARTRATE - PROCYSBI</u>						
N 213491 002	10905662	Aug 16, 2036	U-1399		ODE*	Aug 14, 2022
	8026284	Sep 22, 2027	U-1399		ODE*	Dec 22, 2024
	8026284*PED	Mar 22, 2028			PED	Feb 14, 2023
	9173851	Jun 17, 2034	DP			
	9173851*PED	Dec 17, 2034				
	9192590	Jan 26, 2027	U-1399			
	9192590*PED	Jul 26, 2027				
	9198882	Jan 26, 2027	U-1399			
	9198882*PED	Jul 26, 2027				
	9233077	Jun 17, 2034	DP			
	9233077*PED	Dec 17, 2034				
<u>CYSTEINE HYDROCHLORIDE - ELCYS</u>						
N 210660 001	10905713	Jan 15, 2039	DP			
	10905714	Jan 15, 2039	DP			
	10912795	Jan 15, 2039	DP			
	10918662	Jan 15, 2039	DP			
	10933089	Jan 15, 2039	DP			
<u>CYSTEINE HYDROCHLORIDE - NOURESS</u>						
N 212535 001	10905713	Jan 15, 2039	DP			
	10905714	Jan 15, 2039	DP			
	10912795	Jan 15, 2039	DP			
	10918662	Jan 15, 2039	DP			
	10933089	Jan 15, 2039	DP			
<u>CYTARABINE; DAUNORUBICIN - VYXEOS</u>						
N 209401 001	10028912	Sep 29, 2034	DP U-3149		NPP	Mar 30, 2024
	10028912	Sep 29, 2034	DP U-3150		ODE-350	Mar 30, 2028
	10166184	Oct 15, 2032	DP U-3149			
	10835492	Oct 15, 2032	U-3150			
	7850990	Jan 23, 2027	DP U-3147			
	8022279	Sep 14, 2027	DP U-3147			
	8092828	Apr 01, 2029	U-3147			
	8431806	Apr 22, 2025	DP U-3147			
<u>DABIGATRAN ETEXILATE MESYLATE - PRADAXA</u>						
N 022512 001	6087380	Dec 28, 2021	DS DP U-1931			
	6087380*PED	Jun 28, 2022				
	9034822	Jan 20, 2031	U-1759			
	9034822*PED	Jul 20, 2031				
	9925174	Jun 14, 2023	DP			
	9925174*PED	Dec 14, 2023				
<u>DABIGATRAN ETEXILATE MESYLATE - PRADAXA</u>						
N 022512 002	6087380	Dec 28, 2021	DS DP U-1931			
	6087380*PED	Jun 28, 2022				
	9034822	Jan 20, 2031	U-1759			
	9034822*PED	Jul 20, 2031				
	9925174	Jun 14, 2023	DP			
	9925174*PED	Dec 14, 2023				
<u>DABIGATRAN ETEXILATE MESYLATE - PRADAXA</u>						
N 022512 003	6087380	Dec 28, 2021	DS DP U-1931			
	6087380*PED	Jun 28, 2022				
	7866474	Aug 31, 2027	DP	Y		
	7866474*PED	Mar 02, 2028				
	7932273	Sep 07, 2025	DS DP			
	7932273*PED	Mar 07, 2026				
	9034822	Jan 20, 2031	U-1759			
	9034822*PED	Jul 20, 2031				

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2021

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>DABIGATRAN ETEXILATE MESYLATE - PRADAXA</u>						
N 022512 003	9925174	Jun 14, 2023	DP			
	9925174*PED	Dec 14, 2023				
<u>DAPAGLIFLOZIN - FARXIGA</u>						
N 202293 001					I-857	Apr 30, 2024
<u>DAPAGLIFLOZIN - FARXIGA</u>						
N 202293 002	10973836	Mar 09, 2040	U-3127		I-857	Apr 30, 2024
<u>DASIGLUCAGON HYDROCHLORIDE - ZEGALOGUE</u>						
N 214231 001	10442847	Feb 03, 2035	DS DP		NCE	Mar 22, 2026
<u>DASIGLUCAGON HYDROCHLORIDE - ZEGALOGUE (AUTOINJECTOR)</u>						
N 214231 002	10442847	Feb 03, 2035	DS DP		NCE	Mar 22, 2026
<u>DEFERIPRONE - DEFERIPRONE</u>						
A 208800 001					PC	Mar 27, 2021
<u>DEFERIPRONE - FERRIPROX</u>						
N 021825 001	7049328	Jun 28, 2021	U-3083		I-859	Apr 30, 2024
<u>DEFERIPRONE - FERRIPROX</u>						
N 021825 002	7049328	Jun 28, 2021	U-3083		I-859	Apr 30, 2024
<u>DEFERIPRONE - FERRIPROX</u>						
N 208030 001	7049328	Jun 28, 2021	U-3083		I-859	Apr 30, 2024
	8703156	Oct 26, 2029	DP U-3083			
<u>DEFERIPRONE - FERRIPROX</u>						
N 208030 002	7049328	Jun 28, 2021	U-3083		I-859	Apr 30, 2024
	8703156	Oct 26, 2029	DP U-3083			
<u>DEFERIPRONE - FERRIPROX</u>						
N 212269 001	10780055	Oct 25, 2038	DP U-3083		I-859	Apr 30, 2024
	10780055	Oct 25, 2038	DP U-735			
	10940115	Oct 25, 2038	DP U-3083			
	10940116	Oct 25, 2038	DP			
	7049328	Jun 28, 2021	U-3083			
	7049328	Jun 28, 2021	U-735			
<u>DEGARELIX ACETATE - FIRMAGON</u>						
N 022201 001	10973870	Feb 10, 2029	U-1978			
<u>DEGARELIX ACETATE - FIRMAGON</u>						
N 022201 002	10973870	Feb 10, 2029	U-1978			
<u>DESMOPRESSIN ACETATE - NOCDURNA</u>						
N 022517 001	>A> 11020448	May 21, 2029	U-2327			
<u>DEUTETRABENAZINE - AUSTEDO</u>						
N 208082 001	10959996	Mar 07, 2036	U-3055		NCE	Apr 03, 2022
	10959996*PED	Sep 07, 2036			ODE-134	Apr 03, 2024
	8524733	Mar 27, 2031	DS DP		PED	Oct 03, 2022
	8524733*PED	Sep 27, 2031			PED	Oct 03, 2024
	9233959	Sep 18, 2033	DP			
	9233959*PED	Mar 18, 2034				
	9296739	Sep 18, 2033	DP			
	9296739*PED	Mar 18, 2034				
	9550780	Sep 18, 2033	DS DP U-1995			
	9550780	Sep 18, 2033	DS DP U-3055			
	9550780*PED	Mar 18, 2034				
	9814708	Sep 18, 2033	DP			
	9814708*PED	Mar 18, 2034				

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2021

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>DEUTETRABENAZINE - AUSTEDO</u>						
N 208082 001	10959996	Mar 07, 2036	U-3055		NCE	Apr 03, 2022
	10959996*PED	Sep 07, 2036			ODE-134	Apr 03, 2024
	8524733	Mar 27, 2031	DS DP		PED	Oct 03, 2022
	8524733*PED	Sep 27, 2031			PED	Oct 03, 2024
	9233959	Sep 18, 2033	DP			
	9233959*PED	Mar 18, 2034				
	9296739	Sep 18, 2033	DP			
	9296739*PED	Mar 18, 2034				
	9550780	Sep 18, 2033	DS DP U-1995			
	9550780	Sep 18, 2033	DS DP U-3055			
	9550780*PED	Mar 18, 2034				
	9814708	Sep 18, 2033	DP			
	9814708*PED	Mar 18, 2034				
<u>DEUTETRABENAZINE - AUSTEDO</u>						
N 208082 002	10959996	Mar 07, 2036	U-3055		NCE	Apr 03, 2022
	10959996*PED	Sep 07, 2036			ODE-134	Apr 03, 2024
	8524733	Mar 27, 2031	DS DP		PED	Oct 03, 2022
	8524733*PED	Sep 27, 2031			PED	Oct 03, 2024
	9233959	Sep 18, 2033	DP			
	9233959*PED	Mar 18, 2034				
	9296739	Sep 18, 2033	DP			
	9296739*PED	Mar 18, 2034				
	9550780	Sep 18, 2033	DS DP U-1995			
	9550780	Sep 18, 2033	DS DP U-3055			
	9550780*PED	Mar 18, 2034				
	9814708	Sep 18, 2033	DP			
	9814708*PED	Mar 18, 2034				
<u>DEUTETRABENAZINE - AUSTEDO</u>						
N 208082 003	10959996	Mar 07, 2036	U-3055		NCE	Apr 03, 2022
	10959996*PED	Sep 07, 2036			ODE-134	Apr 03, 2024
	8524733	Mar 27, 2031	DS DP		PED	Oct 03, 2022
	8524733*PED	Sep 27, 2031			PED	Oct 03, 2024
	9233959	Sep 18, 2033	DP			
	9233959*PED	Mar 18, 2034				
	9296739	Sep 18, 2033	DP			
	9296739*PED	Mar 18, 2034				
	9550780	Sep 18, 2033	DS DP U-1995			
	9550780	Sep 18, 2033	DS DP U-3055			
	9550780*PED	Mar 18, 2034				
	9814708	Sep 18, 2033	DP			
	9814708*PED	Mar 18, 2034				
<u>DEXAMETHASONE - DEXYCU KIT</u>						
N 208912 001 >A>	10799642	May 11, 2032	DP			
<u>DEXMETHYLPHENIDATE HYDROCHLORIDE; SERDEXMETHYLPHENIDATE CHLORIDE - AZSTARYS</u>						
N 212994 001	10584112	Dec 09, 2037	DS DP		NCE	May 07, 2026
	10584113	Dec 09, 2037	DP			
	10759778	Dec 09, 2037	DP			
	10858341	Dec 09, 2037	U-3094			
	10954213	Dec 09, 2037	U-3094			
	9079928	Jul 27, 2032	DP			
<u>DEXMETHYLPHENIDATE HYDROCHLORIDE; SERDEXMETHYLPHENIDATE CHLORIDE - AZSTARYS</u>						
N 212994 002	10584112	Dec 09, 2037	DS DP		NCE	May 07, 2026
	10584113	Dec 09, 2037	DP			
	10759778	Dec 09, 2037	DP			
	10858341	Dec 09, 2037	U-3094			
	10954213	Dec 09, 2037	U-3094			
	9079928	Jul 27, 2032	DP			
<u>DEXMETHYLPHENIDATE HYDROCHLORIDE; SERDEXMETHYLPHENIDATE CHLORIDE - AZSTARYS</u>						
N 212994 003	10584112	Dec 09, 2037	DS DP		NCE	May 07, 2026
	10584113	Dec 09, 2037	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2021

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>DEXMETHYLPHENIDATE HYDROCHLORIDE; SERDEXMETHYLPHENIDATE CHLORIDE - AZSTARYS</u>						
N 212994 003	10759778	Dec 09, 2037	DP			
	10858341	Dec 09, 2037	U-3094			
	10954213	Dec 09, 2037	U-3094			
	9079928	Jul 27, 2032	DP			
<u>DICLOFENAC POTASSIUM - ZIPSOR</u>						
N 022202 001					>A> NPP	May 25, 2024
<u>DILTIAZEM HYDROCHLORIDE - DILTIAZEM HYDROCHLORIDE</u>						
A 212317 001					CGT	Sep 26, 2021
<u>DILTIAZEM HYDROCHLORIDE - DILTIAZEM HYDROCHLORIDE</u>						
A 212317 002					CGT	Sep 26, 2021
<u>DILTIAZEM HYDROCHLORIDE - DILTIAZEM HYDROCHLORIDE</u>						
A 212317 003					CGT	Sep 26, 2021
<u>DIMETHYL FUMARATE - TECFIDERA</u>						
N 204063 001	10391160	Mar 13, 2035	U-3148			
	10555993	Mar 13, 2035	U-3148			
	10959972	Nov 16, 2035	U-1384			
	10994003	Mar 13, 2035	U-3148			
	11007166	Nov 16, 2035	U-1384			
	11007167	Nov 16, 2035	U-1384			
<u>DIMETHYL FUMARATE - TECFIDERA</u>						
N 204063 002	10391160	Mar 13, 2035	U-3148			
	10555993	Mar 13, 2035	U-3148			
	10959972	Nov 16, 2035	U-1384			
	10994003	Mar 13, 2035	U-3148			
	11007166	Nov 16, 2035	U-1384			
	11007167	Nov 16, 2035	U-1384			
<u>DOCETAXEL - DOCETAXEL</u>						
N 205934 001	10842770	Aug 07, 2031	DP U-2998			
<u>DOCETAXEL - DOCETAXEL</u>						
N 205934 002	10842770	Aug 07, 2031	DP U-2998			
<u>DOCETAXEL - DOCETAXEL</u>						
N 205934 003	10842770	Aug 07, 2031	DP U-2998			
<u>DROSPIRENONE - SLYND</u>						
N 211367 001	10987364	Jun 28, 2031	DP			
<u>DROSPIRENONE; ESTETROL - NEXTSTELLIS</u>						
N 214154 001	7732430	Mar 02, 2025	DP U-3152		NCE	Apr 15, 2026
<u>DULOXETINE HYDROCHLORIDE - DRIZALMA SPRINKLE</u>						
N 212516 001	10959982	Apr 13, 2037	DP			
<u>DULOXETINE HYDROCHLORIDE - DRIZALMA SPRINKLE</u>						
N 212516 002	10959982	Apr 13, 2037	DP			
<u>DULOXETINE HYDROCHLORIDE - DRIZALMA SPRINKLE</u>						
N 212516 003	10959982	Apr 13, 2037	DP			
<u>DULOXETINE HYDROCHLORIDE - DRIZALMA SPRINKLE</u>						
N 212516 004	10959982	Apr 13, 2037	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2021

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>EDARAVONE - RADICAVA</u>						
N 209176	002				ODE*	May 05, 2024
<u>EDOXABAN TOSYLATE - SAVAYSA</u>						
N 206316	001	7365205	Apr 18, 2027	DS		
<u>EDOXABAN TOSYLATE - SAVAYSA</u>						
N 206316	002	7365205	Apr 18, 2027	DS		
<u>EDOXABAN TOSYLATE - SAVAYSA</u>						
N 206316	003	7365205	Apr 18, 2027	DS		
<u>EFINACONAZOLE - JUBLIA</u>						
N 203567	001	10864274	Oct 02, 2034	U-2720		
		7214506	Feb 22, 2026	U-281		
<u>ELAGOLIX SODIUM, ESTRADIOL, NORETHINDRONE ACETATE; ELAGOLIX SODIUM - ORIAHNN (COPACKAGED)</u>						
N 213388	001	10881659	Mar 14, 2034	U-2842		
<u>ELEXACAFTOR, IVACAFTOR, TEZACAFTOR; IVACAFTOR - TRIKAFTA (COPACKAGED)</u>						
N 212273	001	>A> 10022352	Apr 09, 2027	DP U-2651	ODE-323	Dec 21, 2027
		>A> 10022352	Apr 09, 2027	DP U-3156		
		>A> 10081621	Mar 25, 2031	DP U-2652		
		>A> 10081621	Mar 25, 2031	DP U-3032		
		>A> 10081621	Mar 25, 2031	DP U-3157		
		>A> 10239867	Apr 09, 2027	DS DP U-2653		
		>A> 10239867	Apr 09, 2027	DS DP U-3033		
		>A> 10239867	Apr 09, 2027	DS DP U-3158		
		>A> 10758534	Oct 06, 2035	DS DP U-2645		
		>A> 10758534	Oct 06, 2035	DS DP U-3028		
		>A> 10758534	Oct 06, 2035	DS DP U-3144		
		>A> 10793547	Dec 08, 2037	DS DP U-2645		
		>A> 10793547	Dec 08, 2037	DS DP U-3028		
		>A> 10793547	Dec 08, 2037	DS DP U-3144		
		>A> 8324242	Aug 05, 2027	U-2645		
		>A> 8324242	Aug 05, 2027	U-3028		
		>A> 8324242	Aug 05, 2027	U-3144		
		>A> 8354427	Jul 06, 2026	U-2646		
		>A> 8354427	Jul 06, 2026	U-3029		
		>A> 8354427	Jul 06, 2026	U-3145		
		>A> 8415387	Nov 12, 2027	U-2645		
		>A> 8415387	Nov 12, 2027	U-3028		
		>A> 8415387	Nov 12, 2027	U-3144		
		>A> 8598181	May 01, 2027	U-2645		
		>A> 8598181	May 01, 2027	U-3028		
		>A> 8598181	May 01, 2027	U-3144		
		>A> 8629162	Jun 24, 2025	U-2648		
		>A> 8629162	Jun 24, 2025	U-3030		
		>A> 8629162	Jun 24, 2025	U-3146		
		>A> 9012496	Jul 15, 2033	U-2649		
		>A> 9012496	Jul 15, 2033	U-3154		
		>A> 9670163	Dec 28, 2026	DP U-2650		
		>A> 9670163	Dec 28, 2026	DP U-3031		
		>A> 9670163	Dec 28, 2026	DP U-3155		
		>A> 9931334	Dec 28, 2026	DP U-2650		
		>A> 9931334	Dec 28, 2026	DP U-3031		
		>A> 9931334	Dec 28, 2026	DP U-3155		
		>A> 9974781	Apr 09, 2027	DP U-2645		
		>A> 9974781	Apr 09, 2027	DP U-3028		
		>A> 9974781	Apr 09, 2027	DP U-3144		
<u>ELEXACAFTOR, IVACAFTOR, TEZACAFTOR; IVACAFTOR - TRIKAFTA (COPACKAGED)</u>						
N 212273	002	>A> 10022352	Apr 09, 2027	DP U-3156		
		>A> 10081621	Mar 25, 2031	DP U-3157		
		>A> 10239867	Apr 09, 2027	DS DP U-3158		
		>A> 10646481	Aug 13, 2029	DP		
		>A> 10758534	Oct 06, 2035	DS DP U-3144		

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2021

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ELEXACAFTOR, IVACAFTOR, TEZACAFTOR; IVACAFTOR - TRIKAFTA (COPACKAGED)</u>						
N 212273 002	>A> 10793547	Dec 08, 2037	DS DP U-3144			
	>A> 7495103	May 20, 2027	DS DP			
	>A> 7645789	May 01, 2027	DS DP			
	>A> 7776905	Jun 03, 2027	DS DP			
	>A> 8324242	Aug 05, 2027			U-3144	
	>A> 8354427	Jul 06, 2026			U-3145	
	>A> 8410274	Dec 28, 2026	DP			
	>A> 8415387	Nov 12, 2027			U-3144	
	>A> 8598181	May 01, 2027			U-3144	
	>A> 8623905	May 01, 2027	DS DP			
	>A> 8629162	Jun 24, 2025			U-3146	
	>A> 8754224	Dec 28, 2026	DS DP			
	>A> 9012496	Jul 15, 2033			U-3154	
	>A> 9670163	Dec 28, 2026	DP		U-3155	
	>A> 9931334	Dec 28, 2026	DP		U-3155	
	>A> 9974781	Apr 09, 2027	DP		U-3144	
<u>ELIGLUSTAT TARTRATE - CERDELGA</u>						
N 205494 001	10888544	Dec 13, 2038			U-3040	
	10888544	Dec 13, 2038			U-3041	
	10888547	Jan 31, 2031			U-3042	
	10888547	Jan 31, 2031			U-3043	
<u>ELTROMBOPAG OLAMINE - PROMACTA KIT</u>						
N 207027 001					>A> ODE*	Nov 16, 2025
<u>ELTROMBOPAG OLAMINE - PROMACTA KIT</u>						
N 207027 002					>A> ODE*	Aug 26, 2021
					>A> ODE*	Nov 16, 2025
					>A> PED	Feb 26, 2022
<u>ELUXADOLINE - VIBERZI</u>						
N 206940 001	11007179	Mar 14, 2033	DP			
<u>ELUXADOLINE - VIBERZI</u>						
N 206940 002	11007179	Mar 14, 2033	DP			
<u>EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE - EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE</u>						
A 209721 001					PC	Mar 09, 2021
<u>EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE - EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE</u>						
A 209721 002					PC	Mar 09, 2021
<u>EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE - EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE</u>						
A 209721 003					PC	Mar 09, 2021
<u>ENALAPRIL MALEATE - EPANED</u>						
N 208686 001	>A> 11040023	Mar 25, 2036	DP			
<u>EPINEPHRINE - AUVI-O</u>						
N 201739 001	10960155	Jun 25, 2026	DP			
<u>EPINEPHRINE - AUVI-O</u>						
N 201739 002	10842938	Dec 21, 2037	DP		U-2980	
	10960155	Jun 25, 2026	DP			
<u>EPINEPHRINE - AUVI-O</u>						
N 201739 003	10842938	Dec 21, 2037	DP		U-2980	
	10960155	Jun 25, 2026	DP			
<u>ERDAFITINIB - BALVERSA</u>						
N 212018 001	10898482	Feb 09, 2036	DP		U-2518	
	10898482	Feb 09, 2036	DP		U-3065	

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2021

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ERDAFITINIB - BALVERSA</u>						
N 212018 001	10898482	Feb 09, 2036	DP U-3066			
	10898482	Feb 09, 2036	DP U-3067			
<u>ERDAFITINIB - BALVERSA</u>						
N 212018 002	10898482	Feb 09, 2036	DP U-2518			
	10898482	Feb 09, 2036	DP U-3065			
	10898482	Feb 09, 2036	DP U-3066			
	10898482	Feb 09, 2036	DP U-3067			
<u>ERDAFITINIB - BALVERSA</u>						
N 212018 003	10898482	Feb 09, 2036	DP U-2518			
	10898482	Feb 09, 2036	DP U-3065			
	10898482	Feb 09, 2036	DP U-3066			
	10898482	Feb 09, 2036	DP U-3067			
<u>ESKETAMINE HYDROCHLORIDE - SPRAVATO</u>						
N 211243 001	10869844	Sep 10, 2035	U-3034			
	10869844	Sep 10, 2035	U-3035			
	10869844	Sep 10, 2035	U-3036			
<u>ESLICARBAZEPINE ACETATE - APTIOM</u>						
N 022416 001	10912781	Oct 23, 2028	DP			
<u>ESLICARBAZEPINE ACETATE - APTIOM</u>						
N 022416 002	10912781	Oct 23, 2028	DP			
<u>ESLICARBAZEPINE ACETATE - APTIOM</u>						
N 022416 003	10912781	Oct 23, 2028	DP			
<u>ESLICARBAZEPINE ACETATE - APTIOM</u>						
N 022416 004	10912781	Oct 23, 2028	DP			
<u>ESTRADIOL - IMVEXXY</u>						
N 208564 001	10888516	Jun 18, 2033	U-2316			
	10888516	Jun 18, 2033	U-2317			
<u>ESTRADIOL - IMVEXXY</u>						
N 208564 002	10888516	Jun 18, 2033	U-2316			
	10888516	Jun 18, 2033	U-2317			
<u>ESTRADIOL; NORETHINDRONE ACETATE; RELUGOLIX - MYFEMBREE</u>						
N 214846 001	>A> 11033551	Sep 29, 2037	U-3129		>A> NCE	Dec 18, 2025
	>A> 7300935	Jan 28, 2024	DS		>A> NP	May 26, 2024
	>A> 8058280	Jan 28, 2024	DS DP			
	>A> 9346822	Feb 17, 2024	U-3129			
<u>ETEPLIRSEN - EXONDYS 51</u>						
N 206488 001	RE47769	Feb 02, 2029	DP			
	RE48468	Oct 27, 2028	U-2097			
<u>ETEPLIRSEN - EXONDYS 51</u>						
N 206488 002	RE47769	Feb 02, 2029	DP			
	RE48468	Oct 27, 2028	U-2097			
<u>ETHINYL ESTRADIOL; LEVONORGESTREL - TYBLUME</u>						
N 209405 001					NDF	Mar 30, 2023
<u>ETHINYL ESTRADIOL; NORELGESTROMIN - ETHINYL ESTRADIOL AND NORELGESTROMIN</u>						
A 213950 001					CGT	Aug 25, 2021

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2021

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ETHINYL ESTRADIOL; NORETHINDRONE ACETATE - MERZEE</u>						
A 212706 001					CGT	Jul 17, 2021
<u>ETHINYL ESTRADIOL; SEGESTERONE ACETATE - ANNOVERA</u>						
N 209627 001	10918649	Jun 21, 2039	DP			
	10925882	Jun 21, 2039	DP			
	10940157	Jun 21, 2039	DP			
<u>EXENATIDE - BYDUREON BCISE</u>						
N 209210 001	6515117	Oct 04, 2025	DS DP U-2588		M-240	Feb 15, 2022
	6515117*PED	Apr 04, 2026			PED	Aug 15, 2023
	6824822	Oct 09, 2022	DP			
	6824822*PED	Apr 09, 2023				
	7223440	Aug 31, 2021	DP			
	7223440*PED	Mar 03, 2022				
	7456254	Jun 30, 2025	DP U-2588			
	7456254	Jun 30, 2025	DP U-2589			
	7456254	Jun 30, 2025	DP U-2590			
	7456254	Jun 30, 2025	DP U-2592			
	7456254*PED	Dec 30, 2025				
	7563871	Apr 15, 2024	DP			
	7563871*PED	Oct 15, 2024				
	7612176	Apr 13, 2025	DP U-2589			
	7612176	Apr 13, 2025	DP U-2590			
	7612176	Apr 13, 2025	DP U-2592			
	7612176*PED	Oct 13, 2025				
	8329648	Aug 18, 2026	U-2588			
	8329648	Aug 18, 2026	U-2589			
	8329648	Aug 18, 2026	U-2590			
	8329648	Aug 18, 2026	U-2593			
	8329648	Aug 18, 2026	U-2594			
	8329648	Aug 18, 2026	U-2595			
	8329648	Aug 18, 2026	U-2596			
	8329648*PED	Feb 18, 2027				
	8361972	Mar 21, 2028	U-2588			
	8361972*PED	Sep 21, 2028				
	8431685	Apr 13, 2025	DP U-2589			
	8431685	Apr 13, 2025	DP U-2590			
	8431685	Apr 13, 2025	DP U-2597			
	8431685	Apr 13, 2025	DP U-2598			
	8431685*PED	Oct 13, 2025				
	8461105	Apr 13, 2025	DP U-2589			
	8461105	Apr 13, 2025	DP U-2590			
	8461105	Apr 13, 2025	DP U-2597			
	8461105	Apr 13, 2025	DP U-2598			
	8461105*PED	Oct 13, 2025				
	8501698	Jun 20, 2027	U-2588			
	8501698*PED	Dec 20, 2027				
	8895033	Oct 04, 2030	DP U-2589			
	8895033	Oct 04, 2030	DP U-2590			
	8895033	Oct 04, 2030	DP U-2597			
	8895033	Oct 04, 2030	DP U-2600			
	8895033	Oct 04, 2030	DP U-2601			
	8895033	Oct 04, 2030	DP U-2602			
	8895033*PED	Apr 04, 2031				
	8906851	Aug 18, 2026	U-2589			
	8906851	Aug 18, 2026	U-2590			
	8906851	Aug 18, 2026	U-2593			
	8906851	Aug 18, 2026	U-2597			
	8906851*PED	Feb 18, 2027				
	9238076	Apr 15, 2024	DP U-2589			
	9238076	Apr 15, 2024	DP U-2590			
	9238076	Apr 15, 2024	DP U-2597			
	9238076	Apr 15, 2024	DP U-2599			
	9238076*PED	Oct 15, 2024				
	9884092	Aug 18, 2026	U-2589			
	9884092	Aug 18, 2026	U-2590			
	9884092	Aug 18, 2026	U-2593			
	9884092	Aug 18, 2026	U-2594			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2021

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>EXENATIDE - BYDUREON BCISE</u>						
N 209210 001	9884092	Aug 18, 2026	U-2595			
	9884092	Aug 18, 2026	U-2596			
	9884092	Aug 18, 2026	U-2597			
	9884092*PED	Feb 18, 2027				
<u>EXENATIDE SYNTHETIC - BYDUREON</u>						
N 022200 001	6515117	Oct 04, 2025	DS DP U-2588		M-240	Feb 15, 2022
	6515117*PED	Apr 04, 2026			PED	Aug 15, 2023
	7456254	Jun 30, 2025	DP U-2588			
	7456254	Jun 30, 2025	DP U-2589			
	7456254	Jun 30, 2025	DP U-2590			
	7456254	Jun 30, 2025	DP U-2592			
	7456254*PED	Dec 30, 2025				
	7612176	Apr 13, 2025	DP U-2588			
	7612176	Apr 13, 2025	DP U-2589			
	7612176	Apr 13, 2025	DP U-2590			
	7612176	Apr 13, 2025	DP U-2592			
	7612176*PED	Oct 13, 2025				
	8329648	Aug 18, 2026	U-2588			
	8329648	Aug 18, 2026	U-2589			
	8329648	Aug 18, 2026	U-2590			
	8329648	Aug 18, 2026	U-2593			
	8329648	Aug 18, 2026	U-2594			
	8329648	Aug 18, 2026	U-2595			
	8329648	Aug 18, 2026	U-2596			
	8329648*PED	Feb 18, 2027				
	8361972	Mar 21, 2028	U-2588			
	8361972*PED	Sep 21, 2028				
	8431685	Apr 13, 2025	DP U-2588			
	8431685	Apr 13, 2025	DP U-2589			
	8431685	Apr 13, 2025	DP U-2590			
	8431685	Apr 13, 2025	DP U-2598			
	8431685*PED	Oct 13, 2025				
	8461105	Apr 13, 2025	DP U-2588			
	8461105	Apr 13, 2025	DP U-2589			
	8461105	Apr 13, 2025	DP U-2590			
	8461105	Apr 13, 2025	DP U-2598			
	8461105*PED	Oct 13, 2025				
	8501698	Jun 20, 2027	DP U-2588			
	8501698*PED	Dec 20, 2027				
	8906851	Aug 18, 2026	U-2588			
	8906851	Aug 18, 2026	U-2589			
	8906851	Aug 18, 2026	U-2590			
	8906851	Aug 18, 2026	U-2593			
	8906851*PED	Feb 18, 2027				
	9238076	Apr 15, 2024	DP U-2588			
	9238076	Apr 15, 2024	DP U-2589			
	9238076	Apr 15, 2024	DP U-2590			
	9238076	Apr 15, 2024	DP U-2599			
	9238076*PED	Oct 15, 2024				
	9884092	Aug 18, 2026	U-2588			
	9884092	Aug 18, 2026	U-2589			
	9884092	Aug 18, 2026	U-2590			
	9884092	Aug 18, 2026	U-2593			
	9884092	Aug 18, 2026	U-2594			
	9884092	Aug 18, 2026	U-2595			
	9884092	Aug 18, 2026	U-2596			
	9884092*PED	Feb 18, 2027				
<u>EXENATIDE SYNTHETIC - BYDUREON PEN</u>						
N 022200 002	6515117	Oct 04, 2025	DS DP U-2588		M-240	Feb 15, 2022
	6515117*PED	Apr 04, 2026			PED	Aug 15, 2023
	6824822	Oct 09, 2022	DP			
	6824822*PED	Apr 09, 2023				
	7223440	Aug 31, 2021	DP			
	7223440*PED	Mar 03, 2022				
	7456254	Jun 30, 2025	DP U-2588			
	7456254	Jun 30, 2025	DP U-2589			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2021

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>EXENATIDE SYNTHETIC - BYDUREON PEN</u>						
N 022200 002	7456254	Jun 30, 2025	DP U-2590			
	7456254	Jun 30, 2025	DP U-2592			
	7456254*PED	Dec 30, 2025				
	7563871	Apr 15, 2024	DP			
	7563871*PED	Oct 15, 2024				
	7612176	Apr 13, 2025	DP U-2588			
	7612176	Apr 13, 2025	DP U-2589			
	7612176	Apr 13, 2025	DP U-2590			
	7612176	Apr 13, 2025	DP U-2592			
	7612176*PED	Oct 13, 2025				
	8216180	Jan 12, 2028	DP			
	8216180*PED	Jul 12, 2028				
	8329648	Aug 18, 2026	U-2588			
	8329648	Aug 18, 2026	U-2589			
	8329648	Aug 18, 2026	U-2590			
	8329648	Aug 18, 2026	U-2593			
	8329648	Aug 18, 2026	U-2594			
	8329648	Aug 18, 2026	U-2595			
	8329648	Aug 18, 2026	U-2596			
	8329648*PED	Feb 18, 2027				
	8361972	Mar 21, 2028	U-2588			
	8361972*PED	Sep 21, 2028				
	8431685	Apr 13, 2025	DP U-2588			
	8431685	Apr 13, 2025	DP U-2589			
	8431685	Apr 13, 2025	DP U-2590			
	8431685	Apr 13, 2025	DP U-2598			
	8431685*PED	Oct 13, 2025				
	8439864	Mar 25, 2028	DP			
	8439864*PED	Sep 25, 2028				
	8461105	Apr 13, 2025	DP U-2588			
	8461105	Apr 13, 2025	DP U-2589			
	8461105	Apr 13, 2025	DP U-2590			
	8461105	Apr 13, 2025	DP U-2598			
	8461105*PED	Oct 13, 2025				
	8501698	Jun 20, 2027	DP U-2588			
	8501698*PED	Dec 20, 2027				
	8690837	May 19, 2029	DP			
	8690837*PED	Nov 19, 2029				
	8721615	Jan 18, 2030	DP			
	8721615*PED	Jul 18, 2030				
	8758292	Nov 12, 2027	DP			
	8758292*PED	May 12, 2028				
	8827963	Feb 04, 2029	DP			
	8827963*PED	Aug 04, 2029				
	8906851	Aug 18, 2026	U-2588			
	8906851	Aug 18, 2026	U-2589			
	8906851	Aug 18, 2026	U-2590			
	8906851	Aug 18, 2026	U-2593			
	8906851*PED	Feb 18, 2027				
	8998876	Jan 07, 2030	DP			
	8998876*PED	Jul 07, 2030				
	9238076	Apr 15, 2024	DP U-2588			
	9238076	Apr 15, 2024	DP U-2589			
	9238076	Apr 15, 2024	DP U-2590			
	9238076	Apr 15, 2024	DP U-2599			
	9238076*PED	Oct 15, 2024				
	9320853	Mar 25, 2028	DP			
	9320853*PED	Sep 25, 2028				
	9884092	Aug 18, 2026	U-2588			
	9884092	Aug 18, 2026	U-2589			
	9884092	Aug 18, 2026	U-2590			
	9884092	Aug 18, 2026	U-2593			
	9884092	Aug 18, 2026	U-2594			
	9884092	Aug 18, 2026	U-2595			
	9884092	Aug 18, 2026	U-2596			
	9884092*PED	Feb 18, 2027				

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2021

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>EZETIMIBE; ROSUVASTATIN CALCIUM - ROSZET</u>						
N 213072 001	10376470	May 01, 2033	DP U-3095			
	9763885	May 01, 2033	DP U-3095			
<u>EZETIMIBE; ROSUVASTATIN CALCIUM - ROSZET</u>						
N 213072 002	10376470	May 01, 2033	DP U-3095			
	9763885	May 01, 2033	DP U-3095			
<u>EZETIMIBE; ROSUVASTATIN CALCIUM - ROSZET</u>						
N 213072 003	10376470	May 01, 2033	DP U-3095			
	9763885	May 01, 2033	DP U-3095			
<u>EZETIMIBE; ROSUVASTATIN CALCIUM - ROSZET</u>						
N 213072 004	10376470	May 01, 2033	DP U-3095			
	9763885	May 01, 2033	DP U-3095			
<u>FENFLURAMINE HYDROCHLORIDE - FINTEPLA</u>						
N 212102 001	10947183	Dec 20, 2036	DS DP			
	10950331	Sep 28, 2035	U-3098			
<u>FERRIC CARBOXYMALTOSE - INJECTAFER</u>						
N 203565 001	7754702	Feb 15, 2028	U-1432			
	7754702	Feb 15, 2028	U-2555			
	7754702	Feb 15, 2028	U-2556			
	7754702	Feb 15, 2028	U-2557			
	8895612	Jan 08, 2027	U-1620			
	8895612	Jan 08, 2027	U-3050			
	8895612	Jan 08, 2027	U-3051			
	8895612	Jan 08, 2027	U-3115			
	8895612	Jan 08, 2027	U-3116			
<u>FERRIC CARBOXYMALTOSE - INJECTAFER</u>						
N 203565 002	7612109	Feb 05, 2024	DS DP			
	7754702	Feb 15, 2028	U-2555			
	7754702	Feb 15, 2028	U-2556			
	7754702	Feb 15, 2028	U-2557			
	8895612	Jan 08, 2027	U-1620			
	8895612	Jan 08, 2027	U-3050			
	8895612	Jan 08, 2027	U-3051			
	8895612	Jan 08, 2027	U-3115			
	8895612	Jan 08, 2027	U-3116			
	9376505	Oct 20, 2023	DS DP			
<u>FERRIC CARBOXYMALTOSE - INJECTAFER</u>						
N 203565 003	7612109	Feb 05, 2024	DS DP			
	7754702	Feb 15, 2028	U-2555			
	7754702	Feb 15, 2028	U-2556			
	7754702	Feb 15, 2028	U-2557			
	8895612	Jan 08, 2027	U-1620			
	8895612	Jan 08, 2027	U-3050			
	8895612	Jan 08, 2027	U-3051			
	8895612	Jan 08, 2027	U-3115			
	8895612	Jan 08, 2027	U-3116			
	9376505	Oct 20, 2023	DS DP			
<u>FERRIC OXYHYDROXIDE - VELPHORO</u>						
N 205109 001	10624855	Nov 26, 2034	DP			
	10624855*PED	May 26, 2035				
	10682376	Nov 13, 2028	DP			
	10682376*PED	May 13, 2029				
	10695367	Nov 13, 2028	DP			
	10695367*PED	May 13, 2029				
	10925896	Nov 13, 2028	DP			
	10925896*PED	May 13, 2029				
	10925897	Nov 13, 2028	DP			
	10925897*PED	May 13, 2029				

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2021

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>FERRIC OXYHYDROXIDE - VELPHORO</u>						
N 205109 001	10933090	Nov 13, 2028	DP			
	10933090*PED	May 13, 2029				
	11013761	Nov 13, 2028	DP			
	11013761*PED	May 13, 2029				
	11013762	Nov 13, 2028	DP			
	11013762*PED	May 13, 2029				
	9561251	Jan 23, 2030	DP U-1468			
	9561251*PED	Jul 23, 2030				
<u>FESOTERODINE FUMARATE - TOVIAZ</u>						
N 022030 001	8501723	Jun 07, 2027	DP			
	8501723*PED	Dec 07, 2027				
<u>FESOTERODINE FUMARATE - TOVIAZ</u>						
N 022030 002	8501723	Jun 07, 2027	DP			
	8501723*PED	Dec 07, 2027				
<u>FLUCICLOVINE F-18 - AXUMIN</u>						
N 208054 001	10933147	Dec 30, 2035	U-2450			
	10953112	Nov 28, 2026	U-1879			
	10967077	Dec 30, 2035	U-2450			
<u>FLUTICASONE PROPIONATE - ARMONAIR RESPICLICK</u>						
N 208798 001	>A> 10022510	May 18, 2031	DP			
	>A> 10022510*PED	Nov 18, 2031				
	>A> 10124131	May 18, 2031	DP			
	>A> 10124131*PED	Nov 18, 2031				
	>A> 10195375	Feb 14, 2031	DP			
	>A> 10195375*PED	Aug 14, 2031				
	>A> 10561808	Jan 01, 2032	DP			
	>A> 10561808*PED	Jul 01, 2032				
	>A> 10765820	May 19, 2025	DP			
	>A> 10765820*PED	Nov 19, 2025				
	>A> 7540282	May 06, 2023	DP			
	>A> 7540282*PED	Nov 06, 2023				
	>A> 8651103	Mar 26, 2028	DP			
	>A> 8651103*PED	Sep 26, 2028				
	>A> 8714149	Feb 25, 2032	DP			
	>A> 8714149*PED	Aug 25, 2032				
	>A> 8978966	Jan 13, 2032	DP			
	>A> 8978966*PED	Jul 13, 2032				
	>A> 9216260	Jun 28, 2031	DP			
	>A> 9216260*PED	Dec 28, 2031				
	>A> 9463288	May 19, 2025	DP			
	>A> 9463288*PED	Nov 19, 2025				
	>A> 9616024	Sep 01, 2024	DP			
	>A> 9616024*PED	Mar 01, 2025				
	>A> 9731087	May 18, 2031	DP			
	>A> 9731087*PED	Nov 18, 2031				
<u>FLUTICASONE PROPIONATE - ARMONAIR RESPICLICK</u>						
N 208798 002	>A> 10022510	May 18, 2031	DP			
	>A> 10022510*PED	Nov 18, 2031				
	>A> 10124131	May 18, 2031	DP			
	>A> 10124131*PED	Nov 18, 2031				
	>A> 10195375	Feb 14, 2031	DP			
	>A> 10195375*PED	Aug 14, 2031				
	>A> 10561808	Jan 01, 2032	DP			
	>A> 10561808*PED	Jul 01, 2032				
	>A> 10765820	May 19, 2025	DP			
	>A> 10765820*PED	Nov 19, 2025				
	>A> 7540282	May 06, 2023	DP			
	>A> 7540282*PED	Nov 06, 2023				
	>A> 8651103	Mar 26, 2028	DP			
	>A> 8651103*PED	Sep 26, 2028				
	>A> 8714149	Feb 25, 2032	DP			
	>A> 8714149*PED	Aug 25, 2032				

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2021

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>FLUTICASONE PROPIONATE - ARMONAIR RESPICLICK</u>						
N 208798 002	>A> 8978966	Jan 13, 2032	DP			
	>A> 8978966*PED	Jul 13, 2032				
	>A> 9216260	Jun 28, 2031	DP			
	>A> 9216260*PED	Dec 28, 2031				
	>A> 9463288	May 19, 2025	DP			
	>A> 9463288*PED	Nov 19, 2025				
	>A> 9616024	Sep 01, 2024	DP			
	>A> 9616024*PED	Mar 01, 2025				
	>A> 9731087	May 18, 2031	DP			
	>A> 9731087*PED	Nov 18, 2031				
<u>FLUTICASONE PROPIONATE - ARMONAIR RESPICLICK</u>						
N 208798 003	>A> 10022510	May 18, 2031	DP			
	>A> 10022510*PED	Nov 18, 2031				
	>A> 10124131	May 18, 2031	DP			
	>A> 10124131*PED	Nov 18, 2031				
	>A> 10195375	Feb 14, 2031	DP			
	>A> 10195375*PED	Aug 14, 2031				
	>A> 10561808	Jan 01, 2032	DP			
	>A> 10561808*PED	Jul 01, 2032				
	>A> 10765820	May 19, 2025	DP			
	>A> 10765820*PED	Nov 19, 2025				
	>A> 7540282	May 06, 2023	DP			
	>A> 7540282*PED	Nov 06, 2023				
	>A> 8651103	Mar 26, 2028	DP			
	>A> 8651103*PED	Sep 26, 2028				
	>A> 8714149	Feb 25, 2032	DP			
	>A> 8714149*PED	Aug 25, 2032				
	>A> 8978966	Jan 13, 2032	DP			
	>A> 8978966*PED	Jul 13, 2032				
	>A> 9216260	Jun 28, 2031	DP			
	>A> 9216260*PED	Dec 28, 2031				
	>A> 9463288	May 19, 2025	DP			
	>A> 9463288*PED	Nov 19, 2025				
	>A> 9616024	Sep 01, 2024	DP			
	>A> 9616024*PED	Mar 01, 2025				
	>A> 9731087	May 18, 2031	DP			
	>A> 9731087*PED	Nov 18, 2031				
<u>FLUTICASONE PROPIONATE - ARMONAIR DIGIHALER</u>						
N 208798 004	>A> 10022510	May 18, 2031	DP			
	>A> 10022510*PED	Nov 18, 2031				
	>A> 10124131	May 18, 2031	DP			
	>A> 10124131*PED	Nov 18, 2031				
	>A> 10195375	Feb 14, 2031	DP			
	>A> 10195375*PED	Aug 14, 2031				
	>A> 10561808	Jan 01, 2032	DP			
	>A> 10561808*PED	Jul 01, 2032				
	>A> 10569034	Aug 16, 2036	DP			
	>A> 10569034*PED	Feb 16, 2037				
	>A> 10765820	May 19, 2025	DP			
	>A> 10765820*PED	Nov 19, 2025				
	>A> 10918816	Dec 14, 2035	DP			
	>A> 10918816*PED	Jun 14, 2036				
	>A> 11000653	Dec 18, 2038	DP			
	>A> 11000653*PED	Jun 18, 2039				
	>A> 7540282	May 06, 2023	DP			
	>A> 7540282*PED	Nov 06, 2023				
	>A> 8651103	Mar 26, 2028	DP			
	>A> 8651103*PED	Sep 26, 2028				
	>A> 8714149	Feb 25, 2032	DP			
	>A> 8714149*PED	Aug 25, 2032				
	>A> 8978966	Jan 13, 2032	DP			
	>A> 8978966*PED	Jul 13, 2032				
	>A> 9216260	Jun 28, 2031	DP			
	>A> 9216260*PED	Dec 28, 2031				
	>A> 9463288	May 19, 2025	DP			
	>A> 9463288*PED	Nov 19, 2025				

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2021

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>FLUTICASONE PROPIONATE - ARMONAIR DIGIHALER</u>						
N 208798 004	>A> 9616024	Sep 01, 2024	DP			
	>A> 9616024*PED	Mar 01, 2025				
	>A> 9731087	May 18, 2031	DP			
	>A> 9731087*PED	Nov 18, 2031				
	>A> 9782550	Aug 28, 2035	DP			
	>A> 9782550*PED	Feb 28, 2036				
	>A> 9782551	Aug 28, 2035	DP			
	>A> 9782551*PED	Feb 28, 2036				
<u>FLUTICASONE PROPIONATE - ARMONAIR DIGIHALER</u>						
N 208798 005	>A> 10022510	May 18, 2031	DP			
	>A> 10022510*PED	Nov 18, 2031				
	>A> 10124131	May 18, 2031	DP			
	>A> 10124131*PED	Nov 18, 2031				
	>A> 10195375	Feb 14, 2031	DP			
	>A> 10195375*PED	Aug 14, 2031				
	>A> 10561808	Jan 01, 2032	DP			
	>A> 10561808*PED	Jul 01, 2032				
	>A> 10569034	Aug 16, 2036	DP			
	>A> 10569034*PED	Feb 16, 2037				
	>A> 10765820	May 19, 2025	DP			
	>A> 10765820*PED	Nov 19, 2025				
	>A> 10918816	Dec 14, 2035	DP			
	>A> 10918816*PED	Jun 14, 2036				
	>A> 11000653	Dec 18, 2038	DP			
	>A> 11000653*PED	Jun 18, 2039				
	>A> 7540282	May 06, 2023	DP			
	>A> 7540282*PED	Nov 06, 2023				
	>A> 8651103	Mar 26, 2028	DP			
	>A> 8651103*PED	Sep 26, 2028				
	>A> 8714149	Feb 25, 2032	DP			
	>A> 8714149*PED	Aug 25, 2032				
	>A> 8978966	Jan 13, 2032	DP			
	>A> 8978966*PED	Jul 13, 2032				
	>A> 9216260	Jun 28, 2031	DP			
	>A> 9216260*PED	Dec 28, 2031				
	>A> 9463288	May 19, 2025	DP			
	>A> 9463288*PED	Nov 19, 2025				
	>A> 9616024	Sep 01, 2024	DP			
	>A> 9616024*PED	Mar 01, 2025				
	>A> 9731087	May 18, 2031	DP			
	>A> 9731087*PED	Nov 18, 2031				
	>A> 9782550	Aug 28, 2035	DP			
	>A> 9782550*PED	Feb 28, 2036				
	>A> 9782551	Aug 28, 2035	DP			
	>A> 9782551*PED	Feb 28, 2036				
<u>FLUTICASONE PROPIONATE - ARMONAIR DIGIHALER</u>						
N 208798 006	>A> 10022510	May 18, 2031	DP			
	>A> 10022510*PED	Nov 18, 2031				
	>A> 10124131	May 18, 2031	DP			
	>A> 10124131*PED	Nov 18, 2031				
	>A> 10195375	Feb 14, 2031	DP			
	>A> 10195375*PED	Aug 14, 2031				
	>A> 10561808	Jan 01, 2032	DP			
	>A> 10561808*PED	Jul 01, 2032				
	>A> 10569034	Aug 16, 2036	DP			
	>A> 10569034*PED	Feb 16, 2037				
	>A> 10765820	May 19, 2025	DP			
	>A> 10765820*PED	Nov 19, 2025				
	>A> 10918816	Dec 14, 2035	DP			
	>A> 10918816*PED	Jun 14, 2036				
	>A> 11000653	Dec 18, 2038	DP			
	>A> 11000653*PED	Jun 18, 2039				
	>A> 7540282	May 06, 2023	DP			
	>A> 7540282*PED	Nov 06, 2023				
	>A> 8651103	Mar 26, 2028	DP			
	>A> 8651103*PED	Sep 26, 2028				

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2021

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>FLUTICASONE PROPIONATE - ARMONAIR DIGIHALER</u>						
N 208798 006	>A> 8714149	Feb 25, 2032	DP			
	>A> 8714149*PED	Aug 25, 2032				
	>A> 8978966	Jan 13, 2032	DP			
	>A> 8978966*PED	Jul 13, 2032				
	>A> 9216260	Jun 28, 2031	DP			
	>A> 9216260*PED	Dec 28, 2031				
	>A> 9463288	May 19, 2025	DP			
	>A> 9463288*PED	Nov 19, 2025				
	>A> 9616024	Sep 01, 2024	DP			
	>A> 9616024*PED	Mar 01, 2025				
	>A> 9731087	May 18, 2031	DP			
	>A> 9731087*PED	Nov 18, 2031				
	>A> 9782550	Aug 28, 2035	DP			
	>A> 9782550*PED	Feb 28, 2036				
	>A> 9782551	Aug 28, 2035	DP			
	>A> 9782551*PED	Feb 28, 2036				
<u>FLUTICASONE PROPIONATE - XHANCE</u>						
N 209022 001	>A> 11033696	May 20, 2033	DP			
<u>FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - AIRDUO RESPICLICK</u>						
N 208799 001	>A> 10022510	May 18, 2031	DP			
	>A> 10022510*PED	Nov 18, 2031				
	>A> 10124131	May 18, 2031	DP			
	>A> 10124131*PED	Nov 18, 2031				
	>A> 10195375	Feb 14, 2031	DP			
	>A> 10195375*PED	Aug 14, 2031				
	>A> 10561808	Jan 01, 2032	DP			
	>A> 10561808*PED	Jul 01, 2032				
	>A> 10765820	May 19, 2025	DP			
	>A> 10765820*PED	Nov 19, 2025				
	>A> 7540282	May 06, 2023	DP			
	>A> 7540282*PED	Nov 06, 2023				
	>A> 8651103	Mar 26, 2028	DP			
	>A> 8651103*PED	Sep 26, 2028				
	>A> 8714149	Feb 25, 2032	DP			
	>A> 8714149*PED	Aug 25, 2032				
	>A> 8978966	Jan 13, 2032	DP			
	>A> 8978966*PED	Jul 13, 2032				
	>A> 9066957	Oct 06, 2034	DP U-645			
	>A> 9066957*PED	Apr 06, 2035				
	>A> 9216260	Jun 28, 2031	DP			
	>A> 9216260*PED	Dec 28, 2031				
	>A> 9415008	Oct 06, 2034	DP U-645			
	>A> 9415008*PED	Apr 06, 2035				
	>A> 9463288	May 19, 2025	DP			
	>A> 9463288*PED	Nov 19, 2025				
	>A> 9616024	Sep 01, 2024	DP			
	>A> 9616024*PED	Mar 01, 2025				
	>A> 9731087	May 18, 2031	DP			
	>A> 9731087*PED	Nov 18, 2031				
	>A> 9987229	Sep 01, 2024	DP			
	>A> 9987229*PED	Mar 01, 2025				
<u>FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - AIRDUO RESPICLICK</u>						
N 208799 002	>A> 10022510	May 18, 2031	DP			
	>A> 10022510*PED	Nov 18, 2031				
	>A> 10124131	May 18, 2031	DP			
	>A> 10124131*PED	Nov 18, 2031				
	>A> 10195375	Feb 14, 2031	DP			
	>A> 10195375*PED	Aug 14, 2031				
	>A> 10561808	Jan 01, 2032	DP			
	>A> 10561808*PED	Jul 01, 2032				
	>A> 10765820	May 19, 2025	DP			
	>A> 10765820*PED	Nov 19, 2025				
	>A> 7540282	May 06, 2023	DP			
	>A> 7540282*PED	Nov 06, 2023				

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2021

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - AIRDUO RESPICLICK</u>						
N 208799 002	>A> 8651103	Mar 26, 2028	DP			
	>A> 8651103*PED	Sep 26, 2028				
	>A> 8714149	Feb 25, 2032	DP			
	>A> 8714149*PED	Aug 25, 2032				
	>A> 8978966	Jan 13, 2032	DP			
	>A> 8978966*PED	Jul 13, 2032				
	>A> 9066957	Oct 06, 2034	DP U-645			
	>A> 9066957*PED	Apr 06, 2035				
	>A> 9216260	Jun 28, 2031	DP			
	>A> 9216260*PED	Dec 28, 2031				
	>A> 9463288	May 19, 2025	DP			
	>A> 9463288*PED	Nov 19, 2025				
	>A> 9616024	Sep 01, 2024	DP			
	>A> 9616024*PED	Mar 01, 2025				
	>A> 9731087	May 18, 2031	DP			
	>A> 9731087*PED	Nov 18, 2031				
	>A> 9987229	Sep 01, 2024	DP			
	>A> 9987229*PED	Mar 01, 2025				
<u>FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - AIRDUO RESPICLICK</u>						
N 208799 003	>A> 10022510	May 18, 2031	DP			
	>A> 10022510*PED	Nov 18, 2031				
	>A> 10124131	May 18, 2031	DP			
	>A> 10124131*PED	Nov 18, 2031				
	>A> 10195375	Feb 14, 2031	DP			
	>A> 10195375*PED	Aug 14, 2031				
	>A> 10561808	Jan 01, 2032	DP			
	>A> 10561808*PED	Jul 01, 2032				
	>A> 10765820	May 19, 2025	DP			
	>A> 10765820*PED	Nov 19, 2025				
	>A> 7540282	May 06, 2023	DP			
	>A> 7540282*PED	Nov 06, 2023				
	>A> 8651103	Mar 26, 2028	DP			
	>A> 8651103*PED	Sep 26, 2028				
	>A> 8714149	Feb 25, 2032	DP			
	>A> 8714149*PED	Aug 25, 2032				
	>A> 8978966	Jan 13, 2032	DP			
	>A> 8978966*PED	Jul 13, 2032				
	>A> 9066957	Oct 06, 2034	DP U-645			
	>A> 9066957*PED	Apr 06, 2035				
	>A> 9216260	Jun 28, 2031	DP			
	>A> 9216260*PED	Dec 28, 2031				
	>A> 9463288	May 19, 2025	DP			
	>A> 9463288*PED	Nov 19, 2025				
	>A> 9616024	Sep 01, 2024	DP			
	>A> 9616024*PED	Mar 01, 2025				
	>A> 9731087	May 18, 2031	DP			
	>A> 9731087*PED	Nov 18, 2031				
	>A> 9987229	Sep 01, 2024	DP			
	>A> 9987229*PED	Mar 01, 2025				
<u>FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - AIRDUO DIGIHALER</u>						
N 208799 004	>A> 10022510	May 18, 2031	DP			
	>A> 10022510*PED	Nov 18, 2031				
	>A> 10124131	May 18, 2031	DP			
	>A> 10124131*PED	Nov 18, 2031				
	>A> 10195375	Feb 14, 2031	DP			
	>A> 10195375*PED	Aug 14, 2031				
	>A> 10561808	Jan 01, 2032	DP			
	>A> 10561808*PED	Jul 01, 2032				
	>A> 10569034	Aug 16, 2036	DP			
	>A> 10569034*PED	Feb 16, 2037				
	>A> 10765820	May 19, 2025	DP			
	>A> 10765820*PED	Nov 19, 2025				
	>A> 10918816	Dec 14, 2035	DP			
	>A> 10918816*PED	Jun 14, 2036				
	>A> 11000653	Dec 18, 2038	DP			
	>A> 11000653*PED	Jun 18, 2039				

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2021

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - AIRDUO DIGIHALER</u>						
N 208799 004	>A> 7540282	May 06, 2023	DP			
	>A> 7540282*PED	Nov 06, 2023				
	>A> 8651103	Mar 26, 2028	DP			
	>A> 8651103*PED	Sep 26, 2028				
	>A> 8714149	Feb 25, 2032	DP			
	>A> 8714149*PED	Aug 25, 2032				
	>A> 8978966	Jan 13, 2032	DP			
	>A> 8978966*PED	Jul 13, 2032				
	>A> 9066957	Oct 06, 2034	DP U-645			
	>A> 9066957*PED	Apr 06, 2035				
	>A> 9216260	Jun 28, 2031	DP			
	>A> 9216260*PED	Dec 28, 2031				
	>A> 9415008	Oct 06, 2034	DP U-645			
	>A> 9415008*PED	Apr 06, 2035				
	>A> 9463288	May 19, 2025	DP			
	>A> 9463288*PED	Nov 19, 2025				
	>A> 9616024	Sep 01, 2024	DP			
	>A> 9616024*PED	Mar 01, 2025				
	>A> 9731087	May 18, 2031	DP			
	>A> 9731087*PED	Nov 18, 2031				
	>A> 9782550	Aug 28, 2035	DP			
	>A> 9782550*PED	Feb 28, 2036				
	>A> 9782551	Aug 28, 2035	DP			
	>A> 9782551*PED	Feb 28, 2036				
	>A> 9987229	Sep 01, 2024	DP			
	>A> 9987229*PED	Mar 01, 2025				
<u>FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - AIRDUO DIGIHALER</u>						
N 208799 005	>A> 10022510	May 18, 2031	DP			
	>A> 10022510*PED	Nov 18, 2031				
	>A> 10124131	May 18, 2031	DP			
	>A> 10124131*PED	Nov 18, 2031				
	>A> 10195375	Feb 14, 2031	DP			
	>A> 10195375*PED	Aug 14, 2031				
	>A> 10561808	Jan 01, 2032	DP			
	>A> 10561808*PED	Jul 01, 2032				
	>A> 10569034	Aug 16, 2036	DP			
	>A> 10569034*PED	Feb 16, 2037				
	>A> 10765820	May 19, 2025	DP			
	>A> 10765820*PED	Nov 19, 2025				
	>A> 10918816	Dec 14, 2035	DP			
	>A> 10918816*PED	Jun 14, 2036				
	>A> 11000653	Dec 18, 2038	DP			
	>A> 11000653*PED	Jun 18, 2039				
	>A> 7540282	May 06, 2023	DP			
	>A> 7540282*PED	Nov 06, 2023				
	>A> 8651103	Mar 26, 2028	DP			
	>A> 8651103*PED	Sep 26, 2028				
	>A> 8714149	Feb 25, 2032	DP			
	>A> 8714149*PED	Aug 25, 2032				
	>A> 8978966	Jan 13, 2032	DP			
	>A> 8978966*PED	Jul 13, 2032				
	>A> 9066957	Oct 06, 2034	DP U-645			
	>A> 9066957*PED	Apr 06, 2035				
	>A> 9216260	Jun 28, 2031	DP			
	>A> 9216260*PED	Dec 28, 2031				
	>A> 9463288	May 19, 2025	DP			
	>A> 9463288*PED	Nov 19, 2025				
	>A> 9616024	Sep 01, 2024	DP			
	>A> 9616024*PED	Mar 01, 2025				
	>A> 9731087	May 18, 2031	DP			
	>A> 9731087*PED	Nov 18, 2031				
	>A> 9782550	Aug 28, 2035	DP			
	>A> 9782550*PED	Feb 28, 2036				
	>A> 9782551	Aug 28, 2035	DP			
	>A> 9782551*PED	Feb 28, 2036				
	>A> 9987229	Sep 01, 2024	DP			
	>A> 9987229*PED	Mar 01, 2025				

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2021

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - AIRDUO DIGIHALER</u>						
N 208799 005	>A> 10022510	May 18, 2031	DP			
	>A> 10022510*PED	Nov 18, 2031				
	>A> 10124131	May 18, 2031	DP			
	>A> 10124131*PED	Nov 18, 2031				
	>A> 10195375	Feb 14, 2031	DP			
	>A> 10195375*PED	Aug 14, 2031				
	>A> 10561808	Jan 01, 2032	DP			
	>A> 10561808*PED	Jul 01, 2032				
	>A> 10569034	Aug 16, 2036	DP			
	>A> 10569034*PED	Feb 16, 2037				
	>A> 10765820	May 19, 2025	DP			
	>A> 10765820*PED	Nov 19, 2025				
	>A> 10918816	Dec 14, 2035	DP			
	>A> 10918816*PED	Jun 14, 2036				
	>A> 11000653	Dec 18, 2038	DP			
	>A> 11000653*PED	Jun 18, 2039				
	>A> 7540282	May 06, 2023	DP			
	>A> 7540282*PED	Nov 06, 2023				
	>A> 8651103	Mar 26, 2028	DP			
	>A> 8651103*PED	Sep 26, 2028				
	>A> 8714149	Feb 25, 2032	DP			
	>A> 8714149*PED	Aug 25, 2032				
	>A> 8978966	Jan 13, 2032	DP			
	>A> 8978966*PED	Jul 13, 2032				
	>A> 9066957	Oct 06, 2034	DP U-645			
	>A> 9066957*PED	Apr 06, 2035				
	>A> 9216260	Jun 28, 2031	DP			
	>A> 9216260*PED	Dec 28, 2031				
	>A> 9463288	May 19, 2025	DP			
	>A> 9463288*PED	Nov 19, 2025				
	>A> 9616024	Sep 01, 2024	DP			
	>A> 9616024*PED	Mar 01, 2025				
	>A> 9731087	May 18, 2031	DP			
	>A> 9731087*PED	Nov 18, 2031				
	>A> 9782550	Aug 28, 2035	DP			
	>A> 9782550*PED	Feb 28, 2036				
	>A> 9782551	Aug 28, 2035	DP			
	>A> 9782551*PED	Feb 28, 2036				
	>A> 9987229	Sep 01, 2024	DP			
	>A> 9987229*PED	Mar 01, 2025				
<u>FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - AIRDUO DIGIHALER</u>						
N 208799 006	>A> 10022510	May 18, 2031	DP			
	>A> 10022510*PED	Nov 18, 2031				
	>A> 10124131	May 18, 2031	DP			
	>A> 10124131*PED	Nov 18, 2031				
	>A> 10195375	Feb 14, 2031	DP			
	>A> 10195375*PED	Aug 14, 2031				
	>A> 10561808	Jan 01, 2032	DP			
	>A> 10561808*PED	Jul 01, 2032				
	>A> 10569034	Aug 16, 2036	DP			
	>A> 10569034*PED	Feb 16, 2037				
	>A> 10765820	May 19, 2025	DP			
	>A> 10765820*PED	Nov 19, 2025				
	>A> 10918816	Dec 14, 2035	DP			
	>A> 10918816*PED	Jun 14, 2036				
	>A> 11000653	Dec 18, 2038	DP			
	>A> 11000653*PED	Jun 18, 2039				
	>A> 7540282	May 06, 2023	DP			
	>A> 7540282*PED	Nov 06, 2023				
	>A> 8651103	Mar 26, 2028	DP			
	>A> 8651103*PED	Sep 26, 2028				
	>A> 8714149	Feb 25, 2032	DP			
	>A> 8714149*PED	Aug 25, 2032				
	>A> 8978966	Jan 13, 2032	DP			
	>A> 8978966*PED	Jul 13, 2032				
	>A> 9066957	Oct 06, 2034	DP U-645			
	>A> 9066957*PED	Apr 06, 2035				

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2021

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - AIRDUO DIGIHALER</u>						
N 208799 006	>A> 9216260	Jun 28, 2031	DP			
	>A> 9216260*PED	Dec 28, 2031				
	>A> 9463288	May 19, 2025	DP			
	>A> 9463288*PED	Nov 19, 2025				
	>A> 9616024	Sep 01, 2024	DP			
	>A> 9616024*PED	Mar 01, 2025				
	>A> 9731087	May 18, 2031	DP			
	>A> 9731087*PED	Nov 18, 2031				
	>A> 9782550	Aug 28, 2035	DP			
	>A> 9782550*PED	Feb 28, 2036				
	>A> 9782551	Aug 28, 2035	DP			
	>A> 9782551*PED	Feb 28, 2036				
	>A> 9987229	Sep 01, 2024	DP			
	>A> 9987229*PED	Mar 01, 2025				
<u>FOSCARNET SODIUM - FOSCARNET SODIUM</u>						
A 213001 001					>A> CGT	Dec 28, 2021
<u>FOSDENOPTERIN HYDROBROMIDE - NULIBRY</u>						
N 214018 001	7504095	Jan 31, 2025	DP U-3092		NCE ODE-342	Feb 26, 2026 Feb 26, 2028
<u>GALLIUM GA-68 PSMA-11 - GALLIUM GA 68 PSMA-11</u>						
N 212642 001					NCE W	Dec 01, 2025 Dec 01, 2025
<u>GALLIUM GA-68 PSMA-11 - GALLIUM GA 68 PSMA-11</u>						
N 212643 001					NCE W	Dec 01, 2025 Dec 01, 2025
<u>GLECAPREVIR; PIBRENTASVIR - MAVYRET</u>						
N 209394 001	10028937	Jun 10, 2030	U-2141		D-175	Sep 26, 2022
	10028937	Jun 10, 2030	U-2532		M-259	Apr 10, 2023
	10028937*PED	Dec 10, 2030			NCE	Aug 03, 2022
	10039754	Jun 10, 2030	U-2141		NPP	Apr 30, 2022
	10039754	Jun 10, 2030	U-2532		ODE-232	Apr 30, 2026
	10039754*PED	Dec 10, 2030			ODE-233	Apr 30, 2026
	10286029	Mar 14, 2034	U-2532		PED	Oct 30, 2022
	10286029*PED	Sep 14, 2034			PED	Feb 03, 2023
	8648037	Jan 19, 2032	DS DP U-2141		PED	Mar 26, 2023
	8648037	Jan 19, 2032	DS DP U-2532		PED	Oct 10, 2023
	8648037*PED	Jul 19, 2032			PED	Oct 30, 2026
	8937150	May 18, 2032	DS DP		PED	Oct 30, 2026
	8937150*PED	Nov 18, 2032				
	9321807	Jun 05, 2035	DS			
	9321807*PED	Dec 05, 2035				
	9586978	Jun 10, 2030	U-2141			
	9586978	Jun 10, 2030	U-2532			
	9586978*PED	Dec 10, 2030				
<u>GLUCAGON - BAOSIMI</u>						
N 210134 001	10894133	Jan 03, 2038	DP			
<u>GLYCEROL PHENYLBUTYRATE - RAVICTI</u>						
N 203284 001					>A> NPP	Dec 21, 2021
<u>GLYCOPYRROLATE - LONHALA MAGNAIR KIT</u>						
N 208437 001	10940110	Feb 26, 2029	DP U-1773			
<u>GOLODIRSEN - VYONDYS 53</u>						
N 211970 001	10968450	Jun 28, 2025	DS DP			
	10995337	Jun 28, 2025	DP U-2675			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2021

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>HALOBETASOL PROPIONATE - LEXETTE</u>						
N 210566 001	10857159	Nov 30, 2036	DP			
	10857159*PED	May 30, 2037				
	>A> 11020407	Nov 30, 2036	DP U-3143			
<u>HYDROCORTISONE - ALKINDI SPRINKLE</u>						
N 213876 001	9649280	May 12, 2034	DP U-3075			
	9675559	Jan 10, 2033	U-3075			
	9717740	Nov 19, 2032	U-3075			
<u>HYDROCORTISONE - ALKINDI SPRINKLE</u>						
N 213876 002	9649280	May 12, 2034	DP U-3075			
	9675559	Jan 10, 2033	U-3075			
	9717740	Nov 19, 2032	U-3075			
<u>HYDROCORTISONE - ALKINDI SPRINKLE</u>						
N 213876 003	9649280	May 12, 2034	DP U-3075			
	9675559	Jan 10, 2033	U-3075			
	9717740	Nov 19, 2032	U-3075			
<u>HYDROCORTISONE - ALKINDI SPRINKLE</u>						
N 213876 004	9649280	May 12, 2034	DP U-3075			
	9675559	Jan 10, 2033	U-3075			
	9717740	Nov 19, 2032	U-3075			
<u>IBREXAFUNGERP CITRATE - BREXAFEMME</u>						
N 214900 001	>A> 10174074	Jan 19, 2035	DS DP		>A> NCE	Jun 01, 2026
	>A> 10370406	Jan 19, 2035	U-3159		>A> GAIN	Jun 01, 2031
	>A> 10927142	Jan 19, 2035	DS			
	>A> 8188085	Aug 28, 2030	DS DP U-3159			
<u>IBRUTINIB - IMBRUVICA</u>						
N 205552 001	10961251	Jun 03, 2033	DP			
<u>IBRUTINIB - IMBRUVICA</u>						
N 205552 002	10961251	Jun 03, 2033	DP			
<u>IBRUTINIB - IMBRUVICA</u>						
N 210563 001	10961251	Jun 03, 2033	DP			
<u>IBRUTINIB - IMBRUVICA</u>						
N 210563 002	10961251	Jun 03, 2033	DP			
<u>IBRUTINIB - IMBRUVICA</u>						
N 210563 003	10961251	Jun 03, 2033	DP			
<u>IBRUTINIB - IMBRUVICA</u>						
N 210563 004	10961251	Jun 03, 2033	DP			
<u>ICOSAPENT ETHYL - VASCEPA</u>						
N 202057 001	10881632	Apr 29, 2030	U-3052			
	10894028	Jun 28, 2033	U-3053			
	>A> 11000499	Jun 28, 2033	U-3126			
<u>ICOSAPENT ETHYL - VASCEPA</u>						
N 202057 002	10881632	Apr 29, 2030	U-3052			
	10894028	Jun 28, 2033	U-3053			
	>A> 11000499	Jun 28, 2033	U-3126			
<u>IMIQUIMOD - ZYCLARA</u>						
N 022483 001	10918635	Apr 30, 2030	U-1455			
	10918635	Apr 30, 2030	U-172			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2021

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>INFIGRATINIB PHOSPHATE - TRUSELTIQ</u>						
N 214622 001	10278969	Dec 11, 2034	DP		>A> NCE	May 28, 2026
	8552002	Aug 25, 2029	DS DP		>A> ODE-353	May 28, 2028
	9067896	Dec 20, 2026	DS			
<u>INFIGRATINIB PHOSPHATE - TRUSELTIQ</u>						
N 214622 002	10278969	Dec 11, 2034	DP		>A> NCE	May 28, 2026
	8552002	Aug 25, 2029	DS DP		>A> ODE-353	May 28, 2028
	9067896	Dec 20, 2026	DS			
<u>IRINOTECAN HYDROCHLORIDE - ONIVYDE</u>						
N 207793 001	10980795	Jun 12, 2033		U-1848		
	10993914	Oct 15, 2036	DP			
<u>IVACAFTOR - KALYDECO</u>						
N 203188 001					ODE-338	Dec 21, 2027
<u>IVACAFTOR - KALYDECO</u>						
N 207925 001					ODE-338	Dec 21, 2027
<u>IVACAFTOR - KALYDECO</u>						
N 207925 002					ODE-338	Dec 21, 2027
<u>IVACAFTOR - KALYDECO</u>						
N 207925 003					ODE-338	Dec 21, 2027
<u>IVACAFTOR; IVACAFTOR, TEZACAFTOR - SYMDEKO (COPACKAGED)</u>						
N 210491 001	10058546	Jul 15, 2033		U-2399	ODE-335	Dec 21, 2027
	10058546	Jul 15, 2033		U-2572		
	10058546	Jul 15, 2033		U-3022		
	10058546	Jul 15, 2033		U-3023		
	10081621	Mar 25, 2031	DP	U-2420		
	10081621	Mar 25, 2031	DP	U-2571		
	10081621	Mar 25, 2031	DP	U-3024		
	10081621	Mar 25, 2031	DP	U-3025		
	10206877	Apr 14, 2035	DP	U-2498		
	10206877	Apr 14, 2035	DP	U-2570		
	10206877	Apr 14, 2035	DP	U-3026		
	10206877	Apr 14, 2035	DP	U-3027		
	8354427	Jul 06, 2026		U-3021		
<u>IVACAFTOR; IVACAFTOR, TEZACAFTOR - SYMDEKO (COPACKAGED)</u>						
N 210491 002	10058546	Jul 15, 2033		U-2399	ODE-335	Dec 21, 2027
	10058546	Jul 15, 2033		U-2572		
	10058546	Jul 15, 2033		U-3022		
	10058546	Jul 15, 2033		U-3023		
	10081621	Mar 25, 2031	DP	U-2420		
	10081621	Mar 25, 2031	DP	U-2571		
	10081621	Mar 25, 2031	DP	U-3024		
	10081621	Mar 25, 2031	DP	U-3025		
	10206877	Apr 14, 2035	DP	U-2498		
	10206877	Apr 14, 2035	DP	U-2570		
	10206877	Apr 14, 2035	DP	U-3026		
	10206877	Apr 14, 2035	DP	U-3027		
	8354427	Jul 06, 2026		U-3021		
<u>IVERMECTIN - IVERMECTIN</u>						
A 210720 001					>A> PC	May 29, 2021
<u>IVERMECTIN - SOOLANTRA</u>						
N 206255 001	>A> 11033565	Apr 22, 2024	DP			
<u>IVOSIDENIB - TIBSOVO</u>						
N 211192 001	10980788	Jun 07, 2039		U-3112		
	10980788	Jun 07, 2039		U-3113		

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2021

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>IVOSIDENIB - TIBSOVO</u>						
N 211192 001	10980788	Jun 07, 2039	U-3112			
	10980788	Jun 07, 2039	U-3113			
<u>LAROTRECTINIB SULFATE - VITRAKVI</u>						
N 210861 001	10799505	Aug 15, 2036	DS DP			
<u>LAROTRECTINIB SULFATE - VITRAKVI</u>						
N 210861 002	10799505	Aug 15, 2036	DS DP			
<u>LAROTRECTINIB SULFATE - VITRAKVI</u>						
N 211710 001	10799505	Aug 15, 2036	DS			
<u>LATANOPROST; NETARSUDIL DIMESYLATE - ROCKLATAN</u>						
N 208259 001	10882840	Jul 11, 2026	U-1524			
	>A> 11021456	Jul 11, 2026	U-1524			
	>A> 11028081	Jan 27, 2030	U-1524			
<u>LEUPROLIDE MESYLATE - CAMCEVI KIT</u>						
N 211488 001				>A> NP		May 25, 2024
<u>LEVONORGESTREL - MIRENA</u>						
N 021225 001	10987244	Apr 01, 2031	DP			
<u>LEVONORGESTREL - SKYLA</u>						
N 203159 001	10987244	Apr 01, 2031	DP			
<u>LEVONORGESTREL - KYLEENA</u>						
N 208224 001	10987244	Apr 01, 2031	DP			
<u>LINAGLIPTIN; METFORMIN HYDROCHLORIDE - JENTADUETO</u>						
N 201281 001	10973827	Apr 02, 2029	DP			
<u>LINAGLIPTIN; METFORMIN HYDROCHLORIDE - JENTADUETO</u>						
N 201281 002	10973827	Apr 02, 2029	DP			
<u>LINAGLIPTIN; METFORMIN HYDROCHLORIDE - JENTADUETO</u>						
N 201281 003	10973827	Apr 02, 2029	DP			
<u>LIRAGLUTIDE RECOMBINANT - SAXENDA</u>						
N 206321 001					NPP	Dec 04, 2023
<u>LISINAPRIL - OBRELIS</u>						
N 208401 001	10940177	Nov 06, 2035	DP			
<u>LONAFARNIB - ZOKINVY</u>						
N 213969 001	7838531	Jul 26, 2024	U-3070		ODE-324	Nov 20, 2027
	8828356	Oct 17, 2023	U-3070			
<u>LONAFARNIB - ZOKINVY</u>						
N 213969 002	7838531	Jul 26, 2024	U-3070		ODE-324	Nov 20, 2027
	8828356	Oct 17, 2023	U-3070			
<u>LORLATINIB - LORBRENA</u>						
N 210868 001	10420749	Jul 27, 2036	DS DP U-2633		I-847	Mar 03, 2024
	10420749	Jul 27, 2036	DS DP U-3096		ODE-349	Mar 03, 2028
	>A> 11020376	Jul 27, 2036	DP			
<u>LORLATINIB - LORBRENA</u>						
N 210868 002	10420749	Jul 27, 2036	DS DP U-2633		I-847	Mar 03, 2024
	10420749	Jul 27, 2036	DS DP U-3096		ODE-349	Mar 03, 2028
	>A> 11020376	Jul 27, 2036	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2021

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>LORLATINIB - LORBRENA</u>						
N 210868 002	10420749	Jul 27, 2036	DS DP U-2633		I-847	Mar 03, 2024
	10420749	Jul 27, 2036	DS DP U-3096		ODE-349	Mar 03, 2028
	>A> 11020376	Jul 27, 2036	DP			
<u>LOTEPREDNOL ETABONATE - LOTEPREDNOL ETABONATE</u>						
A 212450 001					CGT	Nov 02, 2021
<u>LOTEPREDNOL ETABONATE - EYSUVIS</u>						
N 210933 001	10940108	May 03, 2033	U-2985			
	10945948	May 03, 2033	U-2985			
	10993908	May 03, 2033	U-3117			
<u>LUMASIRAN SODIUM - OXLUMO</u>						
N 214103 001					ODE-339	Nov 23, 2027
<u>LUMATEPERONE TOSYLATE - CAPLYTA</u>						
N 209500 001	10960009	Dec 03, 2034	U-814			
<u>MACITENTAN - OPSUMIT</u>						
N 204410 001	>A> 10946015	Sep 11, 2026	DP U-1445			
<u>MAGNESIUM SULFATE; POTASSIUM CHLORIDE; SODIUM SULFATE - SUTAB (COPACKAGED)</u>						
N 213135 001	>A> 11033498	Aug 04, 2037	U-3164			
<u>MANNITOL - BRONCHITOL</u>						
N 202049 001					NP ODE-327	Oct 30, 2023 Oct 30, 2027
<u>MELOXICAM - ANJESO</u>						
N 210583 001	10881663	Mar 08, 2039	U-3038			
<u>MELPHALAN FLUFENAMIDE HYDROCHLORIDE - PEPAXTO</u>						
N 214383 001	10285946	Apr 25, 2032	DP		NCE	Feb 26, 2026
	10322182	Apr 25, 2032	DP		ODE-348	Feb 26, 2028
	10543274	Apr 25, 2032	U-3093			
	10869928	Apr 25, 2032	DP			
	6992207	Jun 25, 2022	DS DP U-3093			
<u>MELPHALAN HYDROCHLORIDE - EVOMELA</u>						
N 207155 001	10940128	Jun 14, 2030	DP U-3086			
	>A> 11020363	May 28, 2030	DP			
<u>MEROPENEM; VABORBACTAM - VABOMERE</u>						
N 209776 001	>A> 11007206	Aug 08, 2031	U-3128		NCE	Aug 29, 2022
	8680136	Aug 29, 2031	DS DP		GAIN	Aug 29, 2027
<u>METFORMIN HYDROCHLORIDE; SITAGLIPTIN PHOSPHATE - JANUMET</u>						
N 022044 001					M-187 PED	Dec 04, 2023 Jun 04, 2024
<u>METFORMIN HYDROCHLORIDE; SITAGLIPTIN PHOSPHATE - JANUMET</u>						
N 022044 002					M-187 PED	Dec 04, 2023 Jun 04, 2024
<u>METFORMIN HYDROCHLORIDE; SITAGLIPTIN PHOSPHATE - JANUMET XR</u>						
N 202270 001					M-187 PED	Dec 04, 2023 Jun 04, 2024
<u>METFORMIN HYDROCHLORIDE; SITAGLIPTIN PHOSPHATE - JANUMET XR</u>						
N 202270 002					M-187 PED	Dec 04, 2023 Jun 04, 2024

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2021

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>METHYLPHENIDATE HYDROCHLORIDE - JORNAY PM</u>						
N 209311 001	10881618	Mar 23, 2032	U-2357			
	10905652	Mar 23, 2032	DP			
<u>METHYLPHENIDATE HYDROCHLORIDE - JORNAY PM</u>						
N 209311 002	10881618	Mar 23, 2032	U-2357			
	10905652	Mar 23, 2032	DP			
<u>METHYLPHENIDATE HYDROCHLORIDE - JORNAY PM</u>						
N 209311 003	10881618	Mar 23, 2032	U-2357			
	10905652	Mar 23, 2032	DP			
<u>METHYLPHENIDATE HYDROCHLORIDE - JORNAY PM</u>						
N 209311 004	10881618	Mar 23, 2032	U-2357			
	10905652	Mar 23, 2032	DP			
<u>METHYLPHENIDATE HYDROCHLORIDE - JORNAY PM</u>						
N 209311 005	10881618	Mar 23, 2032	U-2357			
	10905652	Mar 23, 2032	DP			
<u>METOCLOPRAMIDE HYDROCHLORIDE - GIMOTI</u>						
N 209388 001	11020361	Dec 22, 2029	U-2843			
<u>MIDAZOLAM - MIDAZOLAM IN 0.9% SODIUM CHLORIDE</u>						
N 211844 001	10966990	Jun 20, 2038	DP			
<u>MIDAZOLAM - MIDAZOLAM IN 0.9% SODIUM CHLORIDE</u>						
N 211844 002	10966990	Jun 20, 2038	DP			
<u>MIGALASTAT HYDROCHLORIDE - GALAFOLD</u>						
N 208623 001	10874655	May 30, 2038	U-2371			
	10874656	May 30, 2038	U-2371			
	10874657	May 30, 2038	U-2371			
	10925866	Apr 28, 2028	U-2371			
<u>MINOCYCLINE HYDROCHLORIDE - ZILXI</u>						
N 213690 001	10946101	Oct 01, 2030	U-1631			
<u>MIRABEGRON - MYRBETRIO</u>						
N 202611 001	10842780	Sep 28, 2029	DP U-2996		I-777	Apr 27, 2021
	10842780*PED	Mar 28, 2030			I-855	Mar 25, 2024
	6346532	Mar 27, 2022	DS DP		PED	Sep 25, 2024
	6346532*PED	Sep 27, 2022				
	8772315	Oct 30, 2028	U-2300			
	8772315*PED	Apr 30, 2029				
	8835474	Nov 04, 2023	U-1527			
	8835474*PED	May 04, 2024				
	RE44872	Nov 04, 2023	U-1527			
	RE44872*PED	May 04, 2024				
<u>MIRABEGRON - MYRBETRIO</u>						
N 202611 002	10842780	Sep 28, 2029	DP U-2996		I-777	Apr 27, 2021
	10842780*PED	Mar 28, 2030			I-855	Mar 25, 2024
	6346532	Mar 27, 2022	DS DP		PED	Sep 25, 2024
	6346532*PED	Sep 27, 2022				
	8772315	Oct 30, 2028	U-2300			
	8772315*PED	Apr 30, 2029				
	8835474	Nov 04, 2023	U-1527			
	8835474*PED	May 04, 2024				
	RE44872	Nov 04, 2023	U-1527			
	RE44872*PED	May 04, 2024				

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2021

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>MIRABEGRON - MYRBETRIO GRANULES</u>						
N 213801 001	>A> 10058536	Mar 31, 2036	DP U-3108		NP	Mar 25, 2024
	>A> 10058536*PED	Oct 01, 2036			PED	Sep 25, 2024
	>A> 6346532	Mar 27, 2022	DS			
	>A> 6346532*PED	Sep 27, 2022				
	>A> 7342117	Nov 04, 2023	DS			
	>A> 7342117*PED	May 04, 2024				
	>A> 7982049	Nov 04, 2023	DP			
	>A> 7982049*PED	May 04, 2024				
<u>MONOMETHYL FUMARATE - BAFIERTAM</u>						
N 210296 001	10918615	Aug 12, 2035	DP U-1384			
	10918616	Jun 03, 2035	U-1384			
	10918617	Aug 10, 2035	DP			
	10945985	Aug 14, 2035	DP			
<u>MORPHINE SULFATE - MORPHINE SULFATE</u>						
A 212451 001					CGT	Aug 10, 2021
<u>MORPHINE SULFATE - MORPHINE SULFATE</u>						
A 212451 002					CGT	Aug 10, 2021
<u>NALDEMEDINE TOSYLATE - SYMPROIC</u>						
N 208854 001	10952968	May 13, 2033	DS DP			
<u>NALOXONE HYDROCHLORIDE - EVZIO</u>						
N 205787 001	10960155	Jun 25, 2026	DP			
<u>NALOXONE HYDROCHLORIDE - EVZIO (AUTOINJECTOR)</u>						
N 209862 001	10960155	Jun 25, 2026	DP			
<u>NALOXONE HYDROCHLORIDE - KLOXXADO</u>						
N 212045 001	10722510	Aug 26, 2034	DP U-3110			
	10973814	Aug 26, 2034	DP U-3110			
<u>NERATINIB MALEATE - NERLYNX</u>						
N 208051 001	10035788	Oct 15, 2028	U-2043			
	10035788	Oct 15, 2028	U-3047			
	10035788	Oct 15, 2028	U-3097			
	7982043	Oct 08, 2025	U-2043			
	7982043	Oct 08, 2025	U-3047			
	7982043	Oct 08, 2025	U-3097			
	8518446	Nov 20, 2030	DP U-2043			
	8518446	Nov 20, 2030	DP U-3047			
	8518446	Nov 20, 2030	DP U-3097			
	8669273	Jul 18, 2031	U-3047			
	8790708	Nov 05, 2030	DP U-2043			
	8790708	Nov 05, 2030	DP U-3047			
	8790708	Nov 05, 2030	DP U-3097			
	9139558	Oct 15, 2028	U-2043			
	9139558	Oct 15, 2028	U-3047			
	9139558	Oct 15, 2028	U-3097			
	9211291	Mar 24, 2030	U-2043			
	9211291	Mar 24, 2030	U-3097			
	9265784	Aug 04, 2029	U-3047			
	9630946	Oct 15, 2028	U-2043			
	9630946	Oct 15, 2028	U-3047			
	9630946	Oct 15, 2028	U-3097			
<u>NETARSUDIL MESYLATE - RHOPRESSA</u>						
N 208254 001	10882840	Jul 11, 2026	U-1524			
	>A> 11021456	Jul 11, 2026	U-1524			
	>A> 11028081	Jan 27, 2030	U-1524			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2021

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>NETUPITANT; PALONOSETRON HYDROCHLORIDE - AKYNZEO</u>						
N 205718 001	10961195	Sep 25, 2035	DS DP			
<u>NIFURTIMOX - LAMPIT</u>						
N 213464 001					ODE-319	Aug 06, 2027
<u>NIFURTIMOX - LAMPIT</u>						
N 213464 002					ODE-319	Aug 06, 2027
<u>NIRAPARIB TOSYLATE - ZEJULA</u>						
N 208447 001	8071623	Mar 27, 2031	DS DP			
<u>NITAZOXANIDE - NITAZOXANIDE</u>						
A 213820 001					CGT	Jun 05, 2021
<u>NITRIC OXIDE - GENOSYL</u>						
N 202860 001	10124142	Aug 18, 2025		U-3037		
	10814092	Oct 17, 2025		U-3037		
	10926054	Aug 13, 2029	DP			
	7947227	Oct 17, 2026		U-3037		
	8057742	Jan 18, 2026		U-3037		
	8226916	Aug 18, 2025		U-3037		
	8607785	Jul 14, 2030	DP			
	8609028	Aug 18, 2025		U-3037		
	8821801	Aug 18, 2025	DP			
	8944049	Aug 13, 2029	DP			
	9522249	Aug 18, 2025	DP			
	9701538	Jan 28, 2029	DP			
	9956373	Aug 18, 2025		U-3037		
<u>OBETICHOLIC ACID - OCALIVA</u>						
N 207999 001	RE48286	Nov 16, 2027	DS DP			
<u>OBETICHOLIC ACID - OCALIVA</u>						
N 207999 002	RE48286	Nov 16, 2027	DS DP			
<u>OLANZAPINE; SAMIDORPHAN L-MALATE - LYBALVI</u>						
N 213378 001	>A> 10300054	Aug 23, 2031	DP U-3140		>A> NCE	May 28, 2026
	>A> 10300054	Aug 23, 2031	DP U-3141			
	>A> 10716785	Aug 23, 2031		U-3136		
	>A> 10716785	Aug 23, 2031		U-3137		
	>A> 7262298	Nov 23, 2025	DS			
	>A> 7956187	Oct 31, 2021	DS			
	>A> 8252929	Oct 31, 2021	DS			
	>A> 8778960	Feb 13, 2032		U-3136		
	>A> 8778960	Feb 13, 2032		U-3137		
	>A> 9119848	Aug 30, 2031	DS			
	>A> 9126977	Aug 23, 2031	DP U-3136			
	>A> 9126977	Aug 23, 2031	DP U-3137			
	>A> 9517235	Aug 23, 2031		U-3138		
	>A> 9517235	Aug 23, 2031		U-3139		
<u>OLANZAPINE; SAMIDORPHAN L-MALATE - LYBALVI</u>						
N 213378 002	>A> 10300054	Aug 23, 2031	DP U-3140		>A> NCE	May 28, 2026
	>A> 10300054	Aug 23, 2031	DP U-3141			
	>A> 10716785	Aug 23, 2031		U-3136		
	>A> 10716785	Aug 23, 2031		U-3137		
	>A> 7262298	Nov 23, 2025	DS			
	>A> 7956187	Oct 31, 2021	DS			
	>A> 8252929	Oct 31, 2021	DS			
	>A> 8778960	Feb 13, 2032		U-3136		
	>A> 8778960	Feb 13, 2032		U-3137		
	>A> 9119848	Aug 30, 2031	DS			
	>A> 9126977	Aug 23, 2031	DP U-3136			
	>A> 9126977	Aug 23, 2031	DP U-3137			
	>A> 9517235	Aug 23, 2031		U-3138		
	>A> 9517235	Aug 23, 2031		U-3139		

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2021

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>OLANZAPINE; SAMIDORPHAN L-MALATE - LYBALVI</u>						
N 213378 002	>A> 9517235	Aug 23, 2031	U-3139			
<u>OLANZAPINE; SAMIDORPHAN L-MALATE - LYBALVI</u>						
N 213378 003	>A> 10300054	Aug 23, 2031	DP U-3140		>A> NCE	May 28, 2026
	>A> 10300054	Aug 23, 2031	DP U-3141			
	>A> 10716785	Aug 23, 2031	U-3136			
	>A> 10716785	Aug 23, 2031	U-3137			
	>A> 7262298	Nov 23, 2025	DS			
	>A> 7956187	Oct 31, 2021	DS			
	>A> 8252929	Oct 31, 2021	DS			
	>A> 8778960	Feb 13, 2032	U-3136			
	>A> 8778960	Feb 13, 2032	U-3137			
	>A> 9119848	Aug 30, 2031	DS			
	>A> 9126977	Aug 23, 2031	DP U-3136			
	>A> 9126977	Aug 23, 2031	DP U-3137			
	>A> 9517235	Aug 23, 2031	U-3138			
	>A> 9517235	Aug 23, 2031	U-3139			
<u>OLANZAPINE; SAMIDORPHAN L-MALATE - LYBALVI</u>						
N 213378 004	>A> 10300054	Aug 23, 2031	DP U-3140		>A> NCE	May 28, 2026
	>A> 10300054	Aug 23, 2031	DP U-3141			
	>A> 10716785	Aug 23, 2031	U-3136			
	>A> 10716785	Aug 23, 2031	U-3137			
	>A> 7262298	Nov 23, 2025	DS			
	>A> 7956187	Oct 31, 2021	DS			
	>A> 8252929	Oct 31, 2021	DS			
	>A> 8778960	Feb 13, 2032	U-3136			
	>A> 8778960	Feb 13, 2032	U-3137			
	>A> 9119848	Aug 30, 2031	DS			
	>A> 9126977	Aug 23, 2031	DP U-3136			
	>A> 9126977	Aug 23, 2031	DP U-3137			
	>A> 9517235	Aug 23, 2031	U-3138			
	>A> 9517235	Aug 23, 2031	U-3139			
<u>OLAPARIB - LYNPARZA</u>						
N 208558 001	8071579	Aug 12, 2027	U-2101			
	8071579	Aug 12, 2027	U-2103			
	8071579	Aug 12, 2027	U-2480			
	8071579	Aug 12, 2027	U-2481			
	8071579	Aug 12, 2027	U-2482			
	8071579	Aug 12, 2027	U-2483			
	8071579	Aug 12, 2027	U-2716			
	8071579	Aug 12, 2027	U-2819			
	8071579	Aug 12, 2027	U-2820			
	8071579	Aug 12, 2027	U-2821			
	8071579	Aug 12, 2027	U-2822			
	8071579	Aug 12, 2027	U-2823			
	8071579	Aug 12, 2027	U-2824			
	8071579	Aug 12, 2027	U-2832			
	8071579	Aug 12, 2027	U-2833			
	8859562	Aug 04, 2031	U-2101			
	8859562	Aug 04, 2031	U-2103			
	8859562	Aug 04, 2031	U-2480			
	8859562	Aug 04, 2031	U-2481			
	8859562	Aug 04, 2031	U-2482			
	8859562	Aug 04, 2031	U-2483			
	8859562	Aug 04, 2031	U-2716			
	8859562	Aug 04, 2031	U-2819			
	8859562	Aug 04, 2031	U-2820			
	8859562	Aug 04, 2031	U-2821			
	8859562	Aug 04, 2031	U-2822			
	8859562	Aug 04, 2031	U-2823			
	8859562	Aug 04, 2031	U-2824			
	8859562	Aug 04, 2031	U-2832			
	8859562	Aug 04, 2031	U-2833			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2021

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>OLAPARIB - LYNPARZA</u>						
N 208558 002	8071579	Aug 12, 2027	U-2101			
	8071579	Aug 12, 2027	U-2103			
	8071579	Aug 12, 2027	U-2480			
	8071579	Aug 12, 2027	U-2481			
	8071579	Aug 12, 2027	U-2482			
	8071579	Aug 12, 2027	U-2483			
	8071579	Aug 12, 2027	U-2716			
	8071579	Aug 12, 2027	U-2819			
	8071579	Aug 12, 2027	U-2820			
	8071579	Aug 12, 2027	U-2821			
	8071579	Aug 12, 2027	U-2822			
	8071579	Aug 12, 2027	U-2823			
	8071579	Aug 12, 2027	U-2824			
	8071579	Aug 12, 2027	U-2832			
	8071579	Aug 12, 2027	U-2833			
	8859562	Aug 04, 2031	U-2101			
	8859562	Aug 04, 2031	U-2103			
	8859562	Aug 04, 2031	U-2480			
	8859562	Aug 04, 2031	U-2481			
	8859562	Aug 04, 2031	U-2482			
	8859562	Aug 04, 2031	U-2483			
	8859562	Aug 04, 2031	U-2716			
	8859562	Aug 04, 2031	U-2819			
	8859562	Aug 04, 2031	U-2820			
	8859562	Aug 04, 2031	U-2821			
	8859562	Aug 04, 2031	U-2822			
	8859562	Aug 04, 2031	U-2823			
	8859562	Aug 04, 2031	U-2824			
	8859562	Aug 04, 2031	U-2832			
	8859562	Aug 04, 2031	U-2833			
<u>OLICERIDINE - OLINVYK</u>						
N 210730 001					NCE	Oct 30, 2025
<u>OLICERIDINE - OLINVYK</u>						
N 210730 002					NCE	Oct 30, 2025
<u>OLICERIDINE - OLINVYK</u>						
N 210730 003					NCE	Oct 30, 2025
<u>ORITAVANCIN DIPHOSPHATE - KIMYRSA</u>						
N 214155 001	8420592	Aug 29, 2029	U-3101		NP	Mar 12, 2024
	9649352	Jul 16, 2035	DS DP			
	9682061	Apr 26, 2030	U-3101			
<u>OSIMERTINIB MESYLATE - TAGRISSO</u>						
N 208065 001	10183020	Jan 02, 2035	DP U-1777		I-853	Dec 18, 2023
	10183020	Jan 02, 2035	DP U-2289		ODE-337	Dec 18, 2027
	10183020	Jan 02, 2035	DP U-3016			
	8946235	Aug 08, 2032	DS DP U-1777			
	8946235	Aug 08, 2032	DS DP U-2289			
	8946235	Aug 08, 2032	DS DP U-3016			
	9732058	Jul 25, 2032	DS DP U-1777			
	9732058	Jul 25, 2032	DS DP U-2289			
	9732058	Jul 25, 2032	DS DP U-3016			
<u>OSIMERTINIB MESYLATE - TAGRISSO</u>						
N 208065 002	10183020	Jan 02, 2035	DP U-1777		I-853	Dec 18, 2023
	10183020	Jan 02, 2035	DP U-2289		ODE-337	Dec 18, 2027
	10183020	Jan 02, 2035	DP U-3016			
	8946235	Aug 08, 2032	DS DP U-1777			
	8946235	Aug 08, 2032	DS DP U-2289			
	8946235	Aug 08, 2032	DS DP U-3016			
	9732058	Jul 25, 2032	DS DP U-1777			
	9732058	Jul 25, 2032	DS DP U-2289			
	9732058	Jul 25, 2032	DS DP U-3016			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2021

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>OSIMERTINIB MESYLATE - TAGRISSO</u>						
N 208065 002	10183020	Jan 02, 2035	DP U-1777		I-853	Dec 18, 2023
	10183020	Jan 02, 2035	DP U-2289		ODE-337	Dec 18, 2027
	10183020	Jan 02, 2035	DP U-3016			
	8946235	Aug 08, 2032	DS DP U-1777			
	8946235	Aug 08, 2032	DS DP U-2289			
	8946235	Aug 08, 2032	DS DP U-3016			
	9732058	Jul 25, 2032	DS DP U-1777			
	9732058	Jul 25, 2032	DS DP U-2289			
	9732058	Jul 25, 2032	DS DP U-3016			
<u>OSPHEMIFENE - OSPHENA</u>						
N 203505 001	9566252	Nov 02, 2022	U-1370			
<u>OXYMETAZOLINE HYDROCHLORIDE - UPNEEO</u>						
N 212520 001	10898573	Dec 16, 2039	DP			
	10912765	Aug 26, 2031	U-2849			
	10940138	Dec 16, 2039	U-2849			
<u>OXYMORPHONE HYDROCHLORIDE - OPANA ER</u>						
N 021610 001	8309112	Feb 04, 2023	DP			
	8329216	Feb 04, 2023	DP			
	8808737	Jun 21, 2027	U-3085			
	8871779	Nov 22, 2029	DS			
<u>OXYMORPHONE HYDROCHLORIDE - OPANA ER</u>						
N 021610 002	8309112	Feb 04, 2023	DP			
	8329216	Feb 04, 2023	DP			
	8808737	Jun 21, 2027	U-3085			
	8871779	Nov 22, 2029	DS			
<u>OXYMORPHONE HYDROCHLORIDE - OPANA ER</u>						
N 021610 003	8309112	Feb 04, 2023	DP			
	8329216	Feb 04, 2023	DP			
	8808737	Jun 21, 2027	U-3085			
	8871779	Nov 22, 2029	DS			
<u>OXYMORPHONE HYDROCHLORIDE - OPANA ER</u>						
N 021610 004	8309112	Feb 04, 2023	DP			
	8329216	Feb 04, 2023	DP			
	8808737	Jun 21, 2027	U-3085			
	8871779	Nov 22, 2029	DS			
<u>OXYMORPHONE HYDROCHLORIDE - OPANA ER</u>						
N 021610 005	8309112	Feb 04, 2023	DP			
	8329216	Feb 04, 2023	DP			
	8808737	Jun 21, 2027	U-3085			
	8871779	Nov 22, 2029	DS			
<u>OXYMORPHONE HYDROCHLORIDE - OPANA ER</u>						
N 021610 006	8309112	Feb 04, 2023	DP			
	8329216	Feb 04, 2023	DP			
	8808737	Jun 21, 2027	U-3085			
	8871779	Nov 22, 2029	DS			
<u>OXYMORPHONE HYDROCHLORIDE - OPANA ER</u>						
N 021610 007	8309112	Feb 04, 2023	DP			
	8329216	Feb 04, 2023	DP			
	8808737	Jun 21, 2027	U-3085			
	8871779	Nov 22, 2029	DS			
<u>OZANIMOD HYDROCHLORIDE - ZEPOSIA</u>						
N 209899 001	>A> 10239846	Nov 15, 2030	U-3132		>A> I-860	May 27, 2024

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2021

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>OZANIMOD HYDROCHLORIDE - ZEPOSIA</u>						
N 209899 002	>A> 10239846	Nov 15, 2030	U-3132		>A> I-860	May 27, 2024
<u>OZANIMOD HYDROCHLORIDE - ZEPOSIA</u>						
N 209899 003	>A> 10239846	Nov 15, 2030	U-3132		>A> I-860	May 27, 2024
<u>OZENOXACIN - XEPI</u>						
N 208945 001	6335447	Nov 09, 2023	DS			
<u>PALBOCICLIB - IBRANCE</u>						
N 207103 001	RE47739	Mar 05, 2027	DS DP			
<u>PALBOCICLIB - IBRANCE</u>						
N 207103 002	RE47739	Mar 05, 2027	DS DP			
<u>PALBOCICLIB - IBRANCE</u>						
N 207103 003	RE47739	Mar 05, 2027	DS DP			
<u>PALBOCICLIB - IBRANCE</u>						
N 212436 001	RE47739	Mar 05, 2027	DS DP			
<u>PALBOCICLIB - IBRANCE</u>						
N 212436 002	RE47739	Mar 05, 2027	DS DP			
<u>PALBOCICLIB - IBRANCE</u>						
N 212436 003	RE47739	Mar 05, 2027	DS DP			
<u>PEGCETACOPLAN - EMPAVELI</u>						
N 215014 001	10035822	Nov 15, 2033	DS		>A> NCE	May 14, 2026
	10125171	Aug 02, 2033	DS		ODE-351	May 14, 2028
	10875893	Nov 15, 2033	DS	U-3124		
	7888323	Dec 04, 2027	DS			
	7989589	Dec 04, 2027	DS			
	9169307	Nov 18, 2027	DS	U-3123		
<u>PERAMIVIR - RAPIVAB</u>						
N 206426 001	10391075	Feb 12, 2027	U-2622			
	10391075	Feb 12, 2027	U-3069			
	8778997	May 07, 2027	U-1627			
	8778997	May 07, 2027	U-2622			
	8778997	May 07, 2027	U-3069			
<u>PERAMPANEL - FYCOMPA</u>						
N 202834 001	6949571	Jun 08, 2022	DS DP U-106			
	6949571	Jun 08, 2022	DS DP U-2088			
	6949571	Jun 08, 2022	DS DP U-2089			
	6949571	Jun 08, 2022	DS DP U-2428			
	6949571	Jun 08, 2022	DS DP U-2429			
<u>PERAMPANEL - FYCOMPA</u>						
N 202834 002	6949571	Jun 08, 2022	DS DP U-106			
	6949571	Jun 08, 2022	DS DP U-2088			
	6949571	Jun 08, 2022	DS DP U-2089			
	6949571	Jun 08, 2022	DS DP U-2428			
	6949571	Jun 08, 2022	DS DP U-2429			
<u>PERAMPANEL - FYCOMPA</u>						
N 202834 003	6949571	Jun 08, 2022	DS DP U-106			
	6949571	Jun 08, 2022	DS DP U-2088			
	6949571	Jun 08, 2022	DS DP U-2089			
	6949571	Jun 08, 2022	DS DP U-2428			
	6949571	Jun 08, 2022	DS DP U-2429			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2021

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>PERAMPANEL - FYCOMPA</u>						
N 202834 004	6949571	Jun 08, 2022	DS DP U-106			
	6949571	Jun 08, 2022	DS DP U-2088			
	6949571	Jun 08, 2022	DS DP U-2089			
	6949571	Jun 08, 2022	DS DP U-2428			
	6949571	Jun 08, 2022	DS DP U-2429			
<u>PERAMPANEL - FYCOMPA</u>						
N 202834 005	6949571	Jun 08, 2022	DS DP U-106			
	6949571	Jun 08, 2022	DS DP U-2088			
	6949571	Jun 08, 2022	DS DP U-2089			
	6949571	Jun 08, 2022	DS DP U-2428			
	6949571	Jun 08, 2022	DS DP U-2429			
<u>PERAMPANEL - FYCOMPA</u>						
N 202834 006	6949571	Jun 08, 2022	DS DP U-106			
	6949571	Jun 08, 2022	DS DP U-2088			
	6949571	Jun 08, 2022	DS DP U-2089			
	6949571	Jun 08, 2022	DS DP U-2428			
	6949571	Jun 08, 2022	DS DP U-2429			
<u>PERAMPANEL - FYCOMPA</u>						
N 208277 001	6949571	Jun 08, 2022	DS DP U-106			
	6949571	Jun 08, 2022	DS DP U-2088			
	6949571	Jun 08, 2022	DS DP U-2089			
	6949571	Jun 08, 2022	DS DP U-2428			
	6949571	Jun 08, 2022	DS DP U-2429			
<u>PEXIDARTINIB HYDROCHLORIDE - TURALIO</u>						
N 211810 001	10941142	Jul 24, 2038	DP			
	10961240	Jul 24, 2038			U-2606	
<u>PIFLUFOLASTAT F-18 - PYLARIFY</u>						
N 214793 001	>A> 10947197	Jun 09, 2037	DS DP U-3130		>A> NCE	May 26, 2026
	>A> 8487129	Nov 07, 2027	DS DP			
	>A> 8778305	Sep 21, 2030	DS DP U-3130			
	>A> 9861713	Jul 31, 2029	DS DP U-3130			
<u>PIMAVANSERIN TARTRATE - NUPLAZID</u>						
N 207318 002	10953000	Mar 23, 2037	U-1974			
<u>PITOLISANT HYDROCHLORIDE - WAKIX</u>						
N 211150 001					ODE-331	Oct 13, 2027
<u>PITOLISANT HYDROCHLORIDE - WAKIX</u>						
N 211150 002					ODE-331	Oct 13, 2027
<u>POMALIDOMIDE - POMALYST</u>						
N 204026 001					M-14 PED	Nov 20, 2023 May 20, 2024
<u>POMALIDOMIDE - POMALYST</u>						
N 204026 002					M-14 PED	Nov 20, 2023 May 20, 2024
<u>POMALIDOMIDE - POMALYST</u>						
N 204026 003					M-14 PED	Nov 20, 2023 May 20, 2024
<u>POMALIDOMIDE - POMALYST</u>						
N 204026 004					M-14 PED	Nov 20, 2023 May 20, 2024

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2021

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>PONATINIB HYDROCHLORIDE - ICLUSIG</u>						
N 203469 001					I-849	Dec 18, 2023
<u>PONATINIB HYDROCHLORIDE - ICLUSIG</u>						
N 203469 002					I-849	Dec 18, 2023
<u>PONATINIB HYDROCHLORIDE - ICLUSIG</u>						
N 203469 003	8114874	Jan 24, 2027	DS DP		I-849	Dec 18, 2023
<u>PONATINIB HYDROCHLORIDE - ICLUSIG</u>						
N 203469 004	8114874	Jan 24, 2027	DS DP		I-849	Dec 18, 2023
	9029533	Dec 22, 2026		U-1283		
	9029533	Dec 22, 2026		U-1699		
	9029533	Dec 22, 2026		U-1700		
	9029533	Dec 22, 2026		U-1701		
	9029533	Dec 22, 2026		U-836		
	9493470	Dec 12, 2033	DS DP	U-1700		
	9493470	Dec 12, 2033	DS DP	U-1948		
<u>PONESIMOD - PONVORY</u>						
N 213498 001	10220023	Dec 10, 2035		U-3103	NCE	Mar 18, 2026
	8273779	Dec 17, 2025		U-2774		
	9000018	Nov 16, 2024		U-3102		
	9062014	May 06, 2032	DS DP	U-2774		
	RE43728	Nov 16, 2024	DS DP			
<u>PONESIMOD - PONVORY</u>						
N 213498 002	10220023	Dec 10, 2035		U-3103	NCE	Mar 18, 2026
	8273779	Dec 17, 2025		U-2774		
	9000018	Nov 16, 2024		U-3102		
	9062014	May 06, 2032	DS DP	U-2774		
	RE43728	Nov 16, 2024	DS DP			
<u>PONESIMOD - PONVORY</u>						
N 213498 003	10220023	Dec 10, 2035		U-3103	NCE	Mar 18, 2026
	8273779	Dec 17, 2025		U-2774		
	9000018	Nov 16, 2024		U-3102		
	9062014	May 06, 2032	DS DP	U-2774		
	RE43728	Nov 16, 2024	DS DP			
<u>PONESIMOD - PONVORY</u>						
N 213498 004	10220023	Dec 10, 2035		U-3103	NCE	Mar 18, 2026
	8273779	Dec 17, 2025		U-2774		
	9000018	Nov 16, 2024		U-3102		
	9062014	May 06, 2032	DS DP	U-2774		
	RE43728	Nov 16, 2024	DS DP			
<u>PONESIMOD - PONVORY</u>						
N 213498 005	10220023	Dec 10, 2035		U-3103	NCE	Mar 18, 2026
	8273779	Dec 17, 2025		U-2774		
	9000018	Nov 16, 2024		U-3102		
	9062014	May 06, 2032	DS DP	U-2774		
	RE43728	Nov 16, 2024	DS DP			
<u>PONESIMOD - PONVORY</u>						
N 213498 006	10220023	Dec 10, 2035		U-3103	NCE	Mar 18, 2026
	8273779	Dec 17, 2025		U-2774		
	9000018	Nov 16, 2024		U-3102		
	9062014	May 06, 2032	DS DP	U-2774		
	RE43728	Nov 16, 2024	DS DP			
<u>PONESIMOD - PONVORY</u>						
N 213498 007	10220023	Dec 10, 2035		U-3103	NCE	Mar 18, 2026
	8273779	Dec 17, 2025		U-2774		
	9000018	Nov 16, 2024		U-3102		
	9062014	May 06, 2032	DS DP	U-2774		

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2021

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>PONESIMOD - PONVORY</u>						
N 213498 007	RE43728	Nov 16, 2024	DS DP			
<u>PONESIMOD - PONVORY</u>						
N 213498 008	10220023	Dec 10, 2035	U-3103		NCE	Mar 18, 2026
	8273779	Dec 17, 2025	U-2774			
	9000018	Nov 16, 2024	U-3102			
	9062014	May 06, 2032	DS DP U-2774			
	RE43728	Nov 16, 2024	DS DP			
<u>PONESIMOD - PONVORY</u>						
N 213498 009	10220023	Dec 10, 2035	U-3103		NCE	Mar 18, 2026
	8273779	Dec 17, 2025	U-2774			
	9000018	Nov 16, 2024	U-3102			
	9062014	May 06, 2032	DS DP U-2774			
	RE43728	Nov 16, 2024	DS DP			
<u>PONESIMOD - PONVORY</u>						
N 213498 010	10220023	Dec 10, 2035	U-3103		NCE	Mar 18, 2026
	8273779	Dec 17, 2025	U-2774			
	9000018	Nov 16, 2024	U-3102			
	9062014	May 06, 2032	DS DP U-2774			
	RE43728	Nov 16, 2024	DS DP			
<u>POSACONAZOLE - NOXAFIL</u>						
N 205053 001					>A> NPP	May 31, 2024
<u>POSACONAZOLE - NOXAFIL</u>						
N 205596 001	>A> 9023790	Jul 04, 2031	DP U-1698		>A> NPP	May 31, 2024
	>A> 9023790	Jul 04, 2031	DP U-3160			
	>A> 9358297	Jun 24, 2031	DP U-1454			
	>A> 9358297	Jun 24, 2031	DP U-3160			
<u>POSACONAZOLE - NOXAFIL POWDERMIX KIT</u>						
N 214770 001					>A> NP	May 31, 2024
<u>PRALSETINIB - GAVRETO</u>						
N 213721 001					ODE-340	Dec 01, 2027
					ODE-341	Dec 01, 2027
<u>RELUGOLIX - ORGOVYX</u>						
N 214621 001	10350170	Feb 25, 2036	DP		NCE	Dec 18, 2025
	10449191	Sep 29, 2037	U-3020			
	10786501	Sep 29, 2037	U-3020			
	7300935	Jan 28, 2024	DS			
	8058280	Jan 28, 2024	DS DP			
	8735401	Feb 04, 2024	U-3019			
<u>REMGESIVIR - VEKLURY</u>						
N 214787 001	>A> 11007208	Sep 16, 2036	U-2984			
<u>REMGESIVIR - VEKLURY</u>						
N 214787 002	>A> 11007208	Sep 16, 2036	U-2984			
<u>REMIMAZOLAM BESYLATE - BYFAVO</u>						
N 212295 001					NCE	Oct 06, 2025
<u>REVEFENACIN - YUPELRI</u>						
N 210598 001	11008289	Jul 14, 2030	U-2440			
<u>RILPIVIRINE HYDROCHLORIDE - EDURANT</u>						
N 202022 001	7125879	Apr 21, 2025	DS DP U-1153			
	7125879	Apr 21, 2025	DS DP U-1307			
	7125879	Apr 21, 2025	DS DP U-1740			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2021

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>RILPIVIRINE HYDROCHLORIDE - EDURANT</u>						
N 202022 001	7125879	Apr 21, 2025	DS DP U-3068			
<u>RIMEGEPANT SULFATE - NURTEC ODT</u>						
N 212728 001	>A> 8314117	Feb 22, 2031	DS DP U-2718			
	>A> 8314117	Feb 22, 2031	DS DP U-3142			
<u>RIPRETINIB - QINLOCK</u>						
N 213973 001	10966966	Aug 12, 2040	U-3153			
<u>RISDIPLAM - EVRYSDI</u>						
N 213535 001					ODE-334	Aug 07, 2027
<u>RISPERIDONE - PERSERIS KIT</u>						
N 210655 001	>A> 11013809	Feb 13, 2028	DP U-3135			
<u>RISPERIDONE - PERSERIS KIT</u>						
N 210655 002	>A> 11013809	Feb 13, 2028	DP U-3135			
<u>ROLAPITANT HYDROCHLORIDE - VARUBI</u>						
N 206500 001	7049320	Aug 19, 2028	DS DP U-1741			
<u>ROLAPITANT HYDROCHLORIDE - VARUBI</u>						
N 208399 001	7049320	Aug 19, 2028	DS DP U-1741			
<u>RUFINAMIDE - RUFINAMIDE</u>						
A 204988 001				>A> PC		Nov 28, 2021
<u>RUFINAMIDE - RUFINAMIDE</u>						
A 204988 002				>A> PC		Nov 28, 2021
<u>SACUBITRIL; VALSARTAN - ENTRESTO</u>						
N 207620 001	9517226	Aug 22, 2033	U-3084		M-82	Feb 16, 2024
	9937143	Aug 22, 2033	U-3084			
<u>SACUBITRIL; VALSARTAN - ENTRESTO</u>						
N 207620 002	9517226	Aug 22, 2033	U-3084		M-82	Feb 16, 2024
	9937143	Aug 22, 2033	U-3084			
<u>SACUBITRIL; VALSARTAN - ENTRESTO</u>						
N 207620 003	9517226	Aug 22, 2033	U-3084		M-82	Feb 16, 2024
	9937143	Aug 22, 2033	U-3084			
<u>SAFINAMIDE MESYLATE - XADAGO</u>						
N 207145 001	8283380	Mar 21, 2031	U-1993			
<u>SAFINAMIDE MESYLATE - XADAGO</u>						
N 207145 002	8283380	Mar 21, 2031	U-1993			
<u>SECNIDAZOLE - SOLOSEC</u>						
N 209363 001	11000507	Sep 04, 2035	DP U-2583			
	11000508	Sep 04, 2035	DP U-2583			
	>A> 11020377	Sep 04, 2035	DP U-2583			
<u>SELENIOUS ACID - SELENIOUS ACID</u>						
N 209379 002					NCE	Apr 30, 2024
<u>SELINEXOR - XPOVIO</u>						
N 212306 001	10519139	Aug 14, 2035	DS DP U-2584		ODE-346	Dec 18, 2027
	10519139	Aug 14, 2035	DS DP U-2855			
	10519139	Aug 14, 2035	DS DP U-3018			
	10544108	Jul 26, 2032	U-2584			
	10544108	Jul 26, 2032	U-3018			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2021

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>SELINEXOR - XPOVIO</u>						
N 212306 001	9079865	Jul 26, 2032	U-2584			
	9079865	Jul 26, 2032	U-2855			
	9079865	Jul 26, 2032	U-3018			
<u>SELINEXOR - XPOVIO</u>						
N 212306 002					ODE-346	Dec 18, 2027
<u>SELINEXOR - XPOVIO</u>						
N 212306 003					ODE-346	Dec 18, 2027
<u>SELINEXOR - XPOVIO</u>						
N 212306 004					ODE-346	Dec 18, 2027
<u>SEMAGLUTIDE - RYBELSUS</u>						
N 213051 001	10933120	Mar 15, 2033	DP			
	10960052	Dec 16, 2031	DP			
<u>SEMAGLUTIDE - RYBELSUS</u>						
N 213051 002	10933120	Mar 15, 2033	DP			
	10960052	Dec 16, 2031	DP			
<u>SEMAGLUTIDE - RYBELSUS</u>						
N 213051 003	10933120	Mar 15, 2033	DP			
	10960052	Dec 16, 2031	DP			
<u>SEMAGLUTIDE - WEGOVY</u>						
N 215256 001	>A> 10888605	Aug 24, 2038	DP U-3162		>A> NCE	Dec 05, 2022
	>A> 8129343	Jan 29, 2029	DS DP		>A> NP	Jun 04, 2024
	>A> 8536122	Mar 20, 2026	DS DP			
	>A> 9764003	Jun 21, 2033	U-3161			
<u>SEMAGLUTIDE - WEGOVY</u>						
N 215256 002	>A> 10888605	Aug 24, 2038	DP U-3162		>A> NCE	Dec 05, 2022
	>A> 8129343	Jan 29, 2029	DS DP		>A> NP	Jun 04, 2024
	>A> 8536122	Mar 20, 2026	DS DP			
	>A> 9764003	Jun 21, 2033	U-3161			
<u>SEMAGLUTIDE - WEGOVY</u>						
N 215256 003	>A> 10888605	Aug 24, 2038	DP U-3162		>A> NCE	Dec 05, 2022
	>A> 8129343	Jan 29, 2029	DS DP		>A> NP	Jun 04, 2024
	>A> 8536122	Mar 20, 2026	DS DP			
	>A> 9764003	Jun 21, 2033	U-3161			
<u>SEMAGLUTIDE - WEGOVY</u>						
N 215256 004	>A> 10888605	Aug 24, 2038	DP U-3162		>A> NCE	Dec 05, 2022
	>A> 8129343	Jan 29, 2029	DS DP		>A> NP	Jun 04, 2024
	>A> 8536122	Mar 20, 2026	DS DP			
	>A> 9764003	Jun 21, 2033	U-3161			
<u>SEMAGLUTIDE - WEGOVY</u>						
N 215256 005	>A> 10888605	Aug 24, 2038	DP U-3162		>A> NCE	Dec 05, 2022
	>A> 8129343	Jan 29, 2029	DS DP		>A> NP	Jun 04, 2024
	>A> 8536122	Mar 20, 2026	DS DP			
	>A> 9764003	Jun 21, 2033	U-3161			
<u>SETMELANOTIDE ACETATE - IMCIVREE</u>						
N 213793 001					ODE-336	Nov 25, 2027
<u>SITAGLIPTIN PHOSPHATE - JANUVIA</u>						
N 021995 001					M-187 PED	Dec 04, 2023 Jun 04, 2024

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2021

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>SITAGLIPTIN PHOSPHATE - JANUVIA</u>						
N 021995	002				M-187 PED	Dec 04, 2023 Jun 04, 2024
<u>SITAGLIPTIN PHOSPHATE - JANUVIA</u>						
N 021995	003				M-187 PED	Dec 04, 2023 Jun 04, 2024
<u>SODIUM OXYBATE - XYREM</u>						
N 021196	001	10864181	Mar 15, 2033	U-1532		
<u>SOFOSBUVIR - SOVALDI</u>						
N 204671	001				ODE*	Aug 28, 2026
<u>SOFOSBUVIR - SOVALDI</u>						
N 204671	002				ODE* ODE* PED	Apr 07, 2024 Aug 28, 2026 Oct 07, 2024
<u>SOFOSBUVIR; VELPATASVIR - EPCLUSA</u>						
N 208341	001	10086011	Jan 30, 2034	U-1470	D-177	Nov 15, 2022
		10086011*PED	Jul 30, 2034		M-264	Jul 14, 2023
		8575135	Nov 16, 2032	DS DP U-1470	NPP	Mar 19, 2023
		8575135*PED	May 16, 2033		PED	May 15, 2023
		8735372	Mar 21, 2028	U-1470	PED	Sep 19, 2023
		8735372*PED	Sep 21, 2028		PED	Jan 14, 2024
		8921341	Nov 16, 2032	DS DP U-1470		
		8921341*PED	May 16, 2033			
		8940718	Nov 16, 2032	DS DP U-1470		
		8940718*PED	May 16, 2033			
		9757406	Jan 30, 2034	DP		
		9757406*PED	Jul 30, 2034			
<u>SOFOSBUVIR; VELPATASVIR - EPCLUSA</u>						
N 208341	002	10086011	Jan 30, 2034	U-1470	M-264	Jul 14, 2023
		10086011*PED	Jul 30, 2034		NS	Mar 19, 2023
		7964580	Mar 26, 2029	DS DP U-1470	PED	Sep 19, 2023
		7964580*PED	Sep 26, 2029		PED	Jan 14, 2024
		8334270	Mar 21, 2028	DS DP U-1470		
		8334270*PED	Sep 21, 2028			
		8575135	Nov 16, 2032	DS DP U-1470		
		8575135*PED	May 16, 2033			
		8580765	Mar 21, 2028	DS DP U-1470		
		8580765*PED	Sep 21, 2028			
		8618076	Dec 11, 2030	DS DP U-1470		
		8618076*PED	Jun 11, 2031			
		8633309	Mar 26, 2029	DS DP U-1470		
		8633309*PED	Sep 26, 2029			
		8735372	Mar 21, 2028	U-1470		
		8735372*PED	Sep 21, 2028			
		8889159	Mar 26, 2029	DP U-1470		
		8889159*PED	Sep 26, 2029			
		8921341	Nov 16, 2032	DS DP U-1470		
		8921341*PED	May 16, 2033			
		8940718	Nov 16, 2032	DS DP U-1470		
		8940718*PED	May 16, 2033			
		9085573	Mar 21, 2028	DS DP U-1470		
		9085573*PED	Sep 21, 2028			
		9284342	Sep 13, 2030	DS DP U-1470		
		9284342*PED	Mar 13, 2031			
		9757406	Jan 30, 2034	DP		
		9757406*PED	Jul 30, 2034			
<u>SOFOSBUVIR; VELPATASVIR - EPCLUSA</u>						
N 214187	001	>A> 7964580	Mar 26, 2029	DS DP U-1470		
		>A> 8334270	Mar 21, 2028	DS DP U-1470		
		>A> 8575135	Nov 16, 2032	DS DP U-1470		

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2021

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>SOFOSBUVIR; VELPATASVIR - EPCLUSA</u>						
N 214187 001	>A> 8580765	Mar 21, 2028	DS DP U-1470			
	>A> 8618076	Dec 11, 2030	DS DP U-1470			
	>A> 8633309	Mar 26, 2029	DS DP U-1470			
	>A> 8735372	Mar 21, 2028	U-1470			
	>A> 8889159	Mar 26, 2029	DP U-1470			
	>A> 8921341	Nov 16, 2032	DS DP U-1470			
	>A> 8940718	Nov 16, 2032	DS DP U-1470			
	>A> 9085573	Mar 21, 2028	DS DP U-1470			
	>A> 9284342	Sep 13, 2030	DS DP U-1470			
<u>SOFOSBUVIR; VELPATASVIR - EPCLUSA</u>						
N 214187 002	>A> 7964580	Mar 26, 2029	DS DP U-1470			
	>A> 8334270	Mar 21, 2028	DS DP U-1470			
	>A> 8575135	Nov 16, 2032	DS DP U-1470			
	>A> 8580765	Mar 21, 2028	DS DP U-1470			
	>A> 8618076	Dec 11, 2030	DS DP U-1470			
	>A> 8633309	Mar 26, 2029	DS DP U-1470			
	>A> 8735372	Mar 21, 2028	U-1470			
	>A> 8889159	Mar 26, 2029	DP U-1470			
	>A> 8921341	Nov 16, 2032	DS DP U-1470			
	>A> 8940718	Nov 16, 2032	DS DP U-1470			
	>A> 9085573	Mar 21, 2028	DS DP U-1470			
	>A> 9284342	Sep 13, 2030	DS DP U-1470			
<u>SOFOSBUVIR; VELPATASVIR; VOXILAPREVIR - VOSEVI</u>						
N 209195 001	10912814	Jun 01, 2037	DP			
	>A> 8575135	Nov 16, 2032	DS DP U-2039			
	>A> 8575135	Nov 16, 2032	DS DP U-2040			
	>A> 8575135*PED	May 16, 2033				
	8735372	Mar 21, 2028	DS DP U-2039			
	8735372	Mar 21, 2028	DS DP U-2040			
	8735372*PED	Sep 21, 2028				
	8921341	Nov 16, 2032	DS DP U-2039			
	8921341	Nov 16, 2032	DS DP U-2040			
	8921341*PED	May 16, 2033				
	8940718	Nov 16, 2032	DS DP U-2039			
	8940718	Nov 16, 2032	DS DP U-2040			
	8940718*PED	May 16, 2033				
	8957046	Mar 21, 2028	U-2039			
	8957046	Mar 21, 2028	U-2040			
<u>SOLIFENACIN SUCCINATE - VESICARE LS</u>						
N 209529 001	9918970	May 18, 2031	DP			
<u>SOLRIAMFETOL HYDROCHLORIDE - SUNOSI</u>						
N 211230 001	10912754	Jun 01, 2038	U-3082			
	10940133	Mar 19, 2040	U-3099			
	10959976	Jun 01, 2038	U-3151			
<u>SOLRIAMFETOL HYDROCHLORIDE - SUNOSI</u>						
N 211230 002	10912754	Jun 01, 2038	U-3082			
	10959976	Jun 01, 2038	U-3151			
<u>SOTALOL HYDROCHLORIDE - SOTALOL HYDROCHLORIDE</u>						
N 022306 001	>A> 10799138	Apr 05, 2039	U-3125			
<u>SOTALOL HYDROCHLORIDE - SOTYLIZE</u>						
N 205108 001	11013703	Apr 01, 2034	DP			
<u>SOTORASIB - LUMAKRAS</u>						
N 214665 001				>A> NCE		May 28, 2026

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2021

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>SPINOSAD - NATROBA</u>						
N 022408 001					I-858	Apr 28, 2024
<u>SPIRONOLACTONE - CAROSPIR</u>						
N 209478 001	10888570	Oct 28, 2036	DP			
<u>SUFENTANIL CITRATE - DSUVIA</u>						
N 209128 001	10896751	Mar 16, 2030	DP			
<u>TACROLIMUS - ASTAGRAF XL</u>						
N 204096 001					ODE*	May 24, 2025
<u>TACROLIMUS - ASTAGRAF XL</u>						
N 204096 002					ODE*	May 24, 2025
<u>TACROLIMUS - ASTAGRAF XL</u>						
N 204096 003					ODE*	May 24, 2025
<u>TAFENOQUINE SUCCINATE - ARAKODA</u>						
N 210607 001	10888558	Dec 02, 2035	U-2582			
<u>T AFLUPROST - ZIOPTAN</u>						
N 202514 001	10864159	May 28, 2029	DP U-778			
<u>TAPENTADOL HYDROCHLORIDE - NUCYNTA ER</u>						
N 200533 001	>A> 11007156	Oct 22, 2022	DP U-1178			
	>A> 11007156	Oct 22, 2022	DP U-1276			
<u>TAPENTADOL HYDROCHLORIDE - NUCYNTA ER</u>						
N 200533 002	>A> 11007156	Oct 22, 2022	DP U-1178			
	>A> 11007156	Oct 22, 2022	DP U-1276			
<u>TAPENTADOL HYDROCHLORIDE - NUCYNTA ER</u>						
N 200533 003	>A> 11007156	Oct 22, 2022	DP U-1178			
	>A> 11007156	Oct 22, 2022	DP U-1276			
<u>TAPENTADOL HYDROCHLORIDE - NUCYNTA ER</u>						
N 200533 004	>A> 11007156	Oct 22, 2022	DP U-1178			
	>A> 11007156	Oct 22, 2022	DP U-1276			
<u>TAPENTADOL HYDROCHLORIDE - NUCYNTA ER</u>						
N 200533 005	>A> 11007156	Oct 22, 2022	DP U-1178			
	>A> 11007156	Oct 22, 2022	DP U-1276			
<u>TASIMELTEON - HETLIOZ</u>						
N 205677 001	10610511	Oct 10, 2034	U-2615		I-850	Dec 01, 2023
	10610511	Oct 10, 2034	U-3007		ODE-330	Dec 01, 2027
	10945988	Jan 25, 2033	U-2149			
	10980770	Jan 25, 2033	U-3106			
	10980770	Jan 25, 2033	U-3107			
<u>TASIMELTEON - HETLIOZ LQ</u>						
N 214517 001	10980770	Jan 25, 2033	U-3106		NP ODE-329	Dec 01, 2023 Dec 01, 2027
<u>TAVABOROLE - TAVABOROLE</u>						
A 211963 001					PC	Apr 17, 2021
<u>TECHNETIUM TC-99M TILMANOCEPT - LYMPHOSEEK KIT</u>						
N 202207 001					>A> NPP	May 19, 2024

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2021

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>TEPOTINIB HYDROCHLORIDE - TEPMETKO</u>						
N 214096 001	8329692	Oct 30, 2029	DS DP		NCE	Feb 03, 2026
	8580781	Mar 19, 2030	DS DP		ODE-325	Feb 03, 2028
	8658643	Jul 04, 2028		U-3077		
	8921357	May 30, 2028	DS DP			
	8927540	Jul 21, 2028		U-3078		
	9062029	Jul 04, 2028	DP			
	9284300	Apr 29, 2028	DP			
	9403799	Jul 04, 2028		U-3077		
<u>TERIFLUNOMIDE - AUBAGIO</u>						
N 202992 001	6794410	Sep 12, 2026		U-1285	M-61	Apr 30, 2024
	6794410*PED	Mar 12, 2027			PED	Oct 30, 2024
	8802735	Sep 14, 2030	DP			
	8802735*PED	Mar 14, 2031				
	9186346	Feb 04, 2034		U-1786		
	9186346*PED	Aug 04, 2034				
<u>TERIFLUNOMIDE - AUBAGIO</u>						
N 202992 002	6794410	Sep 12, 2026		U-1285	M-61	Apr 30, 2024
	6794410*PED	Mar 12, 2027			PED	Oct 30, 2024
	8802735	Sep 14, 2030	DP			
	8802735*PED	Mar 14, 2031				
	9186346	Feb 04, 2034		U-1786		
	9186346*PED	Aug 04, 2034				
<u>TESTOSTERONE ENANTHATE - XYOSTED (AUTOINJECTOR)</u>						
N 209863 001	10881798	Feb 11, 2034	DP			
	10905827	Aug 21, 2031	DP			
	10912782	Feb 19, 2035	DP	U-2418		
<u>TESTOSTERONE ENANTHATE - XYOSTED (AUTOINJECTOR)</u>						
N 209863 002	10881798	Feb 11, 2034	DP			
	10905827	Aug 21, 2031	DP			
	10912782	Feb 19, 2035	DP	U-2418		
<u>TESTOSTERONE ENANTHATE - XYOSTED (AUTOINJECTOR)</u>						
N 209863 003	10881798	Feb 11, 2034	DP			
	10905827	Aug 21, 2031	DP			
	10912782	Feb 19, 2035	DP	U-2418		
<u>THEOPHYLLINE - THEOPHYLLINE</u>						
A 212184 002					>A> CGT	Dec 08, 2021
<u>TICAGRELOR - BRILINTA</u>						
N 022433 001					I-851	May 28, 2023
<u>TICAGRELOR - BRILINTA</u>						
N 022433 002					I-851	May 28, 2023
<u>TIPIRACIL HYDROCHLORIDE; TRIFLURIDINE - LONSURF</u>						
N 207981 001	10960004	Feb 03, 2037		U-2642		
	RE46284	Sep 22, 2029		U-1751		
	RE46284	Sep 22, 2029		U-2503		
<u>TIPIRACIL HYDROCHLORIDE; TRIFLURIDINE - LONSURF</u>						
N 207981 002	10960004	Feb 03, 2037		U-2642		
	RE46284	Sep 22, 2029		U-1751		
	RE46284	Sep 22, 2029		U-2503		
<u>TIRBANIBULIN - KLISYRI</u>						
N 213189 001	10323001	Dec 28, 2027	DP		NCE	Dec 14, 2025
	10617693	Mar 12, 2038		U-3015		
	10669236	Sep 07, 2038	DS DP			
	7300931	Feb 06, 2026	DS DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2021

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>TIRBANIBULIN - KLISYRI</u>						
N 213189 001	7851470	Feb 02, 2029	DS DP U-3015			
	8236799	Dec 28, 2025	DS DP			
	8980890	Dec 28, 2025	DS DP			
<u>TIVOZANIB HYDROCHLORIDE - FOTIVDA</u>						
N 212904 001	6821987	Apr 26, 2022	DS DP U-3100		NCE	Mar 10, 2026
	7166722	Nov 16, 2023	DS			
<u>TIVOZANIB HYDROCHLORIDE - FOTIVDA</u>						
N 212904 002	6821987	Apr 26, 2022	DS DP U-3100		NCE	Mar 10, 2026
	7166722	Nov 16, 2023	DS			
<u>TOLVAPTAN - SAMSCA</u>						
N 022275 001	10905694	Apr 07, 2030	DP			
<u>TOLVAPTAN - SAMSCA</u>						
N 022275 002	10905694	Apr 07, 2030	DP			
<u>TOLVAPTAN - SAMSCA</u>						
N 022275 003	10905694	Apr 07, 2030	DP			
<u>TOLVAPTAN - JYNARQUE</u>						
N 204441 001	10905694	Apr 07, 2030	DP			
<u>TOLVAPTAN - JYNARQUE</u>						
N 204441 002	10905694	Apr 07, 2030	DP			
<u>TOLVAPTAN - JYNARQUE</u>						
N 204441 003	10905694	Apr 07, 2030	DP			
<u>TOLVAPTAN - JYNARQUE</u>						
N 204441 004	10905694	Apr 07, 2030	DP			
<u>TOLVAPTAN - JYNARQUE</u>						
N 204441 005	10905694	Apr 07, 2030	DP			
<u>TREPROSTINIL - TYVASO</u>						
N 022387 001					I-856	Mar 31, 2024
<u>TRIFAROTENE - AKLIEF</u>						
N 211527 001	>A> 9498465	May 30, 2033	DP U-1033			
<u>TRILACICLIB DIHYDROCHLORIDE - COSELA</u>						
N 214200 001	10085992	Mar 14, 2034	U-3081		NCE	Feb 12, 2026
	10189849	Oct 25, 2031	DS			
	10189850	Oct 25, 2031	DP			
	10927120	Oct 25, 2031	DP			
	10966984	Mar 14, 2034	U-3079			
	10966984	Mar 14, 2034	U-3080			
	8598186	Oct 25, 2031	DS DP			
	8598197	Oct 25, 2031	DS DP			
	9487530	Mar 14, 2034	U-3079			
	9487530	Mar 14, 2034	U-3080			
	9957276	Oct 25, 2031	DS			
<u>UMBRALISIB TOSYLATE - UKONIQ</u>						
N 213176 001	10072013	Jul 02, 2033	U-3063		NCE	Feb 05, 2026
	10072013	Jul 02, 2033	U-3064		ODE-343	Feb 05, 2028
	10414773	May 26, 2035	DS DP U-3063		ODE-344	Feb 05, 2028
	10414773	May 26, 2035	DS DP U-3064			
	10570142	Jul 02, 2033	DS DP U-3063			
	10570142	Jul 02, 2033	DS DP U-3064			
	10947244	May 26, 2035	U-3063			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2021

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>UMBRALISIB TOSYLATE - UKONIO</u>						
N 213176 001	10947244	May 26, 2035				
	9150579	Jul 02, 2033	DS DP			
	9669033	Jul 02, 2033			U-3063	
	9669033	Jul 02, 2033			U-3064	
	9969740	May 26, 2035	DS DP		U-3063	
	9969740	May 26, 2035	DS DP		U-3064	
<u>UPADACITINIB - RINVOO</u>						
N 211675 001	10981923	Oct 17, 2036		DS		
	10981924	Oct 17, 2036			DP	
<u>VALBENAZINE TOSYLATE - INGREZZA</u>						
N 209241 001	10874648	Oct 10, 2037			U-1995	
	10874648	Oct 10, 2037			U-3046	
	10906902	Dec 22, 2036	DS DP			
	10906903	Dec 22, 2036	DS DP			
	10912771	Oct 10, 2037			U-1995	
	10912771	Oct 10, 2037			U-3076	
	10919892	Dec 22, 2036	DS DP			
	10940141	Aug 10, 2040			U-1995	
	10952997	Oct 10, 2037			U-1995	
	10993941	Oct 10, 2037			U-1995	
	>A> 11026931	Aug 14, 2039			U-1995	
	>A> 11026939	Sep 18, 2038	DP		U-1995	
	>A> 11040029	Oct 10, 2037			U-1995	
<u>VALBENAZINE TOSYLATE - INGREZZA</u>						
N 209241 002	10874648	Oct 10, 2037			U-1995	
	10874648	Oct 10, 2037			U-3046	
	10906902	Dec 22, 2036	DS DP			
	10906903	Dec 22, 2036	DS DP			
	10912771	Oct 10, 2037			U-1995	
	10912771	Oct 10, 2037			U-3076	
	10919892	Dec 22, 2036	DS DP			
	10940141	Aug 10, 2040			U-1995	
	10952997	Oct 10, 2037			U-1995	
	10993941	Oct 10, 2037			U-1995	
	>A> 11026931	Aug 14, 2039			U-1995	
	>A> 11026939	Sep 18, 2038	DP		U-1995	
	>A> 11040029	Oct 10, 2037			U-1995	
<u>VALBENAZINE TOSYLATE - INGREZZA</u>						
N 209241 003	10065952	Oct 28, 2036	DS DP			NCE Apr 11, 2022
	10844058	Oct 28, 2036	DS DP		U-1995	
	10851103	Oct 28, 2036	DS DP		U-1995	
	10851104	Oct 28, 2036	DS		U-1995	
	10857137	Oct 10, 2037			U-1995	
	10857148	Oct 10, 2037			U-1995	
	10874648	Oct 10, 2037			U-1995	
	10874648	Oct 10, 2037			U-3046	
	10906902	Dec 22, 2036	DS DP			
	10906903	Dec 22, 2036	DS DP			
	10912771	Oct 10, 2037			U-1995	
	10912771	Oct 10, 2037			U-3076	
	10919892	Dec 22, 2036	DS DP			
	10940141	Aug 10, 2040			U-1995	
	10952997	Oct 10, 2037			U-1995	
	10993941	Oct 10, 2037			U-1995	
	>A> 11026931	Aug 14, 2039			U-1995	
	>A> 11026939	Sep 18, 2038	DP		U-1995	
	>A> 11040029	Oct 10, 2037			U-1995	
	8039627	Oct 06, 2029	DS DP			
	8357697	Nov 08, 2027			U-1995	

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2021

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>VALSARTAN - DIOVAN</u>						
N 021283 001					NPP	Apr 19, 2024
<u>VALSARTAN - DIOVAN</u>						
N 021283 002					NPP	Apr 19, 2024
<u>VALSARTAN - DIOVAN</u>						
N 021283 004					NPP	Apr 19, 2024
<u>VANCOMYCIN HYDROCHLORIDE - FIRVANO KIT</u>						
N 208910 001	10959946	Mar 13, 2035	DP			
	10959947	Mar 13, 2035	DP U-3104			
	10959947	Mar 13, 2035	DP U-3105			
	10959948	Mar 13, 2035	DP U-3104			
	10959948	Mar 13, 2035	DP U-3105			
	10959949	Mar 13, 2035	DP U-3104			
	10959949	Mar 13, 2035	DP U-3105			
<u>VANCOMYCIN HYDROCHLORIDE - FIRVANO KIT</u>						
N 208910 002	10959946	Mar 13, 2035	DP			
	10959947	Mar 13, 2035	DP U-3104			
	10959947	Mar 13, 2035	DP U-3105			
	10959948	Mar 13, 2035	DP U-3104			
	10959948	Mar 13, 2035	DP U-3105			
	10959949	Mar 13, 2035	DP U-3104			
	10959949	Mar 13, 2035	DP U-3105			
<u>VENETOCLAX - VENCLEXTA</u>						
N 208573 001	10993942	Sep 06, 2033	U-3114			
<u>VENETOCLAX - VENCLEXTA</u>						
N 208573 002	10993942	Sep 06, 2033	U-3114			
<u>VENETOCLAX - VENCLEXTA</u>						
N 208573 003	10993942	Sep 06, 2033	U-3114			
<u>VERICIGUAT - VEROUVO</u>						
N 214377 001	10736896	May 19, 2031	DS DP		NCE	Jan 19, 2026
	8420656	May 19, 2031	DS DP			
	8921377	May 19, 2031	U-3062			
	9604948	Nov 26, 2032	DS DP U-3062			
	9993476	May 19, 2031	U-3062			
<u>VERICIGUAT - VEROUVO</u>						
N 214377 002	10736896	May 19, 2031	DS DP		NCE	Jan 19, 2026
	8420656	May 19, 2031	DS DP			
	8921377	May 19, 2031	U-3062			
	9604948	Nov 26, 2032	DS DP U-3062			
	9993476	May 19, 2031	U-3062			
<u>VERICIGUAT - VEROUVO</u>						
N 214377 003	10736896	May 19, 2031	DS DP		NCE	Jan 19, 2026
	8420656	May 19, 2031	DS DP			
	8921377	May 19, 2031	U-3062			
	9604948	Nov 26, 2032	DS DP U-3062			
	9993476	May 19, 2031	U-3062			
<u>VIBEGRON - GEMTESA</u>						
N 213006 001	8247415	Dec 01, 2030	DS DP U-3045		NCE	Dec 23, 2025
	8653260	Apr 02, 2029	DS			
<u>VIGABATRIN - VIGABATRIN</u>						
A 211539 001					CGT	Jul 31, 2021

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2021

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>VILOXAZINE HYDROCHLORIDE - QELBREE</u>						
N 211964 001	9358204	Feb 07, 2033	DP		NCE	Apr 02, 2026
	9603853	Feb 07, 2033	U-727			
	9662338	Feb 07, 2033	DP			
<u>VILOXAZINE HYDROCHLORIDE - QELBREE</u>						
N 211964 002	9358204	Feb 07, 2033	DP		NCE	Apr 02, 2026
	9603853	Feb 07, 2033	U-727			
	9662338	Feb 07, 2033	DP			
<u>VILOXAZINE HYDROCHLORIDE - QELBREE</u>						
N 211964 003	9358204	Feb 07, 2033	DP		NCE	Apr 02, 2026
	9603853	Feb 07, 2033	U-727			
	9662338	Feb 07, 2033	DP			
<u>VILTOLARSEN - VILTEPSO</u>						
N 212154 001	10870676	Aug 31, 2031	DS DP U-3039		ODE-280	Aug 12, 2027
<u>VISMODEGIB - ERIVEDGE</u>						
N 203388 001	9790183	Sep 02, 2025	U-3109			
<u>VOCLOSPORIN - LUPKYNIS</u>						
N 213716 001	10286036	Dec 07, 2037	U-3056		NCE	Jan 22, 2026
	7332472	Oct 17, 2022	DS DP U-3056			
<u>VORTIOXETINE HYDROBROMIDE - TRINTELLIX</u>						
N 204447 001					M-187	Jan 22, 2024
<u>VORTIOXETINE HYDROBROMIDE - TRINTELLIX</u>						
N 204447 002					M-187	Jan 22, 2024
<u>VORTIOXETINE HYDROBROMIDE - TRINTELLIX</u>						
N 204447 003					M-187	Jan 22, 2024
<u>VORTIOXETINE HYDROBROMIDE - TRINTELLIX</u>						
N 204447 004					M-187	Jan 22, 2024
<u>VOXELOTOR - OXBRYTA</u>						
N 213137 001	>A> 11020382	Dec 02, 2036	U-3133			
	>A> 11020382	Dec 02, 2036	U-3134			
<u>ZANUBRUTINIB - BRUKINSA</u>						
N 213217 001	10570139	Apr 22, 2034	DS DP U-2145			
	10927117	Aug 15, 2037	DS DP			

PATENT AND EXCLUSIVITY TERMS

Due to space limitations in the patent and exclusivity columns, abbreviations and references have been developed. Refer to the APPROVED DRUG PRODUCTS WITH THERAPEUTIC EQUIVALENCE EVALUATIONS, 41ST Edition for a full listing of patent and exclusivity terms (Abbreviations, Dosing Schedule, Indications, and Patent Use Codes).

The current complete list of patent terms is available at http://www.accessdata.fda.gov/scripts/cder/ob/results_patent.cfm

The current complete list of exclusivity terms is available at http://www.accessdata.fda.gov/scripts/cder/ob/results_exclusivity.cfm